

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<u>http://bmjopen.bmj.com</u>).

If you have any questions on BMJ Open's open peer review process please email <u>info.bmjopen@bmj.com</u>

BMJ Open

Importance of vitamin D in critically ill children with subgroup analyses of sepsis and respiratory tract infections: a systematic review and meta-analysis

Journal:	BMJ Open
Manuscript ID	bmjopen-2018-027666
Article Type:	Research
Date Submitted by the Author:	01-Nov-2018
Complete List of Authors:	Cariolou, Margarita; Imperial College London School of Public Health, Epidemiology and Biostatistics Cupp, Meghan; Imperial College London School of Public Health, Epidemiology and Biostatistics Evangelou, Evangelos; Imperial College London School of Public Health, Epidemiology and Biostatistics; University of Ioannina School of Medicine, Department of Hygiene and Epidemiology Tzoulaki, Ioanna; Imperial College London, Epidemiology and Public Health; University of Ioannina School of Medicine, Department of Hygiene and Epidemiology Berlanga-Taylor, Antonio; Imperial College London School of Public Health, Epidemiology and Biostatistics
Keywords:	Vitamin D, EPIDEMIOLOGY, meta-analysis, sepsis, PAEDIATRICS, INTENSIVE & CRITICAL CARE

SCHOLARONE[™] Manuscripts

BMJ Open

Importance of vitamin D in critically ill children with subgroup analyses of sepsis and respiratory tract infections: a systematic review and meta-analysis

Margarita Cariolou¹ MPH, Meghan A. Cupp¹ MPH, Evangelos Evangelou^{1,2} PhD, Ioanna Tzoulaki^{1,2} PhD and Antonio J. Berlanga-Taylor^{1*} DPhil

¹MRC-PHE Centre for Environment and Health, Department of Epidemiology & Biostatistics, School of Public Health, Faculty of Medicine, Imperial College London, St Mary's Campus, Norfolk Place, UK, LONDON W2 1PG

²Department of Hygiene and Epidemiology, University of Ioannina Medical School, Ioannina, Greece

*Correspondence should be addressed to Dr. Antonio J. Berlanga-Taylor (a.berlanga@imperial.ac.uk), MRC-PHE Centre for Environment and Health, Department of Epidemiology & Biostatistics, School of Public Health, Faculty of Medicine, Imperial College London, St Mary's Campus, Norfolk Place, LONDON W2 1PG.

4364 words (excluding title page, abstract, references, figures and tables)

ABSTRACT

Objective: Critical care and sepsis remain high priority concerns in children. Associations between deficiency and mortality, particularly in children with sepsis, remain unclear. We performed a systematic review and meta-analysis of observational studies to address this uncertainty.

Methods: We searched PubMed, OVID and Google Scholar to obtain pooled prevalence estimates of vitamin D deficiency and odds ratios for mortality in critically ill children treated in intensive care units, with subgroup analysis for those with sepsis and those with respiratory tract infections.

Results: Forty-eight studies were included. Of 5,520 critically ill children, 2,664 (48%) were vitamin D deficient (< 50 nmol/L). Pooled prevalence estimate of vitamin D deficiency was 54.9% (95% CI 48.0-61.6, I²=95.0%, 95% CI 94.0-95.8, p < 0.0001). Prevalence of deficiency in children with sepsis (16 studies, 788 total individuals) was 63.8% (95% CI 49.9-75.7, I²=90.5%, 95% CI 86.2-93.5%, p < 0.0001) and 49.9% (95% CI 37.6-62.2; I²=93.9%, 95% CI 92.1-95.3, p < 0.0001) in those with respiratory tract infections (24 studies, 1,683 total individuals). Meta-analysis of mortality (18 studies, 2,463 total individuals) showed increased risk of death in vitamin D deficient critically ill children both with random (OR 1.81, 95% CI 1.24-2.64, p = 0.002) and fixed effects (OR 1.72, 95% CI 1.27-2.33, p= 0.0005) models with low heterogeneity (I²= 25.7%, 95% CI 0.0-58.0, p = 0.153). There were insufficient studies to perform meta-analyses for sepsis and respiratory tract infection related mortality.

Conclusions: Circulating vitamin D deficiency is common amongst critically ill children, particularly in those with sepsis. Our results suggest that vitamin D deficiency in critically ill children is associated with increased mortality. Clinical trials, studies with larger sample sizes and

BMJ Open

levels and mortality and other outcomes in the paediatric population.

Registration PROSPERO (CRD42016050638)

Copyright Open access article under terms of CC BY

Keywords paediatric, vitamin D, intensive care, sepsis, meta-analysis, prevalence, mortality, systematic

review, respiratory tract infections

Strengths and limitations of this study

- We comprehensively assessed the magnitude and relevance of vitamin D circulating levels in paediatric acute and critically ill patients using a large number of studies with large total sample size with pre-specified sub-group and sensitivity analyses. We used PRISMA and MOOSE guidelines for reporting.
- We used the currently recommended cut-off of less than 50 nmol/L for vitamin D deficiency.
- We did not find enough studies to perform meta-analyses for mortality from sepsis or respiratory tract infection in relation to vitamin D status.
- We did not identify longitudinal studies with multiple time-point, pre-admission or predisease vitamin D measurements.
- Most studies were single centre with heterogeneous patient groups and few controlled for important confounders that influence vitamin D levels such as age, BMI, gender, season of measurements, vitamin D supplementation and comorbidities.

Vitamin D is an essential nutrient^{1, 2} representing a group of fat soluble secosteroids with key endocrine functions.³ It is synthesized in the skin upon sunlight exposure⁴ while dietary sources, such as oily fish, egg yolk, certain fungi and supplements, are usually secondary sources. Vitamin D is critical in bone metabolism⁵ and calcium homeostasis,⁶ as well as acting as an important regulator in extra-skeletal metabolic processes,⁷ cardiovascular and immune systems.⁸ Many observational and laboratory studies have observed the anti-inflammatory properties of vitamin D,⁹ including direct regulation of endogenous anti-microbial peptide production.¹⁰

It is therefore crucial for humans to have sufficient vitamin D levels to maintain bone health and possibly improve response to infection.^{6, 11, 12} Infants and children are especially dependent on vitamin D to achieve healthy bone development and growth.^{13, 14} Well-known functional outcomes of adequate vitamin D levels in children include rickets prevention, higher bone mineral content and reduced bone fracture rates.^{5, 14} In otherwise healthy children in the United States, the reported prevalence of vitamin D deficiency (250HD levels of < 25 nmol/L) ranges from 9 to 18%.¹⁵ The Endocrine Society Clinical Practice Guidelines and the Institute of Medicine (IOM) suggest that vitamin D levels less than 50 nmol/L (20 ng/mL) reflect a deficient state.^{4, 16}

Studies in adults reflect a high prevalence of vitamin D deficiency both in general intensive care unit (ICU) and sepsis patients and strongly suggest an association between low vitamin D and poor clinical outcomes, including increased mortality, particularly in those suffering from sepsis.^{2, 17} Recent clinical trials of vitamin D supplementation in adults appear promising in both general critical care^{18, 19} and sepsis.²⁰

Sepsis remains a challenging clinical entity with high social and economic costs.²¹ Each year there are approximately 123,000 sepsis cases and around 37,000 deaths in England alone.²² Recent reports show an increased prevalence of paediatric sepsis,²³ likely a reflection of an increased population with chronic comorbidities, higher rates of opportunistic infections and multidrug resistant organisms.²⁴ Respiratory tract infections account for a large proportion of underlying diagnoses in acute and critical care conditions^{24, 25} but remain understudied.²⁶

The magnitude and relevance of vitamin D deficiency in children receiving acute care is not clear. Several recent studies have addressed these questions with mixed results. We sought to summarise the evidence regarding the implications of vitamin D deficiency and its prevalence in general ICU, respiratory tract infection and sepsis patients in the paediatric population. We carried out a systematic review and meta-analysis of circulating vitamin D levels to assess the prevalence of vitamin D deficiency (\leq 50 nmol/L) and its association with mortality in these conditions.

METHODS

We planned and conducted our systematic review and meta-analysis according to the PRISMA guidelines²⁷ (*Additional Table 1*) and since we did not include randomized controlled trials we reported following the Meta-Analysis of Observational Studies in Epidemiology (MOOSE) guidelines.²⁸

Search strategy and selection criteria

Our population of interest consists of paediatric patients with acute conditions and/or treated in ICU or emergency units for acute conditions whose vitamin D status was assessed prior to or

during admission. We included published cross sectional, case-control and cohort studies that measured circulating 25(OH) D levels and either reported prevalence, odds ratios (OR) or data to enable calculation. Studies were excluded if they were reviews, case reports, surveys, commentaries, replies, not original contributions, experimental *in vitro* or if they recruited patients who were not treated in emergency, neonatal intensive care units (NICUs), paediatric intensive care units (PICUs) or for acute conditions. Studies were also excluded if they only enrolled vitamin D deficient patients, investigated healthy populations only or did not measure circulating 25(OH) D levels as an indicator of vitamin D status. When we identified more than one publication utilising the same cohort, we included the publication which shared our review's objective to investigate vitamin D levels and prevalence of deficiency.

For purposes of our review, we classified vitamin D deficiency as being less than 50 nmol/L (equivalent to 20 ng/mL) as suggested by the IOM.¹⁶ Different age categories were used to designate patients as "children" in the studies reviewed. We therefore included all "children" as defined by each treating facility and this included "neonates", "infants", "toddlers", "children" and "adolescents".

We searched PubMed, OVID, Google Scholar and the Cochrane Library from inception up until 5th November 2017, with no language restrictions. Search terms used across these databases included: "critical care", "vitamin D", "pediatric", "child", "neonate", "toddler", "intensive care unit", "sepsis" and "septic shock". Search terms used in OVID and PubMed are listed in the *Additional Tables 2A and 2B*. Literature searches were performed by two investigators independently and included initial screening of titles and abstracts, followed by full text screening. Any disagreements for study eligibility were resolved by discussion between the authors. Reference lists of the selected papers, including reviews, were also checked for relevant titles.

BMJ Open

Abstracts of relevant titles were then assessed for eligibility. A data extraction form was designed a priori.

Study quality assessment

The quality of each included study was assessed using the Newcastle-Ottawa Scale (NOS) for cohort, case-control and cross-sectional study designs (*Additional Tables 3A, 3B* and 3C).²⁹ We classified studies as low (1-3), medium (4-6) or high quality (7-9) for purposes of sensitivity analysis.

Prevalence and mortality outcomes

In the majority of studies (n = 36), prevalence of vitamin D deficiency was extracted as reported with a threshold of \leq 50 nmol/L. If prevalence was not reported directly, it was calculated using data provided in each study (cases \leq 50 nmol/L / total number of study participants, (*Additional Table 4A* and *4B*). Extracted or calculated prevalence values were then combined in a meta-analysis. For mortality, we calculated unadjusted odd ratios (OR) as:

OR = (vitamin D deficient patients who died * vitamin D non-deficient patients who did not die)/ (vitamin D deficient patients who did not die * vitamin D non-deficient patients who died)

We had sufficient information to calculate ORs < 50 nmol/L for 36 studies (75%). For the 12 studies with insufficient information, we used the lower cut-off values reported as a conservative approximation (*Additional Table 5*). We converted 25(OH) D values using: nmol/L = ng/mL * 2.496.

Data analysis

We obtained proportions of vitamin D deficiency with 95% confidence intervals (CI) using the Clopper-Pearson method³⁰ in R. We used a random effects model³¹ to account for the variation observed within and between studies due to the different ages and acute conditions in the populations considered. For mortality, we also obtained pooled proportions and pooled ORs with fixed effect model for sensitivity analysis and to avoid false conclusions that could result from small-study effects.³²

We investigated possible sources of heterogeneity using sensitivity and subgroup analyses. The I² statistic was used to estimate the percentage of total variation across studies which can be attributed to heterogeneity. A Q value of < 0.05 was considered significant and an I² statistic greater or equal to 75% indicated a high level of variation due to heterogeneity.^{33, 34} We used Egger's regression test to present results for publication bias and funnel plot asymmetry³⁵ and generated funnel plots for visual assessment and screen for evidence of publication bias.

To further assess heterogeneity, we utilised meta-regression to identify predictor variables that could explain variation in study prevalence estimates. We used restricted maximum likelihood (REML) estimations in the model to account for residual heterogeneity³⁶ and the Knapp-Hartung method to adjust confidence intervals and test statistics. This method estimates between study variance using a t-distribution, rather than a z-distribution, yielding a more conservative inference.³⁷ We tested the following continuous predictors: year of study publication, total sample size and quality score. Categorical variables included study setting (PICU, NICU), study design (case-control, cross-sectional and cohort) and country group by geographic region and economic development (group 1, group 2, and group 3) and were dummy coded.

BMJ Open

We used R version 3.5.0 and Microsoft Excel 2010 for analyses and data collection. The R packages "meta"³⁸ and "metafor"³⁹ were used for analyses. Only results of the random effects model are reported for prevalence due to the expected heterogeneity between populations being considered. Our protocol is registered in PROSPERO (CRD42016050638).

Role of the funding source

The study received funding from the UK Medical Research Council. The funders had no role in data collection, analysis, interpretation or writing of the report. All authors had access to the data in the study.

RESULTS

Screening and study characteristics

After title and abstract screening, we identified 2,890 potentially relevant studies (Figure 1) and eighty-five full text articles were assessed for eligibility. Rationale for study exclusion included: studies including adults, study populations other than critically ill children or with acute conditions, studies of circulating vitamin D levels and deficiency in healthy children or in children with chronic conditions. Four studies⁴⁰⁻⁴³ were excluded due to insufficient data reporting (Additional Table 6). We also excluded three studies⁴⁴⁻⁴⁶ that used the same cohort of children and included a single study to represent the cohort.⁴⁷ Ultimately, 48 studies met criteria for inclusion (Additional Table 7).

Figure 1 Flow chart of study selection process

The primary objective of most studies was to determine circulating vitamin D concentration ("status") in children and/or prevalence of vitamin D deficiency. Secondary objectives included investigation of associations between deficiency of circulating vitamin D and various outcomes, such as hospital mortality length of stay, requirement of ventilation and/or illness severity (*Additional Table 8*).

All included studies reported vitamin D measurement assay methods used (*Additional Table 9*) and stated that samples were collected and analysed within the first 24 hours of hospital admission. Studies reported ethical approval and consent for participation from parents or guardians (*Additional Table 10*). Included studies were published between 2004 and 2017, with the majority (n = 39, 81.3%) published between 2014 and 2017 (*Additional Table 7*). In total, 5,520 children were hospitalized in paediatric or neonatal intensive care units or emergency units. Sample sizes of critically ill children ranged from 25⁴⁸ to 511.⁴⁹ In 16 studies the total number of cases was greater than 100.

Studies originated from 15 countries, with the majority from India^{8, 50-58} (n = 10) or Turkey^{48, 59-64} (n = 7) (*Additional Table 7*). All were of medium or high quality (NOS score median 6·5, range 4-8). The score range for cohort studies was 6 to 8 (n = 20), for case-control studies 5 to 8 (n = 24) and for cross sectional 4 to 6 (n = 4). Studies used a broad range of ages to classify patients as "children". Six studies (12.5%)^{48, 60, 62-65} included only neonates. In two^{60, 65} of these six studies, neonates were preterm. The largest age range was seen in the study of Ayulo et al 2014, which included individuals between 1 and 21 years of age (*Additional Table 11*).

All studies included both female and male participants. For mortality, four of the 18 studies (22%) carried out multivariate regression analysis with adjustment for confounders. The remaining

BMJ Open

studies presented results using a variety of methods, including Spearman's correlation analysis, chi-square or Fisher's exact tests or descriptive statistics.

Prevalence of vitamin D deficiency

We included 48 studies representing a total of 5,220 critically ill children. Of these, 2,664 (48%) were classified as vitamin D deficient (< 50 nmol/L). Prevalence of deficiency ranged from 5%⁶⁶ to 95%⁵⁴ (*Additional Table 12*). Sample sizes ranged from 25 to 511, with a median of 82 individuals (*Additional Table 13*). Using a random effects model, the pooled prevalence estimate of vitamin D deficiency was 54.9% (95% CI 48.0-61.6) with a high proportion of variation attributed to heterogeneity (I² = 95.0%, 95% CI 94.0-95.8, p < 0.0001) (*Figure 2*) and evidence of funnel plot asymmetry (p = 0.015, Egger's test) (*Table 1* and *Additional Figure 1*).



Table 1 Pooled estimates of vitamin D deficiency in critically ill children and critically ill children with sepsis and those with respiratory tract infections

Patient category	Number of studies (Total number of	Pooled proportion % (95% CI)		Heterogeneity (I ²)	Q value, d.f.	Eggers p-value
	individuals; number of deficient individuals)	Random effects	Fixed effects	% (95% CI)	p-value	
Critically ill children (includes those with sepsis)	48 (5,520; 2,664)	54.9 (48.0-61.6)	46.8 (45.4-48.3)	95.0 (94.0-95.8)	931.46, 57, < 0.0001	0.015
Critically ill children (only those with sepsis)	16 (788; 499)	63.8 (49.9-75.7)	62.6 (58.6-66.5)	90.5 (86.2-93.5)	157.99, 15, < 0.0001	0.828
Only those admitted with respiratory tract infections	24 (1,683; 778)	49.9 (37.6-62.2)	43.2 (40.4-46.1)	93.9 (92.1-95.3)	378.7, 23, < 0.0001	0.217

 $CI = confidence intervals; I^2 = heterogeneity; df = degrees of freedom. Vitamin D deficiency defined in our study as < 50 nmol/L (20 ng/mL). I² statistic used to estimate heterogeneity between pooled studies: I² ≥ 75% was considered high heterogeneity.$

Figure 2 Pooled prevalence estimate for vitamin D deficiency in critically ill children by study design.

Sensitivity analysis for prevalence

We did not detect material differences in prevalence after exclusion of the 12 studies which did not directly report prevalence < 50 nmol/L (53.1%, 95% CI 45.6-60.4; $I^2 = 95.1\%$, 95% CI 93.9-96.0, p < 0.0001) (*Additional Table 13*).

When examining results by sample size (defining "large" as ≥ 100 and "small" as < 100), we found that the 16^{8, 47, 49-51, 59, 60, 67-75} studies with larger sample size included 3,561 total individuals and gave a prevalence estimate of 50.8% (95% CI 40.5-61.1; I² = 96.9%, 95% CI 95.9-97.6, p < 0.0001). The remaining 32 studies with "smaller" sample sizes included 1,959 total children and estimated pooled prevalence as 57.2% (95% 47.3-66.7; I²= 92.7, 95% CI 90.7-94.3, p < 0.0001) (*Additional Table 14*).

We also conducted analysis by study design. Cohort studies (n = 20) yielded a prevalence estimate of 48.4% (95% CI 39.7-57.3; $I^2 = 95.5\%$, 95% CI 94.1-96.5, p < 0.0001). In case-control studies (n = 24) the estimate was 64.1% (95% CI 53.2-73.6; $I^2 = 92.8\%$, 95% CI 90.5-94.6, p < 0.0001) and in cross-sectional (n = 4) 34.8% (95% CI 12.8-66.0; $I^2 = 96.7\%$, 95% CI 94.0-98.2, p <0.0001) (*Additional Table 14, Figure 2*).

We assessed whether studies' country of origin influenced results. Studies in India gave an estimate of 69.5% (95% CI 53.0-81.5; $I^2 = 93.6\%$, 95% CI 90.2-95.8, p < 0.0001). Similarly, we found higher pooled prevalence estimates for studies from Turkey (76.3%, 95% CI 60.9-87.0; $I^2 = 91.1\%$, 95% CI 84.2-95.0, p < 0.0001). We also grouped studies by geography and economic

development. Group 1: USA, Chile, Australia, Canada, Ireland, Japan, Spain; group 2: South Africa, China, Egypt, Iran, Turkey, Saudi Arabia; and group 3: Bangladesh, Thailand, and India. Prevalence was 36.1% (95% CI 27.8-45.4) for group 1 (n = 18), 62.7% (95% CI 52.2-72.2) for group 2 (n = 18) and 71.4% (95% CI 57.9-82.0) for group 3 (n = 12) (Additional Figure 2). Variation attributable to heterogeneity was still high in the three subgroups (I² > 90%).

Given the broad age range in included studies, we combined studies with only neonates^{48, 60, 62-65} and observed a prevalence estimate of 85.6% (95% CI 78.5-90.6) with moderate variation attributable to heterogeneity ($I^2 = 54.3\%$, 95% CI 0.0-81.7, p value = 0.05). In all other studies (n = 42) that included children of broad age ranges, estimated prevalence was lower at 49.7% (95% CI 42.9-56.5; $I^2 = 94.7\%$, 95% CI 93.6-95.6, p value < 0.0001) (*Additional Table 14, Additional Figure 3*).

Post-hoc investigation to determine sources of heterogeneity

To investigate the substantial heterogeneity observed in prevalence estimates, we incorporated study-specific characteristics (year of publication, total study sample size, quality score, study design, country group and clinical setting) as covariates in a random effects meta-regression model. We identified clinical setting and country groups as significant predictors (*Figure 3*). We found that the model fitted with all available covariates can explain 37.52% of I² with F = 5.1119, p = 0.0005 (*Additional Table 15*). We also conducted univariate meta-regressions for each of the six predictors (*Additional Figure 4*).

Figure 3 Bubble plots of univariate meta-regressions.

Prevalence of vitamin D deficiency in critically ill children with sepsis and in those with respiratory tract infections

A total of 788 (median 42, range 9 -160) patients had a diagnosis of sepsis, of which 499 (63.3%) were vitamin D deficient. Nine of the sixteen studies including septic patients were cohort (56.3%) and seven (43.8%) case-control *(Additional Table 16)*. Most studies originated from India (n = 6) Turkey (n = 3) or Ireland (n = 2) and 15 were published between 2014 and 2017. Thirteen studies took place in a PICU and the remaining^{60, 63, 65} in NICUs. We found that all studies were of medium to high quality (median NOS score 6.5, range 5 – 8). Pooled prevalence of vitamin D deficiency was 63.8% (95% CI 49.9-75.7) *(Figure 4)*. Variation attributable to heterogeneity was high ($I^2 = 90.5\%$, 95% CI 86.2-93.5%, p < 0.0001). Funnel plot was symmetric suggesting no publication bias (p = 0.828, Egger's test) *(Additional Figure 5)*.

Figure 4 Pooled prevalence estimate for vitamin D deficiency in critically ill children with sepsis.

We also analysed studies of patients admitted for respiratory tract infections (n = 24) such as acute lower respiratory tract infection (ALRTI), pneumonia and bronchiolitis. Of these 1,683 total individuals (median 49), 778 (46.2%) were vitamin D deficient. These studies were of high to medium quality (median NOS score 6.5, range 6 - 8). Most originated from India (n = 6) and Spain (n = 4). We found a prevalence estimate of 49.9% (95% CI 37.6-62.2; I² = 93.9%, 95% CI 92.1-95.3, p < 0.0001), with no evidence of publication bias (p = 0.217, Egger's test) (*Table 1*). Two of these studies^{50, 76} also investigated sepsis.

Sensitivity analysis for prevalence in children with sepsis

BMJ Open

Exclusion of the studies^{58, 60, 65, 77} utilising thresholds other than < 50 nmol/L for deficiency yielded a similar estimate of prevalence at 61.4% (95% CI 43.5-76.6; I² = 91.2% 86.5-94.2, p < 0.0001) *(Additional Table 17).*

We examined pooled prevalence estimates according to sample size (< 40 versus \ge 40). Studies with a small sample size (n = 7; 123 total individuals) showed a prevalence estimate of 63.2% (95% CI 45.0-78.2) with moderate variation attributable to heterogeneity (I² = 66.2%, 95% CI 24.5-84.9, p = 0.0068). For the remaining nine studies (sample sizes \ge 40, 665 total individuals) the estimate was 63.9% (95% CI 44.9 - 79.4) with high variation attributable to heterogeneity (I² = 94.3%, 95% CI 91.2-96.3, p < 0.0001).

There was no material change in prevalence estimates when analysed according to study design. The nine cohort studies (463 total individuals) gave an estimate of 62.6% (95% CI 40.7-80.4) with high variation attributable to heterogeneity ($I^2 = 92.8\%$, 95% CI 88.6-95.5, p < 0.0001). Case-control studies (n = 7; 325 total individuals) showed a prevalence of 65.2% (95% CI 47.3-79.7; $I^2 = 87.0\%$, 95% CI 75.5-93.1, p < 0.0001) (Additional Table 17, Additional Figure 6).

Studies from India (n = 6) gave a prevalence estimate of 66.4% (95% CI 48.3-80.7; $I^2 = 83.6\%$, 95% CI 65.7-92.2, < 0.0001). The three studies from Turkey assessing septic patients gave a pooled estimate of 59.2% (95% CI 13.6-93.1; $I^2 = 97.8\%$, 95% CI 95.8- 98.8, p < 0.0001) (Additional Table 17).

The prevalence estimate in the three studies^{60, 63, 65} including neonates with sepsis was 76.9% (95% CI 61.9-87.3, $I^2 = 74.7\%$, 95% CI 15.9-92.4, p-value 0.019). The thirteen studies with children of different ages, excluding neonates, gave a pooled estimate of 60.1% (95% CI 43.7-74.5; $I^2 = 90.8\%$, 95% CI 86.1-93.9, p value < 0.0001) (*Additional Table 17*).

Mortality in critically ill children

 We identified 18 studies^{8, 47, 50-53, 55, 58, 59, 65, 68, 69, 71, 76-80} assessing vitamin D status and mortality. These studies included a total of 2,463 individuals, from which 220 deaths (17.2%) were observed in 1,278 (51.9%) individuals with vitamin D deficiency and 99 deaths (8.4%) were observed in 1,185 individuals without deficiency (48.1%).

All 18 studies took place in a PICU apart from one^{65} in a NICU. Sixteen of these studies (89%) were published between 2014 and 2017. Fourteen were cohort (77.8%) and four case-controls (22.2%). Almost half (n = 7) of the studies originated from India. Quality scores ranged from 5 to 8 with a median of 6.

Using a random effects model, we found that vitamin D deficiency in critically ill children significantly increased the risk of death (OR 1.81, 95% CI 1.24-2.64, p-value = 0.002) with low, non-significant heterogeneity ($I^2 = 25.7\%$, 95% CI 0.0-58.0, p = 0.153) (*Table 1, Figure 5*). We did not identify evidence of publication bias (p = 0.084, Egger's test) (*Additional Figure 7*).

Figure 5 Pooled odds ratio (OR) of risk of mortality in vitamin D deficient versus vitamin D non-deficient critically ill children.

Sensitivity analysis for mortality in critically ill children

We obtained similar results through the fixed effects model (OR 1.72, 95% CI 1.27-2.33, p = 0.0005) (*Table 1, Additional Figure 8*). When excluding studies with thresholds other than < 50 nmol/L indicating deficiency, we found the association between vitamin D deficiency and increased risk of mortality still significant but lower, both with the random (OR 1.59, 95% CI 1.05-

BMJ Open

2.41, p = 0.028; $I^2 = 24.3\%$, 95% CI 0.0-59.9, p = 0.191) and fixed effect models (OR 1.52, 95% CI 1.08-2.13, p = 0.016) with no indication of publication bias (p = 0.12, Egger's test) (Additional Table 18).

A significant association was also observed in analysis of the 14 cohort studies, both with the random (OR 1.80, 95% CI 1.15-2.81, p = 0.01) and fixed effects model (OR 1.65, 95% CI 1.17-2.34, p-value = 0.004) with low variation attributable to heterogeneity ($I^2 = 31.3\%$, 95% CI 0.0-63.7). Pooling the four case-control studies together we obtained a significant positive association with the fixed (OR 1.97, 95% CI 1.02-3.82, p = 0.044) effects model but non-significant with the random effects model (OR 1.97, 95% CI 0.88-4.42, p = 0.098). The association was positive but not-significant when pooling the seven studies from India with the random effects model (OR 1.08, 95% CI 0.70-1.69, p = 0.710; $I^2 = 0.0\%$ 0.0-62.4, p = 0.589) and similar with fixed effects (OR 1.08, 95% CI 0.70-1.69, p = 0.710) (*Additional Table 18*).

Mortality in patients with sepsis and respiratory tract infections

We were unable to identify a sufficient number of studies assessing vitamin D and mortality for meta-analysis in individuals with sepsis. Three studies^{8, 58, 60} measured vitamin D levels in paediatric patients with sepsis. One study⁸ assessed mortality and did not find a significant association in children from 1 to 12 years with sepsis (n=124). None of the studies with children admitted for respiratory tract infections looked at the association of vitamin D deficient versus vitamin D not deficient children with mortality.

DISCUSSION

Vitamin D deficiency is highly prevalent worldwide, even in countries with abundant sunshine. Studies demonstrated high prevalence of vitamin D deficiency in otherwise healthy children from high-income countries (9 to 24%) but also from middle and low-income countries in Indian subcontinent (36 to 90%).⁸

We identified 48 studies representing a total of 5,520 children treated in ICU or emergency units for acute conditions who had blood vitamin D levels measured close to or upon admission. Our analysis shows that prevalence of vitamin D deficiency is high (range 5%⁶⁶ to 95%⁵⁴) across ICU and emergency units in the paediatric population, particularly in individuals with sepsis. Importantly, our analysis showed a significantly increased risk of mortality in critically ill children with vitamin D deficiency. We carried out several analyses for sensitivity including fixed effects models, by study design, country group, age and sample size and found consistent results. A recently published meta-analysis⁸¹ also investigated prevalence of vitamin D deficiency in critically ill children and its association with risk of mortality and showed similar results to ours.

Sub-group analyses in patients with sepsis or respiratory tract infections demonstrated a high prevalence of vitamin D deficiency, consistent with the increased risk of bacterial or nosocomial infection in vitamin D deficient individuals identified elsewhere.⁸¹

Although sepsis is a leading cause of paediatric mortality and morbidity worldwide,⁸² we found few studies assessing the relationship between vitamin D status and mortality in this population. We were unable to identify sufficient studies including patients with sepsis to perform a metaanalysis of vitamin D status and mortality. Sepsis remains an area of unmet need with high social and financial costs.²⁴ Diagnostic criteria,⁸³ a lack of adequate biomarkers⁸⁴ and targeted treatment

BMJ Open

remain important challenges in research on sepsis. We did not find studies that assessed the risk of mortality in relation to vitamin D deficiency in children admitted for respiratory tract infections either.

Strengths of our review include the large number of studies and large total sample size, allowing a high-powered investigation to identify meaningful associations. For our systematic review and meta-analysis, we followed pre-specified eligibility criteria and used the PRISMA²⁷ and MOOSE guidelines²⁸ for reporting. We carried out sensitivity analyses with few material differences in results. However, we note that the relationship between vitamin D deficiency and mortality was sensitive to study design and studies from India, probably due to the smaller number of individuals in those analyses. Only the prevalence analysis with neonates indicated lower variation attributable to heterogeneity ($I^2 = 54.3\%$) along with a higher prevalence estimate (86%) compared to other analyses. As expected, heterogeneity across studies is high overall, particularly for prevalence estimates. We utilised meta-regression to investigate this substantial heterogeneity around prevalence estimates. From the six variables in our multi-variable model, only clinical setting and country groups were found to be significant predictors of pooled prevalence estimates of vitamin D deficiency and the full model could explain 37.52% of I². Studies in NICU yielded higher prevalence estimates compared to studies in PICU. Studies from group 3 countries were also associated with higher prevalence estimates compared to studies from countries of group 1 and 2. Other variables, mainly individual patient characteristics such as age and ethnicity, were not directly available to us and may account for significant heterogeneity. Future research should also investigate biological heterogeneity in order to strengthen the evidence and produce generalisable results.

Our systematic review did not identify longitudinal studies with multiple time-point, pre-disease or pre-admission vitamin D measurements. The majority of studies were single centre with heterogeneous patient groups and relatively small sample sizes. Few studies accounted for important confounders that influence vitamin D levels such as age, gender, BMI, season of measurements, vitamin D supplementation and comorbidities. The relationship observed between vitamin D deficiency and mortality could be due to reverse causation and future studies will need to control for these covariates and other confounders.

Although included studies were generally of good quality, sample sizes varied considerably and were typically small. Over half of studies included less than 100 cases and only 10 studies (19.6%) had a total sample size of more than 200 individuals. In addition, studies used a variety of definitions and age ranges to designate individuals as children. Our analysis only included mortality as a clinical outcome. A further general limitation is the difference in thresholds for vitamin D deficiency, particularly in the levels which are considered normal for infants and young children. Our assessment used the currently recommended threshold for deficiency (\leq 50 nmol/L)¹⁶ and used a conservative estimate for studies which used different criteria.

Vitamin D remains an attractive biomarker and potential therapeutic agent in acute and critical care patients. Carefully designed and adequately powered studies are needed to determine the importance and therapeutic value of vitamin D in the general and septic paediatric critical care population.

Availability of data and materials

Data and computational code used for processing and analysis are available at https://github.com/margarc/VitaminD_children

Author contributions

AJBT conceived the study. AJBT and IT designed the study. MC collected data and performed the analysis with input from MAC, IT, ABJT and EE. MC and AJBT wrote the manuscript with contributions from all authors.

Declaration of interests

The authors declare no conflicts of interest.

Funding Medical Research Council UK

Acknowledgements

AJBT was supported by the Medical Research Council (UK MED-BIO Programme Fellowship,

MR/L01632X/1).

з. **Ethics committee approval:** Not applicable.

Main Figures

Figure 1 Flow chart of study selection process

Figure 2 Pooled prevalence estimate for vitamin D deficiency in critically ill children by study design. Forest plot shows results from the random effects model. Each diamond represents the pooled proportion of vitamin D deficiency for each of the subgroups (case-control, cohort, cross-sectional study designs). The diamond at the bottom represents the overall pooled proportion of all the 48 studies together. Each square shows the prevalence estimate of each study and the horizontal line across each square represents the 95% confidence interval (CI) of the prevalence estimate.

Figure 3 Bubble plots of univariate meta-regressions. Each study is represented by a circle. Predictor variables; A clinical setting and B country groups are shown on the x-axis and the effect measure logit transformed proportion shown on the vertical (y-axis). NICU = Neonatal Intensive Care Unit; PICU = Pediatric Intensive Care Unit; grp = country group; country group 1 = USA, Chile, Australia, Canada, Ireland, Japan, Spain; country group 2 = SouthAfrica, China, Egypt, Iran, Turkey, Saudi Arabia; and country group 3 = Bangladesh, Thailand, and India

Figure 4 Pooled prevalence estimate for vitamin D deficiency in critically ill children with sepsis. Forest plot shows result from the random effects model. The diamond represents the overall pooled proportion of vitamin D deficiency from the meta-analysis of the 16 studies. Each square shows the prevalence estimate of each study and the horizontal line across each square represents the 95% confidence interval (CI) of the prevalence estimate.

Figure 5 Pooled odds ratio (OR) of risk of mortality in vitamin D deficient versus vitamin D non-deficient critically ill children. Forest plot shows result from the random effects model. Diamond represents the overall OR (with corresponding 95% Confidence Interval). Each square shows the odds ratio of each study and the horizontal line across each square represents the 95% confidence interval (CI) of the estimate.

Supplementary Material

Additional Tables

Additional Table 1 PRISMA Checklist 2009

- Additional Table 2A Search terms used in OVID
- Additional Table 2B Search terms used in PubMed

Additional Table 3A Newcastle Ottawa study quality scoring system (cohort studies)

Additional Table 3B Newcastle Ottawa study quality scoring system (case-control studies)

Additional Table 3C Newcastle Ottawa study quality scoring system (cross sectional studies)

Additional Table 4A Circulating 25(OH) D threshold levels used in the selected studies

Additional Table 4B Circulating 25(OH) D threshold levels used in the selected studies for prevalence in sepsis

Additional Table 5 Studies with thresholds other than <50 nmol/L

Additional Table 6 Excluded studies

Additional Table 7 Characteristics of the 48 included studies

Additional Table 8 Objectives and outcomes of included studies

Additional Table 9 Assay used in each study to measure Vitamin D levels

Additional Table 10 Funding and ethical approval of included studies

Additional Table 11 Age groups of children in each study

Additional Table 12 Prevalence of vitamin D deficiency in each study of critically ill children (sorted from highest to lowest)

Additional Table 13 Characteristics of studies used in the meta-analysis for prevalence

Additional Table 14 Sensitivity analyses for prevalence of vitamin D deficiency in all critically ill children

Additional Table 15 Multivariate meta-regression model for prevalence

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

BMJ Open

Additional Table 17 Sensitivity analyses for prevalence of vitamin D deficiency in critically ill children with sepsis

Additional Table 18 Sensitivity analyses for mortality

Additional Figures

Additional Figure 1 Funnel plot of studies of prevalence of vitamin D deficiency in critically ill children

Additional Figure 2 Pooled prevalence estimate for vitamin D deficiency in critically ill children (subgroup analysis by country group)

Additional Figure 3 Pooled prevalence estimate for vitamin D deficiency in critically ill children (subgroup analysis of neonates versus all other age groups)

Additional Figure 4 Bubble plots of univariate meta-regressions.

Additional Figure 5 Funnel plot for prevalence of vitamin D deficiency in critically ill children with sepsis

Additional Figure 6 Pooled prevalence estimate for vitamin D deficiency in critically ill children with sepsis (subgroup analysis by study design)

Additional Figure 7 Funnel plot of risk of mortality in vitamin D deficient versus vitamin D non-deficient critically ill children

Additional Figure 8 Pooled odds ratio and 95% CI for risk of mortality in vitamin D deficient versus vitamin D nondeficient critically ill children (fixed effects model)

References

1. Shuler FD, Wingate MK, Moore GH, Giangarra C. Sports health benefits of vitamin d. Sports health. 2012;4(6):496-501.

2. Verceles AC, Weiler B, Koldobskiy D, Goldberg AP, Netzer G, Sorkin JD. Association Between Vitamin D Status and Weaning From Prolonged Mechanical Ventilation in Survivors of Critical Illness. Respiratory care. 2015;60(7):1033-9.

3. Braegger C, Campoy C, Colomb V, Decsi T, Domellof M, Fewtrell M, et al. Vitamin D in the healthy European paediatric population. Journal of pediatric gastroenterology and nutrition. 2013;56(6):692-701.

4. Holick MF, Binkley NC, Bischoff-Ferrari HA, Gordon CM, Hanley DA, Heaney RP, et al. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. The Journal of clinical endocrinology and metabolism. 2011;96(7):1911-30.

5. Holick MF. Vitamin D deficiency. The New England journal of medicine. 2007;357(3):266-81.

6. Aranow C. Vitamin D and the immune system. Journal of investigative medicine : the official publication of the American Federation for Clinical Research. 2011;59(6):881-6.

7. Zhang YP, Wan YD, Sun TW, Kan QC, Wang LX. Association between vitamin D deficiency and mortality in critically ill adult patients: a meta-analysis of cohort studies. Critical care (London, England). 2014;18(6):684.

8. Ponnarmeni S, Kumar Angurana S, Singhi S, Bansal A, Dayal D, Kaur R, et al. Vitamin D deficiency in critically ill children with sepsis. Paediatrics and international child health. 2016;36(1):15-21.

9. Kulie T, Groff A, Redmer J, Hounshell J, Schrager S. Vitamin D: an evidence-based review. Journal of the American Board of Family Medicine : JABFM. 2009;22(6):698-706.

Hewison M. Antibacterial effects of vitamin D. Nature reviews Endocrinology. 2011;7(6):337-45.
 Kempker JA, West KG, Kempker RR, Siwamogsatham O, Alvarez JA, Tangpricha V, et al. Vitamin D status and the risk for hospital-acquired infections in critically ill adults: a prospective cohort study. PloS one. 2015;10(4):e0122136.

12. Martineau AR, Jolliffe DA, Hooper RL, Greenberg L, Aloia JF, Bergman P, et al. Vitamin D supplementation to prevent acute respiratory tract infections: systematic review and meta-analysis of individual participant data. BMJ (Clinical research ed). 2017;356:i6583.

13. Absoud M, Cummins C, Lim MJ, Wassmer E, Shaw N. Prevalence and predictors of vitamin D insufficiency in children: a Great Britain population based study. PloS one. 2011;6(7):e22179.

14. Greer FR. Defining vitamin D deficiency in children: beyond 25-OH vitamin D serum concentrations. Pediatrics. 2009;124(5):1471-3.

15. Abou-Zahr R, Kandil SB. A pediatric critical care perspective on vitamin D. Pediatric research. 2015;77(1-2):164-7.

16. Ross AC, Manson JE, Abrams SA, Aloia JF, Brannon PM, Clinton SK, et al. The 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine: what clinicians need to know. The Journal of clinical endocrinology and metabolism. 2011;96(1):53-8.

17. Ala-Kokko TI, Mutt SJ, Nisula S, Koskenkari J, Liisanantti J, Ohtonen P, et al. Vitamin D deficiency at admission is not associated with 90-day mortality in patients with severe sepsis or septic shock: Observational FINNAKI cohort study. Annals of medicine. 2016;48(1-2):67-75.

18. Putzu A, Belletti A, Cassina T, Clivio S, Monti G, Zangrillo A, et al. Vitamin D and outcomes in adult critically ill patients. A systematic review and meta-analysis of randomized trials. Journal of critical care. 2017;38:109-14.

19. Han JE, Jones JL, Tangpricha V, Brown MA, Brown LAS, Hao L, et al. High Dose Vitamin D Administration in Ventilated Intensive Care Unit Patients: A Pilot Double Blind Randomized Controlled Trial. Journal of clinical & translational endocrinology. 2016;4:59-65.

20. Quraishi SA, De Pascale G, Needleman JS, Nakazawa H, Kaneki M, Bajwa EK, et al. Effect of Cholecalciferol Supplementation on Vitamin D Status and Cathelicidin Levels in Sepsis: A Randomized, Placebo-Controlled Trial. Critical care medicine. 2015;43(9):1928-37.

21. Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). Jama. 2016;315(8):801-10.

22. NHS-England. Improving outcomes for patients with sepsis: a cross-system action plan 2015 [Available from: <u>https://www.england.nhs.uk/ourwork/part-rel/sepsis/</u>.

23. Plunkett A, Tong J. Sepsis in children. BMJ (Clinical research ed). 2015;350:h3017.

24. Weiss SL, Fitzgerald JC, Pappachan J, Wheeler D, Jaramillo-Bustamante JC, Salloo A, et al. Global epidemiology of pediatric severe sepsis: the sepsis prevalence, outcomes, and therapies study. American journal of respiratory and critical care medicine. 2015;191(10):1147-57.

25. Mayr FB, Yende S, Angus DC. Epidemiology of severe sepsis. Virulence. 2014;5(1):4-11.

26. De Pascale G, Ranzani OT, Nseir S, Chastre J, Welte T, Antonelli M, et al. Intensive care unit patients with lower respiratory tract nosocomial infections: the ENIRRIs project. ERJ open research. 2017;3(4).

27. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Journal of clinical epidemiology. 2009;62(10):1006-12.

28. Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. Jama. 2000;283(15):2008-12.

29. Wells GA SB OCD, Peterson J, Welch V, Losos M, Tugwell P. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses [Available from: http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp.

30. Newcombe RG. Two-sided confidence intervals for the single proportion: comparison of seven methods. Statistics in medicine. 1998;17(8):857-72.

31. DerSimonian R, Laird N. Meta-analysis in clinical trials revisited. Contemporary clinical trials. 2015;45(Pt A):139-45.

32. Borenstein M, Hedges LV, Higgins JP, Rothstein HR. A basic introduction to fixed-effect and random-effects models for meta-analysis. Research synthesis methods. 2010;1(2):97-111.

33. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ (Clinical research ed). 2003;327(7414):557-60.

34. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Statistics in medicine. 2002;21(11):1539-58.

35. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ (Clinical research ed). 1997;315(7109):629-34.

36. Panityakul T, Bumrungsup C, Knapp G. On estimating residual heterogeneity in random-effects meta-regression: a comparative study. J Stat Theory Appl. 2013;12(3):253.

37. Knapp G, Hartung J. Improved tests for a random effects meta-regression with a single covariate. Statistics in medicine. 2003;22(17):2693-710.

38. Schwarzer G. meta: An R package for meta-analysis. R news. 2007;7(3):40-5.

39. Viechtbauer W. Conducting meta-analyses in R with the metafor package. Journal of statistical software. 2010;36(3).

40. Garg D, Sharma VK, Karnawat B. Association of serum vitamin D with acute lower respiratory infection in Indian children under 5 years: a case control study. International Journal of Contemporary Pediatrics. 2016;3(4):1164-9.

41. Aydemir G, Cekmez F, Kalkan G, Fidanci MK, Kaya G, Karaoglu A, et al. High serum 25hydroxyvitamin D levels are associated with pediatric sepsis. The Tohoku journal of experimental medicine. 2014;234(4):295-8.

42. Gamal TS, Madiha AS, Hanan MK, Abdel-Azeem ME, Marian GS. Neonatal and Maternal 25-OH Vitamin D Serum Levels in Neonates with Early-Onset Sepsis. Children (Basel, Switzerland). 2017;4(5).

43. Seliem MS, Abdel Haie OM, Mansour AI, Salama SSME. The relation between vitamin D level and increased risk for early-onset neonatal sepsis in full-term infants. Medical Research Journal. 2016;15(1):16-21.

44. McNally JD, Leis K, Matheson LA, Karuananyake C, Sankaran K, Rosenberg AM. Vitamin D deficiency in young children with severe acute lower respiratory infection. Pediatric pulmonology. 2009;44(10):981-8.

45. McNally JD, Doherty DR, Lawson ML, Al-Dirbashi OY, Chakraborty P, Ramsay T, et al. The relationship between vitamin D status and adrenal insufficiency in critically ill children. The Journal of clinical endocrinology and metabolism. 2013;98(5):E877-81.

46. McNally JD, Iliriani K, Pojsupap S, Sampson M, O'Hearn K, McIntyre L, et al. Rapid normalization of vitamin D levels: a meta-analysis. Pediatrics. 2015;135(1):e152-66.

47. McNally JD, Menon K, Chakraborty P, Fisher L, Williams KA, Al-Dirbashi OY, et al. The association of vitamin D status with pediatric critical illness. Pediatrics. 2012;130(3):429-36.

48. Karatekin G, Kaya A, Salihoglu O, Balci H, Nuhoglu A. Association of subclinical vitamin D deficiency in newborns with acute lower respiratory infection and their mothers. European journal of clinical nutrition. 2009;63(4):473-7.

49. Madden K, Feldman HA, Smith EM, Gordon CM, Keisling SM, Sullivan RM, et al. Vitamin D deficiency in critically ill children. Pediatrics. 2012;130(3):421-8.

50. Shah SK, Kabra SK, Gupta N, Pai G, Lodha R. Vitamin D Deficiency and Parathyroid Response in Critically-ill Children: Association with Illness Severity and Clinical Outcomes. Indian pediatrics. 2016;53(6):479-84.

51. Sankar J, Lotha W, Ismail J, Anubhuti C, Meena RS, Sankar MJ. Vitamin D deficiency and length of pediatric intensive care unit stay: a prospective observational study. Annals of intensive care. 2016;6(1):3.

52. Dayal D, Kumar S, Sachdeva N, Kumar R, Singh M, Singhi S. Fall in Vitamin D Levels during Hospitalization in Children. International journal of pediatrics. 2014;2014:291856.

53. Prasad S, Raj D, Warsi S, Chowdhary S. Vitamin D Deficiency and Critical Illness. Indian journal of pediatrics. 2015;82(11):991-5.

54. Wayse V, Yousafzai A, Mogale K, Filteau S. Association of subclinical vitamin D deficiency with severe acute lower respiratory infection in Indian children under 5 y. European journal of clinical nutrition. 2004;58(4):563-7.

55. Ebenezer K, Job V, Antonisamy B, Dawodu A, Manivachagan MN, Steinhoff M. Serum Vitamin D Status and Outcome among Critically III Children Admitted to the Pediatric Intensive Care Unit in South India. Indian journal of pediatrics. 2016;83(2):120-5.

56. Narang GS, Arora S, Kukreja S. Association of Vitamin D Deficiency with Acute Lower Respiratory Infection in Toddlers. Journal of Nepal Paediatric Society. 2016;36(1):14-6.

57. Jat KR, Kaur J, Guglani V. Vitamin D and Pneumonia in Children: A Case Control Study. J Pulm Med Respir Res. 2016;2(004).

58. Sankar J, Ismail J, Das R, Dev N, Chitkara A, Sankar MJ. Effect of Severe Vitamin D Deficiency at Admission on Shock Reversal in Children With Septic Shock. Journal of intensive care medicine. 2017:885066617699802.

Page 27 of 77

BMJ Open

59. Asilioglu N, Cigdem H, Paksu MS. Serum Vitamin D Status and Outcome in Critically III Children. Indian journal of critical care medicine : peer-reviewed, official publication of Indian Society of Critical Care Medicine. 2017;21(10):660-4.

60. Say B, Uras N, Sahin S, Degirmencioglu H, Oguz SS, Canpolat FE. Effects of cord blood vitamin D levels on the risk of neonatal sepsis in premature infants. Korean journal of pediatrics. 2017;60(8):248-53.

61. Cayir A, Turan MI, Ozkan O, Cayir Y. Vitamin D levels in children diagnosed with acute otitis media. JPMA The Journal of the Pakistan Medical Association. 2014;64(11):1274-7.

62. Cetinkaya M, Cekmez F, Buyukkale G, Erener-Ercan T, Demir F, Tunc T, et al. Lower vitamin D levels are associated with increased risk of early-onset neonatal sepsis in term infants. Journal of Perinatology. 2015;35(1):39.

63. Cizmeci MN, Kanburoglu MK, Akelma AZ, Ayyildiz A, Kutukoglu I, Malli DD, et al. Cord-blood 25hydroxyvitamin D levels and risk of early-onset neonatal sepsis: a case-control study from a tertiary care center in Turkey. European journal of pediatrics. 2015;174(6):809-15.

64. Dinlen N, Zenciroglu A, Beken S, Dursun A, Dilli D, Okumus N. Association of vitamin D deficiency with acute lower respiratory tract infections in newborns. The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstet. 2016;29(6):928-32.

65. Onwuneme C, Martin F, McCarthy R, Carroll A, Segurado R, Murphy J, et al. The Association of Vitamin D Status with Acute Respiratory Morbidity in Preterm Infants. The Journal of pediatrics. 2015;166(5):1175-80.e1.

66. Roth DE, Jones AB, Prosser C, Robinson JL, Vohra S. Vitamin D status is not associated with the risk of hospitalization for acute bronchiolitis in early childhood. European journal of clinical nutrition. 2009;63(2):297-9.

67. Cebey-Lopez M, Pardo-Seco J, Gomez-Carballa A, Martinon-Torres N, Rivero-Calle I, Justicia A, et al. Role of Vitamin D in Hospitalized Children With Lower Tract Acute Respiratory Infections. Journal of pediatric gastroenterology and nutrition. 2016;62(3):479-85.

68. García-Soler P, Morales-Martínez A, Rosa-Camacho V, Lillo-Muñoz JA, Milano-Manso G. Vitamin D deficiency and morbimortality in critically ill paediatric patients. Anales de Pediatría (English Edition). 2017;87(2):95-103.

69. Rippel C, South M, Butt WW, Shekerdemian LS. Vitamin D status in critically ill children. Intensive care medicine. 2012;38(12):2055-62.

70. Alonso MA, Pallavicini ZF, Rodriguez J, Avello N, Martinez-Camblor P, Santos F. Can vitamin D status be assessed by serum 25OHD in children? Pediatric nephrology (Berlin, Germany). 2015;30(2):327-32.

71. Ayulo M, Jr., Katyal C, Agarwal C, Sweberg T, Rastogi D, Markowitz M, et al. The prevalence of vitamin D deficiency and its relationship with disease severity in an urban pediatric critical care unit. Endocrine regulations. 2014;48(2):69-76.

72. Rey C, Sanchez-Arango D, Lopez-Herce J, Martinez-Camblor P, Garcia-Hernandez I, Prieto B, et al. Vitamin D deficiency at pediatric intensive care admission. Jornal de pediatria. 2014;90(2):135-42.

73. Onwuneme C, Carroll A, Doherty D, Bruell H, Segurado R, Kilbane M, et al. Inadequate vitamin D levels are associated with culture positive sepsis and poor outcomes in paediatric intensive care. Acta paediatrica (Oslo, Norway : 1992). 2015;104(10):e433-8.

74. Jia K-P, Zhao L-F, Feng N, Ma K, Li Y-X. Lower level of vitamin D3 is associated with susceptibility to acute lower respiratory tract infection (ALRTI) and severity: a hospital based study in Chinese infants. INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE. 2017;10(5):7997-8003.

75. Halwany AS, Deghady AAE, Moustafa AAA, Diab AEM. Study of Serum Vitamin D Level among Critically III Patients Admitted to Alexandria University Pediatric Intensive Care Unit. 2017.

76. Bustos R, Rodriguez-Nunez I, Peña RZ, Soto GG. Vitamin D deficiency in children admitted to the paediatric intensive care unit. Revista chilena de pediatria. 2016;87(6):480-6.

77. El-Gamasy M, Eldeeb M, Abdelmageed M. Prognostic Value of Vitamin D Status in Pediatric Patients with Acute Kidney Injury in Tanta University Emergency Hospital, Egypt. J Emerg Intern Med. 2017;1(1):5.

78. Elmoneim A, Rhill R, Rahalli M, Al-Rahalli M, Alrehally A, Alrohily S. Vitamin D level in pediatric intensive care unit (PICU) patients: its relation to severity of illness. Pediat Therapeut. 2016;6(293):2161-0665.1000293.

79. Korwutthikulrangsri M, Mahachoklertwattana P, Lertbunrian R, Chailurkit LO, Poomthavorn P. Vitamin D deficiency and adrenal function in critically ill children. Journal of the Medical Association of Thailand = Chotmaihet thangphaet. 2015;98(4):365-72.


80. Badawi NES, Algebaly HAF, El Sayed R, Zeid ESA. Vitamin D deficiency in critically ill children. Kasr Al Ainy Medical Journal. 2017;23(1):6.

81. McNally JD, Nama N, O'Hearn K, Sampson M, Amrein K, Iliriani K, et al. Vitamin D deficiency in critically ill children: a systematic review and meta-analysis. Critical care (London, England). 2017;21(1):287.

82. Randolph AG, McCulloh RJ. Pediatric sepsis: important considerations for diagnosing and managing severe infections in infants, children, and adolescents. Virulence. 2014;5(1):179-89.

83. Vincent JL. The Clinical Challenge of Sepsis Identification and Monitoring. PLoS medicine. 2016;13(5):e1002022.

84. Mathias B, Mira JC, Larson SD. Pediatric sepsis. Current opinion in pediatrics. 2016;28(3):380-7.



	Study case control Rey 2014 Pornarmeni 2016 Onvuneme 2015 (1) Ja 2017 Say 2017 Sakka 2014 Cayir 2014 Basha 2014 Wayse 2004 El-Gamasy 2017 Roth 2009 Hebbar 2014 Narang 2016 Cetinkaya 2015 Ahmed 2014 Jat 2016 Cizmeci 2015 Khakshour 2015 Korwutthikulrangsri 201 Elmoneim 2016 Dinlen 2016 Dinlen 2016	17 26	Total (N) 156 124 120 110 100 96 88 81 80 80 80 80 80 80 80 80 80 80		P	0.51 0.59 0.84 0.93 0.57 0.65 0.95 0.32 0.05 0.61 0.56 0.84 0.30 0.84 0.30 0.84 0.70 0.24	95% Cl (0.22: 0.37] (0.42: 0.60) (0.75: 0.93) (0.86: 0.97] (0.54: 0.76) (0.54: 0.76) (0.22: 0.76) (0.23: 0.44] (0.71: 0.73) (0.41: 0.70) (0.71: 0.93) (0.71: 0.93) (0.75: 0.93) (0.75: 0.93)	Weight 2.2% 2.2% 2.1% 2.1% 2.2% 2.2% 2.2% 2.2%
	case control Rey 2014 Ponnarmeni 2016 Orwuneme 2015 (1) Jia 2017 Say 2017 Sakka 2014 Basha 2014 Wayse 2004 El-Gamasy 2017 Roth 2009 Hebbar 2014 Narang 2016 Cetinkaya 2015 Ahmed 2014 Jat 2016 Cizmeci 2015 Khakshour 2016 Dinlen 2016 Dinlen 2016 Dinlen 2016	46 63 71 92 87 89 50 53 76 26 3 37 28 42 42 42 42 42 28 9 9 15 25 17 26	156 124 120 110 96 88 81 80 64 61 50 50 50 50 50 50 50 50 50 50 50 50 50		P	0.29 0.51 0.59 0.84 0.93 0.57 0.65 0.95 0.65 0.61 0.56 0.84 0.30 0.84 0.70 0.24	$\begin{matrix} [0.22; \ 0.37] \\ [0.42; \ 0.60] \\ [0.50; \ 0.68] \\ [0.75; \ 0.90] \\ [0.79; \ 0.93] \\ [0.86; \ 0.97] \\ [0.86; \ 0.97] \\ [0.54; \ 0.76] \\ [0.54; \ 0.76] \\ [0.54; \ 0.76] \\ [0.54; \ 0.76] \\ [0.54; \ 0.76] \\ [0.54; \ 0.76] \\ [0.54; \ 0.76] \\ [0.54; \ 0.76] \\ [0.54; \ 0.76] \\ [0.54; \ 0.76] \\ [0.54; \ 0.76] \\ [0.71; \ 0.93] \\ [0$	2.2% 2.2% 2.1% 2.1% 2.2% 2.2% 1.8% 2.2% 1.8% 2.1% 2.1% 2.1% 2.1% 2.0%
	case control Rey 2014 Ponnarmeni 2016 Orwuneme 2015 (1) Jia 2017 Say 2017 Sakka 2014 Basha 2014 Wayse 2004 El-Gamasy 2017 Roth 2009 Hebbar 2014 Narang 2016 Cetinkaya 2015 Ahmed 2014 Jat 2016 Cizmeci 2015 Khakshour 2016 Dinlen 2016 Dinlen 2016 Dinlen 2016	46 63 71 92 87 89 50 53 76 26 3 37 28 42 42 42 42 42 28 9 9 15 25 17 26	156 124 120 110 96 88 81 80 64 61 50 50 50 50 50 50 50 50 50 50 50 50 50		P 	0.29 0.51 0.59 0.84 0.93 0.57 0.65 0.95 0.65 0.61 0.56 0.84 0.30 0.84 0.70 0.24	$\begin{matrix} [0.22; \ 0.37] \\ [0.42; \ 0.60] \\ [0.50; \ 0.68] \\ [0.75; \ 0.90] \\ [0.79; \ 0.93] \\ [0.86; \ 0.97] \\ [0.86; \ 0.97] \\ [0.54; \ 0.76] \\ [0.54; \ 0.76] \\ [0.54; \ 0.76] \\ [0.54; \ 0.76] \\ [0.54; \ 0.76] \\ [0.54; \ 0.76] \\ [0.54; \ 0.76] \\ [0.54; \ 0.76] \\ [0.54; \ 0.76] \\ [0.54; \ 0.76] \\ [0.54; \ 0.76] \\ [0.71; \ 0.93] \\ [0$	2.2% 2.2% 2.1% 2.1% 2.2% 2.2% 1.8% 2.2% 1.8% 2.1% 2.1% 2.1% 2.1% 2.0%
	case control Rey 2014 Ponnarmeni 2016 Orwuneme 2015 (1) Jia 2017 Say 2017 Sakka 2014 Basha 2014 Wayse 2004 El-Gamasy 2017 Roth 2009 Hebbar 2014 Narang 2016 Cetinkaya 2015 Ahmed 2014 Jat 2016 Cizmeci 2015 Khakshour 2016 Dinlen 2016 Dinlen 2016 Dinlen 2016	46 63 71 92 87 89 50 53 76 26 3 37 28 42 42 42 42 42 28 9 9 15 25 17 26	156 124 120 110 96 88 81 80 64 61 50 50 50 50 50 50 50 50 50 50 50 50 50		P 	0.29 0.51 0.59 0.84 0.93 0.57 0.65 0.95 0.65 0.61 0.56 0.84 0.30 0.84 0.70 0.24	$\begin{matrix} [0.22; \ 0.37] \\ [0.42; \ 0.60] \\ [0.50; \ 0.68] \\ [0.75; \ 0.90] \\ [0.79; \ 0.93] \\ [0.86; \ 0.97] \\ [0.86; \ 0.97] \\ [0.54; \ 0.76] \\ [0.54; \ 0.76] \\ [0.54; \ 0.76] \\ [0.54; \ 0.76] \\ [0.54; \ 0.76] \\ [0.54; \ 0.76] \\ [0.54; \ 0.76] \\ [0.54; \ 0.76] \\ [0.54; \ 0.76] \\ [0.54; \ 0.76] \\ [0.54; \ 0.76] \\ [0.71; \ 0.93] \\ [0$	2.2% 2.2% 2.1% 2.1% 2.2% 2.2% 1.8% 2.2% 1.8% 2.1% 2.1% 2.1% 2.1% 2.0%
	case control Rey 2014 Ponnarmeni 2016 Orwuneme 2015 (1) Jia 2017 Say 2017 Sakka 2014 Basha 2014 Wayse 2004 El-Gamasy 2017 Roth 2009 Hebbar 2014 Narang 2016 Cetinkaya 2015 Ahmed 2014 Jat 2016 Cizmeci 2015 Khakshour 2016 Dinlen 2016 Dinlen 2016 Dinlen 2016	46 63 71 92 87 89 50 53 76 26 3 37 28 42 42 42 42 42 28 9 9 15 25 17 26	156 124 120 110 96 88 81 80 64 61 50 50 50 50 50 50 50 50 50 50 50 50 50		, 	0.29 0.51 0.59 0.84 0.93 0.57 0.65 0.95 0.65 0.61 0.56 0.84 0.30 0.84 0.70 0.24	$\begin{matrix} [0.22; \ 0.37] \\ [0.42; \ 0.60] \\ [0.50; \ 0.68] \\ [0.75; \ 0.90] \\ [0.79; \ 0.93] \\ [0.86; \ 0.97] \\ [0.86; \ 0.97] \\ [0.54; \ 0.76] \\ [0.54; \ 0.76] \\ [0.54; \ 0.76] \\ [0.54; \ 0.76] \\ [0.54; \ 0.76] \\ [0.54; \ 0.76] \\ [0.54; \ 0.76] \\ [0.54; \ 0.76] \\ [0.54; \ 0.76] \\ [0.54; \ 0.76] \\ [0.54; \ 0.76] \\ [0.71; \ 0.93] \\ [0$	2.2% 2.2% 2.1% 2.1% 2.2% 2.2% 1.8% 2.2% 1.8% 2.1% 2.1% 2.1% 2.1% 2.0%
	case control Rey 2014 Ponnarmeni 2016 Orwuneme 2015 (1) Jia 2017 Say 2017 Sakka 2014 Basha 2014 Wayse 2004 El-Gamasy 2017 Roth 2009 Hebbar 2014 Narang 2016 Cetinkaya 2015 Ahmed 2014 Jat 2016 Cizmeci 2015 Khakshour 2016 Dinlen 2016 Dinlen 2016 Dinlen 2016	46 63 71 92 87 89 50 53 76 26 3 37 28 42 42 42 42 42 28 9 9 15 25 17 26	156 124 120 110 96 88 81 80 64 61 50 50 50 50 50 50 50 50 50 50 50 50 50		, 	0.29 0.51 0.59 0.84 0.93 0.57 0.65 0.95 0.65 0.61 0.56 0.84 0.30 0.84 0.70 0.24	$\begin{matrix} [0.22; \ 0.37] \\ [0.42; \ 0.60] \\ [0.50; \ 0.68] \\ [0.75; \ 0.90] \\ [0.79; \ 0.93] \\ [0.86; \ 0.97] \\ [0.86; \ 0.97] \\ [0.54; \ 0.76] \\ [0.54; \ 0.76] \\ [0.54; \ 0.76] \\ [0.54; \ 0.76] \\ [0.54; \ 0.76] \\ [0.54; \ 0.76] \\ [0.54; \ 0.76] \\ [0.54; \ 0.76] \\ [0.54; \ 0.76] \\ [0.54; \ 0.76] \\ [0.54; \ 0.76] \\ [0.71; \ 0.93] \\ [0$	2.2% 2.2% 2.1% 2.1% 2.2% 2.2% 1.8% 2.2% 1.8% 2.1% 2.1% 2.1% 2.1% 2.0%
	case control Rey 2014 Ponnarmeni 2016 Orwuneme 2015 (1) Jia 2017 Say 2017 Sakka 2014 Basha 2014 Wayse 2004 El-Gamasy 2017 Roth 2009 Hebbar 2014 Narang 2016 Cetinkaya 2015 Ahmed 2014 Jat 2016 Cizmeci 2015 Khakshour 2016 Dinlen 2016 Dinlen 2016 Dinlen 2016	46 63 71 92 87 89 50 53 76 26 3 37 28 42 42 42 42 42 28 9 9 15 25 17 26	156 124 120 110 96 88 81 80 64 61 50 50 50 50 50 50 50 50 50 50 50 50 50		P 	0.29 0.51 0.59 0.84 0.93 0.57 0.65 0.95 0.65 0.61 0.56 0.84 0.30 0.84 0.70 0.24	$\begin{matrix} [0.22; \ 0.37] \\ [0.42; \ 0.60] \\ [0.50; \ 0.68] \\ [0.75; \ 0.90] \\ [0.79; \ 0.93] \\ [0.86; \ 0.97] \\ [0.86; \ 0.97] \\ [0.54; \ 0.76] \\ [0.54; \ 0.76] \\ [0.54; \ 0.76] \\ [0.54; \ 0.76] \\ [0.54; \ 0.76] \\ [0.54; \ 0.76] \\ [0.54; \ 0.76] \\ [0.54; \ 0.76] \\ [0.54; \ 0.76] \\ [0.54; \ 0.76] \\ [0.54; \ 0.76] \\ [0.71; \ 0.93] \\ [0$	2.2% 2.2% 2.1% 2.1% 2.2% 2.2% 1.8% 2.2% 1.8% 2.1% 2.1% 2.1% 2.1% 2.0%
	case control Rey 2014 Ponnarmeni 2016 Orwuneme 2015 (1) Jia 2017 Say 2017 Sakka 2014 Basha 2014 Wayse 2004 El-Gamasy 2017 Roth 2009 Hebbar 2014 Narang 2016 Cetinkaya 2015 Ahmed 2014 Jat 2016 Cizmeci 2015 Khakshour 2016 Dinlen 2016 Dinlen 2016 Dinlen 2016	46 63 71 92 87 89 50 53 76 26 3 37 28 42 42 42 42 42 28 9 9 15 25 17 26	156 124 120 110 96 88 81 80 64 61 50 50 50 50 50 50 50 50 50 50 50 50 50		P	0.29 0.51 0.59 0.84 0.93 0.57 0.65 0.95 0.65 0.61 0.56 0.84 0.30 0.84 0.70 0.24	$\begin{matrix} [0.22; \ 0.37] \\ [0.42; \ 0.60] \\ [0.50; \ 0.68] \\ [0.75; \ 0.90] \\ [0.79; \ 0.93] \\ [0.86; \ 0.97] \\ [0.86; \ 0.97] \\ [0.54; \ 0.76] \\ [0.54; \ 0.76] \\ [0.54; \ 0.76] \\ [0.54; \ 0.76] \\ [0.54; \ 0.76] \\ [0.54; \ 0.76] \\ [0.54; \ 0.76] \\ [0.54; \ 0.76] \\ [0.54; \ 0.76] \\ [0.54; \ 0.76] \\ [0.54; \ 0.76] \\ [0.71; \ 0.93] \\ [0$	2.2% 2.2% 2.1% 2.1% 2.2% 2.2% 1.8% 2.2% 1.8% 2.1% 2.1% 2.1% 2.1% 2.0%
	case control Rey 2014 Ponnarmeni 2016 Orwuneme 2015 (1) Jia 2017 Say 2017 Sakka 2014 Basha 2014 Wayse 2004 El-Gamasy 2017 Roth 2009 Hebbar 2014 Narang 2016 Cetinkaya 2015 Ahmed 2014 Jat 2016 Cizmeci 2015 Khakshour 2016 Dinlen 2016 Dinlen 2016 Dinlen 2016	46 63 71 92 87 89 50 53 76 26 3 37 28 42 42 42 42 42 28 9 9 15 25 17 26	156 124 120 110 96 88 81 80 64 61 50 50 50 50 50 50 50 50 50 50 50 50 50		P 	0.29 0.51 0.59 0.84 0.93 0.57 0.65 0.95 0.65 0.61 0.56 0.84 0.30 0.84 0.70 0.24	$\begin{matrix} [0.22; \ 0.37] \\ [0.42; \ 0.60] \\ [0.50; \ 0.68] \\ [0.75; \ 0.90] \\ [0.79; \ 0.93] \\ [0.86; \ 0.97] \\ [0.86; \ 0.97] \\ [0.54; \ 0.76] \\ [0.54; \ 0.76] \\ [0.54; \ 0.76] \\ [0.54; \ 0.76] \\ [0.54; \ 0.76] \\ [0.54; \ 0.76] \\ [0.54; \ 0.76] \\ [0.54; \ 0.76] \\ [0.54; \ 0.76] \\ [0.54; \ 0.76] \\ [0.54; \ 0.76] \\ [0.71; \ 0.93] \\ [0$	2.2% 2.2% 2.1% 2.1% 2.2% 2.2% 1.8% 2.2% 1.8% 2.1% 2.1% 2.1% 2.1% 2.0%
	case control Rey 2014 Ponnarmeni 2016 Orwuneme 2015 (1) Jia 2017 Say 2017 Sakka 2014 Basha 2014 Wayse 2004 El-Gamasy 2017 Roth 2009 Hebbar 2014 Narang 2016 Cetinkaya 2015 Ahmed 2014 Jat 2016 Cizmeci 2015 Khakshour 2016 Dinlen 2016 Dinlen 2016 Dinlen 2016	46 63 71 92 87 89 50 53 76 26 3 37 28 42 42 42 42 42 28 9 9 15 25 17 26	156 124 120 110 96 88 81 80 64 61 50 50 50 50 50 50 50 50 50 50 50 50 50			0.29 0.51 0.59 0.84 0.93 0.57 0.65 0.95 0.65 0.61 0.56 0.84 0.30 0.84 0.70 0.24	$\begin{matrix} [0.22; \ 0.37] \\ [0.42; \ 0.60] \\ [0.50; \ 0.68] \\ [0.75; \ 0.90] \\ [0.79; \ 0.93] \\ [0.86; \ 0.97] \\ [0.86; \ 0.97] \\ [0.54; \ 0.76] \\ [0.54; \ 0.76] \\ [0.54; \ 0.76] \\ [0.54; \ 0.76] \\ [0.54; \ 0.76] \\ [0.54; \ 0.76] \\ [0.54; \ 0.76] \\ [0.54; \ 0.76] \\ [0.54; \ 0.76] \\ [0.54; \ 0.76] \\ [0.54; \ 0.76] \\ [0.71; \ 0.93] \\ [0$	2.2% 2.2% 2.1% 2.1% 2.2% 2.2% 1.8% 2.2% 1.8% 2.1% 2.1% 2.1% 2.1% 2.0%
	Rey 2014 Ponnarmeni 2016 Onwuneme 2015 (1) Jia 2017 Say 2017 Sakka 2014 Cayir 2014 Basha 2014 Wayse 2004 El-Gamasy 2017 Roth 2009 Hebbar 2014 Narang 2016 Cetinkaya 2015 Ahmed 2014 Jat 2016 Cizmeci 2015 Khakshour 2015 Korwutthikulrangsri 201 Elmoneim 2016 Dinlen 2016	63 71 92 87 89 50 53 76 26 3 7 28 42 15 42 15 42 8 9 9 15 25 17 26	124 120 110 96 88 81 80 80 64 61 50 50 50 50 50 40 37 32 30		** - *	0.51 0.59 0.84 0.87 0.65 0.95 0.65 0.95 0.61 0.56 0.84 0.30 0.84 0.30 0.84 0.70 0.24	$ \begin{bmatrix} 0.42, 0.60 \\ 0.50; 0.68 \\ 0.75; 0.90 \\ 0.76; 0.90 \\ 0.76; 0.91 \\ 0.86; 0.97 \\ 0.46; 0.67 \\ 0.46; 0.67 \\ 0.88; 0.99 \\ 0.22; 0.44 \\ 0.01; 0.13 \\ 0.47; 0.73 \\ 0.47; 0.73 \\ 0.41; 0.70 \\ 0.71; 0.93 \\ 0.71; 0.93 \\ 0.71; 0.93 \\ \end{bmatrix} $	2.2% 2.2% 2.1% 2.0% 2.2% 2.2% 1.8% 2.2% 1.8% 2.1% 2.1% 2.0% 2.1% 2.0%
	Onwuneme 2015 (1) Jia 2017 Say 2017 Sakka 2014 Cayir 2014 Wayas 2004 El-Gamasy 2017 Roth 2009 Hebbar 2014 Narang 2016 Cetinkaya 2015 Ahmed 2014 Jat 2016 Cizmeci 2015 Khakshour 2015 Khakshour 2016 Dinlen 2016 Dinlen 2016 Dinlen 2016	71 92 87 89 50 53 76 26 26 28 42 42 42 42 42 28 9 9 15 25 17 26	120 110 96 88 81 80 64 50 50 50 50 50 40 37 32 30		** - * - *	0.59 0.84 0.87 0.93 0.57 0.65 0.95 0.32 0.05 0.61 0.56 0.84 0.30 0.84 0.30 0.84 0.70 0.24	[0.50; 0.68] [0.75; 0.90] [0.78; 0.93] [0.86; 0.97] [0.46; 0.67] [0.86; 0.99] [0.22; 0.44] [0.81; 0.76] [0.47; 0.73] [0.41; 0.70] [0.41; 0.70] [0.71; 0.93]	2.2% 2.1% 2.0% 2.2% 2.2% 1.8% 2.2% 1.6% 2.1% 2.1% 2.0% 2.1% 2.0%
	Say 2017 Sakka 2014 Cayir 2014 Basha 2014 Wayse 2004 El-Garnasy 2017 Roth 2009 Hebbar 2014 Narang 2016 Cetinkaya 2015 Ahmed 2014 Jat 2016 Cizmeci 2015 Khakshour 2015 Korwuttinikulrangsri 201 Elmoneim 2016 Dinlen 2016	87 89 50 53 76 26 37 28 42 42 42 42 42 42 42 45 45 45 45 15 45 25 17 26	100 96 88 81 80 61 50 50 50 50 50 40 37 32 30		- - -	0.87 0.93 0.57 0.65 0.95 0.32 0.05 0.61 0.56 0.84 0.30 0.84 0.30 0.84 0.70 0.24	$\begin{matrix} [0.79; 0.93]\\ [0.86; 0.97]\\ [0.46; 0.67]\\ [0.54; 0.76]\\ [0.58; 0.99]\\ [0.22; 0.44]\\ [0.01; 0.13]\\ [0.47; 0.73]\\ [0.41; 0.70]\\ [0.71; 0.93]\\ [0.71; 0.93] \end{matrix}$	2.1% 2.0% 2.2% 2.2% 1.8% 2.2% 1.6% 2.1% 2.1% 2.0% 2.1% 2.0%
	Cayir 2014 Basha 2014 Wayse 2004 El-Gamasy 2017 Roth 2009 Hebbar 2014 Narang 2016 Cetinkaya 2015 Ahmed 2014 Jat 2016 Cizmeci 2015 Khakshour 2015 Korwutthikulrangsri 201 Elmoneim 2016 Dinlen 2016 Moreno-Solis 2015	50 53 76 26 3 3 7 28 42 42 42 42 42 42 42 45 5 42 28 9 9 15 25 17 26	88 80 64 61 50 50 50 50 40 37 32 30			0.57 0.65 0.95 0.32 0.05 0.61 0.56 0.84 0.30 0.84 0.70 0.24	[0.46; 0.67] [0.54; 0.76] [0.88; 0.99] [0.22; 0.44] [0.01; 0.13] [0.47; 0.73] [0.41; 0.70] [0.71; 0.93] [0.18; 0.45] [0.71; 0.93]	2.2% 2.2% 1.8% 2.2% 1.6% 2.1% 2.1% 2.0% 2.1% 2.0%
	Wayse 2004 EI-Gamasy 2017 Roth 2009 Hebbar 2014 Narang 2016 Cetinkaya 2015 Ahmed 2014 Jat 2016 Cizmeci 2015 Khakshour 2015 Korwutthikulrangsri 201 Elmoneim 2016 Dinlen 2016 Moreno-Solis 2015	76 26 3 37 28 42 15 42 28 9 9 15 25 17 26	80 64 61 50 50 50 40 37 32 30			0.95 0.32 0.05 0.61 0.56 0.84 0.30 0.84 0.70 0.24	[0.88; 0.99] [0.22; 0.44] [0.01; 0.13] [0.47; 0.73] [0.41; 0.70] [0.71; 0.93] [0.18; 0.45] [0.71; 0.93]	1.8% 2.2% 1.6% 2.1% 2.1% 2.0% 2.1% 2.0%
	Roth 2009 Hebbar 2014 Narang 2016 Cetinkaya 2015 Ahmed 2014 Jat 2016 Cizmeci 2015 Knakshour 2015 Korwutthikulrangsri 201 Elmoneim 2016 Dinlen 2016 Moreno-Solis 2015	3 37 28 42 15 42 28 9 15 25 17 26	64 + 61 50 50 50 40 37 32 30	<u>-</u>	-	0.05 0.61 0.56 0.84 0.30 0.84 0.70 0.24	[0.01; 0.13] [0.47; 0.73] [0.41; 0.70] [0.71; 0.93] [0.18; 0.45] [0.71; 0.93]	1.6% 2.1% 2.0% 2.1% 2.0%
	Narang 2016 Cetinkaya 2015 Ahmed 2014 Jat 2016 Cizmeci 2015 Khakshour 2015 Konwuthikulrangsri 201 Elmoneim 2016 Dinlen 2016 Moreno-Solis 2015	42 15 42 28 9 15 25 17 26	50 50 40 37 32 30			0.56 0.84 0.30 0.84 0.70 0.24	[0.41; 0.70] [0.71; 0.93] [0.18; 0.45] [0.71; 0.93]	2.0% 2.1% 2.0%
	Jat 2016 Cizmeci 2015 Khakshour 2015 Korwutthikulrangsri 201 Elmoneim 2016 Dinlen 2016 Moreno-Solis 2015	42 28 9 15 25 17 26	50 40 37 32 30			0.84 0.70 0.24	[0.71; 0.93]	2.0%
	Khakshour 2015 Korwuthikulrangsri 201 Elmoneim 2016 Dinlen 2016 Moreno-Solis 2015	9 15 25 17 26	37 32 30		-	0.24	0.53; 0.831	
	Elmoneim 2016 Dinlen 2016 Moreno-Solis 2015	17 26	30			0 70	[0.12; 0.41]	2.0% 2.0%
	Moreno-Solis 2015	20				0.57	[0.60; 0.91] [0.37; 0.75] [0.69; 0.96]	1.9% 2.0% 1.7%
	Karatekin 2009	9 23	48 - 25	-		0.19	[0.09; 0.33] [0.74; 0.99]	2.0%
	Roth 2010 Random effects mode	21	25 1627	_		0.84	[0.64; 0.95] [0.53; 0.74]	1.7% 47.9%
	Heterogeneity: $I^2 = 92.8\%$						[0.00, 0.1.1]	
	cohort Madden 2012	205	511	-		0.40	[0.36; 0.45]	2.3%
	Lopez 2016 Garcia-Soler 2017	84 149	347 340	* +		0.44	[0.20; 0.29] [0.38; 0.49]	2.3% 2.3%
	McNally 2012 Rippel 2012	225 109	326 316		-	0.34	[0.64; 0.74] [0.29; 0.40]	2.3% 2.3%
	Asilioglu 2017 Ayulo 2014 Shah 2016	120 61 128	250 216 154	+ -		0.28	[0.42; 0.54] [0.22; 0.35] [0.76; 0.89]	2.3% 2.3% 2.2%
	Halwany 2017 Sankar 2016	38	102 101		-	0.37	[0.28; 0.47] [0.65; 0.82]	2.2% 2.2%
	Onwuneme2015 (2) Dayal 2014	86 23	94 92			0.91	[0.84; 0.96] [0.17; 0.35]	2.0%
	Bustos 2016 Hurwitz 2017	39 11	90 90 —			0.43	[0.33; 0.54] [0.06; 0.21]	2.2% 2.1%
	Badawi 2017 Prasad 2015	39 67	88 80			0.44 0.84	[0.34; 0.55] [0.74; 0.91]	2.2% 2.1%
	Banajeh 2009 Ebenezer 2016	29 21	79 52		_	0.40	[0.26; 0.48] [0.27; 0.55]	2.2% 2.1%
	Sankar 2017 Inamo 2011	31 8	43 28 3399		*	0.29	[0.56; 0.85] [0.13; 0.49] [0.40; 0.57]	2.0% 1.9% 43.5%
	Random effects mode Heterogeneity: $l^2 = 95.5\%$	$p_{1}^{2} = 0.6120, p < 0.01$	2222			0.48	[0.40; 0.57]	43.3%
	cross_sectional Alonso 2015	45	288	-		0.16	[0.12; 0.20]	2.2%
	Yaghmaie 2017 Binks 2014	53 11	82 74 -			0.65	[0.53; 0.75] [0.08; 0.25]	2.2%
	Alvarez 2016 Random effects mode	29 el	50 494		-	0.58	[0.43; 0.72] [0.13; 0.66]	2.1% 8.6%
	Heterogeneity: $I^2 = 96.7\%$	$_{b}, \tau^{2} = 1.6695, p < 0.01$						
	Random effects mode Heterogeneity: / ² = 95.0%		5520			0.55	[0.48; 0.62]	100.0%
				0.2 0.4 0.6	0.8			
Fig								

Figure 2 Pooled prevalence estimate for vitamin D deficiency in critically ill children by study design. Forest plot shows results from the random effects model. Each diamond represents the pooled proportion of vitamin D deficiency for each of the subgroups (case-control, cohort, cross-sectional study designs). The diamond at the bottom represents the overall pooled proportion of all the 48 studies together. Each square shows the prevalence estimate of each study and the horizontal line across each square represents the 95% confidence interval (CI) of the prevalence estimate.

203x254mm (300 x 300 DPI)





Figure 3 Bubble plots of univariate meta-regressions. Each study is represented by a circle. Predictor variables; A clinical setting and B country groups are shown on the x-axis and the effect measure logit transformed proportion shown on the vertical (y-axis). NICU = Neonatal Intensive Care Unit; PICU = Pediatric Intensive Care Unit; grp = country group; country group 1 = USA, Chile, Australia, Canada, Ireland, Japan, Spain; country group 2 = South Africa, China, Egypt, Iran, Turkey, Saudi Arabia; and country group 3 = Bangladesh, Thailand, and India

203x127mm (300 x 300 DPI)






Figure 4 Pooled prevalence estimate for vitamin D deficiency in critically ill children with sepsis. Forest plot shows result from the random effects model. The diamond represents the overall pooled proportion of vitamin D deficiency from the meta-analysis of the 16 studies. Each square shows the prevalence estimate of each study and the horizontal line across each square represents the 95% confidence interval (CI) of the prevalence estimate.

254x152mm (300 x 300 DPI)




Figure 5 Pooled odds ratio (OR) of risk of mortality in vitamin D deficient versus vitamin D non-deficient critically ill children. Forest plot shows result from the random effects model. Diamond represents the overall OR (with corresponding 95% Confidence Interval). Each square shows the odds ratio of each study and the horizontal line across each square represents the 95% confidence interval (CI) of the estimate.

203x127mm (300 x 300 DPI)

Supplementary Material

Section/topic	# Checklist item				
TITLE		·			
Title	1	Identify the report as a systematic review, meta-analysis, or both.	1		
ABSTRACT					
Structured summary	2	Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.			
INTRODUCTION					
Rationale	3	Describe the rationale for the review in the context of what is already known.	5-6		
Objectives	4	Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).	6-8		
METHODS					
Protocol and registration	5	Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.	10		
Eligibility criteria	6	Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.			
Information sources	7	Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.			
Search	8	Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.			
Study selection	9	State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).	7-9		
Data collection process	10	Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.	7		
Data items	11	List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.			
Risk of bias in individual studies	12	Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.			
Summary measures	13	State the principal summary measures (e.g., risk ratio, difference in means).	8		
Synthesis of results	14	Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I ²) for each meta-analysis.			

1 2 3
4 5 6 7
6 7 8 9 10 11 12
13 14 15
16 17 18 19 20
20 21 22 23 24 25 26 27 28 29
25 26 27 28
29 30 31 32 33
33 34 35 36 37
37 38 39 40 41
42 43 44 45
46 47 48 49
50 51 52 53
54 55 56 57
58 59 60

Section/topic	#	Checklist item	Reported on page #		
Risk of bias across studies	15	Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).	8		
Additional analyses	16	16 Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta- regression), if done, indicating which were pre-specified.			
RESULTS					
Study selection 17 Give numbers of studies screened, assessed for eligibility, and included in the review with reasons for exclusions at each stage, ideally with a flow diagram.			10		
Study characteristics	18	For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.			
Risk of bias within studies	19	Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).	5-7 (supplementary material)		
Results of individual studies	20	For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.	13,15,18 and supplementary material		
Synthesis of results	21	Present results of each meta-analysis done, including confidence intervals and measures of consistency.	13 and supplementary material pages 32-36		
Risk of bias across studies	22	Present results of any assessment of risk of bias across studies (see Item 15).	5-7 (supplementary material)		
Additional analysis	23	Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).	supplementary material pages 32-36		
DISCUSSION					
Summary of evidence	nmary of 24 Summarize the main findings including the strength of evidence for each main		19-21		
Limitations	25	Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).	20-22		
Conclusions	26	Provide a general interpretation of the results in the context of other evidence, and implications for future research.	22		
FUNDING					
Funding	27	Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.	22		

2
3
4
5
6
0
/
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
30 39
40
41
42
43
44
45
46
48
49
50
51
52
53
55 54
55
56
57
58

Additio	nal Table 2A Search terms used in OVID
Additio	Vitamin D
2.	
	Sepsis or septic shock
<u>3.</u> 4.	Vitamin D or cholecalciferol* or ergocalciferol or 25-hydroxyvitamin D or calcidiol or calcitriol Intensive care unit* or critical care
<u>4.</u> 5.	intensive care unit, or critical care
<u> </u>	Multiple organ dysfunction syndrome or multiple organ failure
7.	(1 and 2) or 5
8.	((1 or 3) and 2 or 4
9.	(1 or 3) and 2
-	(1 or 3) and 4
	(1 or 3) and 5
	Sepsis
13.	
14.	
15.	(2 or 8) and 3
16.	critical* ill or acute condition* or intensive care unit
17.	child* or pediatric*
18.	vitamin D or cholecalciferol or ergocalciferol or 25-hydroxyvitamin D or calcidiol or calcitriol
	15 and 16 and 17
20.	Vitamin D blood levels or 25-hydroxyvitamin
21.	5 and 3 and 15 and 16
	2 and 15 and 16 and 17
	16 and 2
	16 and 2 and 3
	Pediatric*
	Pediatric* and 5 and 2
27.	24 and 3 and 15

Term se	onal Table 2B Search terms used in PubMed earched
1.	Vitamin D.mp.
2.	(sepsis or septic shock).mp.
3.	(vitamin D or cholecalciferol* or ergocalciferol or 25-hydroxyvitamin D or calcidiol or calcitriol).mp.
4.	(intensive care unit* or critical care).mp.
5.	(multi* organ dysfunction syndrome or multiple organ failure).mp.
6.	(critical* ill or acute condition* or intensive care unit).mp.
7.	(toddler or infant or child* or neonate* or baby or teenager or pediatric* or paediatric*).mp.
8.	3 and 6 and 2 and 7
	(critical" il or acute condition" or intensive care unity.mp. (toddler or infant or child* or neonate* or baby or teenager or pediatric* or paediatric*).mp. 3 and 6 and 2 and 7

iven	presentat		Selection		Comparability Outcome				
	ness of e exposed lort	Selection of the non-exposed cohort	Ascertainment of exposure	Demonstration that outcome of interest was not present at the start of the study	Comparability of cohorts on the basis of the design or analysis (maximum 2 stars)	Assessment of outcome	Was follow-up long enough for outcome to occur (≥28 days after admission to the ICU)	Adequacy of follow up of cohorts	Number of stars (out of total)
Ebenezer 2016 1		1	1	1	0	1	0	1	6
Sankar 2016 1		1	1	1	2	1	0	1	8
Rippel 2012 1		1	1	1	1	1	1	1	8
Madden 2012 1		1	1	1	2	1	0	1	8
McNally 2012 1		1	1	0	1	1	1	1	7
Dayal 2014 1		1	1	1	0	1	0	1	6
Ayulo 2014 1		1		1	2	1	0	0	7
Bustos 2016 1		1	1	0	2	1	0	1	7
Prasad 2015 1		1	1	0	2	1	0	1	7
Onwuneme 1 2015 (2)		1	1		2	1	0	1	8
Inamo 2011 1		1	1	0	1	1	0	1	6
Shah 2016 1		1	1	1	0	1	0	1	6
Lopez 2016 1		1	1	1	2	1	0	1	8
Garcia-Soler 1 2017		1	1	1	2	1	0	0	7
Sankar 2017 1		1	1	1	2	1	0	1	8
Asilioglu 2017 1		1	1	1	1	1	0	1	7
Halwany 2017 1		1	1	1		1	0	0	6
Hurwitz 2017 1		1	1	0	1	1	0	1	6
Banajeh 2009 1		1	1	0	1	1	1	1	7
Badawi 2017 1		1	1	1	1	1	1	1	8
<u>http://www.ohri.ca/</u>	programs	<u>semicar epider</u>	<u>Inology/oxiord.as</u>	<u>p</u> .		Ŋ			

Study		SELE	CTION		COMPARABILITY		EXPOSURE		Number of stars
	Is the case definition adequate?	Representati veness of the cases	Selection of controls	Definition of controls	Comparability of cases and controls on the basis of the design or analysis (maximum 2 stars)	Ascertainment of exposure	Same method of ascertainment for cases and controls (yes or no or 0 star if no mention)	Non- response rate	(out of 9 total)
Vayse 2004	1	1	0	0	1	1	1	1	6
Karatekin 2009	1	1	0	0	1	1	1	1	6
toth 2009	1	1	0	1	1	1	1	0	7
oth 2010	1	1	1	1	2	1	1	0	8
etinkaya 2015	1	1	0	0	0 2	1	1	1	6
nwuneme 2015 (1) izmeci 2015	1	1	0	0	2 2	1	1	1	8 7
orwutthikulrangsri 015	1	1	0	0	0	1	1	1	5
Imoneim 2016	1	1	0	0	0	1	1	1	5
0016	1	1	0	0	1	1	1	1	6
inlen 2016	1	1	0	0	1	1	1	1	6
	1	1	0	1	2	1	1	1	8
ayir 2014 ay 2017	1	1	0	0	2	1	1	1	7
ay 2017 asha 2014	1	1	0	0	2 2	1	1	0	6 7
a 2017	1	1	0	1	1	1	1	0	7
at 2016	1	1	0	1	2	1	1	1	8
Aoreno-Solis 2015	1	1	0	1	1	1	0	1	6
	1	1		1	2	1	1	1	
Iebbar 2014	1	1	0	0	1	1	1	1	6
Rey 2014	1	1	1	1	1	1	1	1	8
onnarmeni 2016	1	1	0	0	0		1	1	6
El-Gamasy 2017	1	1	1	0	2	1	1	0	7
hakshour 2015	1	1	0	0	1	1	1	0	5
y 2014 nnarmeni 2016 Gamasy 2017 nakshour 2015	1 1 1	1 1 1 1 1 1 for assessing th	1 0 1 0	1 0 0 0	1 0 2		1 1 1 1 1 <u>hri.ca/programs/clinic</u>	0	8 6 7 5
			For peer review	only - http://bm	jopen.bmj.com/site/abou	ıt/guidelines.xhtml			6

1
2

		ELECTION (M	aximum 5 stars)		COMPARABILITY (Maximum 2 stars)	OUTCOME (Maximum 3 stars)		
Study	Representativene ss of the sample	Sample size	Non- respondents	Ascertainment of the exposure (risk factor)	Subjects in different outcome groups are comparable, based on the study design or analysis. Confounding factors are controlled.	Assessment of the outcome (max=2 stars)	Statistical test (max=1 star)	Number of stars (out of 10 total)
Yaghmaie 2017	1	0	0	0	1	1	1	4
lvarez 2016	1	0	0	1	1	2	1	6
Alonso 2015	1	0	0	1	1	1	1	5
inks 2014	1	0	0	1	1 Idies in meta-analyses. Available at:	2	1	6
<u>nttp://www.ohri.ca/p</u>	<u>rograms/clinical_e</u>	pidemiology/c	<u>oxford.asp</u> .	6 ₆ 6				
2 3 4 5 5 7 3 9 9 9 9 9 9 9 1 2 3 4 5 5 5 7 7 3 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9					idies in meta-analyses. Available at:			

Study	Number of cases	25(OH)D categories (as given)	Number of cases in eac category	
Asilioglu 2017	250	Deficiency: <20 ng/mL	120	
e		Sufficiency: >=20 ng/mL	85	
Halwany 2017	102	Deficiency: <20 ng/ml	38	
11a1// ally 2017	102	Insufficiency: 20-29.9 ng/ml	39	
		"Normal" levels: 30 ng/ml	25	
Hurwitz 2017	90	Deficiency: <20 ng/mL	11	
Garcia-Soler 2017	340	Deficiency: <20 ng/mL	149	
Garcia-Solei 2017	340	Insufficiency: 20-30 ng/mL	128	
		25(OH)D levels: 30-40 ng/mL	41	
D 1 : 0017		Optimal levels >40 ng/mL	22	
Badawi 2017	88	Deficiency: < 50nmol/l	39	
		Severe deficiency: <30 nmol/1	30	
Jia 2017	110	Severe deficiency: <10 ng/ml	36	
		Deficiency: 10-20 ng/ml	56	
		Insufficiency: 21-30 ng/ml	17	
		Sufficiency: >30 ng/ml	1	
Yaghmaie 2017	82	Deficiency: <30 ng/ml	53	
		Sufficiency: >=30 ng/ml	29	
Say 2017	100	Severe deficiency (group 1) <5 ng/mL.	63	
,		Insufficiency (group2): 5 to 15 ng/mL	24	
		Sufficiency (group 3) \geq 15 ng/mL	13	
El-Gamasy 2017	80	Serious deficiency: < 30 nmol/L	26	
- · · · · · · · · · · · · · · · · · · ·		Insufficiency: 30-75 nmol/L	27	
		Adequate levels >75 nmol/L	27	
Sankar 2017	43	Severe deficiency: serum 25 (OH) D <10 ng/mL	31	
Shah 2016	154	25(OH)D < 20 ng/mL	128	
Shall 2010	134	$\frac{25(\text{OH})\text{D} < 20 \text{ ng/mL}}{25(\text{OH})\text{D} \ge 20 \text{ ng/mL}}$	26	
Ponnarmeni 2016	124	Deficiency: < 50nmol/L	63	
			21	
		Insufficiency: 50-75 nmol/L	<u>31</u> 94	
		<75, insufficient and deficient		
C 1 2016	101	Sufficiency: >75 nmol/L	30	
Sankar 2016	101	Deficiency: ≤ 20 ng/mL	75	
		Severe deficiency: <15 ng/mL	62	
		'No deficiency': > 20 ng/mL	26	
Bustos 2016	90	Deficiency: <20 ng/ml	39	
		Normal levels: >20 ng/ml	51	
Ebenezer 2016	52	Deficiency: < 20ng/mL	21	
		Insufficiency: 20–30 ng/ml	12	
		'Normal levels: $\geq 20 \text{ ng/L}$	31	
Elmoneim 2016	21	Deficiency: < 20 ng/mL	17	
		Insufficiency: 20-30 ng/mL	4	
		Normal levels: > 30 ng/mL	9	
Jat 2016	50	Deficiency: <20 ng/ml	42	
		Insufficiency: 20-30 ng/ml	2	
		Sufficiency: >=30 ng/ml	1	
Narang 2016	50	"Severe deficiency": <20ng/ml	28	
Dinlen 2016	30	Deficiency: <=15 ng/mL	26	
Dimen 2010	30	Severe deficiency: <=5 ng/mL	3	
L 2016	347		19	
Lopez 2016	347	25-OHD levels: <10 ng/mL	-	
		25-OHD levels: 10-20 ng/mL	65	
		25-OHD levels: 20-30 ng/mL	134	
Alvarez 2016	50	25(OH) D levels: <20 ng/mL	29	
		25(OH) D levels: 20-30 ng/mL	37	
Onwuneme 2015 (1)	120	25(OH)D levels: <50nmol/L	71	
		$25(OH)D$ levels: ≥ 50 nmol/L	49	
Onwuneme 2015 (2)	94	25(OH)D levels: <20 ng/mL	86	
Griwunenie 2015 (2)		25(OH)D levels: <20 hg/mL 25(OH)D levels: <30 hmol/L	60	
		25(OH)D levels: < 30 hmol/L 25(OH)D levels: >= 30 nmol/L	34	
Dreamd 2015	80			
Prasad 2015	80	Deficiency: < 20 ng/ml	67	
		Sufficiency: ≥ 20 ng/mL	13	
Moreno-Solis 2015	48	Deficiency: <20 ng/ml	9	

		Insufficiency: 21–29 ng/ml	16
A1 2015	200	Sufficiency: ≥30 ng/ml	23 45
Alonso 2015	288	Deficiency: <20 ng/ml	
		<10 ng/ml	6
Korwutthikulrangsri 2015	32	Deficiency: < 20 ng/ml	25
		Insufficiency: 20-29.9 ng/ml	7
		Sufficiency: $\geq 30 \text{ ng/mL}$	0
Khakshour 2015	37	Deficiency: <20 ng/mL	9
Cizmeci 2015	40	Deficiency: ≤20 ng/ml	28
		Insufficiency: 21–29 ng/ml	7
		Normal levels: ≥30 ng/ml	5
Cetinkaya 2015	50	Severe deficiency: <10 ng ml ⁻¹	42
		Insufficiency: 11 to 32 ng ml ⁻¹	8
Ayulo 2014	216	Deficient: < 15 ng/ml	61
		Insufficient: 15-29 ng/mL	102
		Sufficient: \geq 30 ng/mL	53
Dayal 2014	92	Deficiency: < 50 nmol/L	23
		Insufficiency: 50–75 nmol/L	41
		Sufficiency: >75 nmol/L	28
		25(OH) D levels: < 75 nmol/L	64
	· · ·	'Non-deficiency': > 50 nmol/L	69
Hebbar 2014	61	Deficiency: $\leq 10 \text{ ng/mL}$	10
		Insufficiency: 10 to 20 ng/mL	27
		Sufficiency: ≥ 20 ng/mL	24
Rey 2014	156	Deficiency: < 20 ng/mL	46
Rey 2014	150	$25(OH)D$ levels: ≥ 20 ng/mL	110
Ahmed 2014	50	Deficiency: <50 nmol/L	15
Basha 2014	81	Deficiency: <50 nmol/L	53
		Insufficiency: <75 nmol/L	14
		Normal level: >75 nmol/L	14
Sakka 2014	96	Severe deficiency: 0-5 ng/mL	29
		Deficiency: 5–15 ng/mL	49
		Insufficiency: 15-20 ng/mL	11
		Sufficiency: 20–100 ng/mL	7
Cayir 2014	88	Normal levels: 20 ng/mL	38
		Insufficiency: 15-20ng/mL	18
		Deficiency: <15ng/mL	32
Binks 2014	74	25(OH) D levels: < 50 nmol/L	11
Madden 2012	511	25(OH) D levels: < 10 ng/mL	36
		25(OH) D levels: 10-19.9 ng/mL	169
		Deficiency: < 20 ng/ml	205
		Insufficiency: <30 ng/mL	364
Rippel 2012	316	Deficiency: < 50 nmol/L	109
		'Normal levels': ≥50 nmol/L	207
Madden 2012	511	25(OH)D levels: < 10 ng/mL	36
		25(OH)D levels: 10-19.9 ng/mL	169
		Deficiency: < 20 ng/mL	205
		Insufficiency: <30 ng/mL	364
McNally 2012	326	Deficiency: < 50 nmol/L	225
		25(OH)D levels: 50 to 75 nmol/L	75
		'Not deficient': > 50 nmol/L	101
Inamo 2011	28	25(OH)D levels: < 10 ng/mL	4
		25(OH)D levels: < 15 ng/mL	8
		25(OH)D levels: < 25 ng/mL	12
		25(OH)D levels: < 40 ng/mL	28
Roth 2010	25	25(OH)D levels: < 40 nmol/L	21
Banajeh 2009	79	Deficiency: <30 nmol/L	29
Karatekin 2009	25	Serum 25(OH)D <10 (deficiency)	19
		Serum 25(OH)D 11 to 20 (deficiency)	4
	1	Serum 25(OH)D 21 to 32 (insufficiency)	1

BMJ Open

$ \begin{array}{c ccccccccccccccccccccccccccccccccccc$
63 24 13 20 18 8 31 84 26 63 31 94 30 7
24 13 20 18 8 31 84 26 63 31 94 30 7
13 20 18 8 31 84 26 63 31 94 30 7
20 18 8 31 26 63 31 94 30 7
18 8 31 84 26 63 31 94 30 7
8 31 84 26 63 31 94 30 7 7
31 84 26 63 31 94 30 7
84 26 63 31 94 30 7
26 63 31 94 30 7
26 63 31 94 30 7
63 31 94 30 7
31 94 30 7
94 30 7
30 7
7
2
3
8
8
32
3
32
14
9
2
14
3
28
7
5
4
5
17
13
33
15

Additional Table 5 Studi	ies with thresholds other than < 50 nmol/L
Study	Threshold used by study
Roth 2009	< 40 nmol/L
Roth 2010	< 40 nmol/L
Say 2017	<=15 ng/mL (37.4 nmol/L)
Inamo 2011 Ayulo 2014	<=15 ng/mL (37.4 nmol/L) <=15 ng/mL (37.4 nmol/L)
Dinlen 2016	<=15 ng/mL (37.4 nmol/L)
Onwuneme 2015 (2)	< 30 nmol/L
Yaghmaie 2017	< 30 ng/mL (74.88 nmol/L)
Gamasay 2017	< 30 nmol/L
Banajeh 2009	< 30 nmol/L
Sankar 2017	<= 10 ng/mL (24.9 nmol/L)
Cetinkaya 2015	<= 10 ng/mL (24.9 nmol/L)
25(OH) D values nmol/L	8
For poor review and a late	u//bmionon.bmi.com/site/shout/suid-lises.buil
For peer review only - http	://bmjopen.bmj.com/site/about/guidelines.xhtml

Study	Design	Sample size	Characteristics of pediatric population	Country	Reasons for exclusion of paper
Seliem 2016	Hospital-based case-control	Cases, n= 30 Controls, n= 30	Cases: group 1, full-term neonates with EOS and their mothers. Controls, group 2: 30 full-term healthy neonates and their mothers with no clinical or laboratory evidence of sepsis.	Egypt	Requested data without reply or data not available
Gamal 2017	Case-control	Cases, n= 50 Control, n= 30	Cases: neonates with early onset neonatal sepsis that occurred at <72 hours Controls: Age and sex healthy neonates with no prenatal risk factor for early neonatal sepsis enrolled in the study as a control group.	Egypt	Requested data without reply or data not available
Aydemir 2014	Hospital-based case control	Cases, n=40 Controls, n= 20	Cases: children with sepsis between 1 and 16 years old Controls: children without sepsis	Turkey	Requested data without reply or data not available
Garg 2016	Hospital-based case-control	Cases, n= 40 Controls, n= 40	Cases: children from 6 months to 5 years of age admitted or attending OPD in department of Pediatrics. Controls: children receiving care at the Hospital's ambulatory, emergency or in-patient units and presenting with non-respiratory complaints also not having any clinical indication of vitamin D deficiency.	India	Requested data without reply or data not available

having any clinical indication of vitamin D deficiency.

1 2 4 5 6 7 8	
9 10 11 12 13 14 15 16 17	2 3 4 5
18 19 20 21 22 23 24 25	3)) 2 3 4 5
26 27 28 30 31 32 33 34	7 3 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9
35 36 37 38 39 40 41 42	5 7 8 9
43 44 45 46 47	3 1 5

Study	Design	Number of cases (controls, where appropriate)	Characteristics of population	Country and setting	Vitamin D thresholds as defined by the study	Quality score (NOS)
Asilioglu 2017	Historical cohort (single centre)	250	Cases: aged 1 month to ≤ 18 years	Turkey, PICU	Deficiency: <20 ng/mL	7
Halwany 2017	Cohort (single centre)	102	Cases: children aged >1 month to ≤ 5 years	Egypt, PICU	Deficiency: <20 ng/ml Insufficiency: 20-29.9 ng/ml "Normal" levels: 30 ng/ml	6
Hurwitz 2017	Prospective cohort (single centre)	90	Cases: aged <5 years hospitalized with LRTI and RSV and/or hMPV	USA, PICU	Deficiency: <20 ng/mL	6
Garcia-Soler 2017	Cohort (single centre)	340	Cases: aged 6 months to 17 years Critically ill with various conditions	Spain, PICU	Deficient: <20 ng/mL Insufficiency: 20-30 ng/mL 25(OH)D levels: 30-40 ng/mL Optimal levels >40 ng/mL	7
Badawi 2017	Cohort (single centre)	88	Cases: 1 month to 12 years	Egypt, PICU	Deficiency: < 50nmol/l, Severe deficiency: <30 nmol/l	8
Jia 2017	Hospital- based case- control (single centre)	110 (110)	Cases: infants (< 1 year of age) with ALRTI Controls: Healthy from similar areas attending the hospital for vaccination during study period	China, PICU	Severe deficiency: <10 ng/ml Deficiency: 10-20 ng/ml Insufficiency: 21-30 ng/ml Sufficiency: >30 ng/ml	7
Yaghmaie 2017	Cross sectional (single centre)	82	Cases: hospitalized in PICU	Iran, PICU	Deficiency: <30 ng/ml	4
Say 2017	Case- control (single centre)	100 (13)	Cases: premature infants less than 37 weeks diagnosed with early or late -onset neonatal sepsis Controls: From same population of neonates with sepsis but not vitamin D deficient	Turkey, NICU	Severe deficiency (group 1) <5 ng/mL. Insufficiency (group2): 5 to 15 ng/mL Sufficiency (group 3) ≥15 ng/mL	6
El-Gamasy 2017	Case- control	80 (20)	Cases: 3 months to 12 years hospitalized with acute kidney injury	Egypt, PICU	Seriously deficient: < 30 nmol/L	7

	(single centre)		Controls: completely healthy subjects		Insufficient: 30-75 nmol/L Adequate >75 nmol/L	
Sankar 2017	Cohort (single centre)	43	Cases: <=17 years of age	India, PICU	Severe vitamin D deficiency: serum 25 (OH) D <10 ng/mL	8
Shah 2016	Cohort (single centre)	154	Cases: aged between 1 month and 15 years	India, PICU	Deficiency: <20 μg/mL	6
Ponnarmeni 2016	Case- control (single centre)	124 (338)	Cases: aged 1–12 years admitted with a diagnosis of sepsis Controls: from previous prospective study, apparently healthy children of upper socioeconomic status who attended the out-patient department for immunization or with minor ailments	India, PICU	Deficiency: < 50 nmol/L Insufficiency: 50-75 nmol/L Sufficiency: > 75 nmol/L	6
Sankar 2016	Cohort (single centre)	101	Cases: aged 1 month to 17 years	India, PICU	Deficiency: ≤ 20 ng/ml Severe deficiency: <15 ng/mL	8
Bustos 2016	Cohort (single centre)	90	Cases: critically ill, greater than 37 weeks and less than 15 years of age	Chile, PICU	Deficiency: < 20 ng/ml Normal levels: > 20 ng/mL	7
Ebenezer 2016	Cohort (single centre)	52	Cases: <18 years of age; medical and surgical diagnoses	India, PICU	Deficiency: < 20 ng/ml Insufficiency: 20–30 ng/ml Normal levels: ≥ 20 ng/L	6
Elmoneim 2016	Case- control (single centre)	30	Cases: aged less than 14 years Controls: with "normal" vitamin D levels	Saudi Arabia, PICU	Deficiency: < 20ng/ml Insufficiency: 20-30 ng/mL Normal: > 30 ng/mL	5
Jat 2016	Hospital- based case- control (single centre)	50 (50)	Cases: 1 month to 12 years of age admitted with pneumonia Controls: admitted for reasons other than respiratory symptoms, required blood sampling	India, PICU	Deficiency: < 20 ng/ml Insufficiency: 20-30 ng/ml Sufficiency: >= 30 ng/ml	8
Narang 2016	Hospital- based case- control (single centre)	50 (50)	Cases: 2 months to 5 years of age admitted as in-patients or seen in the outpatient department with ALRI Controls: healthy, same age group, attending outpatients' service for immunization or admitted for minor conditions other than ALRI	India, PICU	Severe deficiency: < 20ng/ml	6
Dinlen 2016	Hospital- based case- control	30 (30)	Cases: term neonates with ALRI Controls: healthy neonates, same age as the study group.	Turkey, NICU	Deficient: <= 15 ng/mL	6

	(single centre)				Severe deficiency: <= 5 ng/mL	
Lopez 2016	Prospective cohort (multi centre)	347	Cases: 0 to >48 months admitted to hospital with ALRI prospectively recruited through the GENDRES (GENetic,vitamin D and RESpiratory infections research network)	Spain, PICU	25-OHD levels: <10 ng/mL 25-OHD levels: 10-20 ng/mL 25-OHD levels: 20-30 ng/mL	8
Alvarez 2016	Cross- sectional (single centre)	50	Cases: patients aged 0 to 18 years	USA, PICU	25(OH)D < 20 ng/mL 25(OH)D < 30 ng/mL	6
Onwuneme 2015 (1)	Case- control (single centre)		Cases: with suspected sepsis (<12 years old) Controls: paediatric controls admitted for elective day case surgery during the same study period and were not suspected of having sepsis	Ireland , PICU	25(OH) D levels: <50 nmol/L 25(OH) D levels: ≥50 nmol/L	8
Onwuneme 2015 (2)	Cohort (single centre)	94	Cases: preterm infants <32 weeks gestation	Ireland, NICU	Deficiency: < 30 nmol/L Sufficiency: ≥ 30 nmol/L	8
Prasad 2015	Cohort (single centre)	80	Cases: 2 months to 12 years old	India, PICU	Deficiency: < 20 ng/ml Sufficient: ≥ 20 ng/mL	7
Moreno-Solis 2015	Hospital- based case- control (single centre)	48 (30)	Cases: aged 1–11 months with acute bronchiolitis Controls: healthy, <12 months, admitted to the outpatient clinic without respiratory symptoms or history of hospitalization for bronchiolitis or wheezing	Spain, PICU	Deficiency: < 20 ng/ml Insufficiency: 21–29 ng/ml Sufficiency: ≥ 30 ng/ml	6
Alonso 2015	Cross sectional (single centre)	288	Cases: aged 1 month to 13 years	Spain, PICU	Deficient: < 20 ng/ml and < 10 ng/ml	5
Korwutthikulrangsri M 2015	Nested case- control (single centre)	32 (36)	Cases: requiring PICU admission Controls: Healthy, enrolled during the same period of time and served as the control group (age in months)	Thailand, PICU	Deficiency: < 20 ng/mLl Insufficiency: 20-29.9 ng/ml Sufficiency: ≥ 30 ng/mL	5
Khakshour 2015	Case- control	37 (53)	Cases: below 5 years of age and suffering from respiratory infections Controls: those who were not suffering from respiratory infections	Iran, PICU	Deficiency: < 20 ng/mL	5
Cizmeci 2015	Case- control (single centre)	40 (43)	Cases: infants with suspected early-onset neonatal sepsis. Controls: For each newborn of group 1, one healthy infant selected as a control	Turkey, NICU	Deficiency: ≤ 20 ng/ml Insufficiency: 21–29 ng/ml	7

2	
3	
4	
5	
6	
7	
, 8	
a	
10	
11	
17	
12	
1/	
14	
14	
10	
1/ 10	
10	
יא 20	
∠∪ 21	
∠ I วว	
∠∠ วว	
∠⊃ 24	
2 3 4 5 6 7 8 9 10 11 23 4 5 6 7 8 9 10 11 23 4 5 6 7 8 9 10 11 23 24 25 26 27 28 9 30 1 32 23 24 5 6 7 8 9 10 11 22 23 24 5 6 7 8 9 10 11 22 23 24 5 6 7 8 9 10 11 23 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3	
25	
20 27	
∠/ ว∘	
∠0 20	
29 20	
20 21	
יכ גנ	
∠ ככ	
22 24	
54 2⊑	
55 26	
30 27	
/د مد	
38 20	
39 40	
40	
41 42	
42	
43	
44	
45	
46	
47	

					Normal levels: ≥ 30 ng/ml	
Cetinkaya 2015	Hospital- based case- control (single centre)	50 (50)	Cases: term infants with clinically suspected (probable) early infection (early-onset sepsis) within the first 3 postnatal days of life and were >37 weeks of gestational age Controls: healthy infants with no signs of clinical/laboratory infection	Turkey, NICU	Severe deficiency: <10 ng ml ⁻¹ Insufficiency: 11 to 32 ng ml ⁻¹ Adequacy: 32 to 100 ng ml ⁻¹	6
Ayulo 2014	Cohort (single centre)	216	Cases: between the ages of 1 and 21 years	Spain, PICU	Deficient: $< 15 \text{ ng/ml}$ Insufficient: 15-29 ng/mL Sufficient: $\ge 30 \text{ ng/mL}$	7
Dayal 2014	Cohort (single centre)	92	Cases: Children aged 3 months to 12 years	India, PICU	Deficiency: < 50 nmol/L Insufficiency: 50–75 nmol/L Sufficiency: > 75 nmol/L 25(OH) D levels: < 75 nmol/L	6
Hebbar 2014	Case- control (single centre)	61 (46)	Cases: children 0 to 18 years Controls: patients recruited among children in the magnetic resonance imaging suite.	USA, PICU	$\begin{array}{l} \text{Deficient:} \leq 10 \text{ ng/ml} \\ \text{Insufficient:} 10 \text{ to } 20 \\ \text{ng/ml} \\ \text{Sufficient:} \geq 20 \text{ ng/mL} \end{array}$	6
Rey 2014	Case- control (single centre)	156 (289)	Cases: heterogeneous group of critically ill children aged <16 years Control group for comparison: population of healthy children	Spain, PICU	Deficient: < 20 ng/ml	8
Ahmed 2014	Hospital- based case- control (single centre)	50 (50)	Cases: aged 2–60 months hospitalized with ALRI Controls: age-matched with cases within 1 or 2 months, attending well-child clinics or general clinics without evidence of respiratory infection or admitted to the hospital for elective surgery	Africa, PICU	Deficiency: <50 nmol/L	8
Basha 2014	Hospital- based case- control (single centre)	81 (89)	Cases: under 5 years old with severe pneumonia selected from the inpatient departments and emergency units of the hospital Controls: healthy, selected from the outpatient surgical clinics of the hospital during their visit for umbilical or inguinal hernia repair and not suffering from upper or lower respiratory infections	Egypt, PICU	Deficiency: < 50 nmol/L Insufficiency: < 75 nmol/L Sufficiency: > 75 nmol/L	7

Page 51 of 77

Sakka 2014	Population based case- control (single centre)	96 (96)	Cases: <2 years old with ALRI, 48 diagnosed with pneumonia and 48 with bronchiolitis Controls: age and sex matched with no respiratory symptoms or signs from the Health office	Egypt, PICU	Severe deficiency: 0–5 ng/mL Deficiency: 5– 15 ng/mL Insufficiency: 15– 20 ng/mL Sufficiency: 20–100 ng/mL	8
Cayir 2014	Hospital- based case- control (single centre)	88 (81)	Cases: 1 to 13 years diagnosed with acute otitis media Controls: Healthy same age range	Turkey, PICU	Normal levels: 20 ng/mL Insufficiency: 15- 20ng/mL Deficiency: <15ng/mL	7
Binks 2014	Cross- sectional	74	Cases: aged <3 years admitted with acute lower respiratory infections (ALRIs) or other conditions	Australia, PICU	25(OH) D levels: < 50 nmol/L	(
Madden 2012	Cohort (single centre)	511	Cases: less than 21 years old	USA, PICU	25(OH) D levels: < 10 ng/mL 25(OH) D levels: 10- 19.9 ng/mL Deficiency: < 20 ng/ml Insufficiency: < 30 ng/mL	8
Rippel 2012	Cohort (single centre)	316	Cases: children aged 16.5 (3.1–75.2) months	Australia, PICU	Deficiency: < 50 nmol/L "Normal" levels: ≥ 50 nmol/L	8
McNally 2012	Cohort (multi- centre)	326	Cases: Newborn to 17 years of age	Canada, PICUs	Deficiency: < 50 nmol/L 25(OH) D levels: 50 to 75 nmol/L	7
Inamo 2011	Cohort (single centre)	28	Cases: between 1 and 48 months hospitalized with ALRI, 26 diagnosed with bronchiolitis and two as having pneumonia	Japan, PICU	Deficiency: ≤ 15ng/ml Severe deficiency: ≤ 5ng/mL	Ċ
Roth 2010	Hospital- based case- control (single centre)	25 (25)	Cases: 1–18 months hospitalized with ALRI Controls: selected by population-based sampling. aged 1–23 months, and matched to cases on age (±2 months) and sex	Bangladesh, PICU	Deficiency: < 40 nmol/L	8
Banajeh 2009	Prospective cohort (single centre)	79	Cases: 2–59 months with WHO-defined very severe community acquired (VSP) pneumonia	Iran, PICU	Deficiency: < 30 nmol/L	
Karatekin 2009	Hospital- based case- control,	25 (15)	Cases: newborns with acute respiratory infections	Turkey, NICU	Deficiency: < 20 ng/ml	(

	(single centre)		Controls: healthy, age matched from outpatients' service where they went for immunization.			
Roth 2009	Hospital- based case- control (single centre)	64 (65)	Cases: aged 1-25 months admitted with ALRI Controls: aged 1-25 months undergoing elective surgery, no history of hospitalization for ALRI	Canada, PICU	Deficiency: < 40 nmol/L	7
Wayse 2004	Hospital- based case- control, (single centre)	80 (70)	Cases: < 5 years with severe ALRI Controls: healthy, attending outpatients service for immunization	India, PICU	Deficiency: Plasma 25(OH)D3 < 50 nmol/L	6

LRTI = lower respiratory tract infection; PICU = paediatric intensive care unit; RSV = respiratory syncytial virus; ALRI = acute lower respiratory infection; WHO = World Health Organization; VSP = very severe community acquired pneumonia; NICU = neonatal intensive care unit.

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

Study	Objectives/aims of study	Main outcome(s) and conclusion(s)	
Madden 2012	Prevalence of vitamin D deficiency in critically ill children and factors influencing admission 25-hydroxyvitamin D (25(OH)D) levels		
Lopez 2016	Role of Vitamin D in Children hospitalized with Lower Tract Acute Respiratory Infections	25-hydroxyvitamin D levels of study population below normal range. Correlatio of higher disease severity with lower levels of 25-hydroxyvitamin D.	
Garcia-Soler 2017	Prevalence and risks factors of vitamin D deficiency, as well as its relationship with length of PICU stay morbidity and mortality in a PICU.	Vitamin D deficiency is frequent in paediatric critical patients. It also has	
McNally 2012	Prevalence of vitamin D deficiency, risk factors and potential association with clinically relevant outcomes in critically ill children in Canada.	Most of critically ill children vitamin D deficient at PICU admission. Lower 25(OH) D levels associated with increased catecholamine requirements, fluid bolt administration, hypocalcemia, and longer PICU admission.	
Rippel 2012	Prevalence of hypovitaminosis D and association with outcome in critically ill children requiring admitted in intensive care.	Hypovitaminosis D is frequent in critically ill children in PICU, especially in infan and children with heart disease. Hypovitaminosis D associated with hypocalcem in non-cardiac population, and increased need for calcium replacement in th cardiac population. No association between vitamin D status and survival or PICU length of stat Strong association with early postoperative inotropic needs in the cardiac population.	
Alonso 2015	Investigate relationship of serum 25-hydroxyvitamin D concentrations with serum parathyroid hormone (PTH) levels, body mass index (BMI), and environmental factors in a population of Caucasian children living at latitude 43°N.	dy D deficiency in children.	
Asilioglu 2017	Measure occurrence of VDD in critically ill children. Assess determinants of vitamin D status and compare vitamin D deficient and sufficient cases in respect of severity of illness.		
Ayulo 2014	Prevalence of vitamin D deficiency among children in PICU	Vitamin D deficiency common. No significant correlation between disease severi and vitamin D levels levels of vitamin D. Mortality associated with vitamin D leve	
Rey 2014	Identify prevalence of 25 hydroxivitamin D or 25(OH) vitamin D deficiency on pediatric intensive care unit (PICU) admission, and if associated with increased prediction of mortality risk scores.	Hypovitaminosis D incidence high in PICU patients. Hypovitaminosis D not associated with higher prediction of risk mortality scores.	
Shah 2016	Determine prevalence of vitamin D deficiency in critically ill children its association with illness severity, parathyroid response and clinical outcomes.	High prevalence of vitamin D deficiency. Parathyroid gland response secondary vitamin D deficiency or hypocalcemia impaired in critically ill.	
Ponnarmeni 2016			
Onwuneme 2015 (1)	Assess vitamin D status, and its determinants, in chidren with suspected sepsis admitted to PICU. Also investigated association between vitamin D status and clinical outcomes.	Children admitted to the PICU with suspected sepsis lower 25OH D compared controls. Inadequate 25 OH D levels associated with confirmed sepsis and po outcomes.	
Jia 2017	Association of vitamin D with ALRTI in Chinese infants	Lowered plasma level of 25-OH Vitamin D makes children susceptible to ALRT	
Halwany 2017	Frequency of vitamin D deficiency in critically ill pediatric intensive care unit [PICU] patients and relation to state of serum 25(OH) D to disease severity.	High prevalence of vitamin D deficiency in critically ill children. Negative correlation of Vitamin D level with PELOD score. Recommend screenin of critically ill children for vitamin D deficiency to restore their serum levels.	

2	
3	
4 5 6 7 8 9	
5	
6	
7	
/	
8	
9	
10	
10	
11	
12	
13	
14	
15	
15	
16	
17	
18	
10	
12 13 14 15 16 17 18 19 20	
20 21	
21	
22	
22 23 24 25 26 27 28	
23	
24	
25	
26	
20	
27	
28	
29	
30	
21	
31	
32	
33	
34	
33 34 35	
22	
36 37 38	
37	
38	
39	
40	
41	
42	
43	
44	
45	
46	
47	
. /	

Sankar 2016	Prevalence of vitamin D deficiency on admission and examine association with length of ICU stay	High prevalence of vitamin D deficiency. Vitamin D deficient children with longer ICU stay duration or mortality	
Say 2017	Evaluate effects of low vitamin D levels in cord blood on neonatal sepsis in preterm infants.	No significant relationship between the cord blood vitamin D levels and the risk of neonatal sepsis in premature infants.	
Sakka 2014	Determine the relation between vitamin D deficiency, anemia and the severity of ALRTIs in hospitalized children.	Vitamin D deficiency, low BMI, low hemoglobin level, rachitic signs were risk factors for the severity of ALRTIS.	
Onwuneme2015 (2)	Investigate the association between serum 25-hydroxyvitamin D (250HD) levels and outcomes in preterm infants (<32 weeks gestation).	High prevalence of low 25OHD. Association between vitamin D status and acute respiratory morbidity in preterm infants after birth. In none of the following outcomes was the difference statistically significant: surfactant use, inotrope requirement, RDS, pneumothorax, pulmonary hemorrhage, chronic lung disease, sepsis, retinopathy of prematurity, intraventricular hemorrhage, periventricular leucomalacia, patent ductus arteriosus, and mortality	
Dayal 2014	Prevalence of vitamin D deficiency Association of serum vitamin D levels with duration of stay in hospital, mortality and requirement of ventilation	Reduced serum vitamin D levels in children	
Bustos 2016	Determine prevalence of vitamin D deficiency and its association with other clinically relevant outcomes in children admitted to Paediatric Intensive Care Unit	Vitamin D deficiency was prevalent in critically ill children and associated with adverse clinical outcomes.	
Hurwitz 2017	Measure retinol binding protein and vitamin D in children aged <5 years hospitalized with lower respiratory tract infection and respiratory syncytial virus and/or human meta pneumovirus detections	Low vitamin levels in 50% of the children and associated with significantly elevated risk of the need for intensive care unit admission and invasive mechanical ventilation.	
Cayir 2014	Investigate the relationship between Vitamin D deficiency and acute otitis media infection	Serum 25-hydroxy vitamin D levels significantly lower in children with acute otitis media compared to the controls. Vitamin D deficiency plays a role in otitis media infection.	
Badawi 2017	Investigated if VDD is related to higher severity scores and organ dysfunction. Primary objective of study was to estimate the prevalence of VDD in a group of critically ill children, and secondary objectives was to correlate vitamin D status with pediatric logistic organ dysfunction (PELOD) and pediatric risk ofmortality III (PRISM III) scores.	VDD prevalence was reported in about half of the critically ill patients, and it was observed to be related to multiple organ dysfunctions and rapid clinical deterioration.	
Yaghmaie 2017	Investigate relation of vitamin D deficiency with potential demographic and clinical factors.	Vitamin D deficiency among paediatric intensive care unit patients similar to western countries, also with similar age and BMI distribution. Significant relation observed between age and serum level of vitamin D.	
Basha 2014	Aimed to evaluate vitamin D status as a risk factor for severe pneumonia in Egyptian hospitalized children under 5 years	Significant association between vitamin D deficiency and severe pneumonia in Egyptian children below 5 years	
Prasad 2015	Prevalence of vitamin D deficiency in critically ill children and association with illness severity& other outcomes	High prevalence of vitamin D deficiency in critically ill children and association with PRISM III scores in a developing country. Groups did not differ in terms of PICU stay, duration of hospital stay, culture positivity, biochemical parameters (serum calcium, serum phosphate), need of ventilation or steroids, presence of coagulopathy and mortality.	
Wayse 2004	If vitamin D deficiency in Indian children under 5 years old of age is risk factor for severe acute lower respiratory infection (ALRI).	Subclinical vitamin D deficiency & nonexclusive breastfeeding in four first months of life found to be significant risk factors for severe ALRI in Indian children.	
El-Gamasy 2017	Assess serum 25 (OH)D level in critically ill paediatric patients with AKI at PED of Tanta University Emergency Hospital (TUEH) within the first 24 hours of admission and evaluate its correlation with duration of hospital stay and mortality outcome.	Vitamin D deficiency associated with higher incidence of sepsis and mortality.	

Page 55 of 77

 BMJ Open

Banajeh 2009	Determine if rickets and VDD predict the outcomes in very severe pneumonia (VSP).	In WHO-defined VSP, nutritional rickets was strongly associated with a reduced successful treatment outcome, and VDD was a significant and independen predictor of reduced circulating PMNs and persistent hypoxemia.
Binks 2014	Aimed to determine prevalence of vitamin D insufficiency among children hospitalised with ALRI in the Northern Territory.	Vitamin D insufficiency was observed in about one-third of these hospitalised children. Children hospitalised with an ALRI less likely to have vitamin E insufficiency compared with children hospitalised for other condition (predominantly gastroenteritis).
Roth 2009	Test the hypothesis that vitamin D status is associated with the risk of ALRI in Canadian children (1 month to 2 years old)	Among children aged 1 month to 2 years, vitamin D status not associated with ALR requiring hospitalization
Hebbar 2014	Prevalence of vitamin D insufficiency and relationship between vitamin D levels infection and innate immunity	High prevalence of vitamin D deficiency Serum vitamin D levels - no correlation with illness severity score
Ebenezer 2016	Determine vitamin D status and association with outcomes	Vitamin D deficiency common among pediatric patients No association between vitamin D status and admission and mortality such as higher mortality and/or longer PICU stay Deficiency associated with mechanical ventilation severity of illness, vasopresson need
Narang 2016	Identify an effective nutritional agent that reduces the need for antibiotics, duration of pneumonia and length of hospitalization would be highly cost-beneficial.	Severe vitamin D deficiency (<20 ng/ml), nonexclusive breastfeeding in the firs six months of life, inadequate sun exposure found to be significant risk factors for ALRTI in Indian children.
Alvarez 2016	Study aimed to investigate relationship between vitamin D status and plasma markers of lutathione (GSH) and cysteine (Cys) redox and immunity in critically ill children	Vitamin D sufficiency was associated with more reduced plasma hCySS, indicative of lower oxidative stress, in critically ill children. Plasma GSH, GSSG, and glutamine, however, were lower in the vitamin D sufficient group. Vitamin D role in maintaining redox status during pediatric critical illness requires further study.
Cetinkaya 2015	Evaluate the effect of vitamin D levels on early-onset sepsis (EOS) in term infants	Lower maternal and neonatal 25-OHD levels associated with EOS. Suggest that adequate vitamin D supplementation during pregnancy may be helpful to preven EOS in term neonates.
Ahmed 2014	Examine relationship between vitamin D status and hospitalization for ALRTI in Nigerian children.	ALRTI not associated with vitamin D status, but associated with less exposure to sunlight. Exposure to sunlight & vitamin D supplementation contributed to vitamin D status in this population.
Jat 2016	Evaluate Vitamin D levels and its correlation with severity and outcome of pneumonia in children.	Majority (86.4%) of children were vitamin D deficient. Vitamin D levels were found different in cases and controls and were not related to severity and outcome of pneumonia.
Sankar 2017	Evaluate association of severe vitamin D deficiency with clinically important outcomes in children with septic shock.	Prevalence of severe vitamin D deficiency is high in children with septic shocl admitted to pediatric intensive care unit. Severe vitamin D deficiency at admission seems to be associated with lower rates of shock reversal at 24 hours of ICU stay.
Cizmeci 2015	Investigate if neonates with early-onset neonatal sepsis (EONS) had lower levels of vitamin D	Cord-blood 25(OH) D levels of neonates with EONS significantly lower than tha of the healthy controls, and a low level of cord-blood vitamin D was found to be associated with an increased risk of EONS. Further studies are warranted to confirm this association.
Khakshour 2015	Clarify the association between vitamin D deficiency and acute respiratory infection in children below age 5 years.	The group of children with respiratory disorders, 9 (42.9%) exhibited vitamin I deficiency. No meaningful statistical relation vitamin D deficiency with acute respiratory infections (p>0.05)
Korwutthikulrangsri 2015	Determine vitamin D status in critically ill children and its relationship with adrenal function	Higher prevalence of vitamin D deficiency in critically ill children in comparison to controls. Patients vitamin D deficiency had higher median (IQR) PRISM III score and higher proportion of mortality than those with serum 25-OHD of equal or more than 12 ng/mL.
Elmoneim 2016	Association of the level of vitamin D on admission & length of stay in the PICU, or duration of mechanical ventilation.	High prevalence of vitamin D deficiency among PICU patients & significan association with increased LOS and need for mechanical ventilation. No significant association with mortality rate.

Dinlen 2016	Determine the association between serum 25-hydroxy vitamin D [25(OH)D] levels and acute respiratory tract infections (ALRTI) in newborns	Lower blood 25(OH) D levels might be associated with increased risk of ALRTI in term newborn babies. Appropriate vitamin D supplementation during pregnancy and early childhood may enhance newborns' respiratory health.
Moreno-Solis 2015	Examine prevalence of hypovitaminosis D in infants with acute bronchiolitis compared with control subjects and to evaluate the relationship between serum 25-hydroxyvitamin D (25(OH) D) and the severity of bronchiolitis.	Prevalence of hypovitaminosis D is high in Spanish infants with bronchiolitis. The severity of acute bronchiolitis increases with a decline in serum 25 (OH) D level.
Inamo 2011	Relationship between serum vitamin D concentrations and severity of ALRI in hospitalized children in Japan.	Significantly more children with ALRI that required supplementary oxygen and ventilator management were vitamin D deficient. Findings suggest: immunomodulatory properties of vitamin D may influence the severity of ALRI.
Karatekin 2009	Association of serum 25-hydroxy vitamin D concentrations in newborns with acute lower respiratory infection (ALRI) and without clinical signs of rickets, and their mothers	Newborns with subclinical vitamin D deficiency may have an increased risk of suffering from ALRI. Strong positive correlation between newborns' and mothers' 25(OH) D concentrations indicates that adequate vitamin D supplementation of
Roth 2010	Investigate association between vitamin D status and ALRI	Vitamin D status associated with ALRI in early childhood. Randomized trials needed to establish if interventions to improve vitamin D status could reduce burden of ALRI in early childhood.
		mothers should be emphasized during pregnancy especially in winter months. Vitamin D status associated with ALRI in early childhood. Randomized trials needed to establish if interventions to improve vitamin D status could reduce burden of ALRI in early childhood.

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

Assay	Paper	Number of studies
Radioimmunoassay	Madden 2012; Inamo 2011; Karatekin 2009; Roth 2009; Roth 2010;	8
	Sakka 2014; Moreno-Solis 2015; Khashour 2015	
Competitive binding enzyme linked	Basha 2014	1
mmunoassay		
Binding protein assay	Onwuneme 2015 (2)	1
Liquid chromatography-mass spectrometry	McNally 2012; Korwutthikulrangsri 2015; Binks 2014; Cetinkaya 2015;	7
	Cizmeci 2015; Asilioglu 2017; Onwuneme (1)	
Chemiluminescence immunoassay or	Alonso 2015; Rey 2014; Sankar 2016; Shah 2016; Prasad 2015; Ahmed	11
chemiluminescent tracer	2015; Lopez 2016; Alvarez 2016; Say 2017; Sankar 2017; Jat 2017	
ELISA	Ponnarmeni 2016; Hebbar 2014; Elmoneim 2016; Narang 2016; Jia 2017;	9
	El-Gamasy 2017; Halwany 2017; Banajeh 2009; Badawi 2017	
ELFA (enzyme linked fluorescent assay)	Bustos 2014	1
Electrochemiluminescence Immunoassay	Dayal 2014, Ebenezer 2016, Garcia Soler 2017; Cayir 2014;	4
(ECLIA)		
Clinical Laboratory Improvement	Hurwitz 2017	1
Amendments-approved Vitamin D assay		
Elecsys; Roche Diagnostics, Indianapolis,		
Indiana)		
Commercial immunoassay lit (I RIA Diasorin	Wayse 2004, Ayulo 2014,	2
UK)		
Immunoassay analyzer	Rippel 2012	1
APPLIED 3200 Biosystem	Dinlen 2016	1
Not reported	Yaghmaie 2017	1

Study	Funding Approval of study and ethics		
Madden 2012	Reported	Children's Hospital Boston institutional review board. Informed consent obtained from family.	
Lopez 2016	Reported	Approved by the Ethical Committee of Clinical Investigation of Galicia (CEIC ref 010/015) and all of the regional ethic committees of the participant centres informed consent forms were obtained from either a parent or legal guardian for easily subject before study inclusion.	
Garcia-Soler 2017	Not reported	Study protocol approved by regional research ethics committee. Obtained informed consent from family of patients. Dat recorded anonymously (encrypted electronic database). Project adhered to the principles of Declaration of Helsinki and standards for good clinical practice.	
McNally 2012	Reported	Research ethics board approval for vitamin D sub study obtained from 6 centers, representing 337 of the original 389 study participants.	
Rippel 2012	Not Reported	Approved by Ethics Committee of The Royal Children's Hospital Melbourne	
Alonso 2015	Reported	Regional Ethics Committee of the Principality of Asturias	
Asilioglu 2017	Not reported	Approval of study by the Local Ethics Committee of Ondokuz Mayıs University (Samsun, Turkey).	
Ayulo 2014	Not reported	Institutional Review Board: Montefiore Medical Centre	
Rey 2014	Reported	Hospital Ethics Committee	
Shah 2016	Reported	Ethical approval obtained from Institutional ethics committee. Parents of children satisfying criteria gave written informed consent for participation of their child in the study.	
Ponnarmeni 2016	Not reported	The institution's ethics committee. Informed consent obtained	
Onwuneme 2015 (1)	Reported	Approval by ethics committees of: Children's University Hospital, Temple Street and Our Lady's Children's Hospital, Dublin, Ireland. Participants were informed and provided written consent before recruitment.	
Jia 2017	Not reported	Approved by Human Ethical Committee of Affiliated Hospital of Yan'an University, Yan'an. Informed consent was taken from mothers and/or parent of infants.	
Halwany 2017	Not reported	Approval by the Medical Ethics Committee of the Faculty of Medicine, Alexandria University	
Sankar 2016	Not reported	Institutional Ethics committee. Informed consent obtained	
Say 2017	Not reported	Approval by the local Ethics Committee and informed parental consent was obtained for all infants.	
Sakka 2014	Not reported	Not reported	
Onwuneme2015 (2)	Reported	Ethics Committee of National Maternity Hospital. Informed written consent obtained from parents before recruitment	
Dayal 2014	Not reported	Ethics Committee of the Institute. Informed consent obtained.	
Bustos 2016	Reported	Comité Ético Científico del Servicio de Salud de Concepción	
Hurwitz 2017	Reported	Informed consent obtained and study protocol approved by the Institutional Review Boards at the University of Tennessee, St Jude Research Hospital, and the Centers for Disease Control and Prevention.	
Cayir 2014	Not reported	Approval from the institutional ethics committee and consent from the parents of all children in the study.	
Badawi 2017	Not reported	Children's Cairo University institutional review board approved study. Informed consent obtained from parents	
Yaghmaie 2017	Not reported	Study carried out in accordance with the Declaration of Helsinki, and the ethics committee of the Tehran University of Medical Sciences approved the protocols of the study. Records of patients' were kept confidential. Patients' consent provided for blood sampling and vitamin D serum level was assessed from patients' files, so no invasive method or extra blood sampling was done.	

Page 59 of 77

BMJ Open

Basha 2014	Not reported	Oral consent from the mothers.	
Prasad 2015	Not reported	Institutional review board approved the protocol. Written informed consent obtained from parents or guardians.	
Wayse 2004	Reported	Information not provided	
El-Gamasy 2017	Not reported	Study approved from the Ethical Committee of the Faculty of Medicine, Tanta University. Informed verbal or written parental consents from all subjects involved in the study.	
Banajeh 2009	Reported	Protocol approved and described in previous paper	
Binks 2014	Reported	Testing performed after approval by the Human Research Ethics Committee of the Northern Territory Department of Health and Menzies School of Health Research	
Roth 2009	Reported	Caregiver of each participant provided written informed consent and completed a questionnaire Study approved by the Human Research Ethics Board of the University of Alberta Health Sciences Faculties	
Hebbar 2014	Reported	Institutional Review Boards of Emory University and Children's Healthcare Atlanta Informed consent obtained	
Ebenezer 2016	Reported	Institutional Review Board (IRB), Informed consent from parents	
Narang 2016	Not reported	Not reported	
Alvarez 2016	Reported	Study approved by both the Emory University and Children's Healthcare of Atlanta Institutional Review Boards, and informed consent was obtained from patients' guardians prior to any study procedures	
Cetinkaya 2015	Not reported	Study protocol approved by the local Ethics Committee. Informed parental consent was obtained for all infants	
Ahmed 2014	Not reported	Informed written or oral consent obtained from the parents, and the study was approved by the National Hospital Abuja Ethics Committee	
Jat 2016	Not reported	Ethics committee approval was taken before commencing the study. Parent's informed consent was taken before enrolling children into study.	
Sankar 2017	No funding	Study approved by the institutional ethics committee.	
Cizmeci 2015	Reported	Acquisition of cord-blood was approved by the local ethics committee of Fatih University Medical School.	
Khakshour 2015	Not reported	Obtained informed consent from parents, data collection done using demographic questionnaire and serum level of 25-dehydroxycalcciferol was measured. Samples taken by a trained nurse at admission based on physician orders.	
Korwutthikulrangsri 2015	Not reported	Ramathibodi Hospital Ethics Committee. Written informed consent from legal guardians of all participants	
Elmoneim 2016	Reported	MCH hospital Ethics Committee approved study protocol	
Dinlen 2016	Not reported	Study approved by the Local Ethics Committee. All parents fully informed about this investigation as well as its aim. Writte consent was obtained from all parents.	
Moreno-Solis 2015	Reported	Written informed consent obtained from parents or legal guardian of all enrolled children. Protocol of study approved by t Ethics Committee before the beginning of this study.	
Inamo 2011	Not reported	Ethics Committee of Nihon University Nerima-Hikarigaoka Hospital. Informed consent obtained from the parents of a patients before inclusion in the study.	
Karatekin 2009	Not reported	Study approved by the Institution's Ethics Committee, and informed consent was obtained from the study participants.	
Roth 2010	Reported	Approved by The Johns Hopkins Bloomberg School of Public Health Institutional Review Board and the ethics committee of the Bangladesh Institute for Child Health at the Dhaka Shishu Hospital, Bangladesh. Signed permission prior to enrolment from parents/guardians.	

1 2	
3 4 5	
6 7	
8 9	
10 11 12	
13 14 15 16 17	
18	
19 20 21	
22 23	
24 25	
26 27 28	
20 29 30	
31 32	
33 34 35	
36 37	
38 39	
40 41 42	
42 43 44	
45 46	
47	

First author, date	Age group
Wayse 2004	<5 years
Karatekin 2009	Neonates
Roth 2009	<2 years
Roth 2010	1–18 months
Inamo 2011	<4 years
Madden 2012	<21 years
Rippel 2012	16.5 (3.1 to 75.2) months
McNally 2012	Newborn to 17 years
Ayulo 2014	1 to 21 years
Dayal 2014	3 months to 21 years
Hebbar 2014	0 to 18 years
Rev 2014	<16 years
Cetinkaya 2015	>37 weeks
Onwuneme (1) 2015	<12 years
Onwuneme (2) 2015	<32 weeks gestation
Prasad 2015	2 months to 12 years
Alonso 2015	1 month to 13 years
Korwutthikulrangsri 2015	79 (61) cases; 92 (40) controls months
Cizmeci 2015	Neonates
Shah 2016	1 month to 15 years
Ponnarmeni 2016	1 to 12 years
Sankar 2016	1 month to 17 years
Bustos 2016	>37 weeks and <15 years
Ebenezer 2016	<18 years
Elmoneim 2016	<14 years
Narang 2016	2 months to 5 years
Dinlen 2016	Neonates
Lopez 2016	0 to >48 months
Alvarez 2016	0 to 18 years
Garcia-Soler 2017	6 months to 17 years
Sankar 2017	<17 years
Ahmed 2015	2 to 60 months
Cayir 2014	1 to 13 years
Say 2017	<37 weeks
Asilioglu 2017	<=18 years
Basha 2014	<5 years
Jia 2017	<1 year
Jat 2017	1 month to 12 years
Yaghmaie 2017	Age range not stated
El-Gamasay 2017	3 months to 12 years
Binks 2014	S months to 12 years <3 years
Halwany 2017	>1 month to ≤ 5 years
Badawi 2017	1 month to 12 years
Moreno-Solis 2015	1 to 11 months
Sakka 2014	<pre>// // // // // // // // // // // // //</pre>

Page 61 of 77

 BMJ Open

Hurwitz 2017	<5 years
Banajeh 2009	2 to 59 months
Khakshour 2015	< 5 years

Additional Table 12 Prevalence of vitamin D deficiency in each study of critically ill children (sorted from highest to lowest)

Study	Prevalence of vitamin D deficiency (%)	Number of vitamin D deficient children	Total number of children
Wayse 2004	95.00	76	80
Sakka 2014	92.70	89	96
Karatekin 2009	92.00	23	25
Onwuneme2015 (2)	91.48	86	94
Say 2017	87.00	87	100
Dinlen 2016	86.70	26	30
Cetinkaya 2015	84.00	42	50
Jat 2016	84.00	42	50
Roth 2010	84.00	21	25
Prasad 2015	83.75	67	80
Jia 2017	83.64	92	110
Shah 2016	83.11	128	154
Korwutthikulrangsri 2015	78.12	25	32
Sankar 2016	74.26	75	101
Sankar 2017	72.09	31	43
Cizmeci 2015	70.00	28	40

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

McNally 2012	69.02	225	326
Basha 2014	65.43	53	81
Yaghmaie 2017	64.63	53	82
Hebbar 2014	60.66	37	61
Onwuneme 2015 (1)	59.16	71	120
Alvarez 2016	58.00	29	50
Cayir 2014	56.82	50	88
Elmoneim 2016	56.67	17	30
Narang 2016	56.00	28	50
Ponnarmeni 2016	50.81	63	124
Asilioglu 2017	48.00	120	250
Badawi 2017	44.30	39	88
Garcia-Soler 2017	43.82	149	340
Bustos 2016	43.30	39	90
Ebenezer 2016	40.38	21	52
Madden 2012	40.12	205	511
Halwany 2017	37.25	38	102
Banajeh 2009	36.71	29	79
Rippel 2012	34.49	109	316
El-Gamasy 2017	32.50	26	80
Ahmed 2014	30.00	15	50
Rey 2014	29.49	46	156
Inamo 2011	28.50	8	28
Dayal 2014	25.00	23	92
Khakshour 2015	24.32	9	37
Lopez 2016	24.20	84	347

 BMJ Open

	I	L	I
Roth 2009	4.69	3	64
Hurwitz 2017	12.22	11	90
Moreno-Solis 2015	13.33	9	48
Binks 2014	14.86	11	74
Ayulo 2014	15.63	61	216
Alonso 2015	15.63	45	288

Study	Total number of patients	Total number of vitamin D deficient patients	Country, setting	Age range	Design	Quality score (NOS)
Madden 2012	511	205	Boston US, PICU	<21 years	cohort	8
Lopez 2016	347	84	Spain, hospitalised	0 to >48 months	cohort	8
Garcia-Soler 2017	340	149	Spain, PICU	6 months to 17 years	cohort	7
McNally 2012	326	225	Canada, PICU	newborn to 17 years of age	cohort	7
Rippel 2012	316	109	Australia, PICU	16.5 (3.1–75.2) months	cohort	8
Alonso 2015	288	45	Spain, PICU	1 month to 13 years	cross sectional	5
Asilioglu 2017	250	120	Turkey, PICUs	<= 18 years	cohort	6
Ayulo 2014	216	61	Spain, PICU	1 month to 13 years	cross sectional	5
Rey 2014	156	46	Spain, PICU	<16 years	case-control	8
Shah 2016	154	128	India,PICU	1 month-15 years	cohort	6
Ponnarmeni 2016	124	63	India, PICU	aged 1-12 years	case-control	6
Onwuneme 2015 (1)	120	71	Ireland, PICU	<12 years old	case-control	8
Jia 2017	110	92	China, PICU	infants <1 years old	case-control	7
Halwany 2017	102	38	Alexandria, PICU	>1 month to \leq 5 years	cohort	6
Sankar 2016	101	75	India, PICU	1 month to 17 years	cohort	8

Additional Table 13 Characteristics of studies used in the meta-analysis of prevalence

Say 2017	100	87	Turkey, NICU	gestational age <37 weeks	case-control	6
Sakka 2014	96	89	Egypt, hospitalized	infants (<2 years old)	case-control	8
Onwuneme 2015 (2)	94	86	Ireland, NICU	preterm infants at <32 weeks gestation	cohort	8
Dayal 2014	92	23	India, PICU	3 months to 12 years	cohort	6
Bustos 2016	90	39	Chile, PICU	>37 weeks and <15 years	cohort	7
Hurwitz 2017	90	11	USA, hospitalised	<5 years old	cohort	6
Cayir 2014	88	50	Turkey, PICU	1 to 13 years	case-control	7
Badawi 2017	88	39	Cairo, Egypt PICU	1 month to 12 years	cohort	7
Yaghmaie 2017	82	53	Iran, PICU	children undefined	cross sectional	4
Basha 2014	81	53	Cairo Egypt, PICU	<5 years old	case-control	7
Prasad 2015	80	67	India, PICU	2 months-12 years	cohort	7
Wayse 2004	80	76	Indapur India, PICU	<5 years	case-control	6
El-Gamasy 2017	80	26	Egypt, PICU	3 months to 12 years	Case-control	7
Banajeh 2009	79	29	Iran, hospitalised	aged 2-59 months	cohort	7
Binks 2014	74	11	Australia, PICU	<3 years old	cross sectional	6
Roth 2009	64	3	Canada, PICU	aged 1-25 months	case-control	7
Hebbar 2014	61	37	Atlanta, PICU	0 to 18 years	case-control	6
Ebenezer 2016	52	21	India, PICU	<18 years	cohort	6
Narang 2016	50	28	Punjab, India, PICU	2 months to 5 years	case-control	6
Alvarez 2016	50	29	Atlanta, PICU	0 to 18 years	cross sectional	6
Cetinkaya 2015	50	42	Instabul/Turkey, NICU	neonates	case-control	6
Ahmed 2014	50	15	Nigeria, PICU	2–60 months	case-control	8
Jat 2016	50	42	India, PICU	1 month to 12 years	case-control	8
Sankar 2017	43	31	India, PICU	<=17 years	cohort	8
Cizmeci 2015	40	28	Instabul/Turkey, NICU	neonates	case-control	7
Khakshour 2015	37	9	Iran, hospitalized	<5 years	Case-control	5
Korwutthikulrangsri 2015	32	25	Bangkok, PICU	months not more specific range	nested case- control	5
Elmoneim 2016	30	17	Saudi Arabia, PICU	<14 years	case-control	5

Dinlen 2016	30	26	Ankara Turkey, NICU	neonates	case-control	6
Moreno-Solis 2015	48	9	Spain, PICU	infants 1-11 months	case-control	6
Inamo 2011	28	8	Tokyo Japan, PICU	1-48 months	cohort	6
Karatekin 2009	25	23	Istanbul Turkey, NICU	neonates	case-control	6
Roth 2010	25	21	Bangladesh	1-18 months	case-control	8

Studies arranged from largest to smallest total sample size. NOS = Newcastle Ottawa Score

Additional Table 14 Sens	sitivity analyses for prevale	nce of vitamin D defic	iency in all critically ill	children	
Patient category	Number of studies (Total number of individuals; number of vitamin D deficient individuals)	Pooled proportion % (95% CI) Random effects model	Pooled proportion % (95% CI) Fixed effects model	Heterogeneity (I ²) % (95% CI)	Q value, d.f. p-value
Critically ill children, excluding studies that used other thresholds	36 (4,629; 2,191)	53.1 (45.6-60.4)	46.2 (44.6-47.8)	95.1 (93.9-96.0)	707.2, 35, < 0.0001
Sample size >=100 (large)	16 (3,561; 1,598)	50.8 (40.5-61.1)	44.3 (42.5-46.0)	96.9 (95.9-97.6)	481.7 15 < 0.0001
Sample size <100 (small)	32 (1,959; 1,066)	57.2 (47.3-66.7)	52.5 (49.9-55.1)	92.7 (90.7-94.3)	424.3 31 < 0.0001
Cohort studies	20 (3,399; 1,548)	48.4 (39.7-57.3)	44.4 (42.6-46.2)	95.5 (94.1-96.5)	418.6 19 < 0.0001
Case-control	24 (1,627; 978)	64.1 (53.2-73.6)	57.9 (55.0-60.7)	92.8 (90.5-94.6)	320.5 23 < 0.0001
Cross sectional	4 (494; 138)	34.8 (12.8-66.0)	30.3 (25.9-35.2)	96.7 (94.0-98.2)	90.4 3 < 0.0001
Studies from India	10 (826; 554)	69.5 (53.0-81.5)	64.1 (60.3-67.8)	93.6 (90.2-95.8)	140.2, 9, < 0.0001
Studies from Turkey	7 (583; 376)	76.3 (60.9-87.0)	61.0 (56.6-65.2)	91.1 (842-95.0)	67.5, 6, < 0.0001
Studies that only recruited neonates	6 (292; 339)	85.6 (78.5-90.6)	85.1 (80.7-88.7)	54.3 (0.0-81.7)	11.0, 5, 0.052
Studies with children of all other ages except neonates	42 (5,181; 2,372)	49.7 (42.9-56.5)	45.1 (43.6-46.6)	94.7 (93.6-95.6)	778.7 41 < 0.0001

 I^2 statistic used to estimate heterogeneity between pooled studies: $I^2 >= 75\%$ was considered as high heterogeneity

י ר
2
3
4
5
6
7
8
9
10
11
12
13
17
14
16
10
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 9 0 11 22 23 24 25 26 27 8 9 30 31 32 34
18
19
20
21
22
23
24
25
26
27
28
20
20
50 21
31
32
33
34
35
36
37
31 32 33 34 35 36 37 38
39
40
41
42
43
43 44
44 45
45 46
47

Predictors	k	b-coefficient	se	t-value	p-value	ci.lb	ci.ub	F-value	I^2 (%)	R^2 (%)	QE
year+ cilinical setting+quality score+design+country group+total sample size	48							5.111	95.11	37.52	642.96, p < 0.0001
year		-0.0146	0.0598	-0.2442	0.8083	-0.1354	0.1062				
total study sample size		0.0002	0.0017	0.1016	0.9196	-0.0033	0.0037				
country group		1.3197	0.3853	3.425	0.0014**	0.5415	2.0979				
clinical setting		-2.1096	0.5059	-4.17	0.0002***	-3.1313	-1.0879				
design group (cohort vs other)		0.4242	0.3570	1.1883	0.2415	-0.2967	1.1451				
quality score		0.2066	0.1493	1.3836	0.174	-0.0949	0.5081				

k = number of outcomes included in the model fitting; se = standard errors of the coefficients; ci.lb = lower bound of the confidence intervals for the coefficients; ci.lb = lower bound of the confidence intervals for the coefficients; QE = test statistic for the test of (residual) heterogeneity; I^2 = residual heterogeneity / unaccounted variability; R² (amount of heterogeneity accounted for; PICU = pediatric intensive care units, NICU = neonatal intensive care units; *p < 0.05, **p < 0.01, ***p < 0.001

Study	Total number of patients with sepsis	Total number of vitamin D deficient patients with sepsis	Country, setting	Age	Design	Quality score (NOS)
Shah 2016	160	135	India, PICU	1 month to 16 years	cohort	6
Asilioglu 2017	120	20	Turkey, PICU	1 month to ≤18 years	cohort	7
Say 2017	100	87	Turkey, NICU	preterm infants at <37 weeks gestation	case-control	6
Ponnarmeni 2016	62	32	India, PICU	1 to 12 years	case-control	6
McNally 2012	48	33	Canada, PICU	newborn to 17 years	cohort	7
Onwuneme 2015 (2)	46	32	Ireland, NICU	preterm infants at <32 weeks gestation	cohort	8
El-Gamasy 2017	46	20	Egypt, pediatric emergency department	3 months to 12 years	case-control	7
Sankar 2017	43	31	India, PICU	<=17 years	cohort	8

 BMJ Open

Onwuneme 2015 (1)	35	32	Ireland, PICU	<12 years old	case-control	8
Hebbar 2014	30	17	Atlanta, PICU	0 to 18 years	case-control	6
Ebenezer 2016	16	8	India, PICU	<18 years	cohort	6
Korwutthikulrangsri 2015	12	4	Bangkok, PICU	moths (<8/9)	nested-case control	5
Prasad 2015	11	9	India, PICU	2 months to 12 years	cohort	7
Bustos 2016	10	7	Chile, PICU	>37 weeks and < than 15 years	cohort	7
Dayal 2014	9	4	India, tertiary care hospital	3 months to 12 years	cohort	6
			Chile, PICU India, tertiary care hospital			

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

Patient category	Number of studies (Total number of individuals; number of	Pooled proportion (%, 95% CI)	Pooled proportion (%, 95% CI)	Heterogeneity (I ²) %, 95% CI	Q value, d.f. p-value
	vitamin D deficient individuals)	Random effects	Fixed effects		
Excluding studies that used other thresholds	12 (553; 329)	61.4 (43.5-76.6)	59.2 (54.3- 64.0)	91.2 (86.5-94.2)	125.0, 11, < 0.0001
Sample size >=40 (large)	9 (665; 418)	63.9 (44.9-79.4)	62.9 (58.5-67.1)	94.3 (91.2-96.3)	140.1, 8, < 0.0001
Sample size <40 (small)	7 (123; 81)	63.2 (45.0-78.2)	61.2 (51.1-70.4)	66.2 (24.5-84.9)	17.8, 6, 0.0068
Cohort studies	9 (463; 279)	62.6 (40.7-80.4)	61.8 (56.4-67.0)	92.8 (88.6-95.5)	111.5, 8, < 0.0001
Case-control	7 (325; 220)	65.2 (47.3-79.7)	63.7 (57.6-69.3)	87.0 (75.5-93.1)	46.3, 6, < 0.0001
Studies from India	6 (219; 301)	66.4 (48.3-80.7)	70.7 (64.8-75.9)	83.6 (65.7-92.2)	30.5, 5, < 0.0001
Studies from Turkey	3 (260; 135)	59.2 (13.6-93.1)	51.2 (43.2-59.3)	97.8 (95.8-98.8)	90.0, 2, <0.0001
Studies that only included neonates	3 (186, 147)	76.9 (61.9-87.3)	77.7 (70.8-83.3)	74.7 (15.9-92.4)	7.9, 2, 0.019
Studies that included children of all other ages except neonates	13 (602, 352)	60.1 (43.7-74.5)	57.8 (53.1-62.4)	90.8 (86.1-93.9)	130.2, 12, < 0.0001

 $CI = confidence intervals; I^2 = heterogeneity; df = degrees of freedom. Vitamin D deficiency defined in our study as <50 nmol/L (20 ng/mL). I^2 statistic used to estimate heterogeneity between pooled studies: I^2 >= 75% was considered as high heterogeneity$

Page	69	of	77
------	----	----	----


Patient category	Number of studies (Total number of individuals)	Pooled OR (95% CI) Vitamin D deficient/ Vitamin D non-deficient p-value		Heterogeneity (I ²) % (95% CI)	Q value, d.f. p-value	Eggers p-value (4d.p)
		Random effects	Fixed effects			
Excluding studies that used other thresholds	14 (2,030)	1.59 (1.05-2.41) p-value = 0.028	1.52 (1.08-2.13) p-value = 0.016	24.3 (0.0-59.9)	17.18, 13, 0.1910	p-value = 0.12
Cohort studies only	14 (2,197)	1.80 (1.15-2.81) p-value = 0.009	1.65 (1.17-2.34) p-value = 0.004	31.3 (0.0-63.7)	18.92, 13, 0.1255	p-value = 0.0423
Studies from India	7 (646)	1.08 (0.70-1.69) p-value = 0.710	1.08 (0.70-1.69) p-value = 0.710	0.0 (0.0-62.4)	4.56, 6, 0.589	Number of studies (k= too small to test for sma study effects (k.min=10

CI = Confidence Intervals; I² = I squared statistic used to estimate heterogeneity (inconsistency); df = degrees of freedom, results reported in 1 decimal place; OR= odds ratio. Vitamin D deficiency defined as < 50 nmol/L or 20 ng/ml. We used the I² statistic to estimate heterogeneity between pooled studies: I² >= 75% was considered as high heterogeneity.

Additional Figures

Additional Figure 1 Funnel plot of studies of prevalence of vitamin D deficiency in critically ill children. Horizontal axis shows logit transformed proportion and the standard error of the logit transformed proportion is plotted on the vertical axis. Each dot represents an individual study and the vertical line represents the pooled proportion from a random-effects meta-analysis. The diagonal lines represent pseudo 95% confidence limits (p = 0.015, Egger's test)

Funnel Plot with pseudo 95% Confidence Intervals



BMJ Open

Additional Figure 2. Pooled prevalence estimate for vitamin D deficiency in critically ill children (by country group). Forest plot shows results from the random effects model. Diamonds represent pooled proportion of vitamin D deficiency for the countries in each subgroup (group 1, group2, group 3). The diamond at the bottom shows the overall pooled estimate of all the 48 studies. Each square shows the prevalence estimate of each study and the horizontal line across each square represents the 95% confidence interval (CI) of the prevalence estimate.


)	Study	VD deficient (n)	Total (N)		Prevalence	95% CI	Weight
	group1		1000 C 1000				1997 (1998) -
	Madden 2012	205	511		0.40	[0.36; 0.45]	2.3%
	Lopez 2016 Garcia-Soler 2017	84 149	347 340		0.24 0.44	[0.20; 0.29] [0.38; 0.49]	2.3%
	McNally 2012	225	326		0.44	[0.64; 0.74]	2.3%
	Rippel 2012	109	316		0.34	[0.29; 0.40]	2.3%
	Alonso 2015	45	288		0.16	[0.12; 0.20]	2.2%
	Ayulo 2014	61	216		0.28	[0.22; 0.35]	2.3%
	Rey 2014	46	156		0.29	[0.22; 0.37]	2.2%
	Onwuneme 2015 (1)	71	120		0.59	[0.50; 0.68]	2.2%
	Onwuneme2015 (2)	86	94		0.91	[0.84; 0.96]	2.0%
	Bustos 2016 Hurwitz 2017	39 11	90 90		0.43	[0.33; 0.54] [0.06; 0.21]	2.2% 2.1%
	Binks 2014	11	90 74		0.12	[0.08; 0.21]	2.1%
	Roth 2009	3	64	-	0.05	[0.01; 0.13]	1.6%
	Hebbar 2014	37	61		0.61	[0.47; 0.73]	2.1%
	Alvarez 2016	29	50		0.58	[0.43; 0.72]	2.1%
	Moreno-Solis 2015	9	48		0.19	[0.09; 0.33]	2.0%
	Inamo 2011	8	28		0.29	[0.13; 0.49]	1.9%
	Random effects model		3219		0.36	[0.28; 0.45]	38.5%
	Heterogeneity: $I^2 = 95.6\%$, τ^2	= 0.6310, <i>p</i> < 0.01					
	group2	100	050	_	0.40	10 10 0 5 11	0.00/
	Asilioglu 2017 Jia 2017	120 92	250 110		0.48 0.84	[0.42; 0.54]	2.3% 2.1%
	Halwany 2017	38	102		0.84	[0.75; 0.90] [0.28; 0.47]	2.1%
	Say 2017	87	100		0.87	[0.79; 0.93]	2.1%
,	Sakka 2014	89	96		0.93	[0.86; 0.97]	2.0%
	Cayir 2014	50	88	<u> </u>	0.57	[0.46; 0.67]	2.2%
	Badawi 2017	39	88		0.44	[0.34; 0.55]	2.2%
	Yaghmaie 2017	53	82		0.65	[0.53; 0.75]	2.2%
	Basha 2014	53	81		0.65	[0.54; 0.76]	2.2%
	El-Gamasy 2017	26 29	80 79		0.32	[0.22; 0.44]	2.2%
	Banajeh 2009 Cetinkaya 2015	29 42	79 50		0.37 0.84	[0.26; 0.48] [0.71; 0.93]	2.2%
	Ahmed 2014	42	50		0.30	[0.18; 0.45]	2.0%
	Cizmeci 2015	28	40	-	0.70	[0.53; 0.83]	2.0%
	Khakshour 2015	9	37		0.24	[0.12; 0.41]	2.0%
	Elmoneim 2016	17	30		0.57	[0.37; 0.75]	2.0%
	Dinlen 2016	26	30		0.87	[0.69; 0.96]	1.7%
	Karatekin 2009	23	25		0.92	[0.74; 0.99]	1.4%
	Random effects model		1418		0.63	[0.52; 0.72]	37.0%
	Heterogeneity: $I^2 = 92\%$, $\tau^2 =$	0.7717, p < 0.01					
,	group3						
	Shah 2016	128	154		0.83	[0.76; 0.89]	2.2%
	Ponnarmeni 2016	63	124		0.51	[0.42; 0.60]	2.2%
	Sankar 2016	75	101		0.74	[0.65; 0.82]	2.2%
	Dayal 2014	23	92 80		0.25	[0.17; 0.35]	2.2%
	Prasad 2015 Wayse 2004	67 76	80		0.84	[0.74; 0.91] [0.88; 0.99]	2.1% 1.8%
	Ebenezer 2016	21	52		0.40	[0.27; 0.55]	2.1%
	Narang 2016	28	50		0.56	[0.41; 0.70]	2.1%
	Jat 2016	42	50		0.84	[0.71; 0.93]	2.0%
	Sankar 2017	31	43		0.72	[0.56; 0.85]	2.0%
	Korwutthikulrangsri 2015		32		0.78	[0.60; 0.91]	1.9%
-	Roth 2010	21	25		0.84	[0.64; 0.95]	1.7%
	Random effects model	1 0010	883		0.71	[0.58; 0.82]	24.5%
	Heterogeneity: $I^2 = 92.5\%$, τ^2	= 1.0012, <i>p</i> < 0.01					
	Random effects model		5520	<u> </u>	0.55	[0.48; 0.62]	100.0%
,	Heterogeneity: $I^2 = 95.0\%$, τ^2	= 0.8587, <i>p</i> < 0.01	1.0000000000 00 00500				
				0.2 0.4 0.6 0.8			

Additional Figure 3. Pooled prevalence estimates for vitamin D deficiency in critically ill children (neonates versus all other age groups). Forest plot shows results from the random effects model. Diamonds represent pooled proportion of vitamin D deficiency for the studies in neonates and all other age groups. The diamond at the bottom shows the overall pooled estimate of all the 48 studies. Each square shows the prevalence estimate of each study and the horizontal line across each square represents the 95% confidence interval (CI) of the prevalence estimate.

Study	VD deficient (n)	Total (N)		Prevalence	95% CI	Weig
neonates						
Karatekin 2009	23	25		0.92	[0.74; 0.99]	1.
Cizmeci 2015	28	40	· · · ·	0.70	[0.53; 0.83]	2.
Dinlen 2016	26	30		0.87	[0.69; 0.96]	1.
Cetinkaya 2015	42	50	· · · · · · · · · · · · · · · · · · ·	0.84	[0.71; 0.93]	2.
Onwuneme2015 (2)	86	94		0.91	[0.84; 0.96]	2
Say 2017	87	100		0.87	0.79; 0.93	2
Random effects model		339		0.86	[0.78; 0.91]	11
Heterogeneity: $I^2 = 54.3\%$,					Terres ere of	
other						
Rippel 2012	109	316		0.34	[0.29; 0.40]	2
Jia 2017	92	110		0.84	[0.75; 0.90]	2
Halwany 2017	38	102		0.37	[0.28; 0.47]	2
Sakka 2014	89	96		0.93	[0.86; 0.97]	2
Hurwitz 2017	11	90		0.12	[0.06; 0.21]	2
Basha 2014	53	81		0.65	[0.54; 0.76]	2
Wayse 2004	76	80	-	0.95	[0.88; 0.99]	1
Banajeh 2009	29	79		0.37	[0.26; 0.48]	2
Binks 2014	11	74		0.15	[0.08; 0.25]	2
Narang 2016	28	50		0.56	[0.41; 0.70]	2
Ahmed 2014	15	50		0.30	[0.18; 0.45]	2
Khakshour 2015	9	37		0.24	[0.12; 0.41]	2
Moreno-Solis 2015	9	48		0.19	0.09; 0.33	2
Inamo 2011	8	28		0.29	0.13, 0.49	1
Roth 2010	21	25		0.84	[0.64, 0.95]	1
Roth 2009	3	64		0.05	[0.01; 0.13]	1
Madden 2012	205	511		0.40	[0.36; 0.45]	2
Lopez 2016	84	347		0.24	[0.20; 0.29]	2
	149	340		0.44		2
Garcia-Soler 2017	225	340			[0.38; 0.49]	
McNally 2012				0.69	[0.64; 0.74]	2
Alonso 2015	45	288		0.16	[0.12; 0.20]	2
Asilioglu 2017	120	250		0.48	[0.42; 0.54]	2
Ayulo 2014	61	216		0.28	[0.22; 0.35]	2
Rey 2014	46	156		0.29	[0.22; 0.37]	2
Shah 2016	128	154		0.83	[0.76; 0.89]	2
Ponnarmeni 2016	63	124		0.51	[0.42; 0.60]	2
Onwuneme 2015 (1)	71	120		0.59	[0.50; 0.68]	2
Sankar 2016	75	101		0.74	[0.65; 0.82]	2
Dayal 2014	23	92	— ·	0.25	[0.17; 0.35]	2
Bustos 2016	39	90		0.43	0.33, 0.541	2
Cavir 2014	50	88		0.57	[0.46; 0.67]	2
Badawi 2017	39	88		0.44	[0.34; 0.55]	2
Yaghmaie 2017	53	82		0.65	[0.53; 0.75]	2
Prasad 2015	67	80		0.84		2
El-Gamasy 2017	26	80		0.84	[0.74; 0.91] [0.22; 0.44]	2
	20					
Hebbar 2014		61		0.61	[0.47; 0.73]	2
Ebenezer 2016	21	52		0.40	[0.27; 0.55]	2
Alvarez 2016	29	50		0.58	[0.43; 0.72]	2
Jat 2016	42	50		0.84	[0.71; 0.93]	2
Sankar 2017	31	43		0.72	[0.56; 0.85]	2
Korwutthikulrangsri 2015		32		0.78	[0.60; 0.91]	1
Elmoneim 2016	17	30		0.57	[0.37; 0.75]	2
Random effects model		5181		0.50	[0.43; 0.57]	88
Heterogeneity: $I^2 = 94.7\%$,						
					10 40. 0 001	400
Random effects model		5520		0.55	[0.48; 0.62]	100
Random effects model Heterogeneity: $I^2 = 95.0\%$,		5520		0.55	[0.48; 0.62]	100


BMJ Open

Additional Figure 4 Bubble plots of univariate meta-regressions. Each study is represented by a circle. Predictor variables: A study design, B year of publication, C quality score and D total children are plotted on the x-axis with the effect measure "logit transformed proportion" shown on the vertical (y-axis).



Additional Figure 5 Funnel plot for prevalence of vitamin D deficiency in critically ill children with sepsis. Horizontal axis shows logit transformed proportion and the standard error of the logit transformed proportion is plotted on the vertical axis. Each dot represents an individual study and the vertical line represents the pooled proportion from a random-effects meta-analysis. The diagonal lines represent pseudo 95% confidence limits (p = 0.828, Egger's test).

Funnel Plot with pseudo 95% Confidence Intervals



Logit Transformed Proportion


BMJ Open

Additional Figure 6 Pooled prevalence estimate for vitamin D deficiency in critically ill children with sepsis (subgroup analysis by study design). Forest plot shows results from the random effects model. Diamonds represent the pooled proportion of vitamin D deficiency for the studies in each subgroup (case-control and cohort). The diamond at the bottom shows the overall pooled estimate of all the 16 studies. Each square shows the prevalence estimate of each study and the horizontal line across each square represents the 95% confidence interval (CI) of the prevalence estimate.

12								
13	Study	VD deficient (n)	Total (N)			Prevalence	95% CI	Weight
14	case_control				_			
15	Say 2017 Ponnarmeni 2016	87 32	100 62			0.87	[0.79; 0.93] [0.39; 0.65]	6.8% 6.9%
16	El-Gamasy 2017	20	46			0.43	[0.29; 0.59]	6.8%
17	Cizmeci 2015	28 32	40 35			- 0.70 0.91	[0.53; 0.83]	6.6% 5.6%
18	Onwuneme 2015 (1) Hebbar 2014	32 17	30			0.91	[0.77; 0.98] [0.37; 0.75]	6.5%
19	Korwutthikulrangsri 2015		12		<u>_</u>	0.33	[0.10; 0.65]	5.5%
20	Random effects model Heterogeneity: $l^2 = 87\%$, τ^2	$= 0.8288 \ n < 0.01$	325		:	0.65	[0.47; 0.80]	44.7%
21		0.0200, p 0.01						
22	cohort Shah 2016	135	160			0.84	[0.78; 0.90]	7.0%
23	Asilioglu 2017	20	120			0.17	[0.10; 0.25]	6.9%
24	McNally 2012 Onwuneme 2015 (2)	33 32	48 46			0.69 0.70	[0.54; 0.81] [0.54; 0.82]	6.7% 6.7%
25	Sankar 2017	31	43			0.72	[0.56; 0.85]	6.6%
26	Ebenezer 2016	8 9	16 11			0.50	[0.25; 0.75]	6.0% 4.8%
27	Prasad 2015 Bustos 2016	9	10			0.82	[0.48; 0.98] [0.35; 0.93]	4.8%
28	Dayal 2014	4	9			0.44	[0.14; 0.79]	5.3%
29	Random effects model Heterogeneity: $I^2 = 92.8\%$,	$\tau^2 = 1.6438, p < 0.01$	463			0.63	[0.41; 0.80]	55.3%
30	Random effects model		788			0.64	[0.50; 0.76]	100.0%
31	Heterogeneity: $l^2 = 90.5\%$,		700	Г		0.04	[0.50, 0.76]	100.0 %
32	-			0.2 0.4	0.6 0.8			
33								
34								
35								
36								
37								
38								
39								
40								
41								
42								
43								
44								


Additional Figure 7 Funnel plot of risk of mortality in vitamin D deficient versus vitamin D non-deficient critically ill children. Horizontal axis shows logit transformed odds ratio and the standard error of the log odds ratio is plotted on the vertical axis. Each dot represents an individual study and the vertical line represents the overall pooled odds ratio from random-effects meta-analysis. The diagonal lines represent pseudo 95% confidence limits (p = 0.084, Egger's test).

Funnel Plot with pseudo 95% Confidence Intervals





Additional Figure 8 Pooled odds ratio (OR) and 95% CI for risk of mortality in vitamin D deficient versus vitamin D non-deficient critically ill children (fixed effects model). Diamond represents the overall odds ratio (with corresponding 95% Confidence Interval). Each square shows the odds ratio of each study and the horizontal line across each square represents the 95% confidence interval (CI) of the estimate.



BMJ Open

Importance of vitamin D in acute and critically ill children with subgroup analyses of sepsis and respiratory tract infections: a systematic review and meta-analysis

Journal:	BMJ Open
Manuscript ID	bmjopen-2018-027666.R1
Article Type:	Research
Date Submitted by the Author:	18-Jan-2019
Complete List of Authors:	Cariolou, Margarita; Imperial College London School of Public Health, Epidemiology and Biostatistics Cupp, Meghan; Imperial College London School of Public Health, Epidemiology and Biostatistics Evangelou, Evangelos; Imperial College London School of Public Health, Epidemiology and Biostatistics; University of Ioannina School of Medicine, Department of Hygiene and Epidemiology Tzoulaki, Ioanna; Imperial College London, Epidemiology and Public Health; University of Ioannina School of Medicine, Department of Hygiene and Epidemiology Berlanga-Taylor, Antonio; Imperial College London School of Public Health, Epidemiology and Biostatistics
Primary Subject Heading :	Epidemiology
Secondary Subject Heading:	Paediatrics, Research methods
Keywords:	Vitamin D, EPIDEMIOLOGY, meta-analysis, sepsis, PAEDIATRICS, INTENSIVE & CRITICAL CARE

SCHOLARONE[™] Manuscripts

1		
2		
3 4	1	
5		
6 7	2	Importance of vitamin D in acute and critically ill children with subgroup analyses of
8 9 10	3	sepsis and respiratory tract infections: a systematic review and meta-analysis
11 12 13	4	
14 15 16	5	Margarita Cariolou ¹ MPH, Meghan A. Cupp ¹ MPH, Evangelos Evangelou ^{1,2} PhD, Ioanna
17 18	6	Tzoulaki ^{1,2} PhD and Antonio J. Berlanga-Taylor ^{1*} DPhil
19 20 21	7	¹ MRC-PHE Centre for Environment and Health, Department of Epidemiology & Biostatistics,
22 23 24	8	School of Public Health, Faculty of Medicine, Imperial College London, St Mary's Campus,
25 26	9	Norfolk Place, UK, LONDON W2 1PG
27 28 29	10	² Department of Hygiene and Epidemiology, University of Ioannina Medical School, Ioannina,
30 31 32	11	Greece
33 34	12	*Correspondence should be addressed to Dr. Antonio J. Berlanga-Taylor
35 36 37	13	(a.berlanga@imperial.ac.uk), MRC-PHE Centre for Environment and Health, Department of
38 39	14	Epidemiology & Biostatistics, School of Public Health, Faculty of Medicine, Imperial College
40 41 42	15	London, St Mary's Campus, Norfolk Place, LONDON W2 1PG.
43 44 45	16	
46 47 48	17	
49 50 51	18	
52 53 54 55 56	19	
57 58		1
59 60		For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

1 ABSTRACT

Objectives: To estimate the prevalence of 25-hydroxyvitamin D (25(OH)D) deficiency and
investigate its association with mortality in children with acute or critical conditions.

Design: Systematic review and meta-analysis of observational studies.

5 Data sources: PubMed, OVID, Google Scholar and the Cochrane Library searched until 21
6 December 2018.

7 Eligibility criteria: Studies of children hospitalised with acute or critical conditions who had
8 blood 25(OH)D levels measured.

9 Data extraction and synthesis: We obtained pooled prevalence estimates of 25(OH)D deficiency
10 and odds ratios for mortality. We calculated 95% confidence and prediction intervals and
11 investigated heterogeneity and evidence of small-study effects.

Results: Fifty-two studies were included. Of 7,434 children, 3,473 (47.0%) were 25(OH)D deficient (<50 nmol/L). The pooled prevalence estimate of 25(OH)D deficiency was 54.6% (95% CI 48.5-60.6, $I^2=95.3\%$, p<0.0001). Prevalence was similar after excluding smaller studies (51.5%). In children with sepsis (18 studies, 889 total individuals) prevalence was 64.0% (95% CI 52.0-74.4, $I^2=89.3\%$, p<0.0001) and 48.7% (95% CI 38.2-59.3; $I^2=94.3\%$, p<0.0001) in those with respiratory tract infections (RTI) (25 studies, 2,699 total individuals). Overall, meta-analysis of mortality (18 studies, 2,463 total individuals) showed increased risk of death in 25(OH)D deficient children (OR 1.81, 95% CI 1.24-2.64, p=0.002, I²=25.7%, p=0.153). A cohort-only sensitivity analysis agreed with the overall observation (n=14, OR 1.80, 95% CI 1.15-2.81, p=0.009, $I^2=31.3\%$, p=0.126) but showed small-study effects (Egger's test p=0.042). Four (22.0%) of 18

1

BMJ Open

studies statistically adjusted for confounders. There were insufficient studies to meta-analyse

2		
3		
4		
5		
6		
7		
8		
9		
1	0	
1	1	
	2	
1	3	
1	4	
	5	
1		
1		
	, 8	
	9	
	0	
2		
	י 2	
	3	
	4	
	5	
	6	
2		
	8	
	9	
	0	
3		
	2	
3		
	4	
	5	
3		
3		
	8	
3	9	
4	0	
4	1	
4		
4	3	
	4	
4	5	
	6	
4		
	8	
	9	
	0	
5		
5		
5	3	
	4	
5		
5		
5		
5		
-	-	

59

60

sepsis and RTI related mortality. 2 3 **Conclusions:** Our results suggest that 25(OH)D deficiency in acute and critically ill children is 4 high and associated with increased mortality. Small-study effects, reverse causation and other biases may have confounded results. Larger, carefully designed studies in homogeneous 5 6 populations with confounder adjustment are needed to clarify the association between 25(OH)D 7 levels with mortality and other outcomes. 8 **Registration** PROSPERO (CRD42016050638) 9 **Copyright** Open access article under terms of CC BY 10 11 Keywords paediatric, vitamin D, intensive care, sepsis, meta-analysis, prevalence, mortality, 12 systematic review, respiratory tract infections 13 Strengths and limitations of this study 14 • We comprehensively assessed the magnitude and relevance of vitamin D (25(OH)D) 15 circulating levels in paediatric acute and critically ill patients using a large number of 16 studies with large total sample size with pre-specified sub-group and sensitivity analyses. 17 • We used PRISMA and MOOSE guidelines for reporting. 18 • We used the currently recommended cut-off of less than 50 nmol/L for vitamin D 19 deficiency. 20 • We did not find enough studies to perform meta-analyses for mortality from sepsis or 21 22 respiratory tract infection in relation to vitamin D status. • We did not identify longitudinal studies with multiple time-point, pre-admission or pre-23 disease vitamin D measurements. 24 Most studies were single centre with heterogeneous patient groups and few controlled for 25 • 26 important confounders that influence vitamin D levels such as age, BMI, gender, season of measurements, vitamin D supplementation and comorbidities. 27

1 INTRODUCTION

Vitamin D is an essential nutrient^{1, 2} representing a group of fat soluble secosteroids with key endocrine functions.³ It is synthesized in the skin upon sunlight exposure⁴ while dietary sources, such as oily fish, egg yolk, certain fungi and supplements, are usually secondary sources. Vitamin D is critical in bone metabolism⁵ and calcium homeostasis,⁶ as well as acting as an important regulator in extra-skeletal metabolic processes,⁷ cardiovascular and immune systems.⁸ Many observational and laboratory studies have observed the anti-inflammatory properties of vitamin D,⁹ including direct regulation of endogenous anti-microbial peptide production.¹⁰

It is therefore crucial for humans to have sufficient vitamin D levels to maintain bone health and possibly improve response to infection.^{6, 11, 12} Infants and children are especially dependent on vitamin D to achieve healthy bone development and growth.^{13, 14} Well-known functional outcomes of adequate vitamin D levels in children include rickets prevention, higher bone mineral content and reduced bone fracture rates.^{5, 14} In otherwise healthy children in the United States, the reported prevalence of vitamin D deficiency (250HD levels of < 25 nmol/L) ranges from 9 to 18%.¹⁵ The Endocrine Society Clinical Practice Guidelines and the Institute of Medicine (IOM) suggest that 25(OH)D levels less than 50 nmol/L (20 ng/mL) reflect a deficient state.^{4, 16}

Studies in adults reflect a high prevalence of vitamin D deficiency both in general intensive care
unit (ICU) and sepsis patients and strongly suggest an association between low vitamin D and poor
clinical outcomes, including increased mortality, particularly in those suffering from sepsis.^{2, 17}
Recent clinical trials of vitamin D supplementation in adults appear promising in both general
critical care^{18, 19} and sepsis.²⁰

BMJ Open

Sepsis remains a challenging clinical entity with high social and economic costs.²¹ Each year there are approximately 123,000 sepsis cases and around 37,000 deaths in England alone.²² Recent reports show an increased prevalence of paediatric sepsis,²³ likely a reflection of an increased population with chronic comorbidities, higher rates of opportunistic infections and multi-drug resistant organisms.²⁴ Respiratory tract infections account for a large proportion of underlying diagnoses in acute and critical care conditions^{24, 25} but remain understudied.²⁶

The magnitude, relevance and quality of evidence of vitamin D deficiency in children receiving
acute care is not clear. Several recent studies have addressed these questions with mixed results.
We sought to summarise the evidence regarding the implications of vitamin D deficiency and its
prevalence in general acute care, ICU, respiratory tract infection and sepsis patients in the
paediatric population. We carried out a systematic review and meta-analysis of circulating vitamin
D levels, as measured by 25(OH)D, to assess the prevalence of vitamin D deficiency (≤ 50 nmol/L)
and its association with mortality in these conditions.

15 METHODS

We planned and conducted our systematic review and meta-analysis according to the PRISMA guidelines²⁷ (*Additional Table 1*). We also followed the Meta-Analysis of Observational Studies in Epidemiology (MOOSE) guidelines²⁸ as no relevant randomized controlled trials have been reported.

20 Search strategy and selection criteria

Our population of interest consists of paediatric patients with acute conditions and/or those treated in ICU or emergency units for acute conditions whose vitamin D status was assessed prior to or during admission. We included published cross sectional, case-control and cohort studies that measured circulating 25(OH)D levels and either reported prevalence, odds ratios (OR) or data to enable calculation of these measures. Studies were excluded if they were reviews, case reports, surveys, commentaries, replies, not original contributions, experimental *in vitro* or if they recruited patients who were not treated in emergency, neonatal intensive care units (NICUs), paediatric intensive care units (PICUs) or for acute conditions. Studies were also excluded if they only enrolled vitamin D deficient patients, investigated healthy populations only or did not measure circulating 25(OH)D levels as an indicator of vitamin D status. When we identified more than one publication utilising the same cohort, we included the publication which shared our review's objective to investigate vitamin D levels and prevalence of deficiency.

For purposes of our review, we classified vitamin D deficiency as being 25(OH)D less than 50 nmol/L (equivalent to 20 ng/mL), as suggested by the IOM.¹⁶ Different age categories were used to designate patients as "children" in the studies reviewed. We therefore included all "children" (neonates up to 21 years) as defined by each treating facility and this included "neonates", "infants", "toddlers", "children" and "adolescents".

We searched PubMed, OVID, Google Scholar and the Cochrane Library from inception up until 21st December 2018, with no language restrictions. Search terms used across these databases included: "critical care", "vitamin D", "pediatric", "child", "neonate", "toddler", "intensive care unit", "sepsis" and "septic shock". Search terms used in OVID and PubMed are listed in the *Additional Tables 2A and 2B*. Literature searches were performed by two investigators independently (MC and AJBT) and included initial screening of titles and abstracts, followed by

BMJ Open

full text screening. Any disagreements for study eligibility were resolved by discussion between the two investigators. Reference lists of the selected papers, including reviews, were also checked for relevant titles. Abstracts of relevant titles were then assessed for eligibility. Corresponding authors were contacted to obtain additional information if necessary. A data extraction form was designed a priori in Excel. Variables extracted from each study included year of publication, country of study, clinical setting, cut-off given to define vitamin D deficiency, total number of children, total number of cases, study design and age range.

Study quality assessment

The quality of each included study was assessed using the Newcastle-Ottawa Scale (NOS) for cohort, case-control and cross-sectional study designs (Additional Tables 3A, 3B and 3C).²⁹ We classified studies as low (1-3), medium (4-6) or high quality (7-9) for purposes of sensitivity 4.04 analysis.

Prevalence and mortality outcomes

In the majority of studies (n = 40), prevalence of vitamin D deficiency was extracted as reported with a threshold of \leq 50 nmol/L. If prevalence was not reported directly, it was calculated using data provided in each study (cases \leq 50 nmol/L / total number of study participants) (*Additional* Table 4A and 4B). Extracted or calculated prevalence values were then combined in a meta-analysis. For mortality, we calculated unadjusted odd ratios (OR) as:

OR = (vitamin D deficient patients who died * vitamin D non-deficient patients who did not die)/ (vitamin D deficient patients who did not die * vitamin D non-deficient patients who died)

We had sufficient information to calculate ORs < 50 nmol/L for 40 studies (77.0%). For the 12 studies with insufficient information, we used the lower cut-off values reported as a conservative approximation (*Additional Table 5*). We converted 25(OH)D values using: nmol/L = ng/mL * 2.496.

5 Data analysis

We obtained proportions of vitamin D deficiency with 95% confidence intervals (CI) using the Clopper-Pearson method³⁰ in R. We used a random effects model³¹ to account for the variation observed within and between studies due to the different ages and acute conditions in the populations considered. For each meta-analysis we also obtained the 95% prediction interval (PI) to further account for between study heterogeneity. This helps to evaluate how consistent an observed effect would be in a future study that will investigate the same association.³² We obtained pooled proportions and pooled ORs with fixed effect model for sensitivity analysis or in cases where heterogeneity was low.³³⁻³⁵ For prevalence we also calculated median and interguartile range (IQR) for comparisons with pooled prevalence estimates.

We investigated possible sources of heterogeneity using sensitivity and subgroup analyses. Cochran's Q was used to assess the heterogeneity and the I² statistic was used to estimate the percentage of total variation across studies which can be attributed to heterogeneity. Confidence intervals of I^2 were calculated to aid interpretation.³⁶ A Q value of < 0.05 was considered significant and an I² statistic greater or equal to 75% indicated a high level of variation due to heterogeneity.^{37, 38} We used Egger's regression test to present results of small-study effects and funnel plot asymmetry³⁹ and generated funnel plots for visual assessment and screening. A p-value < 0.05 indicated evidence of small-study effects. With few studies, Egger's test has low power to

BMJ Open

detect such bias, therefore we only estimated small-study effects for analyses with more than ten
studies.⁴⁰ When small-study effects were detected based on this threshold, we used trim-and-fill
methods to add potentially missed studies and re-calculate an adjusted pooled estimate.⁴¹

To further assess heterogeneity, we utilised meta-regression to identify predictor variables that could explain variation in study prevalence estimates. We used restricted maximum likelihood (REML) estimations in the model to account for residual heterogeneity⁴² and the Knapp-Hartung method to adjust confidence intervals and test statistics. This method estimates between study variance using a t-distribution, rather than a z-distribution, vielding a more conservative inference.⁴³ We tested the following continuous predictors: year of study publication, total sample size and quality score. Categorical variables included study setting (PICU, NICU), study design (case-control, cross-sectional and cohort) and country group by geographic region and economic development (group 1, group 2, and group 3) and were dummy coded.

We used R version 3.5.0 and Microsoft Excel 2010 for analyses and data collection. The R
packages "meta"⁴⁴ and "metafor"⁴⁵ were used for analyses. Only results of the random effects
model are reported for prevalence due to the expected heterogeneity between populations being
considered. Our protocol is registered in PROSPERO (CRD42016050638).

17 Role of the funding source

The study received funding from the UK Medical Research Council. The funders had no role in
data collection, analysis, interpretation or writing of the report. All authors had access to the data
in the study.

21 Patient involvement

1 No patients were involved in this study. We only used data from previously published studies.

RESULTS

Screening and study characteristics

After title and abstract screening, we identified 2,890 potentially relevant studies (Figure 1) and eighty-five full text articles were assessed for eligibility. Rationale for study exclusion included: studies including adults, study populations other than critically ill children or with acute conditions, studies of circulating vitamin D levels and deficiency in healthy children or in children with chronic conditions. Four studies⁴⁶⁻⁴⁹ were excluded due to insufficient data reporting (Additional Table 6). We also excluded three studies⁵⁰⁻⁵² that used the same cohort of children and included a single study to represent the cohort.⁵³ Ultimately, 52 studies met criteria for inclusion (Additional Table 7).

Figure 1 Flow chart of study selection process

The primary objective of most included studies was to determine circulating vitamin D concentration ("status") in children and/or prevalence of vitamin D deficiency. Secondary objectives included investigation of associations between deficiency of circulating vitamin D and various outcomes, such as hospital mortality length of stay, requirement of ventilation and/or illness severity (*Additional Table 8*).

All included studies reported vitamin D measurement assay methods used (*Additional Table 9*)
and stated that samples were collected and analysed within the first 24 hours of hospital admission.
Studies reported ethical approval and consent for participation from parents or guardians
(*Additional Table 10*). Included studies were published between 2004 and 2018, with the majority

Page 11 of 84

BMJ Open

(n = 40, 77.0%) published between 2014 and 2017 (*Additional Table 7*). In total, 7,434 children
were hospitalized in paediatric or neonatal intensive care units or emergency units or for acute
conditions. Sample sizes of critically ill children ranged from 25⁵⁴ to 1,016.⁵⁵ In 18 studies the
total number of cases was greater than 100.

Studies originated from 15 countries, with the majority from $India^{8, 56-65}$ (n = 11) or Turkey^{54, 66-71} (n = 7) (Additional Table 7). All were of medium or high quality (NOS score median 6.5, range 4-8). The score range for cohort studies was 6 to 8 (n = 22), for case-control studies 5 to 8 (n = 26) and for cross sectional 4 to 6 (n = 4). Studies used a broad range of ages to classify patients as "children". Seven studies (13.5%)^{54, 65, 67, 69-72} included only neonates. In two^{67, 72} of these studies, neonates were preterm. The largest age range was seen in the study of Ayulo et al 2014, which included individuals between 1 and 21 years of age (Additional Table 11). Forty-two of the included studies (80.8%) included patients admitted for medical conditions and the other ten^{53, 61,} ^{66, 73-78} included both surgical and medical patients. Of the 52 included studies 26 used a control group and had a total number of 2,479 controls of which 773 (31.2%) were vitamin D deficient.

All studies included both female and male participants. For mortality, four of the 18 studies (22.0%) carried out multivariate regression analysis with adjustment for confounders. The remaining studies presented results using a variety of methods, including Spearman's correlation analysis, chi-square or Fisher's exact tests or descriptive statistics.

20 Prevalence of vitamin D deficiency

We included 52 studies representing a total of 7,434 children hospitalised with critical or acute conditions. Of these, 3,473 (47.0%) were classified as vitamin D deficient (< 50 nmol/L).

L	Prevalence of deficiency ranged from $5.0\%^{79}$ to $95.0\%^{60}$, median (IQR) 56.3% (31.9 to 75.2%)
2	(Additional Table 12). Sample sizes ranged from 25 to 1,016, with a median of 82 individuals
3	(Additional Table 13). Using a random effects model, the pooled prevalence estimate of vitamin
ļ	D deficiency was 54.6% (95% CI 48.5-60.6) with a high proportion of variation attributed to
5	heterogeneity ($I^2 = 95.3\%$, 95% CI 94.5-96.0, p < 0.0001) (<i>Figure 2</i>) and evidence of funnel plot
5	asymmetry ($p = 0.01$, Egger's test) (<i>Table 1</i> and <i>Additional Figure 1</i>). Trim and fill analysis
7	estimated 11 unpublished studies in the lower left-hand side of the funnel plot (Additional Figure
3	1). The re-calculated adjusted pooled estimate was lower 43.6% (95% CI 37.5-50.0) with
)	significant heterogeneity ($p < 0.0001$).

		sepsi	is or respirato	ry tract infections	5		
Patient category	Number of studies (Total number of individuals; number of deficient individuals)	Pooled proportion (%, 95% CI) Random effects	95% PI	Pooled proportion (%, 95% CI) Fixed effects	Heterogeneity (1 ²) % (95% CI)	Q value, d.f. p-value for heterogeneity	Eggers p-value
All children (includes those with sepsis and respiratory tract infections)	52 (7,434; 3,473)	54.6 (48.5-60.6)	17.5-87.2	45.7 (44.4-46.9)	95.3 (94.5-96.0)	1086.6, 51, < 0.0001	0.01
Critically ill children with sepsis only	18 (889; 565)	64.0 (52.0-74.4)	17.1-93.9	63.0 (59.3-66.6)	89.3 (84.6-92.5)	158.52 17 < 0.0001	0.81
Critically ill children with respiratory tract infections only	25 (2,699; 1,076)	48.7 (38.2-59.3)	9.96-89.1	37.0 (35.0-39.1)	94.3 (92.7-95.6)	423.07 24 < 0.0001	0.05
	< 50 nmol/L (20 ng/ high heterogeneity	mL). I ² statistic u	used to estimate	freedom. Vitamin I e heterogeneity bet			
<u>considered</u> 10 11	< 50 nmol/L (20 ng/ high heterogeneity	(mL). I ² statistic u ; PI = Prediction 1	ised to estimate	e heterogeneity bet	ween pooled stu	dies: $I^2 \ge 75\% v$	was
<u>considered</u> 10 11 12 <i>Figure</i>	< 50 nmol/L (20 ng/	(mL). I ² statistic u ; PI = Prediction 1	ised to estimate	e heterogeneity bet	ween pooled stu	dies: $I^2 \ge 75\% v$	was
<u>considered</u> 10 11 12 <i>Figure</i> 13	< 50 nmol/L (20 ng/ high heterogeneity	(mL). I ² statistic u ; PI = Prediction 1	ised to estimate Interval	e heterogeneity bet	ween pooled stu	dies: $I^2 \ge 75\% v$	was
considered 10 11 12 Figure . 13 14	< 50 nmol/L (20 ng/ high heterogeneity	(mL). I ² statistic u ; PI = Prediction) nce estimate for	ised to estimate Interval	e heterogeneity bet	ween pooled stu	dies: $I^2 \ge 75\% v$	was

Page 13 of 84

BMJ Open

We did not detect material differences in prevalence after exclusion of the 12 studies which did
 not directly report prevalence < 50 nmol/L (53.0%, 95% CI 46.4-59.5; I² = 95.5%, 95% CI (94.5 96.2, p < 0.0001) (*Additional Table 14*).

When examining results by median sample size (defining "large" as ≥ 82 and "small" as < 82), we found that the 26^{8, 53, 55-58, 66-68, 72-74, 77, 78, 80-91} studies with larger sample size included 6,094 total individuals and gave a prevalence estimate of 51.5% (95% CI 43.6-59.4; I² = 96.8%, 95% CI 96.0-97.4, p < 0.0001). The remaining 26 studies with "smaller" sample sizes included 1,340 total children and estimated pooled prevalence as 58.2% (95% CI 47.5-68.2; I² = 90.9%, 95% CI 87.9-93.2, p < 0.0001) (*Additional Table 14*).

We also conducted analysis by study design. Cohort studies (n = 22) yielded a prevalence estimate
of 48.3% (95% CI 40.2-56.5; I² = 95.8%, 95% CI 94.6-96.7, p < 0.0001). In case-control studies
(n = 26) the estimate was 63.4% (95% CI 54.9-71.2; I² = 92.2%, 95% CI 89.8-94.1, p < 0.0001)
and in cross-sectional (n = 4) 34.8% (95% CI 12.8-66.0; I² = 96.7%, 95% CI 94.0-98.2, p < 0.0001)
(*Additional Table 14, Figure 2*).

We assessed whether studies' country of origin influenced results. Studies in India gave an estimate of 68.9% (95% CI 54.9-80.1; $I^2 = 96.7\%$ (95% CI 94.0-98.2, p < 0.0001). Similarly, we found higher pooled prevalence estimates for studies from Turkey (76.3%, 95% CI 60.9-87.0; $I^2 =$ 91.1%, 95% CI 84.2-95.0, p < 0.0001). We also grouped studies by geography and economic development. Group 1: USA, Chile, Australia, Canada, Ireland, Japan, Spain; group 2: South Africa, China, Egypt, Iran, Turkey, Saudi Arabia; and group 3: Bangladesh, Thailand, and India. Prevalence was 37.2% (95% CI 29.7-45.5) for group 1 (n = 20), 61.8% (95% CI 53.2-69.7) for

group 2 (n = 19) and 70.8% (95% CI 58.3-80.7) for group 3 (n = 13) (Additional Figure 2).

3
4
5
6
7
/
8
9
10
11
12
13
14
15
16
17
18
19
20
21
4 5 6 7 8 9 10 11 12 13 14 15 16 7 8 9 10 11 23 24 25 26 27 28 9 30 31 22 33 34 5 36 37 38
∠∠ วว
23
24
25
26
27
28
29
30
31
32
33
34
35
36
34 35 36 37 38
20
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
55 54
54 55
56
57
58
59
60

16

17

18

1 2

1

2

3

4

5

6

Variation attributable to heterogeneity was still high in the three subgroups ($I^2 > 90.0\%$). Given the broad age range in included studies, we combined studies with only neonates^{54, 65, 67, 69-} 72 and observed a prevalence estimate of 83.0% (95% CI 73.1-89.8) with less variation attributable to heterogeneity ($I^2 = 76.6\%$, 95% CI 51.0-88.9, p = 0.0003). In all other studies (n = 45) that included children of other age ranges, estimated prevalence was lower at 49.7% (95% CI 43.5-

55.8; $I^2 = 95.2\%$, 95% CI 94.3-96.0, p < 0.0001) (Additional Table 14, Additional Figure 3). 7

Post-hoc investigation to determine sources of heterogeneity 8

9 To investigate the substantial heterogeneity observed in prevalence estimates, we incorporated study-specific characteristics (year of publication, total study sample size, quality score, study 10 design, country group and clinical setting) as covariates in a random effects meta-regression 11 12 model. We identified clinical setting and country groups as significant predictors, p < 0.01 (Figure 3). We found that the model fitted with all available covariates can explain 29.6% of I² with F =13 4.14, p = 0.002 (Additional Table 15). We also conducted univariate meta-regressions for each of 14 the six predictors (Additional Figure 4).

15

Prevalence of vitamin D deficiency in children with sepsis and in those with respiratory tract 19 infections 20 A total of 889 (median 42, range 9 -160) patients had a diagnosis of sepsis, of which 565 (63.5%) 21

Figure 3 Bubble plots of univariate meta-regressions.

22 were vitamin D deficient. Ten of the eighteen studies including septic patients were cohort (55.6%)

BMJ Open

and eight (44.4%) case-control (Additional Table 16). Most studies originated from India (n = 7) Turkey (n = 3) or Ireland (n = 2) and 16 were published between 2014 and 2017. Thirteen studies took place in a PICU and the remaining^{65, 67, 70, 72} in NICUs. We found that all studies were of medium to high quality (median NOS score 6.5, range 5 - 8). Pooled prevalence of vitamin D deficiency was 64.0% (95% CI 52.0-74.4) (Figure 4) and median (IQR), 68.5% (50.4 to 71.6%). Variation attributable to heterogeneity was high ($I^2 = 89.3\%$, 95% CI 84.6-92.5, p < 0.0001). Funnel plot was symmetric (p > 0.05) suggesting no small-study effects (p = 0.81, Egger's test) (Additional Figure 5).

Figure 4 Pooled prevalence estimate for vitamin D deficiency in children with sepsis.

We also separately analysed studies of patients admitted for respiratory tract infections (n = 25)such as acute lower respiratory tract infection (ALRTI), pneumonia and bronchiolitis. Of these 2,699 total individuals (median 50), 1,076 (39.9%) were vitamin D deficient. These studies were of high to medium quality (median NOS score 7, range 6 - 8). Most originated from India (n = 6)and Spain (n = 4). We found a prevalence estimate of 48.7% (95% CI 38.2-59.3; $I^2 = 94.3\%$, 95% CI 92.7-95.6, p < 0.0001) and median (IQR) at 36.7% (24.3 to 83.6%) with marginally non-significant evidence of bias (p = 0.05, Egger's test) (*Table 1*). We therefore applied the trim and fill method and obtained an adjusted pooled estimate of 37.4% (95% CI 27.6-48.4) after four studies were added.

20 Sensitivity analysis for prevalence in children with sepsis

Exclusion of the studies^{64, 67, 72, 92} utilising thresholds other than < 50 nmol/L for deficiency yielded a similar estimate of prevalence at 62.0% (95% CI 47.3-74.7; $I^2 = 89.7\%$, 95% CI 84.5-93.2, p < 0.0001) (Additional Table 17).

We examined pooled prevalence estimates according to median sample size (< 42 versus \ge 42). Studies with a smaller sample size (n = 9; 204 total individuals) showed a pooled prevalence estimate of 64.7% (95% CI 52.5-75.3) with moderate variation attributable to heterogeneity (I² = 57.9%, 95% CI 11.8-79.9, p = 0.015). For the remaining nine studies (sample sizes \ge 42, 685 total individuals) the estimate was 63.2% (95% CI 44.6-78.5) with high variation attributable to heterogeneity (I² = 94.3%, 95% CI 91.1-96.3, p < 0.0001).

There was no material change in prevalence estimates when analysed according to study design. The ten cohort studies (504 total individuals) gave an estimate of 63.2% (95% CI 43.7-79.1) with high variation attributable to heterogeneity ($I^2 = 92.0$, 95% CI 87.3-94.9 p < 0.0001). Case-control studies (n = 8; 385 total individuals) showed a pooled prevalence of 64.9% (95% CI 50.1-77.3; I^2 = 84.9%, 95% CI 72.0-91.8, p < 0.0001) (*Additional Table 17, Additional Figure 6*).

Studies from India (n = 7) gave a prevalence estimate of 66.0% (95% CI 51.4-78.1); I² = 81.1%,
95% CI 61.8-90.6, p < 0.0001). The three studies from Turkey assessing septic patients gave a
pooled estimate of 59.2% (95% CI 13.6-93.1; I² = 97.8%, 95% CI 95.8-98.8, p < 0.0001)
(*Additional Table 17*).

The pooled prevalence estimate in the four studies^{65, 67, 70, 72} including neonates with sepsis was 73.7% (95% CI 60.3-83.8, $I^2 = 76.0\%$ 34.1-91.3, p = 0.006). The fourteen studies with children of different ages, excluding neonates, gave a pooled estimate of 60.7% (95% CI 45.5-74.0); $I^2 =$ 90.1%, 95% CI 85.2-93.4, p < 0.0001) (*Additional Table 17*). Four of the studies^{56, 61, 87, 89} included children admitted with either sepsis or respiratory tract infections.

21 Mortality in acute and critically ill children

Page 17 of 84

1

BMJ Open

2
3
د ۸
4
5
6
7
8
9
10
11
12
13
14
14 15
15
16 17
17
18
19
20
21
22
22 23 24
24
25
26
27
28
20 29
30
31
32
33
34
35
36
37
38
39
40
41
41
43
43 44
45
46
47
48
49
50
51
52
53
55 54
54 55
56
57
58
59

1	We identified 18 studies ^{8, 53, 56-59, 61, 64, 66, 72, 74-78, 82, 89, 92} assessing vitamin D status and mortality.
2	These studies included a total of 2,463 individuals, from which 220 deaths (17.2%) were observed
3	in 1,278 (51.9%) individuals with vitamin D deficiency and 99 deaths (8.4%) were observed in
4	1,185 individuals without deficiency (48.1%).
5	All 18 studies took place in a PICU apart from one ⁷² , which considered only NICU patients.
6	Sixteen of these studies (89.0%) were published between 2014 and 2017. Fourteen were cohort
7	(77.8%) and four case-controls (22.2%). Almost half ($n = 7$) of the studies originated from India.
8	Quality scores ranged from 5 to 8 with a median of 6.
9	Using a random effects model, we found that vitamin D deficiency in critically ill children
10	significantly increased the risk of death (OR 1.81, 95% CI 1.24-2.64, $p = 0.002$) with low, non-
11	significant heterogeneity ($I^2 = 25.7\%$, 95% CI 0.0-58.0, p = 0.153) (<i>Figure 5</i>). However, small-
12	study effects cannot be easily excluded ($p = 0.084$, Egger's test) (<i>Additional Figure 7</i>) and the 95%
13	prediction interval (0.71-4.62) included the null value.
14	
15 16	Figure 5 Pooled odds ratio (OR) of risk of mortality in vitamin D deficient versus vitamin D non-deficient acute and critically ill children.
17	
18	Sensitivity analysis for mortality in acute and critically ill children
19	We obtained similar results through the fixed effects model (OR 1.72, 95% CI 1.27-2.33, $p =$
20	0.0005) (Additional Figure 8). When excluding studies with thresholds other than < 50 nmol/L
21	indicating deficiency, we found the association between vitamin D deficiency and increased risk
22	of mortality still significant but lower, both with the random (OR 1.59, 95% CI 1.05-2.41, $p =$
23	0.028; I ² = 24.3%, 95% CI 0.00-59.9, p = 0.191) and fixed effect models (OR 1.52, 95% CI 1.08-

2.13, p = 0.016) without clear indication of small-study effects (p = 0.120, Egger's test) (Additional Table 18).

A significant association was also observed in analysis of the 14 cohort studies, both with the random (OR 1.80, 95% CI 1.15-2.81, p = 0.01) and fixed effects model (OR 1.65, 95% CI 1.17-2.34, p = 0.004) with low variation attributable to heterogeneity (I² = 31.3%, 95% CI 0.0-63.7) but significant small-study effects (p = 0.042). Trim and fill analysis estimated five unpublished studies and a non-significant association (OR 1.57, 95% CI 1.09-2.28, p = 0.131). Pooling the four case-control studies together, we obtained a significant positive association with the fixed (OR 1.97, 95% CI 1.02-3.82, p = 0.044) effects model but non-significant with the random effects model (OR 1.97, 95% CI 0.88-4.42, p = 0.098). The association was positive but not-significant when pooling the seven studies from India with the random effects model (OR 1.08, 95% CI 0.70-1.69, p = 0.710; $I^2 = 0.0\%$ 0.0-62.4, p = 0.589) and similar with fixed effects (OR 1.08, 95% CI 0.70-1.69, p = 0.710) (Additional Table 18).

14 Mortality in patients with sepsis and respiratory tract infections

We were unable to identify a sufficient number of studies assessing vitamin D and mortality for meta-analysis in individuals with sepsis. Three studies^{8, 64, 67} measured vitamin D levels in paediatric patients with sepsis. One study⁸ assessed mortality and did not find a significant association in children from 1 to 12 years with sepsis (n=124). None of the studies with children admitted for respiratory tract infections looked at the association between vitamin D deficiency and childhood mortality.

22 DISCUSSION

Page 19 of 84

BMJ Open

Vitamin D deficiency is highly prevalent worldwide, even in countries with abundant sunshine.
 Studies have shown high prevalence of vitamin D deficiency in otherwise healthy children from
 high-income countries (9 to 24%) but also from middle and low-income countries in the Indian
 subcontinent (36 to 90%).⁸

We identified 52 studies representing a total of 7,434 children treated in ICU or emergency units for acute conditions who had blood 25(OH)D levels measured close to or upon admission. Our analysis shows that prevalence of vitamin D deficiency is generally high but very variable (range $5\%^{79}$ to $95\%^{60}$) across ICU and emergency units in the paediatric population, particularly in individuals with sepsis. Importantly, our analysis showed a significantly increased risk of mortality in critically ill children with vitamin D deficiency. We carried out several analyses for sensitivity including fixed effects models, by study design, country group, age and sample size and found generally consistent results. A recently published meta-analysis⁹³ also investigated prevalence of vitamin D deficiency in critically ill children and its association with risk of mortality and showed similar results to ours. The study did not clearly report heterogeneity and small-study effects however, which we found to be critical limitations that must be addressed.

Subgroup analyses in patients with sepsis or respiratory tract infections demonstrated a high
prevalence of vitamin D deficiency, consistent with the increased risk of bacterial or nosocomial
infection in vitamin D deficient individuals identified elsewhere.⁹³

Although sepsis is a leading cause of paediatric mortality and morbidity worldwide,⁹⁴ we found
few studies assessing the relationship between vitamin D status and mortality in this population.
We were unable to identify sufficient studies including patients with sepsis to perform a metaanalysis of vitamin D status and mortality. Sepsis remains an area of unmet need with high social

and financial costs.²⁴ Diagnostic criteria,⁹⁵ a lack of adequate biomarkers⁹⁶ and targeted treatment
remain important challenges in research on sepsis. We did not find studies that assessed the risk
of mortality in relation to vitamin D deficiency in children admitted for respiratory tract infections
either.

Strengths of our review include the large number of studies and large total sample size, allowing a high-powered investigation to identify meaningful associations. For our systematic review and meta-analysis, we followed pre-specified eligibility criteria and used the PRISMA²⁷ and MOOSE guidelines²⁸ for reporting. We carried out multiple sensitivity analyses with few material differences in results. However, we note that the relationship between vitamin D deficiency and mortality was sensitive to study design and studies from India, probably due to the smaller number of individuals in those analyses. As expected for prevalence estimates, heterogeneity across studies was high overall. Only the prevalence analysis with neonates indicated somewhat lower variation attributable to heterogeneity ($I^2 = 76.6\%$) along with a higher prevalence estimate (83.0%) compared to other analyses. We utilised meta-regression to investigate this substantial heterogeneity. From the six variables in our multi-variable model, only clinical setting and country groups were found to be significant predictors of pooled prevalence estimates of vitamin D deficiency and the full model could explain 29.6% of heterogeneity (I^2) . Studies in NICU yielded higher prevalence estimates compared to studies in PICU. Studies from group 3 countries were also associated with higher prevalence estimates compared to studies from countries of group 1 and 2. Other variables, mainly individual patient characteristics such as age and ethnicity, were not directly available to us and may account for significant heterogeneity.

Our systematic review did not identify longitudinal studies with multiple time-point, pre-diseaseor pre-admission vitamin D measurements. The majority of studies were single centre with

Page 21 of 84

BMJ Open

heterogeneous patient groups and relatively small sample sizes. Few studies accounted for important confounders that influence vitamin D levels such as age, gender, BMI, season of measurements, vitamin D supplementation and comorbidities. The relationship observed between vitamin D deficiency and mortality could be due to reverse causation and future studies will need to control for covariates and other confounders. Low vitamin D levels could also represent a chronically deficient state due to reduced sunlight exposure, because of chronic illness, lifestyle factors or different country latitudes. In addition, we cannot rule out measurement bias such as dilution from intravenous fluids. Our results should be interpreted with caution since our review is based on evidence from observational studies. More research is warranted to strengthen the evidence and investigate whether vitamin D could be causally linked to acute or critical illness and what its contribution might be through various mechanisms such as anti-inflammatory or anti-microbial peptide responses.

Although included studies were generally of good quality, sample sizes varied considerably and were typically small. Half of the studies included less than 100 cases and only 10 (19.2 %) had a total sample size of more than 200 individuals. In addition, studies used a variety of definitions and age ranges to designate individuals as children. Our analysis only included mortality as a clinical outcome. A further general limitation is the difference in thresholds for vitamin D deficiency, particularly in the levels which are considered normal for infants and young children. Our assessment used the currently recommended threshold for deficiency $(25(OH)D \le 50)$ nmol/L)¹⁶ and a conservative estimate for studies which used different criteria. Although our review included a large number of studies and individuals, all studies were observational, and results could be subject to small-study effects.

Vitamin D remains an attractive biomarker and potential therapeutic agent in acute and critical care patients. Our review suggests that high quality focussed studies in each relevant paediatric population are needed first, which could then be followed by trials to establish safety and appropriate treatment regimens in children with acute or critical illness.

6 Availability of data and materials

7 Data and computational code used for processing and analysis are available at
 8 <u>https://github.com/margarc/VitaminD_children</u>

9 Author contributions

AJBT conceived the study. AJBT and IT designed the study. MC collected data and performed the
analysis with input from MAC, IT, ABJT and EE. MC and AJBT wrote the manuscript with
contributions from all authors.

13 Declaration of interests

- 14 The authors declare no conflicts of interest.
- **Funding** Medical Research Council UK

16 Acknowledgements

17 AJBT was supported by the Medical Research Council (UK MED-BIO Programme Fellowship,

18 MR/L01632X/1).

Ethics committee approval: Not applicable.

1		
2		
3	1	
4		
5	2	
6		
7	3	Main Figures
8	-	
9 10	4	Figure 1 Flow chart of study selection process
11	5	Figure 2 Pooled prevalence estimate for vitamin D deficiency in acute and critically ill children by study design.
12	6	Forest plot shows results from the random effects model. Each diamond represents the pooled proportion of 25(OH)D
13	7	deficiency for each of the subgroups (case-control, cohort, cross-sectional study designs). The diamond at the bottom
14	8	represents the overall pooled proportion of all the 52 studies together. Each square shows the prevalence estimate of
15		
16	9	each study and the horizontal line across each square represents the 95% confidence interval (CI) of the prevalence
17	10	estimate.
18	11	Figure 3 Bubble plots of univariate meta-regressions. Each study is represented by a circle. Predictor variables;
19	12	A clinical setting and B country groups are shown on the x-axis and the effect measure logit transformed proportion
20	13	shown on the vertical (y-axis). NICU = Neonatal Intensive Care Unit; PICU = Pediatric Intensive Care Unit; grp =
21	14	country group; country group $1 = USA$, Chile, Australia, Canada, Ireland, Japan, Spain; country group $2 = South$
22		Africa, China, Egypt, Iran, Turkey, Saudi Arabia; and country group 3 = Bangladesh, Thailand, and India
23	15	Africa, Cinna, Egypt, fran, Turkey, Saudi Arabia, and country group 5 – Bangiadesh, Thanand, and finda
24	16	Figure 4 Pooled prevalence estimate for vitamin D deficiency in children with sepsis. Forest plot shows result
25	17	from the random effects model. The diamond represents the overall pooled proportion of 25(OH)D deficiency from
26	18	the meta-analysis of the 18 studies. Each square shows the prevalence estimate of each study and the horizontal line
27	19	across each square represents the 95% confidence interval (CI) of the prevalence estimate.
28	10	deross eden square represents the 95% confidence intervar (cr) of the prevalence estimate.
29 30	20	Figure 5 Pooled odds ratio (OR) of risk of mortality in vitamin D deficient versus vitamin D non-deficient acute
30 31	21	and critically ill children. Forest plot shows result from the random effects model. Diamond represents the
32	22	overall OR (with corresponding 95% Confidence Interval). Each square shows the odds ratio of each study and the
33	23	horizontal line across each square represents the 95% confidence interval (CI) of the estimate.
34		
35	24	
36		
37	25	
38		
39	26	
40		Supplementary Material
41	27	Supplementary Material
42		
43	28	Additional Tables
44	20	
45	29	Additional Table 1 PRISMA Checklist 2009
46	30	Additional Table 2A Search terms used in OVID
47	50	Additional Table 2A Seatch terms used in OVID
48 49	31	Additional Table 2B Search terms used in PubMed
49 50	51	
50	32	Additional Table 3A Newcastle Ottawa study quality scoring system (cohort studies)
52		
53	33	Additional Table 3B Newcastle Ottawa study quality scoring system (case-control studies)
54		
55	34	Additional Table 3C Newcastle Ottawa study quality scoring system (cross sectional studies)
56		
57		
58		23
59		For poor roution, only between the improvement of the factor of the state of the st
60		For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

1

1 A	Additional Table 4A	Circulating 25(OH)E	threshold levels us	sed in the selected studies
-----	---------------------	---------------------	---------------------	-----------------------------

- 2 Additional Table 4B Circulating 25(OH)D threshold levels used in the selected studies for prevalence in sepsis
- 3 Additional Table 5 Studies with thresholds other than <50 nmol/L
- 4 Additional Table 6 Excluded studies
- 5 Additional Table 7 Characteristics of the 52 included studies
- 6 Additional Table 8 Objectives and outcomes of included studies
- 7 Additional Table 9 Assay used in each study to measure Vitamin D levels
- 8 Additional Table 10 Funding and ethical approval of included studies
- 9 Additional Table 11 Age groups of children in each study
- Additional Table 12 Prevalence of vitamin D deficiency in each study of acute and critically ill children (sorted from
 highest to lowest)
- 12 Additional Table 13 Characteristics of studies used in the meta-analysis for prevalence
- 13 Additional Table 14 Sensitivity analyses for prevalence of vitamin D deficiency in acute and critically ill children
- 14 Additional Table 15 Multivariate meta-regression model for prevalence
- 15 Additional Table 16 Characteristics of studies included in the meta-analysis for prevalence in individuals with sepsis
- Additional Table 17 Sensitivity analyses for prevalence of vitamin D deficiency in acute and critically ill childrenwith sepsis
- 18 Additional Table 18 Sensitivity analyses for mortality
- 19
- 20

21

60

22 Additional Figures

- Additional Figure 1 Funnel plot of studies of prevalence of vitamin D deficiency in acute and critically ill children
- Additional Figure 2 Pooled prevalence estimate for vitamin D deficiency in acute and critically ill children
 (subgroup analysis by country group)
- Additional Figure 3 Pooled prevalence estimate for vitamin D deficiency in acute and critically ill children (subgroup analysis of neonates versus all other age groups)
- 28 Additional Figure 4 Bubble plots of univariate meta-regressions.
- Additional Figure 5 Funnel plot for prevalence of vitamin D deficiency in acute and critically ill children with sepsis
- Additional Figure 6 Pooled prevalence estimate for vitamin D deficiency in acute and critically ill children with
 sepsis (subgroup analysis by study design)

Page 25 of 84

2 3	1	Additional Figure 7 Funnel plot of risk of mortality in vitamin D deficient versus vitamin D non-deficient acute and
4 5	2	critically ill children
6 7	3 4	Additional Figure 8 Pooled odds ratio and 95% CI for risk of mortality in vitamin D deficient versus vitamin D non- deficient acute and critically ill children (fixed effects model)
7 8 9 10 11 12 13 14 15 16 17 18 90 21 22 23 24 25 26 27 28 90 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 90 51 52 53 54 57 58	4	
59 60		For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

References

1. Shuler FD, Wingate MK, Moore GH, *et al.* Sports health benefits of vitamin d. *Sports health* 2012;4(6):496-501.

2. Verceles AC, Weiler B, Koldobskiy D, *et al.* Association Between Vitamin D Status and Weaning From Prolonged Mechanical Ventilation in Survivors of Critical Illness. *Respir Care* 2015;60(7):1033-9.

3. Braegger C, Campoy C, Colomb V, *et al.* Vitamin D in the healthy European paediatric population. *J Pediatr Gastroenterol Nutr* 2013;56(6):692-701.

4. Holick MF, Binkley NC, Bischoff-Ferrari HA, *et al.* Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. *J Clin Endocrinol Metab* 2011;96(7):1911-30.

5. Holick MF. Vitamin D deficiency. *N Engl J Med* 2007;357(3):266-81.

6. Aranow C. Vitamin D and the immune system. *J Investig Med* 2011;59(6):881-6.

7. Zhang YP, Wan YD, Sun TW, *et al.* Association between vitamin D deficiency and mortality in critically ill adult patients: a meta-analysis of cohort studies. *Crit Care* 2014;18(6):684.

8. Ponnarmeni S, Kumar Angurana S, Singhi S, *et al.* Vitamin D deficiency in critically ill children with sepsis. *Paediatr Int Child Health* 2016;36(1):15-21.

9. Kulie T, Groff A, Redmer J, *et al.* Vitamin D: an evidence-based review. *J Am Board Fam Med* 2009;22(6):698-706.

10. Hewison M. Antibacterial effects of vitamin D. *Nat Rev Endocrinol* 2011;7(6):337-45.

11. Kempker JA, West KG, Kempker RR, *et al.* Vitamin D status and the risk for hospital-acquired infections in critically ill adults: a prospective cohort study. *PLoS One* 2015;10(4):e0122136.

12. Martineau AR, Jolliffe DA, Hooper RL, *et al.* Vitamin D supplementation to prevent acute respiratory tract infections: systematic review and meta-analysis of individual participant data. *BMJ* 2017;356:i6583.

13. Absoud M, Cummins C, Lim MJ, *et al.* Prevalence and predictors of vitamin D insufficiency in children: a Great Britain population based study. *PLoS One* 2011;6(7):e22179.

14. Greer FR. Defining vitamin D deficiency in children: beyond 25-OH vitamin D serum concentrations. *Pediatrics* 2009;124(5):1471-3.

15. Abou-Zahr R, Kandil SB. A pediatric critical care perspective on vitamin D. *Pediatr Res* 2015;77(1-2):164-7.

16. Ross AC, Manson JE, Abrams SA, *et al*. The 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine: what clinicians need to know. *J Clin Endocrinol Metab* 2011;96(1):53-8.

17. Ala-Kokko TI, Mutt SJ, Nisula S, *et al.* Vitamin D deficiency at admission is not associated with 90day mortality in patients with severe sepsis or septic shock: Observational FINNAKI cohort study. *Ann Med* 2016;48(1-2):67-75.

18. Putzu A, Belletti A, Cassina T, *et al.* Vitamin D and outcomes in adult critically ill patients. A systematic review and meta-analysis of randomized trials. *J Crit Care* 2017;38:109-14.

19. Han JE, Jones JL, Tangpricha V, *et al.* High Dose Vitamin D Administration in Ventilated Intensive Care Unit Patients: A Pilot Double Blind Randomized Controlled Trial. *J Clin Transl Endocrinol* 2016;4:59-65.

20. Quraishi SA, De Pascale G, Needleman JS, *et al.* Effect of Cholecalciferol Supplementation on Vitamin D Status and Cathelicidin Levels in Sepsis: A Randomized, Placebo-Controlled Trial. *Crit Care Med* 2015;43(9):1928-37.

21. Singer M, Deutschman CS, Seymour CW, *et al.* The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). *JAMA* 2016;315(8):801-10.

Page 27 of 84	BMJ Open
1	
2	
3	22. NHS-England. Improving outcomes for patients with sepsis: a cross-system action plan 2015
4	[Available from: <u>https://www.england.nhs.uk/ourwork/part-rel/sepsis/</u> .
5	23. Plunkett A, Tong J. Sepsis in children. <i>BMJ</i> 2015;350:h3017.
6 7	24. Weiss SL, Fitzgerald JC, Pappachan J, et al. Global epidemiology of pediatric severe sepsis: the
8	sepsis prevalence, outcomes, and therapies study. Am J Respir Crit Care Med 2015;191(10):1147-57.
9	25. Mayr FB, Yende S, Angus DC. Epidemiology of severe sepsis. <i>Virulence</i> 2014;5(1):4-11.
10	26. De Pascale G, Ranzani OT, Nseir S, <i>et al.</i> Intensive care unit patients with lower respiratory tract
11	nosocomial infections: the ENIRRIs project. ERJ Open Res 2017;3(4).
12	27. Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-
13	analyses: the PRISMA statement. PloS Med 2009;6.
14	28. Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of observational studies in epidemiology: a
15	proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA
16 17	2000;283(15):2008-12.
17	29. Wells GA SB OCD, Peterson J, Welch V, Losos M, Tugwell P. The Newcastle-Ottawa Scale (NOS)
19	for assessing the quality of nonrandomised studies in meta-analyses [Available from:
20	http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp.
21	30. Newcombe RG. Two-sided confidence intervals for the single proportion: comparison of seven
22	methods. Stat Med 1998;17(8):857-72.
23	31. DerSimonian R, Laird N. Meta-analysis in clinical trials revisited. <i>Contemp Clin Trials</i> 2015;45(Pt
24	A):139-45.
25	32. Higgins JP, Thompson SG, Spiegelhalter DJ. A re-evaluation of random-effects meta-analysis. J R
26 27	Stat Soc Ser A Stat Soc 2009;172(1):137-59.
27 28	33. Borenstein M, Hedges LV, Higgins JP, <i>et al.</i> A basic introduction to fixed-effect and random-
29	effects models for meta-analysis. <i>Res Synth Methods</i> 2010;1(2):97-111.
30	34. Haidich A-BJ. Meta-analysis in medical research. <i>Hippokratia</i> 2010;14(Suppl 1):29.
31	35. Lau J, Ioannidis JP, Schmid CH. Quantitative synthesis in systematic reviews. Ann Intern Med
32	1997;127(9):820-6.
33	36. Ioannidis JP, Patsopoulos NA, Evangelou E. Uncertainty in heterogeneity estimates in meta-
34	analyses. BMJ 2007;335(7626):914-6.
35	37. Higgins JP, Thompson SG, Deeks JJ, <i>et al.</i> Measuring inconsistency in meta-analyses. <i>BMJ</i>
36 37	2003;327(7414):557-60.
38	38. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. <i>Stat Med</i>
39	2002;21(11):1539-58.
40	39. Egger M, Davey Smith G, Schneider M, <i>et al.</i> Bias in meta-analysis detected by a simple,
41	graphical test. <i>BMJ</i> 1997;315(7109):629-34.
42	40. Sterne JA, Sutton AJ, Ioannidis JP, <i>et al.</i> Recommendations for examining and interpreting funnel
43	plot asymmetry in meta-analyses of randomised controlled trials. <i>BMJ</i> 2011;343:d4002.
44	41. Duval S, Tweedie R. Trim and fill: A simple funnel-plot-based method of testing and adjusting for
45 46	publication bias in meta-analysis. <i>Biometrics</i> 2000;56(2):455-63.
40	42. Panityakul T, Bumrungsup C, Knapp G. On estimating residual heterogeneity in random-effects
48	meta-regression: a comparative study. J Stat Theory Appl 2013;12(3):253.
49	43. Knapp G, Hartung J. Improved tests for a random effects meta-regression with a single
50	covariate. <i>Stat Med</i> 2003;22(17):2693-710.
51	44. Schwarzer G. meta: An R package for meta-analysis. <i>R news</i> 2007;7(3):40-5.
52	45. Viechtbauer W. Conducting meta-analyses in R with the metafor package. J Stat Softw
53	2010;36(3).
54 55	
56	
57	
58	27
59	
60	For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

46. Garg D, Sharma VK, Karnawat B. Association of serum vitamin D with acute lower respiratory infection in Indian children under 5 years: a case control study. *Int J Contemp Pediatrics* 2016;3(4):1164-9.

47. Aydemir G, Cekmez F, Kalkan G, *et al.* High serum 25-hydroxyvitamin D levels are associated with pediatric sepsis. *Tohoku J Exp Med* 2014;234(4):295-8.

48. Gamal TS, Madiha AS, Hanan MK, *et al.* Neonatal and Maternal 25-OH Vitamin D Serum Levels in Neonates with Early-Onset Sepsis. *Children (Basel)* 2017;4(5).

49. Seliem MS, Abdel Haie OM, Mansour AI, *et al.* The relation between vitamin D level and increased risk for early-onset neonatal sepsis in full-term infants. *Medical Research Journal* 2016;15(1):16-21.

50. McNally JD, Leis K, Matheson LA, *et al.* Vitamin D deficiency in young children with severe acute lower respiratory infection. *Pediatr Pulmonol* 2009;44(10):981-8.

51. McNally JD, Doherty DR, Lawson ML, *et al*. The relationship between vitamin D status and adrenal insufficiency in critically ill children. *J Clin Endocrinol Metab* 2013;98(5):E877-81.

52. McNally JD, Iliriani K, Pojsupap S, *et al.* Rapid normalization of vitamin D levels: a meta-analysis. *Pediatrics* 2015;135(1):e152-66.

53. McNally JD, Menon K, Chakraborty P, *et al.* The association of vitamin D status with pediatric critical illness. *Pediatrics* 2012;130(3):429-36.

54. Karatekin G, Kaya A, Salihoglu O, *et al.* Association of subclinical vitamin D deficiency in newborns with acute lower respiratory infection and their mothers. *Eur J Clin Nutr* 2009;63(4):473-7.

55. Vo P, Koppel C, Espinola JA, *et al.* Vitamin D Status at the Time of Hospitalization for Bronchiolitis and Its Association with Disease Severity. *J Pediatr* 2018;203:416-22.e1.

56. Shah SK, Kabra SK, Gupta N, *et al.* Vitamin D Deficiency and Parathyroid Response in Critically-ill Children: Association with Illness Severity and Clinical Outcomes. *Indian Pediatr* 2016;53(6):479-84.

57. Sankar J, Lotha W, Ismail J, *et al.* Vitamin D deficiency and length of pediatric intensive care unit stay: a prospective observational study. *Ann Intensive Care* 2016;6(1):3.

58. Dayal D, Kumar S, Sachdeva N, *et al.* Fall in Vitamin D Levels during Hospitalization in Children. *Int J Pediatr* 2014;2014:291856.

59. Prasad S, Raj D, Warsi S, *et al.* Vitamin D Deficiency and Critical Illness. *Indian J Pediatr* 2015;82(11):991-5.

60. Wayse V, Yousafzai A, Mogale K, *et al.* Association of subclinical vitamin D deficiency with severe acute lower respiratory infection in Indian children under 5 y. *Eur J Clin Nutr* 2004;58(4):563-7.

61. Ebenezer K, Job V, Antonisamy B, *et al.* Serum Vitamin D Status and Outcome among Critically III Children Admitted to the Pediatric Intensive Care Unit in South India. *Indian J Pediatr* 2016;83(2):120-5.

62. Narang GS, Arora S, Kukreja S. Association of Vitamin D Deficiency with Acute Lower Respiratory Infection in Toddlers. *Journal of Nepal Paediatric Society* 2016;36(1):14-6.

63. Jat KR, Kaur J, Guglani V. Vitamin D and Pneumonia in Children: A Case Control Study. *J Pulm Med Respir Res* 2016;2(004).

64. Sankar J, Ismail J, Das R, *et al.* Effect of Severe Vitamin D Deficiency at Admission on Shock Reversal in Children With Septic Shock. *J Intensive Care Med* 2017.

65. Dhandai R, Jajoo M, Singh A, *et al.* Association of vitamin D deficiency with an increased risk of late-onset neonatal sepsis. *Paediatr Int Child Health* 2018;38(3):193-7.

66. Asilioglu N, Cigdem H, Paksu MS. Serum Vitamin D Status and Outcome in Critically III Children. Indian J Crit Care Med 2017;21(10):660-4.

67. Say B, Uras N, Sahin S, *et al.* Effects of cord blood vitamin D levels on the risk of neonatal sepsis in premature infants. *Korean J Pediatr* 2017;60(8):248-53.

68. Cayir A, Turan MI, Ozkan O, *et al.* Vitamin D levels in children diagnosed with acute otitis media. *J Pak Med Assoc* 2014;64(11):1274-7.

1	
2	
3	69. Cetinkaya M, Cekmez F, Buyukkale G, et al. Lower vitamin D levels are associated with increased
4	risk of early-onset neonatal sepsis in term infants. J Perinatol 2015;35(1):39.
5	70. Cizmeci MN, Kanburoglu MK, Akelma AZ, <i>et al.</i> Cord-blood 25-hydroxyvitamin D levels and risk
6	of early-onset neonatal sepsis: a case-control study from a tertiary care center in Turkey. Eur J Pediatr
7	
8	2015;174(6):809-15.
9	71. Dinlen N, Zenciroglu A, Beken S, <i>et al.</i> Association of vitamin D deficiency with acute lower
10	respiratory tract infections in newborns. J Matern Fetal Neonatal Med 2016;29(6):928-32.
11	72. Onwuneme C, Martin F, McCarthy R, et al. The Association of Vitamin D Status with Acute
12	Respiratory Morbidity in Preterm Infants. J Pediatr 2015;166(5):1175-80.e1.
13	73. Madden K, Feldman HA, Smith EM, et al. Vitamin D deficiency in critically ill children. Pediatrics
14	2012;130(3):421-8.
15	74. Rippel C, South M, Butt WW, et al. Vitamin D status in critically ill children. Intensive Care Med
16	2012;38(12):2055-62.
17	
18	75. Korwutthikulrangsri M, Mahachoklertwattana P, Lertbunrian R, <i>et al.</i> Vitamin D deficiency and
19	adrenal function in critically ill children. J Med Assoc Thai 2015;98(4):365-72.
20	76. Elmoneim A, Rhill R, Rahalli M, et al. Vitamin D level in pediatric intensive care unit (PICU)
21	patients: its relation to severity of illness. Pediat Therapeut 2016;6(293):2161-0665.
22	77. García-Soler P, Morales-Martínez A, Rosa-Camacho V, et al. Vitamin D deficiency and
23	morbimortality in critically ill paediatric patients. Anales de Pediatría (English Edition) 2017;87(2):95-
24	103.
25	78. Badawi NES, Algebaly HAF, El Sayed R, <i>et al</i> . Vitamin D deficiency in critically ill children. <i>Kasr Al</i>
26	
27	Ainy Medical Journal 2017;23(1):6.
28	79. Roth DE, Jones AB, Prosser C, et al. Vitamin D status is not associated with the risk of
29	hospitalization for acute bronchiolitis in early childhood. <i>Eur J Clin Nutr</i> 2009;63(2):297-9.
30	80. Cebey-Lopez M, Pardo-Seco J, Gomez-Carballa A, et al. Role of Vitamin D in Hospitalized
31	Children With Lower Tract Acute Respiratory Infections. J Pediatr Gastroenterol Nutr 2016;62(3):479-85.
32	81. Alonso MA, Pallavicini ZF, Rodriguez J, et al. Can vitamin D status be assessed by serum 25OHD
33	in children? Pediatr Nephrol 2015;30(2):327-32.
34	82. Ayulo M, Jr., Katyal C, Agarwal C, <i>et al.</i> The prevalence of vitamin D deficiency and its
35	
36	relationship with disease severity in an urban pediatric critical care unit. <i>Endocr Regul</i> 2014;48(2):69-76.
37	83. Rey C, Sanchez-Arango D, Lopez-Herce J, et al. Vitamin D deficiency at pediatric intensive care
38	admission. J Pediatr (Rio J) 2014;90(2):135-42.
39	84. Onwuneme C, Carroll A, Doherty D, et al. Inadequate vitamin D levels are associated with
40	culture positive sepsis and poor outcomes in paediatric intensive care. Acta Paediatr 2015;104(10):e433-
41	8.
42	85. Jia K-P, Zhao L-F, Feng N, et al. Lower level of vitamin D3 is associated with susceptibility to
43	acute lower respiratory tract infection (ALRTI) and severity: a hospital based study in Chinese infants. Int
44	
45	J Clin Exp Med 2017;10(5):7997-8003.
46	86. Halwany AS, Deghady AAE, Moustafa AAA, <i>et al.</i> Study of Serum Vitamin D Level among Critically
47	Ill Patients Admitted to Alexandria University Pediatric Intensive Care Unit. JMSCR 2017;5(4):20776-81.
48	87. Li W, Cheng X, Guo L, et al. Association between serum 25-hydroxyvitamin D concentration and
49	pulmonary infection in children. <i>Medicine</i> 2018;97(1):e9060.
50	88. El Sakka AS, Imam SS, Amer HA, et al. Vitamin D deficiency and low hemoglobin level as risk
51	factors for severity of acute lower respiratory tract infections in Egyptian children: A case-control study.
52	Egyptian Pediatric Association Gazette 2014;62(1):1-7.
53	
54	89. Bustos R, Rodriguez-Nunez I, Peña RZ, <i>et al.</i> Vitamin D deficiency in children admitted to the
55	paediatric intensive care unit. <i>Revista chilena de pediatria</i> 2016;87(6):480-6.
56	
57	
58	29
59	
60	For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

90. Hurwitz JL, Jones BG, Penkert RR, *et al.* Low Retinol-Binding Protein and Vitamin D Levels Are Associated with Severe Outcomes in Children Hospitalized with Lower Respiratory Tract Infection and Respiratory Syncytial Virus or Human Metapneumovirus Detection. *J Pediatr* 2017;187:323-7.

 Yaghmaie B, Sayarifard F, Modarresi M, *et al.* Investigation of serum 25 hydroxy vitamin D level in critically ill children and its relation with demographic and clinical risk factors. *Biomed Res* 2017;28(5).
 El-Gamasy M, Eldeeb M, Abdelmageed M. Prognostic Value of Vitamin D Status in Pediatric Patients with Acute Kidney Injury in Tanta University Emergency Hospital, Egypt. *J Emerg Intern Med* 2017;1(1):5.

93. McNally JD, Nama N, O'Hearn K, *et al.* Vitamin D deficiency in critically ill children: a systematic review and meta-analysis. *Crit Care* 2017;21(1):287.

94. Randolph AG, McCulloh RJ. Pediatric sepsis: important considerations for diagnosing and managing severe infections in infants, children, and adolescents. *Virulence* 2014;5(1):179-89.

95. Vincent JL. The Clinical Challenge of Sepsis Identification and Monitoring. *PLoS Med* 2016;13(5):e1002022.

96. Mathias B, Mira JC, Larson SD. Pediatric sepsis. *Curr Opin Pediatr* 2016;28(3):380-7.





Figure 1 Flow chart of study selection process







Figure 3 Bubble plots of univariate meta-regressions. Each study is represented by a circle. Predictor variables; A clinical setting and B country groups are shown on the x-axis and the effect measure logit transformed proportion shown on the vertical (y-axis). NICU = Neonatal Intensive Care Unit; PICU = Pediatric Intensive Care Unit; grp = country group; country group 1 = USA, Chile, Australia, Canada, Ireland, Japan, Spain; country group 2 = South Africa, China, Egypt, Iran, Turkey, Saudi Arabia; and country group 3 = Bangladesh, Thailand, and India

203x203mm (300 x 300 DPI)






Figure 4 Pooled prevalence estimate for vitamin D deficiency in children with sepsis. Forest plot shows result from the random effects model. The diamond represents the overall pooled proportion of 25(OH)D deficiency from the meta-analysis of the 18 studies. Each square shows the prevalence estimate of each study and the horizontal line across each square represents the 95% confidence interval (CI) of the prevalence estimate.

254x152mm (300 x 300 DPI)

1	
2	
3	
4	
5	
6	
7	
/	
8	
9	
10	
11	
12	
13	
14	
15	
16	
16 17	
10	
18	
19	
20	
21	
21	
22	
23	
24	
25	
26	
27	
28	
29	
30	
31	
32	
33	
34	
35	
36	
37	
38	
39	
40	
41	
42	
43	
44	
45	
46	
47	
48	
49	
50	
51	
52	
52	
53	
54	
55	
56	
57	
58	
59	
59	
nn	




Figure 5 Pooled odds ratio (OR) of risk of mortality in vitamin D deficient versus vitamin D non-deficient acute and critically ill children. Forest plot shows result from the random effects model. Diamond represents the overall OR (with corresponding 95% Confidence Interval). Each square shows the odds ratio of each study and the horizontal line across each square represents the 95% confidence interval (CI) of the estimate.

203x127mm (300 x 300 DPI)

Supplementary Material

Table of Contents

Additional Table 1 PRISMA Checklist 2009
Additional Table 2A Search terms used in OVID5
Additional Table 2B Search terms used in PubMed6
Additional Table 3A Newcastle Ottawa study quality scoring system (cohort studies)7
Additional Table 3B Newcastle Ottawa study quality scoring system (case-control studies)
Additional Table 3C Newcastle Ottawa study quality scoring system (cross-sectional studies)9
Additional Table 4A Circulating 25(OH)D threshold levels used in the selected studies
Additional Table 4B Circulating 25(OH)D threshold levels used in the selected studies for prevalence in sepsis
Additional Table 5 Studies with thresholds other than < 50 nmol/L14
Additional Table 6 Excluded studies
Additional Table 7 Characteristics of the 52 included studies16
Additional Table 8 Objectives and outcomes of included studies
Additional Table 9 Assay used in each study to measure Vitamin D levels
Additional Table 10 Funding and ethical approval of included studies
Additional Table 11 Age groups of children in each study
Additional Table 11 Age groups of children in each study
Additional Table 12 Prevalence of vitamin D deficiency in each study of acute and critically ill children
Additional Table 12 Prevalence of vitamin D deficiency in each study of acute and critically ill children (sorted from highest to lowest)
Additional Table 12 Prevalence of vitamin D deficiency in each study of acute and critically ill children (sorted from highest to lowest)
Additional Table 12 Prevalence of vitamin D deficiency in each study of acute and critically ill children (sorted from highest to lowest)
Additional Table 12 Prevalence of vitamin D deficiency in each study of acute and critically ill children (sorted from highest to lowest) 31 Additional Table 13 Characteristics of studies used in the meta-analysis of prevalence. 33 Additional Table 14 Sensitivity analyses for prevalence of vitamin D deficiency in acute and critically ill children 35 Additional Table 15 Multivariate meta-regression model for prevalence 36 Additional Table 16 Characteristics of studies included in the meta-analysis for prevalence in 36
Additional Table 12 Prevalence of vitamin D deficiency in each study of acute and critically ill children (sorted from highest to lowest) 31 Additional Table 13 Characteristics of studies used in the meta-analysis of prevalence. 33 Additional Table 14 Sensitivity analyses for prevalence of vitamin D deficiency in acute and critically ill children 35 Additional Table 15 Multivariate meta-regression model for prevalence 36 Additional Table 16 Characteristics of studies included in the meta-analysis for prevalence in individuals with sepsis 37 Additional Table 17 Sensitivity analyses for prevalence of vitamin D deficiency in acute and critically 37
Additional Table 12 Prevalence of vitamin D deficiency in each study of acute and critically ill children (sorted from highest to lowest) 31 Additional Table 13 Characteristics of studies used in the meta-analysis of prevalence. 33 Additional Table 14 Sensitivity analyses for prevalence of vitamin D deficiency in acute and critically ill children 35 Additional Table 15 Multivariate meta-regression model for prevalence 36 Additional Table 16 Characteristics of studies included in the meta-analysis for prevalence in individuals with sepsis 37 Additional Table 17 Sensitivity analyses for prevalence of vitamin D deficiency in acute and critically ill children with sepsis 38 Additional Table 18 Sensitivity analyses for prevalence of vitamin D deficiency in acute and critically ill children with sepsis 38

1	
2	
r	
3	
4	
7	
5	
~	
6	
7	
'	
8	
0	
9	
10	
10	
11	
12	
12	
15	
14	
15	
9 10 11 12 13 14 15 16 17 18	
10	
17	
18	
10	
19 20	
20	
~~	
21	
21 22 23 24 25 26	
22	
23	
23	
24	
25	
25	
26	
20	
27	
20	
28	
29	
29	
30	
24	
31 32 33	
22	
52	
33	
34 35	
25	
22	
36	
~-	
37	
38	
39	
40	
41	
41	
42	
43	
44	
45	
46	
47	
48	
49	
50	
51	
52	
53	
54	
55	
56	
57	

Additional Figure 2. Pooled prevalence estimate for vitamin D deficiency in acute and critically ill children (by country group)
Additional Figure 3. Pooled prevalence estimates for vitamin D deficiency in acute and critically ill children (neonates versus all other age groups)
Additional Figure 4 Bubble plots of univariate meta-regressions
Additional Figure 5 Funnel plot for prevalence of vitamin D deficiency in acute and critically ill children with sepsis
Additional Figure 6 Pooled prevalence estimate for vitamin D deficiency in acute and critically ill children with sepsis (subgroup analysis by study design)
Additional Figure 7 Funnel plot of risk of mortality in vitamin D deficient versus vitamin D non- deficient acute and critically ill children
Additional Figure 8 Pooled odds ratio (OR) and 95% CI for risk of mortality in vitamin D deficient versus vitamin D non-deficient acute and critically ill children (fixed effects model)

$\begin{array}{cccccccccccccccccccccccccccccccccccc$	1 2 4 5 6 7 8 9 10	
$\begin{array}{c} 22\\ 23\\ 24\\ 25\\ 26\\ 27\\ 28\\ 29\\ 30\\ 31\\ 32\\ 33\\ 34\\ 35\\ 37\\ 38\\ 39\\ 40\\ 41\\ 43\\ 44\\ 56\\ 47\\ 48\\ 9\\ 51\\ 52\\ 53\\ 54\\ 55\\ 56\end{array}$	12 13 14 15 16 17 18 19 20	
32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 50 51 52 53 54 55	22 23 24 25 26 27 28 29	
41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56	31 32 33 34 35 36 37 38	
50 51 52 53 54 55 56	41 42 43 44 45 46 47 48	
57 58 59 60	50 51 52 53 54 55 56 57 58 59	

Section/topic	#	Checklist item	Reported or page #
TITLE			
Title	1	Identify the report as a systematic review, meta-analysis, or both.	1
ABSTRACT			
Structured summary	J 8/11 8/J		2-3
INTRODUCTION			
Rationale	3	Describe the rationale for the review in the context of what is already known.	4-5
Objectives	4	Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).	6-8
METHODS			
Protocol and registration	5	Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.	9
Eligibility criteria	6	Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.	5-7
Information sources	7	Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.	6-7
Search	ch 8 Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.		6 and supplementary material
Study selection	udy selection9State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).		6-7
Data collection process	10	Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.	7
Data items	11	List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.	7-8
Risk of bias in individual studies	12	Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.	8
Summary measures	13	State the principal summary measures (e.g., risk ratio, difference in means).	8
Synthesis of results	14	Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I^2) for each meta-analysis.	8-10

Additional Table 1 PRISMA Checklist 2009

Section/topic	#	Checklist item	Reported on page #
Risk of bias across studies	15	Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).	8
Additional analyses	16	Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta- regression), if done, indicating which were pre-specified.	9-10 and 15
RESULTS		<u>.</u>	
Study selection	17	Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.	10
Study characteristics	18	For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.	14-19 (supplementa material)
Risk of bias within studies	19	Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).	5-7 (supplementa material)
Results of individual studies	20	For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.	13,15,18 and supplementar material
Synthesis of results	21	Present results of each meta-analysis done, including confidence intervals and measures of consistency.	13 and supplementar material page 32-36
Risk of bias across studies	22	Present results of any assessment of risk of bias across studies (see Item 15).	
Additional analysis	23	Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).	supplementar material page 32-36
DISCUSSION			
Summary of evidence	24	Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).	19-21
Limitations	25	Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).	20-22
Conclusions	26	Provide a general interpretation of the results in the context of other evidence, and implications for future research.	22
FUNDING			
Funding	27	Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.	22
Reviews and Met	a-Analy	A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Sys yses: The PRISMA Statement. PLoS Med 6(6): e1000097. doi:10.1371/journal.pmed10000 prisma-statement.org.	

2
3
4
5
5 6
7
8
7 8 9
9
10
11
12
10
14
14
13 14 15 16 17 18 19
16
17
18
10
19 20
20
21
22
23
24
24
25
26
27
24 25 26 27 28
29
30
31
32
33
34
34 35 36 37 38
22
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58

60

Additio	nal Table 2A Search terms used in OVID
1.	Vitamin D
2.	Sepsis or septic shock
3.	Vitamin D or cholecalciferol* or ergocalciferol or 25-hydroxyvitamin D or calcidiol or calcitriol
4.	Intensive care unit* or critical care
5.	
6.	Multiple organ dysfunction syndrome or multiple organ failure
7.	(1 and 2) or 5
8.	((1 or 3) and 2 or 4
9.	(1 or 3) and 2
	(1 or 3) and 4
	(1 or 3) and 5
	Sepsis 🥒
	multi* organ dysfunction syndrome or multiple organ failure
	multi* organ dysfunction syndrome or multi* organ failure
	(2 or 8) and 3
16.	
	child* or pediatric*
	vitamin D or cholecalciferol or ergocalciferol or 25-hydroxyvitamin D or calcidiol or calcitriol
	15 and 16 and 17
	Vitamin D blood levels or 25-hydroxyvitamin
	5 and 3 and 15 and 16
	2 and 15 and 16 and 17
	16 and 2
	16 and 2 and 3
	Pediatric*
-	Pediatric* and 5 and 2
27.	24 and 3 and 15

2	
3	Additional Table 2B Search terms used in PubMed
4 <u>T</u>	erm searched
5	1. Vitamin D.mp.
6	 (sepsis or septic shock).mp. (vitamin D or cholecalciferol* or ergocalciferol or 25-hydroxyvitamin D or calcidiol or calcitriol).mp.
7	3. (vitamin D or cholecalciferol* or ergocalciferol or 25-hydroxyvitamin D or calcidiol or calcitriol).mp.
8 —	4. (intensive care unit* or critical care).mp.
9	5. (multi* organ dysfunction syndrome or multiple organ failure).mp.
10	6. (critical* ill or acute condition* or intensive care unit).mp.
11	 (ordear in or acute condition or intensive care unit). (toddler or infant or child* or neonate* or baby or teenager or pediatric* or paediatric*).mp.
12 —	8. 3 and 6 and 2 and 7
13 —	
14	
15	
16	
17	
18 19	
19	
20 21	
21	
22	
23	
24 25	
26	
27	
28	
29	
30	
31	
32	
33	
34	
35	
36	
37	
38	
39	
40	
41	
42	
43	6. (critical* il or acute condition* or intensive care unit).mp. 7. (toddler or infant or child* or neonate* or baby or teenager or pediatric* or paediatric*).mp. 8. 3 and 6 and 2 and 7
11	
45	
46	
47	
48	
49	
50	
51	
52	
53	
54	
55	
56	
57	
58	
59	For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml
60	r or peer review only intep.//binjopen.binj.com/bite/about/guidelines.khtilli

			Selection	•	Comparability Outcome				
	Representat iveness of the exposed cohort	Selection of the non-exposed cohort	Ascertainment of exposure	Demonstration that outcome of interest was not present at the start of the study	Comparability of cohorts on the basis of the design or analysis (maximum 2 stars)	Assessment of outcome	Was follow-up long enough for outcome to occur (≥28 days after admission to the ICU)	Adequacy of follow up of cohorts	Number of stars (out of 9 total)
Ebenezer 2016	1	1	1	1	0	1	0	1	6
Sankar 2016	1	1	1	1	2	1	0	1	8
Rippel 2012	1	1	1	1	1	1	1	1	8
Madden 2012	1	1	1	1	2	1	0	1	8
McNally 2012	1	1	1	0	1	1	1	1	7
Dayal 2014	1	1	1	1	0	1	0	1	6
Ayulo 2014	1	1	1	1	2	1	0	0	7
Bustos 2016	1	1	1	0	2	1	0	1	7
Prasad 2015	1	1	1	0	2	1	0	1	7
Onwuneme 2015 (2)	1	1	1		2	1	0	1	8
namo 2011	1	1	1	0	1	1	0	1	6
Shah 2016	1	1	1	1	0	1	0	1	6
Lopez 2016	1	1	1	1	2	1	0	1	8
Garcia-Soler 2017	1	1	1	1	2	1	0	0	7
Sankar 2017	1	1	1	1	2	1	0	1	8
Asilioglu 2017	1	1	1	1	1	1	0	1	7
Halwany 2017	1	1	1	1	1	1	0	0	6
Hurwitz 2017	1	1	1	0	1	1	0	1	6
Banajeh 2009	1	1	1	0	1	1	1	1	7
Badawi 2017	1	1	1	1	1	1	1	1	8
Vo 2018	1	1	1	1	2	1	0	1	8
Mathias 2017	1	1	1	1	0		0	1	6
	stle-Ottawa ri.ca/program		OS) for as <u>miology/oxford.as</u>	sessing the qual sp.	ity of non-ra	ndomised studie	s in meta-analy	yses. Availa	ble

Study		SELE	CTION		COMPARABILITY	COMPARABILITY EXPOSURE			
d	Is the case definition adequate?	Representati veness of the cases	Selection of controls	Definition of controls	Comparability of cases and controls on the basis of the design or analysis (maximum 2 stars)	Ascertainment of exposure	Same method of ascertainment for cases and controls (yes or no or 0 star if no mention)	Non- response rate	_ (out of 9 total)
Wayse 2004	1	1	0	0	1	1	1	1	6
Karatekin 2009	1	1	0	0	1	1	1	1	6
Roth 2009	1	1	0	1	1	1	1	0	7
Roth 2010	1	1	1	1	2	1	1	0	8
Cetinkaya 2015	1	1	0	0	0	1	1	1	6
Dnwuneme 2015 (1)	1	1	0	1	2	1	1	1	8
Cizmeci 2015	1	1	0	0	2	1	1	1	7
Korwutthikulrangsri 2015	1	1	0	0	0	1	1	1	5
Elmoneim 2016	1	1	0	0	0	1	1	1	5
Varang 2016	1	1	0	0	1	1	1	1	6
Dinlen 2016 Ahmed 2015	1	1	0	0	1	1	1	1	6
	1	1	0	1	2	1	1	1	8
ayir 2014 ay 2017	1	1	0	0	2	1	1	0	6
Basha 2014	1	1	0	0	2	1	1	0	7
ia 2017	1	1	0	1	1	1	1	1	7
at 2016	1	1	0	1	2	1	1	1	8
Aoreno-Solis 2015	1	1	0	1	1	1	0	1	6
Moreno-Solis 2015 Sakka 2014	1	1	0	1	2	1	1	1	8
Hebbar 2014	1	1	0	0	1	1	1	1	6
Rey 2014	1	1	1	1	1	1	1	1	8
onnarmeni 2016	1	1	0	0	0		1	1	6
l-Gamasy 2017	1	1	1	0	2	1	1	0	7
makshour 2015	1	1	0	0	1	1	1	0	5
Dhandai 2018	1	1	0	0	1	1	1	1	6
i 2018	1	1	1	1	2	1	1	0	8
<u>The Newcastle-Ott</u>	awa Scale (NOS)) for assessing th	e quality of non-r	andomised studie	es in meta-analyses. Availa	ble at: <u>http://www.o</u>	<u>hri.ca/programs/clinic</u>	al_epidemiol	ogy/oxford.asp
									8
			_		jopen.bmj.com/site/abou	1			

	2	SELECTION (M	laximum 5 stars)		COMPARABILITY (Maximum 2 stars)	OUTCOME (Maximum 3 stars)		
udy	Representativene ss of the sample	Sample size	Non- respondents	Ascertainment of the exposure (risk factor)	Subjects in different outcome groups are comparable, based on the study design or analysis. Confounding factors are controlled.	Assessment of the outcome (max=2 stars)	Statistical test (max=1 star)	Number of stars (out of 10 total)
aghmaie 2017	1	0	0	0	1	1	1	4
varez 2016	1	0	0	1	1	2	1	6
onso 2015 1ks 2014	1	0	0	1	1	1 2	1	5
ie Newcastle-C	Ottawa Scale (NOS) for ca/programs/clinical e	r assessing the	e quality of nor	n-randomised stu	udies in meta-analyses. Available at:			
					adies in meta-analyses. Available at:			

Study	Number of cases	25(OH)D categories (as given)	Number of cases in category
Asilioglu 2017	250	Deficiency: <20 ng/mL	120
Asiliogiu 2017	230	Sufficiency: >=20 ng/mL	85
Halwany 2017	102	Deficiency: <20 ng/ml	38
That wanty 2017	102	Insufficiency: 20-29.9 ng/ml	39
		"Normal" levels: 30 ng/ml	25
Hurwitz 2017	90	Deficiency: <20 ng/mL	11
Garcia-Soler 2017	340	Deficiency: <20 ng/mL	149
	2.10	Insufficiency: 20-30 ng/mL	128
		25(OH)D levels: 30-40 ng/mL	41
		Optimal levels >40 ng/mL	22
Badawi 2017	88	Deficiency: < 50nmol/l	39
		Severe deficiency: <30 nmol/l	30
Jia 2017	110	Severe deficiency: <10 ng/ml	36
		Deficiency: 10-20 ng/ml	56
		Insufficiency: 21-30 ng/ml	17
		Sufficiency: >30 ng/ml	1
Yaghmaie 2017	82	Deficiency: <30 ng/ml	53
		Sufficiency: >=30 ng/ml	29
Say 2017	100	Severe deficiency (group 1) <5 ng/mL.	63
		Insufficiency (group2): 5 to 15 ng/mL	24
		Sufficiency (group 3)≥15 ng/mL	13
El-Gamasy 2017	80	Serious deficiency: < 30 nmol/L	26
		Insufficiency: 30-75 nmol/L	27
		Adequate levels >75 nmol/L	27
Sankar 2017	43	Severe deficiency: serum 25 (OH) D <10 ng/mL	31
Shah 2016	154	25(OH)D < 20 ng/mL	128
		25(OH)D ≥20 ng/mL	26
Ponnarmeni 2016	124	Deficiency: < 50nmol/L	63
		Insufficiency: 50-75 nmol/L	31
		<pre></pre>	94
			30
Sankar 2016	101	Sufficiency: >75 nmol/L	75
Sankar 2016	101	Deficiency: ≤ 20 ng/mL	62
		Severe deficiency: <15 ng/mL 'No deficiency': > 20 ng/mL	26
Bustos 2016	90	Deficiency: <20 ng/ml	39
Busios 2010	90	Normal levels: >20 ng/ml	51
Ebenezer 2016	52	Deficiency: < 20ng/mL	21
Lochezer 2010	52	Insufficiency: 20–30 ng/ml	12
		'Normal levels: $> 20 \text{ ng/L}$	31
Elmoneim 2016	21	Deficiency: < 20 ng/mL	17
Emionemi 2010	21	Insufficiency: 20-30 ng/mL	4
		Normal levels: > 30 ng/mL	9
Jat 2016	50	Deficiency: <20 ng/ml	42
		Insufficiency: 20-30 ng/ml	2
		Sufficiency: >=30 ng/ml	1
Narang 2016	50	"Severe deficiency": <20ng/ml	28
Dinlen 2016	30	Deficiency: <=15 ng/mL	26
		Severe deficiency: <=5 ng/mL	3
Lopez 2016	347	25-OHD levels: <10 ng/mL	19
· r		25-OHD levels: 10-20 ng/mL	65
		25-OHD levels: 20-30 ng/mL	134
Alvarez 2016	50	25(OH) D levels: <20 ng/mL	29
		25(OH) D levels: 20-30 ng/mL	37
Onwuneme 2015 (1)	120	25(OH)D levels: <50nmol/L	71
~ /		25(OH)D levels: ≥50nmol/L	49
Onwuneme 2015 (2)	94	25(OH)D levels: <20 ng/mL	86
× /		25(OH)D levels: < 30 nmol/L	60
		25(OH)D levels: >=30 nmol/L	34
Prasad 2015	80	Deficiency: < 20 ng/ml	67
		Sufficiency: $\geq 20 \text{ ng/mL}$	13
Moreno-Solis 2015	48	Deficiency: <20 ng/ml	9

		Insufficiency: 21–29 ng/ml	16
		Sufficiency: ≥30 ng/ml	23
Alonso 2015	288	Deficiency: <20 ng/ml	45
		<10 ng/ml	6
Korwutthikulrangsri 2015	32	Deficiency: < 20 ng/ml	25
		Insufficiency: 20-29.9 ng/ml	7
		Sufficiency: $\geq 30 \text{ ng/mL}$	0
Khakshour 2015	37	Deficiency: <20 ng/mL	9
Cizmeci 2015	40	Deficiency: ≤20 ng/ml	28
		Insufficiency: 21–29 ng/ml	7
		Normal levels: ≥30 ng/ml	5
Cetinkaya 2015	50	Severe deficiency: $<10 \text{ ng ml}^{-1}$	42
		Insufficiency: 11 to 32 ng ml ⁻¹	8
Ayulo 2014	216	Deficient: < 15 ng/ml	61
		Insufficient: 15-29 ng/mL	102
		Sufficient: $\geq 30 \text{ ng/mL}$	53
Dayal 2014	92	Deficiency: < 50 nmol/L	23
		Insufficiency: 50–75 nmol/L	41
		Sufficiency: >75 nmol/L	28
		25(OH) D levels: < 75 nmol/L	64
		'Non-deficiency': > 50 nmol/L	69
Hebbar 2014	61	Deficiency: ≤ 10 ng/mL	10
	01	Insufficiency: 10 to 20 ng/mL	27
		Sufficiency: $\geq 20 \text{ ng/mL}$	24
Rey 2014	156	Deficiency: < 20 ng/mL	46
Rey 2014	150	$25(OH)D levels: \ge 20 \text{ ng/mL}$	110
Ahmed 2014	50	Deficiency: <50 nmol/L	15
Basha 2014	81	Deficiency: <50 nmol/L	53
Dasha 2014	01	Insufficiency: <75 nmol/L	14
		Normal level: >75 nmol/L	14
Sakka 2014	96	Severe deficiency: 0–5 ng/mL	29
Sakka 2014	30	Deficiency: 5–15 ng/mL	49
		Insufficiency: 15–20 ng/mL	11
		Sufficiency: 20–100 ng/mL	7
Cayir 2014	88	Normal levels: 20 ng/mL	38
Cuyii 2014	00	Insufficiency: 15-20ng/mL	18
		Deficiency: <15ng/mL	32
Binks 2014	74	25(OH) D levels: < 50 nmol/L	11
Madden 2012	511	25(OH) D levels: < 30 million 2 25(OH) D levels: < 10 ng/mL	36
	511	25(OH) D levels: < 10 lg/llD 25(OH) D levels: 10-19.9 ng/llD	169
		Deficiency: < 20 ng/ml	205
		Insufficiency: <30 ng/mL	364
Rippel 2012	316	Deficiency: < 50 mol/L	109
Ripper 2012	510	'Normal levels': \geq 50 nmol/L	207
Madden 2012	511	25(OH)D levels: < 10 ng/mL	36
		25(OH)D levels: 10-19.9 ng/mL	169
		Deficiency: < 20 ng/mL	205
		Insufficiency: <30 ng/mL	364
McNally 2012	326	Deficiency: < 50 nmol/L	225
		25(OH)D levels: 50 to 75 nmol/L	75
		'Not deficient': > 50 nmol/L	101
Inamo 2011	28	25(OH)D levels: < 10 ng/mL	4
		25(OH)D levels: < 15 ng/mL	8
		25(OH)D levels: < 25 ng/mL	12
		25(OH)D levels: < 40 ng/mL	28
Roth 2010	25	25(OH)D levels: < 40 nmol/L	21
Banajeh 2009	79	Deficiency: <30 nmol/L	29
Karatekin 2009	25	Serum 25(OH)D <10 (deficiency)	19
		Serum 25(OH)D 11 to 20 (deficiency)	4
		Serum 25(OH)D 21 to 32 (insufficiency)	1

Roth 2009 Wayse 2004			
		Serum 25(OH)D 32 to 100 (sufficiency)	1
Wayse 2004	64	< 40 nmol/L	3
Wayse 2004	80	Plasma 25(OH)D3 > 22.5 nmol/L	26
		Plasma 25(OH)D3 > 50 nmol/L	4
Mathias 2017	41	25(OH)D < 20 ng/ml	28
D1 1 1 0010		25(OH)D < 30 ng/ml	36
Dhandai 2018	60	Deficiency: < 20 ng/ml	38
		Insufficiency: <29 ng/ml Optimum: 30-50 ng/ml	17
Vo 2018	1016	25(OH)D < 20 ng/ml	298
VO 2010	1010	20-29.9 ng/ml	352
		>=30 ng/ml	366
Li 2018	797	Severe deficiency: < 10 ng/mL	159
		Deficiency: 10–20 ng/mL	286
		Insufficiency: 20– 30 ng/mL	223
		Sufficiency: > 30 ng/mL	127
25(OH)D in nmol/L	= 25(OH)D in ng/mL mu	ltiplied by 2.496	
		Itiplied by 2.496	
			12

udy	Number of cases	25(OH)D categories (as provided by each study)	Number of cases
silioglu 2017	30	Deficiency: <20 ng/mL	20
	sepsis	Sufficiency: >=20 ng/mL	10
y 2017	100	Severe deficiency (group 1) <5 ng/mL.	63
	neonatal sepsis	Insufficiency (group2): 5 to 15 ng/mL	24
		Sufficiency (group 3) ≥15 ng/mL	13
Gamasy 2017	46	Serious deficiency: < 30 nmol/L	20
	sepsis	Insufficiency: 30-75 nmol/L	18
		Adequate levels >75 nmol/L	8
nkar 2017	43 septic shock	Severe deficiency: serum 25 (OH) D <10 ng/mL	31
ah 2016	100	25(OH)D <20 ng/mL	84
	sepsis	25(OH)D >= 20 ng/mL	26
nnarmeni 2016	124	Deficiency: <50nmol/L	63
	sepsis	Insufficiency: 50-75 nmol/L	31
		<75, insufficient + deficient	94
		Sufficiency: >75 nmol/L	30
stos 2016	10	Deficiency: < 20 ng/ml	7
	sepsis intraabdominal	Normal levels: > 20 ng/mL	3
enezer 2016	16	25(OH)D <20 ng/mL	8
	shock	25(OH)D >= 20 ng/mL	8
wuneme 2015 (1)	35	25(OH)D <50 ng/mL	32
	culture positive sepsis	25(OH)D >= 50 ng/mL	3
wuneme 2015 (2)	46	Deficiency: < 30 nmol/L	32
	culture positive sepsis and late-onset sepsis	Sufficiency: ≥ 30 nmol/L	14
asad 2015		25(OH)D <20 ng/mL	9
13dd 2013	positive blood culture	25(OH)D >= 20 ng/mL	2
rwutthikulrangsri 2015	17	25(OH)D <20 ng/mL	14
r valuintan angorr 2010	shock and septicaemia	25(OH)D >= 20 ng/mL	3
zmez 2015	40	Deficiency: ≤20 ng/ml	28
	suspected sepsis	Insufficiency: 21–29 ng/ml	7
	suspected sepsis	Normal levels: \geq 30 ng/ml	5
yal 2014	9	25(OH)D <20 ng/mL	4
Jui 2011	nosocomial sepsis	25(OH)D >= 20 ng/mL	5
bbar 2014	30	25(OH)D <20 ng/mL	17
2011	shock and/or Sepsis	25(OH)D >= 20 ng/mL	13
Nally2012	48	25(OH) D levels: <50 nmol/L	33
Nally2012	septic	$25(OH)$ D levels: ≤ 50 hmol/L $25(OH)$ D levels: ≥ 50 nmol/L	15
thias 2017	41	25(OH) D levels. 250 mmore 25(OH)D < 20 ng/ml	28
unias 2017	sepsis, severe sepsis or		36
	septic shock	25(OH)D < 30 ng/ml	50
andai 2018	60	Deficiency: < 20 ng/ml	38
2010	sepsis	Insufficiency: <29 ng/ml	17
	sepsis	Optimum: 30-50 ng/ml	5
	- -		

1		
2		
3 4	Additional Table 5 Stud	lies with thresholds other than < 50 nmol/L
5	Study	Threshold used by study
6	Roth 2009 Roth 2010	< 40 nmol/L < 40 nmol/L
7	Say 2017	<=15 ng/mL (37.4 nmol/L)
7 8	Inamo 2011	<=15 ng/mL (37.4 nmol/L)
9	Ayulo 2014	<=15 ng/mL (37.4 nmol/L)
	Dinlen 2016	<=15 ng/mL (37.4 nmol/L)
10	Onwuneme 2015 (2) Yaghmaie 2017	< 30 nmol/L < 30 ng/mL (74.88 nmol/L)
11	El-Gamasy 2017	< 30 nmol/L
12	Banajeh 2009	< 30 nmol/L
13	Sankar 2017	<= 10 ng/mL (24.9 nmol/L)
14	Cetinkaya 2015	<= 10 ng/mL (24.9 nmol/L)
15	25(OH) D values nmol/L	= ng/mL * 2.496
16		
17		
18		
19		
20		
21		= ng/mL * 2.496
22		
23		
24		
25		
26		
27		
28		
29		
30		
31		
32		
33		
34		
35		
36		
37		
38		
39		
40		
41		
41		
42 43		
43		
44 45		
46		
47		
48		
49		
50		
51		
52		
53		
54		
55		
56		
57		
58		
59		
60	For peer review only - http	p://bmjopen.bmj.com/site/about/guidelines.xhtml

Study	Design	Sample size	Characteristics of pediatric population	Country	Reasons for exclusion of paper
Seliem 2016	Hospital-based case-control	Cases, n= 30 Controls, n= 30	Cases: group 1, full-term neonates with EOS and their mothers. Controls, group 2: 30 full-term healthy neonates and their mothers with no clinical or laboratory evidence of sepsis.	Egypt	Requested data without reply or data not available
Gamal 2017	Case-control	Cases, n= 50 Control, n= 30	Cases: neonates with early onset neonatal sepsis that occurred at <72 hours Controls: Age and sex healthy neonates with no prenatal risk factor for early neonatal sepsis enrolled in the study as a control group.	Egypt	Requested data without reply or data not available
Aydemir 2014	Hospital-based case control	Cases, n=40 Controls, n= 20	Cases: children with sepsis between 1 and 16 years old Controls: children without sepsis	Turkey	Requested data without reply or data not available
Garg 2016	Hospital-based case-control	Cases, n= 40 Controls, n= 40	Cases: children from 6 months to 5 years of age admitted or attending OPD in department of Pediatrics. Controls: children receiving care at the Hospital's ambulatory, emergency or in-patient units and presenting with non-respiratory complaints also not having any clinical indication of vitamin D deficiency.	India	Requested data without reply or data not available

In-pauent units and presenting with non-respiratory complaints also not having any clinical indication of vitamin D deficiency.

Study	Design	Number of cases (controls, where appropriate)	Characteristics of population	Country and setting	Vitamin D thresholds as defined by the study	Quality score (NOS)
Asilioglu 2017	Historical cohort (single centre)	250	Cases: aged 1 month to ≤ 18 years	Turkey, PICU	Deficiency: <20 ng/mL	7
Halwany 2017	Cohort (single centre)		Cases: children aged >1 month to ≤ 5 years	Egypt, PICU	Deficiency: <20 ng/ml Insufficiency: 20-29.9 ng/ml "Normal" levels: 30 ng/ml	6
Hurwitz 2017	Prospective cohort (single centre)	90	Cases: aged <5 years hospitalized with LRTI and RSV and/or hMPV	USA, PICU	Deficiency: <20 ng/mL	6
Garcia-Soler 2017	Cohort (single centre)	340	Cases: aged 6 months to 17 years Critically ill with various conditions	Spain, PICU	Deficient: <20 ng/mL Insufficiency: 20-30 ng/mL 25(OH)D levels: 30-40 ng/mL Optimal levels >40 ng/mL	7
Badawi 2017	Cohort (single centre)	88	Cases: 1 month to 12 years	Egypt, PICU	Deficiency: < 50nmol/l, Severe deficiency: <30 nmol/l	8
Jia 2017	Hospital- based case- control (single centre)	110 (110)	Cases: infants (< 1 year of age) with ALRTI Controls: Healthy from similar areas attending the hospital for vaccination during study period	China, PICU	Severe deficiency: <10 ng/ml Deficiency: 10-20 ng/ml Insufficiency: 21-30 ng/ml Sufficiency: >30 ng/ml	7
Yaghmaie 2017	Cross sectional (single centre)	82	Cases: hospitalized in PICU	Iran, PICU	Deficiency: <30 ng/ml	4
Say 2017	Case- control (single centre)	100 (13)	Cases: premature infants less than 37 weeks diagnosed with early or late -onset neonatal sepsis Controls: From same population of neonates with sepsis but not vitamin D deficient	Turkey, NICU	Severe deficiency (group 1) <5 ng/mL. Insufficiency (group2): 5 to 15 ng/mL Sufficiency (group 3) ≥15 ng/mL	6

El-Gamasy 2017	Case- control (single centre)	80 (20)	Cases: 3 months to 12 years hospitalized with acute kidney injury Controls: completely healthy subjects	Egypt, PICU	Seriously deficient: < 30 nmol/L Insufficient: 30-75 nmol/L Adequate >75 nmol/L	7
Sankar 2017	Cohort (single centre)	43	Cases: <=17 years of age	India, PICU	Severe vitamin D deficiency: serum 25 (OH) D <10 ng/mL	8
Shah 2016	Cohort (single centre)	154	Cases: aged between 1 month and 15 years	India, PICU	Deficiency: <20 μg/mL	6
Ponnarmeni 2016	Case- control (single centre)	124 (338)	Cases: aged 1–12 years admitted with a diagnosis of sepsis Controls: from previous prospective study, apparently healthy children of upper socioeconomic status who attended the out-patient department for immunization or with minor ailments	India, PICU	Deficiency: < 50 nmol/L Insufficiency: 50-75 nmol/L Sufficiency: > 75 nmol/L	6
Sankar 2016	Cohort (single centre)	101	Cases: aged 1 month to 17 years	India, PICU	Deficiency: ≤ 20 ng/ml Severe deficiency: <15 ng/mL	8
Bustos 2016	Cohort (single centre)	90	Cases: critically ill, greater than 37 weeks and less than 15 years of age	Chile, PICU	Deficiency: < 20 ng/ml Normal levels: > 20 ng/mL	7
Ebenezer 2016	Cohort (single centre)	52	Cases: <18 years of age; medical and surgical diagnoses	India, PICU	Deficiency: < 20 ng/ml Insufficiency: 20–30 ng/ml Normal levels: ≥ 20 ng/L	6
Elmoneim 2016	Case- control (single centre)	30	Cases: aged less than 14 years Controls: with "normal" vitamin D levels	Saudi Arabia, PICU	Deficiency: < 20ng/ml Insufficiency: 20-30 ng/mL Normal: > 30 ng/mL	5
Jat 2016	Hospital- based case- control (single centre)	50 (50)	Cases: 1 month to 12 years of age admitted with pneumonia Controls: admitted for reasons other than respiratory symptoms, required blood sampling	India, PICU	Deficiency: < 20 ng/ml Insufficiency: 20-30 ng/ml Sufficiency: >= 30 ng/ml	8
Narang 2016	Hospital- based case- control (single centre)	50 (50)	Cases: 2 months to 5 years of age admitted as in-patients or seen in the outpatient department with ALRI Controls: healthy, same age group, attending outpatients' service for immunization or admitted for minor conditions other than ALRI	India, PICU	Severe deficiency: < 20ng/ml	6

Dinlen 2016	Hospital- based case- control (single centre)	30 (30)	Cases: term neonates with ALRI Controls: healthy neonates, same age as the study group.	Turkey, NICU	Deficient: <= 15 ng/mL Severe deficiency: <= 5 ng/mL	6
Lopez 2016	Prospective cohort (multi centre)	347	Cases: 0 to >48 months admitted to hospital with ALRI prospectively recruited through the GENDRES (GENetic,vitamin D and RESpiratory infections research network)	Spain, PICU	25-OHD levels: <10 ng/mL 25-OHD levels: 10-20 ng/mL 25-OHD levels: 20-30 ng/mL	8
Alvarez 2016	Cross- sectional (single centre)	50	Cases: patients aged 0 to 18 years	USA, PICU	25(OH)D < 20 ng/mL 25(OH)D < 30 ng/mL	6
Onwuneme 2015 (1)	Case- control (single centre)	120 (30)	Cases: with suspected sepsis (<12 years old) Controls: paediatric controls admitted for elective day case surgery during the same study period and were not suspected of having sepsis	Ireland , PICU	25(OH) D levels: <50 nmol/L 25(OH) D levels: ≥50 nmol/L	8
Onwuneme 2015 (2)	Cohort (single centre)	94	Cases: preterm infants <32 weeks gestation	Ireland, NICU	Deficiency: < 30 nmol/L Sufficiency: ≥ 30 nmol/L	8
Prasad 2015	Cohort (single centre)	80	Cases: 2 months to 12 years old	India, PICU	Deficiency: < 20 ng/ml Sufficient: ≥ 20 ng/mL	7
Moreno-Solis 2015	Hospital- based case- control (single centre)	48 (30)	Cases: aged 1–11 months with acute bronchiolitis Controls: healthy, <12 months, admitted to the outpatient clinic without respiratory symptoms or history of hospitalization for bronchiolitis or wheezing	Spain, PICU	Deficiency: < 20 ng/ml Insufficiency: 21–29 ng/ml Sufficiency: ≥ 30 ng/ml	6
Alonso 2015	Cross sectional (single centre)	288	Cases: aged 1 month to 13 years	Spain, PICU	Deficient: < 20 ng/ml and < 10 ng/ml	5
Korwutthikulrangsri M 2015	Nested case- control (single centre)	32 (36)	Cases: requiring PICU admission Controls: Healthy, enrolled during the same period of time and served as the control group (age in months)	Thailand, PICU	Deficiency: < 20 ng/mLl Insufficiency: 20-29.9 ng/ml Sufficiency: ≥ 30 ng/mL	5
Khakshour 2015	Case- control	37 (53)	Cases: below 5 years of age and suffering from respiratory infections Controls: those who were not suffering from respiratory infections	Iran, PICU	Deficiency: < 20 ng/mL	5

Cizmeci 2015	Case- control (single centre)	40 (43)	Cases: infants with suspected early-onset neonatal sepsis. Controls: For each newborn of group 1, one healthy infant selected as a control	Turkey, NICU	Deficiency: $\leq 20 \text{ ng/ml}$ Insufficiency: 21–29 ng/ml Normal levels: ≥ 30 ng/ml	7
Cetinkaya 2015	Hospital- based case- control (single centre)	50 (50)	Cases: term infants with clinically suspected (probable) early infection (early-onset sepsis) within the first 3 postnatal days of life and were >37 weeks of gestational age Controls: healthy infants with no signs of clinical/laboratory infection	Turkey, NICU	Severe deficiency: <10 ng ml ⁻¹ Insufficiency: 11 to 32 ng ml ⁻¹ Adequacy: 32 to 100 ng ml ⁻¹	6
Ayulo 2014	Cohort (single centre)	216	Cases: between the ages of 1 and 21 years	Spain, PICU	Deficient: < 15 ng/ml Insufficient: 15-29 ng/mL Sufficient: ≥ 30 ng/mL	7
Dayal 2014	Cohort (single centre)	92	Cases: Children aged 3 months to 12 years	India, PICU	Deficiency: < 50 nmol/L Insufficiency: 50–75 nmol/L Sufficiency: > 75 nmol/L 25(OH) D levels: < 75 nmol/L	6
Hebbar 2014	Case- control (single centre)	61 (46)	Cases: children 0 to 18 years Controls: patients recruited among children in the magnetic resonance imaging suite.	USA, PICU	Deficient: $\leq 10 \text{ ng/ml}$ Insufficient: 10 to 20 ng/ml Sufficient: $\geq 20 \text{ ng/mL}$	6
Rey 2014	Case- control (single centre)	156 (289)	Cases: heterogeneous group of critically ill children aged <16 years Control group for comparison: population of healthy children	Spain, PICU	Deficient: < 20 ng/ml	8
Ahmed 2014	Hospital- based case- control (single centre)	50 (50)	Cases: aged 2–60 months hospitalized with ALRI Controls: age-matched with cases within 1 or 2 months, attending well-child clinics or general clinics without evidence of respiratory infection or admitted to the hospital for elective surgery	Africa, PICU	Deficiency: <50 nmol/L	8
Basha 2014	Hospital- based case- control (single centre)	81 (89)	Cases: under 5 years old with severe pneumonia selected from the inpatient departments and emergency units of the hospital Controls: healthy, selected from the outpatient surgical clinics of the hospital during their visit for umbilical or inguinal hernia repair and not suffering	Egypt, PICU	Deficiency: < 50 nmol/L Insufficiency: < 75 nmol/L Sufficiency: > 75 nmol/L	7

			from upper or lower respiratory infections			
Sakka 2014	Population based case- control (single centre)	96 (96)	Cases: <2 years old with ALRI, 48 diagnosed with pneumonia and 48 with bronchiolitis Controls: age and sex matched with no respiratory symptoms or signs from the Health office	Egypt, PICU	Severe deficiency: 0–5 ng/mL Deficiency: 5– 15 ng/mL Insufficiency: 15– 20 ng/mL Sufficiency: 20–100 ng/mL	1
Cayir 2014	Hospital- based case- control (single centre)	88 (81)	Cases: 1 to 13 years diagnosed with acute otitis media Controls: Healthy same age range	Turkey, PICU	Normal levels: 20 ng/mL Insufficiency: 15- 20ng/mL Deficiency: <15ng/mL	7
Binks 2014	Cross- sectional	74	Cases: aged <3 years admitted with acute lower respiratory infections (ALRIs) or other conditions	Australia, PICU	25(OH) D levels: < 50 nmol/L	
Madden 2012	Cohort (single centre)	511	Cases: less than 21 years old	USA, PICU	25(OH) D levels: < 10 ng/mL 25(OH) D levels: 10- 19.9 ng/mL Deficiency: < 20 ng/ml Insufficiency: < 30 ng/mL	5
Rippel 2012	Cohort (single centre)	316	Cases: children aged 16.5 (3.1–75.2) months	Australia, PICU	Deficiency: < 50 nmol/L "Normal" levels: ≥ 50 nmol/L	5
McNally 2012	Cohort (multi- centre)	326	Cases: Newborn to 17 years of age	Canada, PICUs	Deficiency: < 50 nmol/L 25(OH) D levels: 50 to 75 nmol/L	
Inamo 2011	Cohort (single centre)	28	Cases: between 1 and 48 months hospitalized with ALRI, 26 diagnosed with bronchiolitis and two as having pneumonia	Japan, PICU	Deficiency: ≤ 15ng/ml Severe deficiency: ≤ 5ng/mL	(
Roth 2010	Hospital- based case- control (single centre)	25 (25)	Cases: 1–18 months hospitalized with ALRI Controls: selected by population-based sampling. aged 1–23 months, and matched to cases on age (±2 months) and sex	Bangladesh, PICU	Deficiency: < 40 nmol/L	
Banajeh 2009	Prospective cohort (single centre)	79	Cases: 2–59 months with WHO-defined very severe community acquired (VSP) pneumonia	Iran, PICU	Deficiency: < 30 nmol/L	,
Karatekin 2009	Hospital- based case-	25 (15)	Cases: newborns with acute respiratory infections	Turkey, NICU	Deficiency: < 20 ng/ml	(

	control, (single centre)		Controls: healthy, age matched from outpatients' service where they went for immunization.		D.C.: 10	
Roth 2009	Hospital- based case- control (single centre)	64 (65)	Cases: aged 1-25 months admitted with ALRI Controls: aged 1-25 months undergoing elective surgery, no history of hospitalization for ALRI	Canada, PICU	Deficiency: < 40 nmol/L	7
Wayse 2004	Hospital- based case- control, (single centre)	80 (70)	Cases: < 5 years with severe ALRI Controls: healthy, attending outpatients service for immunization	India, PICU	Deficiency: Plasma 25(OH)D3 < 50 nmol/L	6
Mathias 2017	Prospective cohort (single centre)	41	Cases: less than 18 years admitted with diagnosis of sepsis, severe sepsis or septic shock.	USA, PICU	25(OH)D levels < 20 ng/ml 25(OH)D levels <30 ng/ml	6
Dhandai 2018	Case- control (multi- centre)	60 (60)	Cases: neonates admitted with late-onset sepsis (LOS) Controls: neonates admitted during same period with clinically significant physiological hyperbilirubinaemia (without sepsis)	India, NICU	Deficiency: < 20 ng/ml Insufficiency: <29 ng/ml Optimum: 30-50 ng/ml	6
Vo 2018	Prospective cohort (multi- centre)	1016	Cases: Infants less than twelve months old hospitalized for bronchiolitis	USA, PICU	25(OH)D < 20 ng/ml 25(OH)D: 20-29.9 ng/ml 25(OH)D >= 30 ng/ml	8
Li 2018	Case- control (single- centre)	797 (785)	Cases: children with pneumonia or pneumonia-induced sepsis group	China, PICU	Severe deficiency: < 10 ng/mL Deficiency: 10–20 ng/mL Insufficiency: 20– 30 ng/mL Sufficiency: > 30 ng/mL	8

LRTI = lower respiratory tract infection; PICU = paediatric intensive care unit; RSV = respiratory syncytial virus; ALRI = acute lower respiratory infection; WHO = World Health Organization; VSP = very severe community acquired pneumonia; NICU = neonatal intensive care unit.

Study	Objectives/aims of study	Main outcome(s) and conclusion(s)		
Madden 2012	Prevalence of vitamin D deficiency in critically ill children and factors influencing admission 25-hydroxyvitamin D (25(OH)D) levels			
Lopez 2016	Role of Vitamin D in Children hospitalized with Lower Tract Acute Respiratory Infections	25-hydroxyvitamin D levels of study population below normal range. Correlation of higher disease severity with lower levels of 25-hydroxyvitamin D.		
Garcia-Soler 2017	Prevalence and risks factors of vitamin D deficiency, as well as its relationship with length of PICU stay morbidity and mortality in a PICU.	Vitamin D deficiency is frequent in paediatric critical patients. It also has a association with higher severity scores, season of year and parental education attainment. Vitamin D levels associated with various laboratory parameters of SIRS. Vitam D deficiency associated with increased risk of morbidity and mortalit Inconclusive findings on its association with PICU length of stay were inconclusive		
McNally 2012	Prevalence of vitamin D deficiency, risk factors and potential association with clinically relevant outcomes in critically ill children in Canada.	Most of critically ill children vitamin D deficient at PICU admission. Low 25(OH) D levels associated with increased catecholamine requirements, fluid bolt administration, hypocalcemia, and longer PICU admission.		
Rippel 2012	Prevalence of hypovitaminosis D and association with outcome in critically ill children requiring admitted in intensive care.	Hypovitaminosis D is frequent in critically ill children in PICU, especially in infan and children with heart disease. Hypovitaminosis D associated with hypocalcem in non-cardiac population, and increased need for calcium replacement in th cardiac population. No association between vitamin D status and survival or PICU length of sta Strong association with early postoperative inotropic needs in the cardia population.		
Alonso 2015	Investigate relationship of serum 25-hydroxyvitamin D concentrations with serum parathyroid hormone (PTH) levels, body mass index (BMI), and environmental factors in a population of Caucasian children living at latitude 43°N.	Results doubt the assumption that a serum 25OH D threshold indicates vitamin D deficiency in children.		
Asilioglu 2017	Measure occurrence of VDD in critically ill children. Assess determinants of vitamin D status and compare vitamin D deficient and sufficient cases in respect of severity of illness.	Hypovitaminosis D occurrence high in critically ill children and associated wi higher vasopressor requirement. Not associated with other markers of illne severity including mortality.		
Ayulo 2014	Prevalence of vitamin D deficiency among children in PICU	Vitamin D deficiency common. No significant correlation between disease severi and vitamin D levels levels of vitamin D. Mortality associated with vitamin D leve		
Rey 2014	Identify prevalence of 25 hydroxivitamin D or 25(OH) vitamin D deficiency on pediatric intensive care unit (PICU) admission, and if associated with increased prediction of mortality risk scores.	Hypovitaminosis D incidence high in PICU patients. Hypovitaminosis D not associated with higher prediction of risk mortality scores.		
Shah 2016	Determine prevalence of vitamin D deficiency in critically ill children its association with illness severity, parathyroid response and clinical outcomes.	High prevalence of vitamin D deficiency. Parathyroid gland response secondary vitamin D deficiency or hypocalcemia impaired in critically ill.		
Ponnarmeni 2016	Vitamin D deficiency in critically ill children with sepsis admitted to PICU and its association with: mortality, length of stay, illness severity, requirement for ventilation and catecholamines	High prevalence of vitamin D deficiency No significant association between vitamin D deficiency and other outcomes such as mortality		
Onwuneme 2015 (1)	Assess vitamin D status, and its determinants, in chidren with suspected sepsis admitted to PICU. Also investigated association between vitamin D status and clinical outcomes.	Children admitted to the PICU with suspected sepsis lower 25OH D compared controls. Inadequate 25 OH D levels associated with confirmed sepsis and po outcomes.		
Jia 2017	Association of vitamin D with ALRTI in Chinese infants	Lowered plasma level of 25-OH Vitamin D makes children susceptible to ALRT		
Halwany 2017	Frequency of vitamin D deficiency in critically ill pediatric intensive care unit [PICU] patients and relation to state of serum 25(OH) D to disease severity.	High prevalence of vitamin D deficiency in critically ill children. Negative correlation of Vitamin D level with PELOD score. Recommend screeni of critically ill children for vitamin D deficiency to restore their serum levels.		

High prevalence of vitamin D deficiency. Vitamin D deficient children with longer

No significant relationship between the cord blood vitamin D levels and the risk

Vitamin D deficiency, low BMI, low hemoglobin level, rachitic signs were risk

High prevalence of low 250HD. Association between vitamin D status and acute

respiratory morbidity in preterm infants after birth. In none of the following outcomes was the difference statistically significant: surfactant use, inotrope requirement, RDS, pneumothorax, pulmonary hemorrhage, chronic lung disease, sepsis, retinopathy of prematurity, intraventricular hemorrhage, periventricular

Vitamin D deficiency was prevalent in critically ill children and associated with

Low vitamin levels in 50% of the children and associated with significantly

Serum 25-hydroxy vitamin D levels significantly lower in children with acute otitis media compared to the controls. Vitamin D deficiency plays a role in otitis

VDD prevalence was reported in about half of the critically ill patients, and it was

observed to be related to multiple organ dysfunctions and rapid clinical

Vitamin D deficiency among paediatric intensive care unit patients similar to western countries, also with similar age and BMI distribution. Significant relation

Significant association between vitamin D deficiency and severe pneumonia in

High prevalence of vitamin D deficiency in critically ill children and association

Groups did not differ in terms of PICU stay, duration of hospital stay, culture positivity, biochemical parameters (serum calcium, serum phosphate), need of

Subclinical vitamin D deficiency & nonexclusive breastfeeding in four first months

of life found to be significant risk factors for severe ALRI in Indian children.

Vitamin D deficiency associated with higher incidence of sepsis and mortality.

elevated risk of the need for intensive care unit admission and invasive

ICU stay duration or mortality

of neonatal sepsis in premature infants.

leucomalacia, patent ductus arteriosus, and mortality Reduced serum vitamin D levels in children

observed between age and serum level of vitamin D.

ventilation or steroids, presence of coagulopathy and mortality.

with PRISM III scores in a developing country.

Egyptian children below 5 years

factors for the severity of ALRTIs.

adverse clinical outcomes.

mechanical ventilation.

media infection.

deterioration.

2		
3	Sankar 2016	Prevalence of vitamin D deficiency on admission and examine
4		association with length of ICU stay
5	Say 2017	Evaluate effects of low vitamin D levels in cord blood on neonatal sepsis in preterm infants.
6	Sakka 2014	Determine the relation between vitamin D deficiency, anemia and
7		the severity of ALRTIs in hospitalized children.
8	Onwuneme2015 (2)	Investigate the association between serum 25-hydroxyvitamin D
9		(250HD) levels and outcomes in preterm infants (<32 weeks gestation).
10		gestation).
11		
12	D 10014	
13	Dayal 2014	Prevalence of vitamin D deficiency Association of serum vitamin D levels with duration of stay in
14		hospital, mortality and requirement of ventilation
15	Bustos 2016	Determine prevalence of vitamin D deficiency and its association
16		with other clinically relevant outcomes in children admitted to
17	Hurwitz 2017	Paediatric Intensive Care Unit Measure retinol binding protein and vitamin D in children aged <5
18	Hurwitz 2017	years hospitalized with lower respiratory tract infection and
19		respiratory syncytial virus and/or human meta pneumovirus
20		detections
21	Cayir 2014	Investigate the relationship between Vitamin D deficiency and
22		acute otitis media infection
23	Badawi 2017	Investigated if VDD is related to higher severity scores and organ
24		dysfunction. Primary objective of study was to estimate the
25		prevalence of VDD in a group of critically ill children, and
		secondary objectives was to correlate vitamin D status with pediatric logistic organ dysfunction (PELOD) and pediatric risk ofmortality
26		III (PRISM III) scores.
27	Yaghmaie 2017	Investigate relation of vitamin D deficiency with potential
28		demographic and clinical factors.
29	Basha 2014	Aimed to evaluate vitamin D status as a risk factor for severe
30	Bushu 2011	pneumonia in Egyptian hospitalized children under 5 years
31	Prasad 2015	Prevalence of vitamin D deficiency in critically ill children and
32		association with illness severity& other outcomes
33		
34		
35	Wayse 2004	If vitamin D deficiency in Indian children under 5 years old of age
36	FI C 2017	is risk factor for severe acute lower respiratory infection (ALRI).
37	El-Gamasy 2017	Assess serum 25 (OH)D level in critically ill paediatric patients with AKI at PED of Tanta University Emergency Hospital (TUEH)
38		within the first 24 hours of admission and evaluate its correlation
39		with duration of hospital stay and mortality outcome.
40		
41		
42		
43		
44		
45		For peer review only - http://bmjopen.bmj

1

Page 59 of 84

 BMJ Open

Banajeh 2009	Determine if rickets and VDD predict the outcomes in very severe pneumonia (VSP).	In WHO-defined VSP, nutritional rickets was strongly associated with a reduced successful treatment outcome, and VDD was a significant and independen predictor of reduced circulating PMNs and persistent hypoxemia.	
Binks 2014	Aimed to determine prevalence of vitamin D insufficiency among children hospitalised with ALRI in the Northern Territory.	Vitamin D insufficiency was observed in about one-third of these hospitalised children. Children hospitalised with an ALRI less likely to have vitamin I insufficiency compared with children hospitalised for other condition (predominantly gastroenteritis).	
Roth 2009	Test the hypothesis that vitamin D status is associated with the risk of ALRI in Canadian children (1 month to 2 years old)	Among children aged 1 month to 2 years, vitamin D status not associated with ALR requiring hospitalization	
Hebbar 2014	Prevalence of vitamin D insufficiency and relationship between vitamin D levels infection and innate immunity	High prevalence of vitamin D deficiency Serum vitamin D levels - no correlation with illness severity score	
Ebenezer 2016	Determine vitamin D status and association with outcomes	Vitamin D deficiency common among pediatric patients No association between vitamin D status and admission and mortality such a higher mortality and/or longer PICU stay Deficiency associated with mechanical ventilation severity of illness, vasopresso need	
Narang 2016	Identify an effective nutritional agent that reduces the need for antibiotics, duration of pneumonia and length of hospitalization would be highly cost-beneficial.	Severe vitamin D deficiency (<20 ng/ml), nonexclusive breastfeeding in the first	
Alvarez 2016	Study aimed to investigate relationship between vitamin D status and plasma markers of lutathione (GSH) and cysteine (Cys) redox and immunity in critically ill children	Vitamin D sufficiency was associated with more reduced plasma hCySS, indicativ of lower oxidative stress, in critically ill children. Plasma GSH, GSSG, an glutamine, however, were lower in the vitamin D sufficient group. Vitamin D rol in maintaining redox status during pediatric critical illness requires further study.	
Cetinkaya 2015	Evaluate the effect of vitamin D levels on early-onset sepsis (EOS) in term infants	Lower maternal and neonatal 25-OHD levels associated with EOS. Suggest the adequate vitamin D supplementation during pregnancy may be helpful to prever EOS in term neonates.	
Ahmed 2014	Examine relationship between vitamin D status and hospitalization for ALRTI in Nigerian children.	ALRTI not associated with vitamin D status, but associated with less exposure t sunlight. Exposure to sunlight & vitamin D supplementation contributed to vitami D status in this population.	
Jat 2016	Evaluate Vitamin D levels and its correlation with severity and outcome of pneumonia in children.	Majority (86.4%) of children were vitamin D deficient. Vitamin D levels wer found different in cases and controls and were not related to severity and outcom of pneumonia.	
Sankar 2017	Evaluate association of severe vitamin D deficiency with clinically important outcomes in children with septic shock.	Prevalence of severe vitamin D deficiency is high in children with septic shoc admitted to pediatric intensive care unit. Severe vitamin D deficiency at admission seems to be associated with lower rates of shock reversal at 24 hours of ICU stay	
Cizmeci 2015	Investigate if neonates with early-onset neonatal sepsis (EONS) had lower levels of vitamin D	Cord-blood 25(OH) D levels of neonates with EONS significantly lower than the of the healthy controls, and a low level of cord-blood vitamin D was found to be associated with an increased risk of EONS. Further studies are warranted to confirm this association.	
Khakshour 2015	Clarify the association between vitamin D deficiency and acute respiratory infection in children below age 5 years.	The group of children with respiratory disorders, 9 (42.9%) exhibited vitamin deficiency. No meaningful statistical relation vitamin D deficiency with acurespiratory infections (p>0.05)	
Korwutthikulrangsri 2015	Determine vitamin D status in critically ill children and its relationship with adrenal function	Higher prevalence of vitamin D deficiency in critically ill children in compariso to controls. Patients vitamin D deficiency had higher median (IQR) PRISM III scor and higher proportion of mortality than those with serum 25-OHD of equal or more than 12 ng/mL.	
Elmoneim 2016 Association of the level of vitamin D on admission & length of stay in the PICU, or duration of mechanical ventilation.		High prevalence of vitamin D deficiency among PICU patients & significan association with increased LOS and need for mechanical ventilation. Ne significant association with mortality rate.	

Determine the association between serum 25-hydroxy vitamin D	Lower blood 25(OH) D levels might be associated with increased risk of ALRTI in
newborns	term newborn babies. Appropriate vitamin D supplementation during pregnancy and early childhood may enhance newborns' respiratory health.
Examine prevalence of hypovitaminosis D in infants with acute bronchiolitis compared with control subjects and to evaluate the relationship between serum 25-hydroxyvitamin D (25(OH) D) and the severity of bronchiolitis.	Prevalence of hypovitaminosis D is high in Spanish infants with bronchiolitis. The severity of acute bronchiolitis increases with a decline in serum 25 (OH) D level.
Relationship between serum vitamin D concentrations and severity of ALRI in hospitalized children in Japan.	Significantly more children with ALRI that required supplementary oxygen and ventilator management were vitamin D deficient. Findings suggest: immunomodulatory properties of vitamin D may influence the severity of ALRI.
Association of serum 25-hydroxy vitamin D concentrations in newborns with acute lower respiratory infection (ALRI) and without clinical signs of rickets, and their mothers	Newborns with subclinical vitamin D deficiency may have an increased risk of suffering from ALRI. Strong positive correlation between newborns' and mothers' 25(OH) D concentrations indicates that adequate vitamin D supplementation of mothers should be emphasized during pregnancy especially in winter months.
Investigate association between vitamin D status and ALRI	Vitamin D status associated with ALRI in early childhood. Randomized trials needed to establish if interventions to improve vitamin D status could reduce burden of ALRI in early childhood.
Determination of association of 25(OH)D with cathelicidin and DBP (D binding protein) in children with sepsis	No association between vitamin D and cathelicidin or DBP (D binding protein) levels
Assess vitamin D deficiency as possible risk factor for late-onset sepsis in term and late preterm neonates	Vitamin D deficient neonates are at greater risk for late onset sepsis compared to those with sufficient vitamin D levels
Investigate the association between circulating 25-hydroxyvitamin D status upon admission and disease severity in infants hospitalized for bronchiolitis. Also, to determine if the association differs by the form of 25(OH)D (total, bioavailable or free 25 (OH) D.	Infants with total 25 (OH) D < 20 ng/ml had higher risk of intensive care and longer hospital length-of-stay
Assess vitamin D nutritional status of children of 3 days to 14 years and investigated the relationship between community-acquired pneumonia and serum 25(OH)D level	Children with low serum 25 (OH) D levels may be at higher risk of receiving mechanical ventilation and presenting with multiple organ dysfunction. Vitamin D supplementation could be beneficial for the treatment and prevention of CAP
	 [25(OH)D] levels and acute respiratory tract infections (ALRTI) in newborns Examine prevalence of hypovitaminosis D in infants with acute bronchiolitis compared with control subjects and to evaluate the relationship between serum 25-hydroxyvitamin D (25(OH) D) and the severity of bronchiolitis. Relationship between serum vitamin D concentrations and severity of ALRI in hospitalized children in Japan. Association of serum 25-hydroxy vitamin D concentrations in newborns with acute lower respiratory infection (ALRI) and without clinical signs of rickets, and their mothers Investigate association between vitamin D status and ALRI Determination of association of 25(OH)D with cathelicidin and DBP (D binding protein) in children with sepsis Assess vitamin D deficiency as possible risk factor for late-onset sepsis in term and late preterm neonates Investigate the association between circulating 25-hydroxyvitamin D status upon admission and disease severity in infants hospitalized for bronchiolitis. Also, to determine if the association differs by the form of 25(OH)D (total, bioavailable or free 25 (OH) D. Assess vitamin D nutritional status of children of 3 days to 14 years and investigated the relationship between community-acquired

Assay	Paper	Total Number of studies
Radioimmunoassay	Madden 2012; Inamo 2011; Karatekin 2009; Roth 2009; Roth 2010;	8
-	Sakka 2014; Moreno-Solis 2015; Khashour 2015	
Competitive binding enzyme linked	Basha 2014	1
immunoassay		
Binding protein assay	Onwuneme 2015 (2)	1
Liquid chromatography-mass spectrometry	McNally 2012; Korwutthikulrangsri 2015; Binks 2014; Cetinkaya 2015;	7
	Cizmeci 2015; Asilioglu 2017; Onwuneme (1)	
Chemiluminescence immunoassay or	Alonso 2015; Rey 2014; Sankar 2016; Shah 2016; Prasad 2015; Ahmed	13
chemiluminescent tracer	2015; Lopez 2016; Alvarez 2016; Say 2017; Sankar 2017; Jat 2017;	
	Mathias 2017; Li 2018	
ELISA	Ponnarmeni 2016; Hebbar 2014; Elmoneim 2016; Narang 2016; Jia 2017;	9
	El-Gamasy 2017; Halwany 2017; Banajeh 2009; Badawi 2017	
ELFA (enzyme linked fluorescent assay)	Bustos 2014	1
Electrochemiluminescence Immunoassay	Daval 2014, Ebenezer 2016, Garcia Soler 2017; Cavir 2014;	4
(ECLIA)		
Clinical Laboratory Improvement	Hurwitz 2017	1
Amendments-approved Vitamin D assay		
(Elecsys; Roche Diagnostics, Indianapolis,		
Indiana)		
Commercial immunoassay lit (I RIA Diasorin	Wayse 2004, Ayulo 2014,	2
UK)		
Immunoassay analyzer	Rippel 2012	1
APPLIED 3200 Biosystem	Dinlen 2016	1
Not reported	Yaghmaie 2017; Dhandai 2018	2
Abbott Architect assay (Abbott, Waukegan,	Vo 2018	1
Illinois)		
	0 7 1	

Study	Funding	Approval of study and ethics	
Madden 2012	Reported	Children's Hospital Boston institutional review board. Informed consent obtained from family.	
Lopez 2016	Reported	Approved by the Ethical Committee of Clinical Investigation of Galicia (CEIC ref 010/015) and all of the regional et committees of the participant centres informed consent forms were obtained from either a parent or legal guardian for subject before study inclusion.	
Garcia-Soler 2017	Not reported	Study protocol approved by regional research ethics committee. Obtained informed consent from family of patients. D recorded anonymously (encrypted electronic database). Project adhered to the principles of Declaration of Helsinki and standards for good clinical practice.	
McNally 2012	Reported	Research ethics board approval for vitamin D sub study obtained from 6 centers, representing 337 of the original 389 study participants.	
Rippel 2012	Not Reported	Approved by Ethics Committee of The Royal Children's Hospital Melbourne	
Alonso 2015	Reported	Regional Ethics Committee of the Principality of Asturias	
Asilioglu 2017	Not reported	Approval of study by the Local Ethics Committee of Ondokuz Mayıs University (Samsun, Turkey).	
Ayulo 2014	Not reported	Institutional Review Board: Montefiore Medical Centre	
Rey 2014	Reported	Hospital Ethics Committee	
Shah 2016	Reported	Ethical approval obtained from Institutional ethics committee. Parents of children satisfying criteria gave written informed consent for participation of their child in the study.	
Ponnarmeni 2016	Not reported	The institution's ethics committee. Informed consent obtained	
Onwuneme 2015 (1)	Reported	Approval by ethics committees of: Children's University Hospital, Temple Street and Our Lady's Children's Hospital, Dublin, Ireland. Participants were informed and provided written consent before recruitment.	
Jia 2017	Not reported	Approved by Human Ethical Committee of Affiliated Hospital of Yan'an University, Yan'an. Informed consent was taken from mothers and/or parent of infants.	
Halwany 2017	Not reported	Approval by the Medical Ethics Committee of the Faculty of Medicine, Alexandria University	
Sankar 2016	Not reported	Institutional Ethics committee. Informed consent obtained	
Say 2017	Not reported	Approval by the local Ethics Committee and informed parental consent was obtained for all infants.	
Sakka 2014	Not reported	Not reported	
Onwuneme2015 (2)	Reported	Ethics Committee of National Maternity Hospital. Informed written consent obtained from parents before recruitment	
Dayal 2014	Not reported	Ethics Committee of the Institute. Informed consent obtained.	
Bustos 2016	Reported	Comité Ético Científico del Servicio de Salud de Concepción	
Hurwitz 2017	Reported	Informed consent obtained and study protocol approved by the Institutional Review Boards at the University of Tennessee, St Jude Research Hospital, and the Centers for Disease Control and Prevention.	
Cayir 2014	Not reported	Approval from the institutional ethics committee and consent from the parents of all children in the study.	
Badawi 2017	Not reported	Children's Cairo University institutional review board approved study. Informed consent obtained from parents	
Yaghmaie 2017	Not reported	Study carried out in accordance with the Declaration of Helsinki, and the ethics committee of the Tehran University of Medical Sciences approved the protocols of the study. Records of patients' were kept confidential. Patients' consent provide	

 BMJ Open

		for blood sampling and vitamin D serum level was assessed from patients' files, so no invasive method or extra blood sampling was done.
Basha 2014	Not reported	Oral consent from the mothers.
Prasad 2015	Not reported	Institutional review board approved the protocol. Written informed consent obtained from parents or guardians.
Wayse 2004	Reported	Information not provided
El-Gamasy 2017	Not reported	Study approved from the Ethical Committee of the Faculty of Medicine, Tanta University. Informed verbal or written parental consents from all subjects involved in the study.
Banajeh 2009	Reported	Protocol approved and described in previous paper
Binks 2014	Reported	Testing performed after approval by the Human Research Ethics Committee of the Northern Territory Department of Health and Menzies School of Health Research
Roth 2009	Reported	Caregiver of each participant provided written informed consent and completed a questionnaire Study approved by the Human Research Ethics Board of the University of Alberta Health Sciences Faculties
Hebbar 2014	Reported	Institutional Review Boards of Emory University and Children's Healthcare Atlanta Informed consent obtained
Ebenezer 2016	Reported	Institutional Review Board (IRB), Informed consent from parents
Narang 2016	Not reported	Not reported
Alvarez 2016	Reported	Study approved by both the Emory University and Children's Healthcare of Atlanta Institutional Review Boards, and informed consent was obtained from patients' guardians prior to any study procedures
Cetinkaya 2015	Not reported	Study protocol approved by the local Ethics Committee. Informed parental consent was obtained for all infants
Ahmed 2014	Not reported	Informed written or oral consent obtained from the parents, and the study was approved by the National Hospital Abuja Ethics Committee
Jat 2016	Not reported	Ethics committee approval was taken before commencing the study. Parent's informed consent was taken before enrol children into study.
Sankar 2017	No funding	Study approved by the institutional ethics committee.
Cizmeci 2015	Reported	Acquisition of cord-blood was approved by the local ethics committee of Fatih University Medical School.
Khakshour 2015	Not reported	Obtained informed consent from parents, data collection done using demographic questionnaire and serum level of 25-dehydroxycalcciferol was measured. Samples taken by a trained nurse at admission based on physici orders.
Korwutthikulrangsri 2015	Not reported	Ramathibodi Hospital Ethics Committee. Written informed consent from legal guardians of all participants
Elmoneim 2016	Reported	MCH hospital Ethics Committee approved study protocol
Dinlen 2016	Not reported	Study approved by the Local Ethics Committee. All parents fully informed about this investigation as well as its aim. Wr consent was obtained from all parents.
Moreno-Solis 2015	Reported	Written informed consent obtained from parents or legal guardian of all enrolled children. Protocol of study approved by Ethics Committee before the beginning of this study.
Inamo 2011	Not reported	Ethics Committee of Nihon University Nerima-Hikarigaoka Hospital. Informed consent obtained from the parents o patients before inclusion in the study.
Karatekin 2009	Not reported	Study approved by the Institution's Ethics Committee, and informed consent was obtained from the study participants.
Roth 2010	Reported	Approved by The Johns Hopkins Bloomberg School of Public Health Institutional Review Board and the ethics committee the Bangladesh Institute for Child Health at the Dhaka Shishu Hospital, Bangladesh. Signed permission prior to enrol from parents/guardians.

Mathias 2017	Reported	The institution's Human Investigation Committee approved the study after a full board review and informed consent obtained
Dhandai 2018	Not reported	The institute's ethics committee approved the study and informed written consent had been given by their parents or guardians
Vo 2018	Reported	The institutional review boards at all participating sites approved the protocol and informed consent obtained from the infants' parents/legal guardians
Li 2018	Not reported	Protocols for the study and written consent approved by the ethics committee of the Capital Institute of Pediatrics at Beijing, China

For peer review only

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

1 2	
3	
4 5	
6	
7	
8 9	
10	
11 12	
13	
14 15	
16	
17	
18 19	
20	
21 22	
23	
24 25	
26	
27 20	
28 29	
30	
31 32	
33	
34 35	
36	
37 38	
39	
40 41	
42	
43	
44 45	
46	
47 48	
49	
50 51	
52	
53 54	
55	
56 57	
57 58	
59	
60	

First author, date	Age group
Wayse 2004	<5 years
Karatekin 2009	Neonates
Roth 2009	<2 years
Roth 2010	1–18 months
Inamo 2011	<4 years
Madden 2012	<21 years
Rippel 2012	16.5 (3.1 to 75.2) months
McNally 2012	Newborn to 17 years
Ayulo 2014	1 to 21 years
Dayal 2014	3 months to 12 years
Hebbar 2014	0 to 18 years
Rey 2014	<16 years
Cetinkaya 2015	>37 weeks
Onwuneme (1) 2015	<12 years
Onwuneme (2) 2015	<32 weeks gestation
Prasad 2015	2 months to 12 years
Alonso 2015	1 month to 13 years
Korwutthikulrangsri 2015	79 (61) cases; 92 (40) controls months
Cizmeci 2015	Neonates
Shah 2016	1 month to 15 years
Ponnarmeni 2016	1 to 12 years
Sankar 2016	1 month to 17 years
Bustos 2016	>37 weeks and <15 years
Ebenezer 2016	<18 years
Elmoneim 2016	<14 years
Narang 2016	2 months to 5 years
Dinlen 2016	Neonates
Lopez 2016	0 to >48 months
Alvarez 2016	0 to 18 years
Garcia-Soler 2017	6 months to 17 years
Sankar 2017	<17 years
Ahmed 2015	2 to 60 months
Cayir 2014	1 to 13 years
Say 2017	<37 weeks
Asilioglu 2017	<=18 years
Basha 2014	<5 years
Jia 2017	<1 year
Jat 2017	1 month to 12 years
Yaghmaie 2017	Age range not stated
El-Gamasy 2017	3 months to 12 years
Binks 2014	<3 years
Halwany 2017	>1 month to $<= 5$ years
Badawi 2017	1 month to 12 years
Moreno-Solis 2015	1 to 11 months
Sakka 2014	<2 years
Hurwitz 2017	<5 years
Banajeh 2009	2 to 59 months
Khakshour 2015	< 5 years
Mathias 2017	<= 18 years
Dhandai 2018	Neonates
Vo 2018	< 12 months
Li 2018	3 days to 14 years

Study	d from highest to lowest) Prevalence of vitamin D deficiency (%)	Number of vitamin D deficient children	Total number of children
Wayse 2004	95.00	76	80
Sakka 2014	92.70	89	96
Karatekin 2009	92.00	23	25
Onwuneme2015 (2)	91.48	86	94
Say 2017	87.00	87	100
Dinlen 2016	86.70	26	30
Cetinkaya 2015	84.00	42	50
Jat 2016	84.00	42	50
Roth 2010	84.00	21	25
Prasad 2015	83.75	67	80
Jia 2017	83.64	92	110
Shah 2016	83.11	128	154
Korwutthikulrangsri 2015	78.12	25	32
Sankar 2016	74.26	75	101
Sankar 2017	72.09	31	43
Cizmeci 2015	70.00	28	40
Mathias 2017	70.00	28	41
McNally 2012	69.02	225	326
Basha 2014	65.43	53	81
Yaghmaie 2017	64.63	53	82
Dhandai 2018	63.30	38	60
Hebbar 2014	60.66	37	61
Onwuneme 2015 (1)	59.16	71	120
Alvarez 2016	58.00	29	50
Cayir 2014	56.82	50	88
Elmoneim 2016	56.67	17	30
Narang 2016	56.00	28	50
Li 2018	55.83	445	797
Ponnarmeni 2016	50.81	63	124
Asilioglu 2017	48.00	120	250
Badawi 2017	44.30	39	88
Garcia-Soler 2017	43.82	149	340

1 2	
2 3 4	
5 6	
7 8	
9 10	
11 12	
13 14	
15 16	
17 18	
19 20	
21 22	
23 24	
25 26	
27 28	
29 30	
31 32	
33 34	
35 36	
37 38	
39 40 41	
41 42 43	
44 45	
46 47	
48 49	
50 51	
52 53	
54 55	
56 57	
58 59	
60	

60

Bustos 2016	43.30	39	90
Ebenezer 2016	40.38	21	52
Madden 2012	40.12	205	511
Halwany 2017	37.25	38	102
Banajeh 2009	36.71	29	79
Rippel 2012	34.49	109	316
El-Gamasy 2017	32.50	26	80
Ahmed 2014	30.00	15	50
Rey 2014	29.49	46	156
Vo 2018	29.33	298	1016
Inamo 2011	28.50	8	28
Dayal 2014	\$ 25.00	23	92
Khakshour 2015	24.32	9	37
Lopez 2016	24.20	84	347
Alonso 2015	15.63	45	288
Ayulo 2014	15.63	61	216
Binks 2014	14.86	11	74
Moreno-Solis 2015	13.33	9	48
Hurwitz 2017	12.22	11	90
Roth 2009	4.69	3	64

Cz oni

2	
3	
4	
5	
2	
6	
7 8	
8	
9	
10 11	
11	
12	
13	
14	
15 16	
16	
17	
17	
17 18	
19	
20	
20	
21	
22	
23	
24	
25	
25	
26	
27	
27 28	
20	
29	
30	
31	
32	
52	
33	
34	
35	
35 36 37 38	
50	
37	
38	
39	
40	
41	
42	
43	
44	
•••	
45	
46	
47	
48	
49	
50	
51	
52	
53	
54	
55	
56	
57	
58	
50	

60

Study	number of vitam patients defici patier		Country, setting	Age range	Design	Quality score (NOS)	
Vo 2018	1016	298	USA, PICU	< 12 months	cohort	8	
Li 2018	797	445	China, PICU	3 days to 14 years	case-control	8	
Madden 2012	511	205	Boston US, PICU	< 21 years	cohort	8	
Lopez 2016	347	84	Spain, hospitalised	0 to >48 months	cohort	8	
Garcia-Soler 2017	340	149	Spain, PICU	6 months to 17 years	cohort	7	
McNally 2012	326	225	Canada, PICU	newborn to 17 years of age	cohort	7	
Rippel 2012	316	109	Australia, PICU	16.5 (3.1–75.2) months	cohort	8	
Alonso 2015	288	45	Spain, PICU	1 month to 13 years	cross sectional	5	
Asilioglu 2017	250	120	Turkey, PICUs	<= 18 years	cohort	6	
Ayulo 2014	216	61	Spain, PICU			5	
Rey 2014	156	46	Spain, PICU	<16 years	sectional case-control	8	
Shah 2016	154	128	India,PICU	1 month-15 years	cohort	6	
Ponnarmeni 2016	124	63	India, PICU	aged 1-12 years	case-control	6	
Onwuneme 2015 (1)	120	71	Ireland, PICU	<12 years old	case-control	8	
Jia 2017	110	92	China, PICU	infants <1 years old	case-control	7	
Halwany 2017	102	38	Alexandria, PICU	>1 month to \leq 5 years	cohort	6	
Sankar 2016	101	75	India, PICU	1 month to 17 years	cohort	8	
Say 2017	100	87	Turkey, NICU	gestational age <37 weeks	case-control	6	
Sakka 2014	96	89	Egypt, hospitalized	infants (<2 years old)	case-control	8	
Onwuneme 2015 (2)	94	86	Ireland, NICU	preterm infants at <32 weeks gestation	cohort	8	
Dayal 2014	92	23	India, PICU	3 months to 12 years	cohort	6	
Bustos 2016	90	39	Chile, PICU	>37 weeks and <15 years	cohort	7	
Hurwitz 2017	90	11	USA, hospitalised	<5 years old	cohort	6	
Cayir 2014	88	50	Turkey, PICU	1 to 13 years	case-control	7	
Badawi 2017	88	39	Cairo, Egypt PICU	1 month to 12 years	cohort	7	
Yaghmaie 2017	82	53	Iran, PICU	children undefined	cross sectional	4	
Basha 2014	81	53	Cairo Egypt, PICU	<5 years old	case-control	7	
Prasad 2015	80	67	India, PICU	2 months-12 years	cohort	7	
Wayse 2004	80	76	Indapur India, PICU	<5 years	case-control	6	
El-Gamasy 2017	80	26	Egypt, PICU	3 months to 12 years	Case-control	7	
Banajeh 2009	79	29	Iran, hospitalised	aged 2-59 months	cohort	7	
Binks 2014	74	11	Australia, PICU	<3 years old	cross sectional	6	
Roth 2009	64	3	Canada, PICU	aged 1-25 months	case-control	7	
Hebbar 2014	61	37	Atlanta, PICU	0 to 18 years	case-control	6	
Dhandai 2018	60	38	India, NICU	neonates	case-control	6	

1
2
3
4
5
6 7
8
9
10
11
12
13 14
14
16
17
18
19
20 21
21 22
23
24
25
26
27
28 29
30
31
32
33
34
35
36 37
38
39
40
41
42 43
43 44
45
46
47
48
49 50
50 51
52
53
54
55
F (

56 57 58

59

60

Ebenezer 2016	52	21	India, PICU	<18 years	cohort	6
Narang 2016	50	28	Punjab, India, PICU	2 months to 5 years	case-control	6
Alvarez 2016	50	29	Atlanta, PICU	0 to 18 years	cross sectional	6
Cetinkaya 2015	50	42	Instabul/Turkey, neonates NICU		case-control	6
Ahmed 2014	50	15	15 Nigeria, PICU 2–60 months		case-control	8
Jat 2016	50	42	India, PICU 1 month to 12 year		case-control	8
Sankar 2017	43	31	India, PICU	<=17 years	cohort	8
Mathias 2017	41	28	USA, PICU	<= 18 years	cohort	6
Cizmeci 2015	40	28	Instabul/Turkey, NICU	neonates	case-control	7
Khakshour 2015	37	9	Iran, hospitalized	<5 years	Case-control	5
Korwutthikulrangsri 2015	32	25	Bangkok, PICU months no specific ra		nested case- control	5
Elmoneim 2016	30	17	Saudi Arabia, <14 years PICU			5
Dinlen 2016	30	26	Ankara Turkey, NICU	neonates	case-control	6
Moreno-Solis 2015	48	9	Spain, PICU	infants 1-11 months	case-control	6
Inamo 2011	28	8	Tokyo Japan, PICU	1-48 months	cohort	6
Karatekin 2009	25	23	Istanbul Turkey, NICU	neonates	case-control	6
Roth 2010	25	21	Bangladesh	1-18 months	case-control	8

Studies arranged from largest to smallest total sample size. NOS = Newcastle Ottawa Score

1
2
3
4
5
6
6
7
8
9
10
10
11
12
13
14
9 10 11 12 13 14 15 16
16
10
17
18
19
20
20
21
22
23
24 25
25
25
26
27
28
29
30
31
32
33
34 35 36
35
26
30
37
38
39
40
41
42
43
44
45
46
17

1

Patient category	Number of studies (Total number of individuals; number	Pooled proportion % (95% CI)	95% PI	Pooled proportion % (95% CI)	Heterogeneity (I ²) % (95% CI)	Q value, d.f. p-value for heterogeneity	Median % (IQR) of vitamin D deficiency
	of vitamin D deficient individuals)	Random effects model		Fixed effects model			
Acute and critically ill children, excluding studies that used other thresholds	40 (6,543; 3,000)	53.0 (46.4-59.5)	17.7-85.5	45.1 (43.8-46.5)	95.5 (94.5-96.2)	859.8, 39, < 0.0001	55.9 (33.4-55.9)
Sample size >= 82 (large)	26 (6,094; 2,731)	51.5 (43.6-59.4)	16.5-85.2	44.0 (42.6-45.3)	96.8 (96.0-97.4)	773.1, 25, < 0.0001	46.2 (30.7-67.9)
Sample size < 82 (small)	26 (1,340; 742)	58.2 (47.5-68.2)	13.2-92.8	54.8 (51.7-58.0)	90.9 (87.9-93.2)	275.4, 25, < 0.0001	62.0 (33.6-82.3)
Cohort studies	22 (4,456; 1,874)	48.3 (40.2-56.5)	15.7-82.4	41.0 (39.5-42.6)	95.8 (94.6-96.7)	499.6, 21, < 0.0001	41.9 (30.6-68.8)
Case-control	26 (2,484; 1,461)	63.4 (54.9-71.2)	22.2-91.4	57.2 (55.1-59.4)	92.2 (89.8-94.1)	322.2, 25, < 0.0001	62.0 (52.1-84.0)
Cross sectional	4 (494; 138)	34.8 (12.8-66.0)	0.10-99.6	30.3 (25.9-35.2)	96.7 (94.0-98.2)	90.4, 3, < 0.0001	36.8 (15.4-59.7)
Studies from India	11 (886; 592)	68.9 (54.9-80.1)	18.3-95.6	64.0 (60.4-67.5)	96.7 (94.0 98.2)	140.2, 10, < 0.0001	72.1 (53.4-83.4)
Studies from Turkey	7 (583; 376)	76.3 (60.9-87.0)	20.9-97.5	61.0 (56.6-65.2)	91.1 (84.2-95.0)	67.5, 6, < 0.0001	84 (63.4-86.8)
Studies that only recruited neonates	7 (399; 330)	83.0 (73.1-90.0)	42.4-97.0	80.7 (76.1-84.5)	76.6 (51.0-88.9)	25.7, 6, 0.0003	86.7 (77.0-89.2)
Studies with children of all other ages except neonates	45 (7,035; 3,143)	49.7 (43.5-55.8)	16.1-83.5	44.2 (43.0-45.5)	95.2 (94.3-96.0)	919.9, 44, < 0.0001	48.0 (29.5-68.3)

 $CI = confidence intervals; I^2 = heterogeneity; df = degrees of freedom. Vitamin D deficiency defined in our study as <50 nmol/L (20 ng/mL) I² statistic used to estimate heterogeneity between pooled studies: I² >= 75% was considered as high heterogeneity, PI= Prediction interval; IQR = interquartile range: Lower (Q1) to Upper (Q3) quartile$

Predictors	k	b- coefficient	se	t-value	p-value	ci.lb	ci.ub	F-value	I^2 (%)	R^2 (%)	QE
Full model: year + clinical setting + quality score + design + country group + total sample size	52							4.14	96.0	29.6	759.8 p < 0.0022
year		-0.024	0.059	-0.419	0.677	-0.143	0.094				
total study sample size		-0.0005	0.001	-0.545	0.588	-0.002	0.001				
country group (group 1 or 2 versus group 3)		0.996	0.359	2.771	0.008	0.272	1.719				
clinical setting (NICU versus PICU)		-1.645	0.471	-3.496	0.001	-2.593	-0.698				
design group (cohort vs other i.e. case-control or cross sectional)		0.288	0.321	0.899	0.374	-0.358	0.935				
quality score		0.214	0.152	1.410	0.165	-0.092	0.521				

k = number of outcomes included in the model fitting; se = standard errors of the coefficients; ci.lb = lower bound of the confidence intervals for the coefficients; ci.ub = upper bound of the confidence intervals for the coefficients; QE = test statistic for the test of (residual) heterogeneity; I^2 = residual heterogeneity / unaccounted variability; R^2 (amount of heterogeneity accounted for; PICU = pediatric intensive care units, NICU = neonatal intensive care units

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

2	
3	
4	
5	
6	
7	
8	
9	
10	
11	
12	
13	
14	
14 15	
16	
16	
17	
18	
19	
20	
21	
22	
23	
24	
25	
26	
27	
28	
29	
30	
31	
32	
32 33	
34	
35	
36	
37	
38	
39	
40	
41	
42	
43	
44	
45	
46	
47	
4/	

Study	Total number of patients with sepsis	Total number of vitamin D deficient patients with sepsis	Country, setting	Age	Design	Quality score (NOS)
Shah 2016	160	135	India, PICU	1 month to 16 years	cohort	6
Asilioglu 2017	120	20	Turkey, PICU	1 month to ≤18 years	cohort	7
Say 2017	100	87	Turkey, NICU	preterm infants at <37 weeks gestation	case-control	6
Dhandai 2018	60	38	India, NICU	neonates	case-control	6
Ponnarmeni 2016	62	32	India, PICU	1 to 12 years	case-control	6
McNally 2012	48	33	Canada, PICU	newborn to 17 years	cohort	7
Onwuneme 2015 (2)	46	32	Ireland, NICU	preterm infants at <32 weeks gestation	cohort	8
El-Gamasy 2017	46	20	Egypt, pediatric emergency department	3 months to 12 years	case-control	7
Sankar 2017	43	31	India, PICU	<=17 years	cohort	8
Mathias 2017	41	28	USA, PICU	<=18 years	cohort	6
Cizmeci 2015	40	28	Turkey, NICU	neonates	case-control	7
Onwuneme 2015 (1)	35	32	Ireland, PICU	<12 years old	case-control	8
Hebbar 2014	30	17	Atlanta, PICU	0 to 18 years	case-control	6
Ebenezer 2016	16	8	India, PICU	<18 years	cohort	6
Korwutthikulrangsri 2015	12	4	Bangkok, PICU	moths (<8/9)	nested-case control	5
Prasad 2015	11	9	India, PICU	2 months to 12 years	cohort	7
Bustos 2016	10	7	Chile, PICU	>37 weeks and < than 15 years	cohort	7
Dayal 2014	9	4	India, tertiary care hospital	3 months to 12 years	cohort	6

	Sensitivity analyses for	1		, i i i i i i i i i i i i i i i i i i i		, ,	
Patient category	Number of studies (Total number of individuals; number of vitamin D deficient individuals)	Pooled proportion (%, 95% CI) Random effects	95% PI	Pooled proportion (%, 95% CI) Fixed effects	Heterogeneity (I ²) %, 95% CI	Q value, d.f. p-value for heterogeneity	Median % (IQR) of vitamin D deficiency
Excluding studies that used other thresholds	14 (654; 395)	62.0 (47.3-74.72)	13.3-94.5	60.4 (56.0-64.7)	89.7 (84.5-93.2)	126.5, 13, < 0.0001	65.8 (50.4-70.0)
Sample size >= 42 (large)	9 (685; 428)	63.2 (44.6-78.5)	9.4-96.6	62.5 (58.2-66.6)	94.3 (91.1-96.3)	139.2, 8 < 0.0001	68.8 (51.6-72.1)
Sample size < 42 (small)	9 (204; 137)	64.7 (52.5-75.3)	29.5-89.0	64.7 (57.4-71.4)	57.9 (11.8-79.9)	19.0, 8, 0.0148	68.3 (50.0-70.0)
Cohort studies	10 (504; 307)	63.2 (43.7-79.1)	8.57-96.9	62.5 (57.5-67.4)	92.0 (87.3-94.9)	112.2, 9 < 0.0001	69.2 (54.6-71.6)
Case-control	8 (385; 285)	64.9 (50.1-77.3)	18.6-93.8	63.6 (58.2-68.7)	84.9 (72.0-91.8)	46.3, 7 < 0.0001	60 (49.6-74.3)
Studies from India	7 (361; 257)	66.0 (51.4-78.1)	21.3-93.3	69.2 (63.9-74.1)	81.1 (61.8-90.6)	31.7, 6 < 0.0001	63.3 (50.8-77.0)
Studies from Turkey	3 (260; 135)	59.2 (13.6-93.1)	0.00-100	51.2 (43.2-59.3)	97.8 (95.8-98.8)	90.0, 2, < 0.0001	70.0 (43.3-78.5)
Studies that only included neonates	4 (246; 185)	73.7 (60.3-83.8)	15.9-97.7	73.5 (67.3-78.9)	76.0 (34.1-91.3)	12.5, 3, 0.0058	69.8 (68.0-74.3)
Studies that included children of all other ages except neonates	14 (643; 380)	60.7 (45.5-74.0)	11.8-94.7	58.7 (54.2-63.0)	90.1 (85.2-93.4)	131.8, 13 < 0.0001	62.5 (45.8-71.6

CI = confidence intervals; I² = heterogeneity; df = degrees of freedom. Vitamin D deficiency defined in our study as <50 nmol/L (20 ng/mL). I² statistic used to estimate heterogeneity between pooled studies: I² >= 75% was considered as high heterogeneity; PI= Prediction interval; IQR = interquartile range: Lower (Q1) to Upper (Q3) quartile

2	
3	
4	
5	
6	
-	
7	
8	
9	
10	
11	
12	
14	
15	
16	
17	
18	
19	
20	
20	
21	
22	
23	
24	
25	
26	
20 27	
27	
28	
29	
30	
31	
32	
34	
35	
36	
37	
38	
39	
40	
41	
42	
43	
44	
45	
46	
47	


Patient category	Number of studies (Total number	Pooled OR Vitamin D deficient/ V p-va	itamin D non-deficient	Heterogeneity (I ²) % (95% CI)	Q value, d.f. p-value for	Eggers p-value	
	of individuals)	Random effects	Fixed effects		heterogeneity		
Excluding studies that used other thresholds	14 (2,030)	1.59 (1.05-2.41) p-value = 0.028	1.52 (1.08-2.13) p-value = 0.016	24.3 (0.0-59.9)	17.18, 13, 0.1910	p-value = 0.120	
Cohort studies only	14 (2,197)	1.80 (1.15-2.81) p-value = 0.009	1.65 (1.17-2.34) p-value = 0.004	31.3 (0.0-63.7)	18.92, 13, 0.1255	p-value = 0.042	
Case-control studies only	7 (266)	1.97 (0.88-4.42) p-value = 0.098	1.97 (1.02-3.82) p-value = 0.044	19.7 (0.0-87.7)	3.73, 3, 0.2916	Number of studies to small to test for smal study effects (k.min=10)	
Studies from India	7 (646)	1.08 (0.70-1.69) p-value = 0.710	1.08 (0.70-1.69) p-value = 0.710	0.0 (0.0-62.4)	4.56, 6, 0.589	Number of studies too small to test for smal study effects (k.min=10)	

 $CI = Confidence Intervals; I^2 = I$ squared statistic used to estimate heterogeneity (inconsistency); df = degrees of freedom, results reported in 1 decimal place; OR = odds ratio. Vitamin D deficiency defined as < 50 nmol/L or 20 ng/ml. We used the I² statistic to estimate heterogeneity between pooled studies: I² >= 75% was considered as high heterogeneity.

Additional Figures

Additional Figure 1 Funnel plot of studies of prevalence of vitamin D deficiency in acute and critically ill children. Horizontal axis shows logit transformed proportion and the standard error of the logit transformed proportion is plotted on the vertical axis. Each dot represents an individual study and the vertical line represents the pooled proportion from a random-effects meta-analysis. The diagonal lines represent pseudo 95% confidence limits (p = 0.01, Egger's test).

Plot A shows the funnel plot before trim and fill method was applied and B after. Solid circles in plot B represent original data and open circles represent imputed filled studies (11 studies added) on the left-hand side of the funnel plot.



Additional Figure 2. Pooled prevalence estimate for vitamin D deficiency in acute and critically ill children (by country group). Forest plot shows results from the random effects model. Diamonds represent pooled proportion of vitamin D deficiency for the countries in each subgroup (group 1, group2, group 3). The diamond at the bottom shows the overall pooled estimate of all the 52 studies. Each square shows the prevalence estimate of each study and the horizontal line across each square represents the 95% confidence interval (CI) of the prevalence estimate.

Study	VD deficient (n)	Total (N)		Prevalence	95% CI	Weight
group1 Vo 2018 Madden 2012 Lopez 2016 Garcia-Soler 2017 McNaily 2012 Rippel 2012 Alonso 2015 Ayulo 2014 Rey 2014 Onwuneme 2015 (1) Onwuneme 2015 (2) Bustos 2016 Hurwitz 2017 Binks 2014 Roth 2009 Hebbar 2014 Alvarez 2016 Mathias 2017 Moreno-Solis 2015 Inamo 2011 Random effects model Heterogeneity: J^2 = 95.5%, τ ²		1016 511 347 326 288 216 120 94 90 90 74 64 61 50 41 48 28 4276		0.29 0.40 0.24 0.69 0.34 0.16 0.28 0.29 0.59 0.91 0.43 0.12 0.15 0.05 0.61 0.58 0.61 0.58 0.61 0.58 0.61 0.59	$\begin{bmatrix} 0.27; \ 0.32 \\ 0.36; \ 0.45 \\ 0.20; \ 0.29 \\ 0.38; \ 0.49 \\ 0.64; \ 0.74 \\ 0.29; \ 0.40 \\ 0.12; \ 0.22 \\ 0.35 \\ 0.22; \ 0.35 \\ 0.22; \ 0.35 \\ 0.22; \ 0.35 \\ 0.22; \ 0.35 \\ 0.33; \ 0.54 \\ 0.66; \ 0.21 \\ 0.06; \ 0.21; \ 0.21 \\ 0.06; \ 0.21; \ 0.21 \\ 0.06; \ 0.21; \ 0.21; \ 0.21; \ 0.21; \ 0.21; \ 0.21; $	2.1% 2.1% 2.1% 2.1% 2.1% 2.1% 2.1% 2.1%
group2 Li 2018 Asilioglu 2017 Jia 2017 Halwany 2017 Sayka 2017 Sakka 2014 Cayir 2014 Badawi 2017 Yaghmaie 2017 Basha 2014 El-Gamasy 2017 Banajeh 2009 Cetinkaya 2015 Ahmed 2014 Cizmeci 2015 Khakshour 2015 Elmoneim 2016 Dinlen 2016 Karatekin 2009 Random effects model Heterogeneity: J ² = 91.5%, t ²		797 250 110 102 96 88 88 88 88 82 81 80 79 50 50 40 37 30 30 25 2215		$\begin{array}{c} 0.56\\ 0.48\\ 0.84\\ 0.37\\ 0.93\\ 0.57\\ 0.44\\ 0.65\\ 0.65\\ 0.32\\ 0.37\\ 0.84\\ 0.30\\ 0.70\\ 0.24\\ 0.57\\ 0.87\\ 0.92\\ 0.62\\ \end{array}$	$\begin{matrix} [0.52; \ 0.59]\\ [0.42; \ 0.54]\\ [0.75; \ 0.90]\\ [0.28; \ 0.47]\\ [0.79; \ 0.93]\\ [0.86; \ 0.97]\\ [0.86; \ 0.97]\\ [0.54; \ 0.75]\\ [0.54; \ 0.75]\\ [0.54; \ 0.76]\\ [0.22; \ 0.44]\\ [0.26; \ 0.48]\\ [0.71; \ 0.93]\\ [0.18; \ 0.45]\\ [0.53; \ 0.83]\\ [0.12; \ 0.41]\\ [0.37; \ 0.75]\\ [0.69; \ 0.96]\\ [0.74; \ 0.99]\\ [0.53; \ 0.70] \end{matrix}$	2.1% 2.0% 2.0% 2.0% 2.0% 2.0% 2.0% 2.0% 2.0
group3 Shah 2016 Ponnarmeni 2016 Dayal 2014 Prasad 2015 Wayse 2004 Dhandai 2018 Ebenezer 2016 Narang 2016 Jat 2016 Sankar 2017 Korwutthikulrangsri 2018 Roth 2010 Random effects model Heterogeneity: / ² = 91.8%, τ ²	21	154 124 101 92 80 60 52 50 50 43 32 25 943		0.83 0.51 0.74 0.25 0.84 0.95 0.63 0.40 0.56 0.84 0.72 0.78 0.84 0.71	$\begin{matrix} [0.76; \ 0.89] \\ [0.42; \ 0.60] \\ [0.45; \ 0.82] \\ [0.77; \ 0.35] \\ [0.74; \ 0.91] \\ [0.56; \ 0.75] \\ [0.27; \ 0.55] \\ [0.41; \ 0.70] \\ [0.71; \ 0.93] \\ [0.56; \ 0.85] \\ [0.64; \ 0.95] \\ [0.56; \ 0.81] \end{matrix}$	2.0% 2.1% 2.0% 1.9% 1.6% 2.0% 1.9% 1.9% 1.9% 1.9% 1.5% 24.4%
Random effects model Prediction interval Heterogeneity: $I^2 = 95.3\%$, τ^2		7434	0.2 0.4 0.6 0.8	0.55	[0.48; 0.61] [0.18; 0.87]	100.0%


1	0
1	1
1	2
1	3
	4
1	5
	6
	7
	8
	9
	0
	1
2	2
	3
	4
	5
2	6
2	7
2	8
	9
	0
3	
3	
	3
	4
	5
	6
	7
	8
	9
	0
4	
4	
	3 4
	4 5
	.5 .6
	0
4	0
-	.8 .9
	0
5	
5	
5	
	5 4
-	4 5
-	5 6
5	·
5	
5	
	0
J	-

BMJ Open

Additional Figure 3. Pooled prevalence estimates for vitamin D deficiency in acute and critically ill children (neonates versus all other age groups). Forest plot shows results from the random effects model. Diamonds represent pooled proportion of vitamin D deficiency for the studies in neonates and all other age groups. The diamond at the bottom shows the overall pooled estimate of all the 52 studies. Each square shows the prevalence estimate of each study and the horizontal line across each square represents the 95% confidence interval (CI) of the prevalence estimate.

Study	VD deficient (n)	Total (N)		Prevalence	95% CI	Weight
neonates	23	25		0.92	10 74: 0 001	1.2%
Karatekin 2009 Cizmeci 2015	23	25 40			[0.74; 0.99]	1.2%
	20			0.70	[0.53; 0.83]	
Dinlen 2016		30		0.87	[0.69; 0.96]	1.5%
Cetinkaya 2015	42	50		0.84	[0.71; 0.93]	1.8%
Onwuneme2015 (2)	86	94		0.91	[0.84; 0.96]	1.8%
Say 2017	87	100		0.87	[0.79; 0.93]	1.9%
Dhandai 2018	38	60		0.63	[0.50; 0.75]	2.0%
Random effects model		399		0.83	[0.73; 0.90]	12.2%
Heterogeneity: $l^2 = 76.6\%$,	$\tau^2 = 0.4533, p < 0.01$					
other						
Mathias 2017	28	41		0.68	[0.52; 0.82]	1.9%
Vo 2018	298	1016	-	0.29	[0.27; 0.32]	2.1%
Li 2018	445	797	- <u>-</u>	0.56	[0.52; 0.59]	2.1%
Rippel 2012	109	316		0.34	[0.29; 0.40]	2.1%
Jia 2017	92	110		0.84	[0.75; 0.90]	2.0%
Halwany 2017	38	102		0.37	[0.28; 0.47]	2.0%
Sakka 2014	89	96		0.93	0.86; 0.97	1.8%
Hurwitz 2017	11	90		0.12	[0.06: 0.21]	1.9%
Basha 2014	53	81		0.65	[0.54; 0.76]	2.0%
Wayse 2004	76	80		0.95	[0.88: 0.99]	1.6%
Banajeh 2009	29	79		0.37	[0.26; 0.48]	2.0%
Binks 2014	11	74		0.15	[0.08; 0.25]	1.9%
Narang 2016	28	50		0.56	[0.41; 0.70]	1.9%
Ahmed 2014	15	50		0.30	[0.18; 0.45]	1.9%
Khakshour 2015	9	37		0.30		
					[0.12; 0.41]	1.8%
Moreno-Solis 2015	9	48		0.19	[0.09; 0.33]	1.8%
Inamo 2011	8	28		0.29	[0.13; 0.49]	1.7%
Roth 2010	21	25		0.84	[0.64; 0.95]	1.5%
Roth 2009	3	64	<u> </u>	0.05	[0.01; 0.13]	1.5%
Madden 2012	205	511		0.40	[0.36; 0.45]	2.1%
Lopez 2016	84	347		0.24	[0.20; 0.29]	2.1%
Garcia-Soler 2017	149	340		0.44	[0.38; 0.49]	2.1%
McNally 2012	225	326		0.69	[0.64; 0.74]	2.1%
Alonso 2015	45	288		0.16	[0.12; 0.20]	2.1%
Asilioglu 2017	120	250		0.48	[0.42; 0.54]	2.1%
Ayulo 2014	61	216	- <u></u>	0.28	[0.22; 0.35]	2.1%
Rey 2014	46	156		0.29	[0.22; 0.37]	2.1%
Shah 2016	128	154		0.83	[0.76; 0.89]	2.0%
Ponnarmeni 2016	63	124		0.51	[0.42; 0.60]	2.1%
Onwuneme 2015 (1)	71	120		0.59	[0.50; 0.68]	2.1%
Sankar 2016	75	101		0.74	[0.65; 0.82]	2.0%
Dayal 2014	23	92		0.25	[0.17; 0.35]	2.0%
Bustos 2016	39	90		0.43	[0.33; 0.54]	2.0%
Cayir 2014	50	88		0.57	[0.46: 0.67]	2.0%
Badawi 2017	39	88		0.44	[0.34; 0.55]	2.0%
Yaghmaie 2017	53	82		0.44	[0.53; 0.75]	2.0%
Prasad 2015	67	80		0.85	[0.53, 0.75]	1.9%
					[0.74, 0.91]	
El-Gamasy 2017	26	80		0.32	[0.22; 0.44]	2.0%
Hebbar 2014	37	61		0.61	[0.47; 0.73]	2.0%
Ebenezer 2016	21	52		0.40	[0.27; 0.55]	1.9%
Alvarez 2016	29	50		0.58	[0.43; 0.72]	1.9%
Jat 2016	42	50		0.84	[0.71; 0.93]	1.8%
Sankar 2017	31	43		0.72	[0.56; 0.85]	1.9%
Korwutthikulrangsri 2015		32		0.78	[0.60; 0.91]	1.7%
Elmoneim 2016	17	30		0.57	[0.37; 0.75]	1.8%
Random effects model		7035		0.50	[0.44; 0.56]	87.8%
Heterogeneity: $I^2 = 95.2\%$,	$\tau^2 = 0.6427, p < 0.01$					
Random effects model		7434	-	0.55	[0.48; 0.61]	100.0%
Prediction interval					[0.18; 0.87]	000000000
Heterogeneity: $I^2 = 95.3\%$,	$\tau^2 = 0.7300$. $p < 0.01$				•	
			0.2 0.4 0.6 0.8			
			0.2 0.7 0.0 0.0			


Additional Figure 4 Bubble plots of univariate meta-regressions. Each study is represented by a circle. Predictor variables: A study design, B year of publication, C quality score and D total children are plotted on the x-axis with the effect measure logit transformed proportion shown on the vertical (y-axis).



BMJ Open


Additional Figure 5 Funnel plot for prevalence of vitamin D deficiency in acute and critically ill children with sepsis. Horizontal axis shows logit transformed proportion and the standard error of the logit transformed proportion is plotted on the vertical axis. Each dot represents an individual study and the vertical line represents the pooled proportion from a random-effects meta-analysis. The diagonal lines represent pseudo 95% confidence limits (p = 0.81, Egger's test).

Funnel Plot with pseudo 95% Confidence Intervals





Logit Transformed Proportion

Additional Figure 6 Pooled prevalence estimate for vitamin D deficiency in acute and critically ill children with sepsis (subgroup analysis by study design). Forest plot shows results from the random effects model. Diamonds represent the pooled proportion of vitamin D deficiency for the studies in each subgroup (case-control and cohort). The diamond at the bottom shows the overall pooled estimate of all the 18 studies. Each square shows the prevalence estimate of each study and the horizontal line across each square represents the 95% confidence interval (CI) of the prevalence estimate.



Additional Figure 7 Funnel plot of risk of mortality in vitamin D deficient versus vitamin D non-deficient acute and critically ill children. Horizontal axis shows logit transformed odds ratio and the standard error of the log odds ratio is plotted on the vertical axis. Each dot represents an individual study and the vertical line represents the overall pooled odds ratio from random-effects meta-analysis. The diagonal lines represent pseudo 95% confidence limits (p = 0.084, Egger's test).





Additional Figure 8 Pooled odds ratio (OR) and 95% CI for risk of mortality in vitamin D deficient versus vitamin D non-deficient acute and critically ill children (fixed effects model). Diamond represents the overall odds ratio (with corresponding 95% Confidence Interval). Each square shows the odds ratio of each study and the horizontal line across each square represents the 95% confidence interval (CI) of the estimate.

0									
9		Deficien	t	Not de	ficient				
10	Study	Dead (n) Tot		Dead (n) T	otal (N)	Odds Ratio	OR	95% CI	Weight
11	Ebenezer 2016	5	21	5	31		1.62	[0.41; 6.51]	4.9%
12	Ponnarmeni 2016 Sankar 2016	10	63 75	9	61	<u></u>	1.09	0 41 2 901	9.8% 10.0%
13	Rippel 2012	23 3 3	109	8 7	26 207		0.81	[0.38; 2.62] [0.20; 3.19]	5.0%
14	Dayal 2014 Shah 2016	3 54	23 128	3 14	69 26		3.30	[0.62, 17.65] [0.27 1.46]	3.3% 13.0%
15	Prasad 2015	14	67	1	13		3.17	[0.27; 1.46] [0.38; 26.50] [0.68; 250.17]	2.1%
16	Bustos 2016 McNally 2012	4 5	39 225	0	51 101		3.06	[0.68; 250.17]	1.1% 1.1%
17	Elmoneim 2016	1	17	1	13 7		0.75	[0.28; 92.45] [0.04; 13.24] [0.25; 100.15]	1.1%
18	Korwutthikulrangsri 2015 Ayulo 2014	5 6 4	25 61	02	155		5.00 5.37	10.96 30.111	1.0% 3.1%
19 20	Garcia-Soler 2017 Onwuneme 2015 (2)	4 7 5	149 60	2 3 0	191 34		3.09 6.84	[0.79; 12.16] [0.37; 127.56]	5.0%
20	Asilioglu 2017	16	120	9	85		1.30	$\begin{bmatrix} 0.37, 127.36 \\ [0.55; 3.10] \\ [1.36; 9.92] \end{bmatrix}$	1.1% 12.4%
21	El-Gamasy 2017 Badawi 2017	14 27	26 39	13 17	54		3.68	[1.36; 9.92] [1.72; 10.41]	9.5% 11.5%
22 23	Sankar 2017	19	31	7	49 12		1.13	[0.29; 4.39]	5.1%
23 24	Fixed effect model		1278		1185	4	1.72	[1.27; 2.33]	100.0%
24 25	Heterogeneity: $I^2 = 25.7\%$, τ^2	= 0.1564, <i>p</i> = 0.1	5					[, 1.00]	1001070
25 26						0.01 0.1 1 10 100			
20 27									
27									
29									
30									
31									
32									
33									
34									
35									
36									
37									
38									
39									
40									
41									
42									
43									
44									
45									

MOOSE (Meta-analyses Of Observational Studies in Epidemiology) Checklist

A reporting checklist for Authors, Editors, and Reviewers of Meta-analyses of Observational Studies. You must report the page number in your manuscript where you consider each of the items listed in this checklist. If you have not included this information, either revise your manuscript accordingly before submitting or note N/A.

_			
7	Reporting Criteria	Reported (Yes/No)	Reported on Page No.
3	Reporting of Background		
, 0	Problem definition		
1	Hypothesis statement		
2	Description of Study Outcome(s)		
3	Type of exposure or intervention used		
4	Type of study design used		
5	Study population		
6 7	Reporting of Search Strategy		
8	Qualifications of searchers (eg, librarians		
)	and investigators)		
)	Search strategy, including time period		
1			
2	included in the synthesis and keywords		
3	Effort to include all available studies,		
4	including contact with authors		
5	Databases and registries searched		
5 7	Search software used, name and		
8	version, including special features used		
9	(eg, explosion)		
0	Use of hand searching (eg, reference		
1	lists of obtained articles)	6.	
2	List of citations located and those		
3	excluded, including justification		
4	Method for addressing articles		
5	published in languages other than		
5 7	English		
3	Method of handling abstracts and		
9	unpublished studies		
)	Description of any contact with authors		
1			
2	Reporting of Methods		
3	Description of relevance or		
4 5	appropriateness of studies assembled for		
5	assessing the hypothesis to be tested		
7	Rationale for the selection and coding of		
8	data (eg, sound clinical principles or		
9	convenience)		
C	Documentation of how data were		
1	classified and coded (eg, multiple raters,		
2	blinding, and interrater reliability)		
3	Assessment of confounding (eg,		
4	comparability of cases and controls in		
5	studies where appropriate		
6 7	studies where appropriate		<u> </u>

Reporting Criteria	Reported (Yes/No)	Reported on Page N
Assessment of study quality, including		
blinding of quality assessors;		
stratification or regression on possible		
predictors of study results		
Assessment of heterogeneity		
Description of statistical methods (eg,		
complete description of fixed or random		
effects models, justification of whether		
the chosen models account for predictors		
of study results, dose-response models,		
or cumulative meta-analysis) in sufficient		
detail to be replicated		
Provision of appropriate tables and		
graphics		
Reporting of Results		
Table giving descriptive information for		
each study included		
Results of sensitivity testing (eg,		
subgroup analysis)		
Indication of statistical uncertainty of		
findings		
Reporting of Discussion		
Quantitative assessment of bias (eg,	4	
publication bias)		
Justification for exclusion (eg, exclusion		
of non–English-language citations)	6.	
Assessment of quality of included studies		
Reporting of Conclusions		
Consideration of alternative explanations	4	
for observed results		
Generalization of the conclusions (ie,		
appropriate for the data presented and		
within the domain of the literature review)		
Guidelines for future research		
Disclosure of funding source		

Once you have completed this checklist, please save a copy and upload it as part of your submission. DO NOT include this checklist as part of the main manuscript document. It must be uploaded as a separate file.

BMJ Open

Importance of vitamin D in acute and critically ill children with subgroup analyses of sepsis and respiratory tract infections: a systematic review and meta-analysis

Journal:	BMJ Open
Manuscript ID	bmjopen-2018-027666.R2
Article Type:	Research
Date Submitted by the Author:	13-Mar-2019
Complete List of Authors:	Cariolou, Margarita; Imperial College London School of Public Health, Epidemiology and Biostatistics Cupp, Meghan; Imperial College London School of Public Health, Epidemiology and Biostatistics Evangelou, Evangelos; Imperial College London School of Public Health, Epidemiology and Biostatistics; University of Ioannina School of Medicine, Department of Hygiene and Epidemiology Tzoulaki, Ioanna; Imperial College London School of Public Health, Epidemiology and Biostatistics; University of Ioannina School of Medicine, Department of Hygiene and Epidemiology Berlanga-Taylor, Antonio; Imperial College London School of Public Health, Epidemiology and Biostatistics
Primary Subject Heading :	Epidemiology
Secondary Subject Heading:	Paediatrics, Research methods
Keywords:	Vitamin D, EPIDEMIOLOGY, meta-analysis, sepsis, PAEDIATRICS, INTENSIVE & CRITICAL CARE

SCHOLARONE[™] Manuscripts

1		
2		
3 4	1	
4 5		
6 7	2	Importance of vitamin D in acute and critically ill children with subgroup analyses of
8 9 10	3	sepsis and respiratory tract infections: a systematic review and meta-analysis
11 12 13	4	
14 15 16	5	Margarita Cariolou ¹ MPH, Meghan A. Cupp ¹ MPH, Evangelos Evangelou ^{1,2} PhD, Ioanna
17 18	6	Tzoulaki ^{1,2} PhD and Antonio J. Berlanga-Taylor ¹ * DPhil
19 20 21	7	¹ MRC-PHE Centre for Environment and Health, Department of Epidemiology & Biostatistics,
22 23 24	8	School of Public Health, Faculty of Medicine, Imperial College London, St Mary's Campus,
25 26	9	Norfolk Place, UK, LONDON W2 1PG
27 28 29	10	² Department of Hygiene and Epidemiology, University of Ioannina Medical School, Ioannina,
30 31 32	11	Greece
33 34	12	*Correspondence should be addressed to Dr. Antonio J. Berlanga-Taylor
35 36 37	13	(a.berlanga@imperial.ac.uk), MRC-PHE Centre for Environment and Health, Department of
38 39	14	Epidemiology & Biostatistics, School of Public Health, Faculty of Medicine, Imperial College
40 41 42	15	London, St Mary's Campus, Norfolk Place, LONDON W2 1PG.
43 44 45	16	
46 47 48	17	
49 50 51	18	
52 53 54 55 56 57 58	19	1
59 60		For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

1 ABSTRACT

Objectives: To estimate the prevalence of 25-hydroxyvitamin D (25(OH)D) deficiency and
investigate its association with mortality in children with acute or critical conditions.

Design: Systematic review and meta-analysis of observational studies.

5 Data sources: PubMed, OVID, Google Scholar and the Cochrane Library searched until 21
6 December 2018.

7 Eligibility criteria: Studies of children hospitalised with acute or critical conditions who had
8 blood 25(OH)D levels measured.

9 Data extraction and synthesis: We obtained pooled prevalence estimates of 25(OH)D deficiency
10 and odds ratios for mortality. We calculated 95% confidence and prediction intervals and
11 investigated heterogeneity and evidence of small-study effects.

Results: Fifty-two studies were included. Of 7,434 children, 3,473 (47.0%) were 25(OH)D deficient (<50 nmol/L). The pooled prevalence estimate of 25(OH)D deficiency was 54.6% (95% CI 48.5-60.6, $I^2=95.3\%$, p<0.0001). Prevalence was similar after excluding smaller studies (51.5%). In children with sepsis (18 studies, 889 total individuals) prevalence was 64.0% (95% CI 52.0-74.4, $I^2=89.3\%$, p<0.0001) and 48.7% (95% CI 38.2-59.3; $I^2=94.3\%$, p<0.0001) in those with respiratory tract infections (RTI) (25 studies, 2,699 total individuals). Overall, meta-analysis of mortality (18 cohort studies, 2,463 total individuals) showed increased risk of death in 25(OH)D deficient children (OR 1.81, 95% CI 1.24-2.64, p=0.002, I²=25.7%, p=0.153). Four (22.0%) of the 18 studies statistically adjusted for confounders. There were insufficient studies to meta-analyse sepsis and RTI related mortality.

BMJ Open

3
4
- -
5
6
5 6 7
8 9 10
9
10
11
12
13
14
15
16
16
17
18
19
20
21
22
23
21 22 23 24 25 26 27 28 29 30
25
26
27
27
20
29 30
31
32
33
34
35
36
37
38
39
40
40
41
42
43
44
45
46
47
48
49
50
51
52
53
51
55
56
57
58
59
60

Conclusions: Our results suggest that 25(OH)D deficiency in acute and critically ill children is 1 high and associated with increased mortality. Small-study effects, reverse causation and other 2 biases may have confounded results. Larger, carefully designed studies in homogeneous 3 populations with confounder adjustment are needed to clarify the association between 25(OH)D 4 5 levels with mortality and other outcomes. 6 7 **Registration** PROSPERO (CRD42016050638) **Copyright** Open access article under terms of CC BY 8 **Keywords** paediatric, vitamin D, intensive care, sepsis, meta-analysis, prevalence, mortality, 9 systematic review, respiratory tract infections 10 è le 11 Strengths and limitations of this study 12 • We comprehensively assessed the magnitude and relevance of vitamin D (25(OH)D) 13 circulating levels in paediatric acute and critically ill patients using a large number of 14 studies with large total sample size with pre-specified sub-group and sensitivity analyses. 15 • We used the currently recommended cut-off of less than 50 nmol/L for vitamin D 16 deficiency. 17 • We did not find enough studies to perform meta-analyses for mortality from sepsis or 18 respiratory tract infection in relation to vitamin D status. 19 20 • We did not identify longitudinal studies with multiple time-point, pre-admission or predisease vitamin D measurements. 21 • Most studies were single centre with heterogeneous patient groups and few controlled for 22 important confounders that influence vitamin D levels such as age, BMI, gender, season of 23 24 measurements, vitamin D supplementation and comorbidities. 25 26 27 28 29 30

1 INTRODUCTION

Vitamin D is an essential nutrient^{1, 2} representing a group of fat soluble secosteroids with key endocrine functions.³ It is synthesized in the skin upon sunlight exposure⁴ while dietary sources, such as oily fish, egg yolk, certain fungi and supplements, are usually secondary sources. Vitamin D is critical in bone metabolism⁵ and calcium homeostasis,⁶ as well as acting as an important regulator in extra-skeletal metabolic processes,⁷ cardiovascular and immune systems.⁸ Many observational and laboratory studies have observed the anti-inflammatory properties of vitamin D,⁹ including direct regulation of endogenous anti-microbial peptide production.¹⁰

It is therefore crucial for humans to have sufficient vitamin D levels to maintain bone health and possibly improve response to infection.^{6, 11, 12} Infants and children are especially dependent on vitamin D to achieve healthy bone development and growth.^{13, 14} Well-known functional outcomes of adequate vitamin D levels in children include rickets prevention, higher bone mineral content and reduced bone fracture rates.^{5, 14} In otherwise healthy children in the United States, the reported prevalence of vitamin D deficiency (250HD levels of < 25 nmol/L) ranges from 9 to 18%.¹⁵ The Endocrine Society Clinical Practice Guidelines and the Institute of Medicine (IOM) suggest that 25(OH)D levels less than 50 nmol/L (20 ng/mL) reflect a deficient state.^{4, 16}

Studies in adults reflect a high prevalence of vitamin D deficiency both in general intensive care
unit (ICU) and sepsis patients and strongly suggest an association between low vitamin D and poor
clinical outcomes, including increased mortality, particularly in those suffering from sepsis.^{2, 17}
Recent clinical trials of vitamin D supplementation in adults appear promising in both general
critical care^{18, 19} and sepsis.²⁰

BMJ Open

Sepsis remains a challenging clinical entity with high social and economic costs.²¹ Each year there are approximately 123,000 sepsis cases and around 37,000 deaths in England alone.²² Recent reports show an increased prevalence of paediatric sepsis,²³ likely a reflection of an increased population with chronic comorbidities, higher rates of opportunistic infections and multi-drug resistant organisms.²⁴ Respiratory tract infections account for a large proportion of underlying diagnoses in acute and critical care conditions^{24, 25} but remain understudied.²⁶

The magnitude, relevance and quality of evidence of vitamin D deficiency in children receiving
acute care is not clear. Several recent studies have addressed these questions with mixed results.
We sought to summarise the evidence regarding the implications of vitamin D deficiency and its
prevalence in general acute care, ICU, respiratory tract infection and sepsis patients in the
paediatric population. We carried out a systematic review and meta-analysis of circulating vitamin
D levels, as measured by 25(OH)D, to assess the prevalence of vitamin D deficiency (≤ 50 nmol/L)
and its association with mortality in these conditions.

15 METHODS

We used the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA)
guidelines to report our review.²⁷ (*Additional Table 1*). We also followed the Meta-Analysis of
Observational Studies in Epidemiology (MOOSE) guidelines²⁸ as no relevant randomized
controlled trials have been reported.

20 Search strategy and selection criteria

Our population of interest consists of paediatric patients with acute conditions and/or those treated in ICU or emergency units for acute conditions whose vitamin D status was assessed prior to or during admission. We included published cross sectional, case-control and cohort studies that measured circulating 25(OH)D levels and either reported prevalence, odds ratios (OR) or data to enable calculation of these measures. Studies were excluded if they were reviews, case reports, surveys, commentaries, replies, not original contributions, experimental *in vitro* or if they recruited patients who were not treated in emergency, neonatal intensive care units (NICUs), paediatric intensive care units (PICUs) or for acute conditions. Studies were also excluded if they only enrolled vitamin D deficient patients, investigated healthy populations only or did not measure circulating 25(OH)D levels as an indicator of vitamin D status. When we identified more than one publication utilising the same cohort, we included the publication which shared our review's objective to investigate vitamin D levels and prevalence of deficiency.

For purposes of our review, we classified vitamin D deficiency as being 25(OH)D less than 50 nmol/L (equivalent to 20 ng/mL), as suggested by the IOM.¹⁶ Different age categories were used to designate patients as "children" in the studies reviewed. We therefore included all "children" (neonates up to 21 years) as defined by each treating facility and this included "neonates", "infants", "toddlers", "children" and "adolescents".

We searched PubMed, OVID, Google Scholar and the Cochrane Library from inception up until 21st December 2018, with no language restrictions. Search terms used across these databases included: "critical care", "vitamin D", "pediatric", "child", "neonate", "toddler", "intensive care unit", "sepsis" and "septic shock". Search terms used in OVID and PubMed are listed in the *Additional Tables 2A and 2B*. Literature searches were performed by two investigators independently (MC and AJBT) and included initial screening of titles and abstracts, followed by

BMJ Open

full text screening. Any disagreements for study eligibility were resolved by discussion between the two investigators. Reference lists of the selected papers, including reviews, were also checked for relevant titles. Abstracts of relevant titles were then assessed for eligibility. Corresponding authors were contacted to obtain additional information if necessary. A data extraction form was designed *a priori* in Excel. Variables extracted from each study included year of publication, country of study, clinical setting, cut-off given to define vitamin D deficiency, total number of children, total number of cases, study design and age range.

Study quality assessment

The quality of each included study was assessed using the Newcastle-Ottawa Scale (NOS) adapted a priori for this review, for cohort, case-control and cross-sectional study designs (Additional *Tables 3A*, *3B* and *3C*).²⁹ We classified studies as low (1-3), medium (4-6) or high quality (7-9) 4.64 for purposes of sensitivity analysis.

Prevalence and mortality outcomes

In the majority of studies (n = 40), prevalence of vitamin D deficiency was extracted as reported with a threshold of \leq 50 nmol/L. If prevalence was not reported directly, it was calculated using data provided in each study (cases \leq 50 nmol/L / total number of study participants) (*Additional* Tables 4A and 4B). Extracted or calculated prevalence values were then combined in a meta-analysis. For mortality, we calculated unadjusted odd ratios (OR) as:

OR = (vitamin D deficient patients who died * vitamin D non-deficient patients who did not die)/(vitamin D deficient patients who did not die * vitamin D non-deficient patients who died)

We had sufficient information to calculate ORs < 50 nmol/L for 40 studies (77.0%). For the 12 studies with insufficient information, we used the lower cut-off values reported as a conservative approximation (*Additional Table 5*). We converted 25(OH)D values using: nmol/L = ng/mL * 2.496.

5 Data analysis

We obtained proportions of vitamin D deficiency with 95% confidence intervals (CI) using the Clopper-Pearson method³⁰ in R. We used a random effects model³¹ to account for the variation observed within and between studies due to the different ages and acute conditions in the populations considered. For each meta-analysis we also obtained the 95% prediction interval (PI) to further account for between study heterogeneity. This helps to evaluate how consistent an observed effect would be in a future study that will investigate the same association.³² We obtained pooled proportions and pooled ORs with fixed effect model for sensitivity analysis or in cases where heterogeneity was low.³³⁻³⁵ For prevalence we also calculated median and interguartile range (IQR) for comparisons with pooled prevalence estimates.

We investigated possible sources of heterogeneity using sensitivity and subgroup analyses. Cochran's Q was used to assess the heterogeneity and the I² statistic was used to estimate the percentage of total variation across studies which can be attributed to heterogeneity. Confidence intervals of I^2 were calculated to aid interpretation.³⁶ A Q value of < 0.05 was considered significant and an I² statistic greater or equal to 75% indicated a high level of variation due to heterogeneity.^{37, 38} We used Egger's regression test to present results of small-study effects and funnel plot asymmetry³⁹ and generated funnel plots for visual assessment and screening. A p-value < 0.05 indicated evidence of small-study effects. With few studies, Egger's test has low power to

BMJ Open

detect such bias, therefore we only estimated small-study effects for analyses with more than ten
studies.⁴⁰ When small-study effects were detected based on this threshold, we used trim-and-fill
methods to add potentially missed studies and re-calculate an adjusted pooled estimate.⁴¹

To further assess heterogeneity, we utilised meta-regression to identify predictor variables that could explain variation in study prevalence estimates. We used restricted maximum likelihood (REML) estimations in the model to account for residual heterogeneity⁴² and the Knapp-Hartung method to adjust confidence intervals and test statistics. This method estimates between study variance using a t-distribution, rather than a z-distribution, vielding a more conservative inference.⁴³ We tested the following continuous predictors: year of study publication, total sample size and quality score. Categorical variables included study setting (PICU, NICU), study design (case-control, cross-sectional and cohort) and country group by geographic region and economic development (group 1, group 2, and group 3) and were dummy coded.

We used R version 3.5.0 and Microsoft Excel 2010 for analyses and data collection. The R
packages "meta"⁴⁴ and "metafor"⁴⁵ were used for analyses. Only results of the random effects
model are reported for prevalence due to the expected heterogeneity between populations being
considered. Our protocol is registered in PROSPERO (CRD42016050638).

17 Role of the funding source

18 The study received funding from the UK Medical Research Council. The funders had no role in 19 data collection, analysis, interpretation or writing of the report. All authors had access to the data 20 in the study.

21 Patient involvement

1 No patients were involved in this study. We only used data from previously published studies.

RESULTS

Screening and study characteristics

After title and abstract screening, we identified 2,890 potentially relevant studies (Figure 1) and eighty-five full text articles were assessed for eligibility. Rationale for study exclusion included: studies including adults, study populations other than critically ill children or with acute conditions, studies of circulating vitamin D levels and deficiency in healthy children or in children with chronic conditions. Four studies⁴⁶⁻⁴⁹ were excluded due to insufficient data reporting (Additional Table 6). We also excluded three studies⁵⁰⁻⁵² that used the same cohort of children and included a single study to represent the cohort.⁵³ Ultimately, 52 studies met criteria for inclusion (Additional Table 7).

Figure 1 Flow chart of study selection process

The primary objective of most included studies was to determine circulating vitamin D concentration ("status") in children and/or prevalence of vitamin D deficiency. Secondary objectives included investigation of associations between deficiency of circulating vitamin D and various outcomes, such as hospital mortality length of stay, requirement of ventilation and/or illness severity (*Additional Table 8*).

All included studies reported vitamin D measurement assay methods used (*Additional Table 9*)
and stated that samples were collected and analysed within the first 24 hours of hospital admission.
Studies reported ethical approval and consent for participation from parents or guardians
(*Additional Table 10*). Included studies were published between 2004 and 2018, with the majority

Page 11 of 83

BMJ Open

(n = 40, 77.0%) published between 2014 and 2017 (*Additional Table 7*). In total, 7,434 children
were hospitalized in paediatric or neonatal intensive care units or emergency units or for acute
conditions. Sample sizes of critically ill children ranged from 25⁵⁴ to 1,016.⁵⁵ In 18 studies the
total number of cases was greater than 100.

Studies originated from 15 countries, with the majority from $India^{8, 56-65}$ (n = 11) or Turkey^{54, 66-71} (n = 7) (Additional Table 7). All were of medium or high quality (NOS score median 7, range 4-8). The score range for cohort studies was 6 to 8 (n = 30), for case-control studies 5 to 8 (n = 18) and for cross sectional 4 to 6 (n = 4). Studies used a broad range of ages to classify patients as "children". Seven studies (13.5%)^{54, 65, 67, 69-72} included only neonates. In two^{67, 72} of these studies, neonates were preterm. The largest age range was seen in the study of Ayulo et al 2014, which included individuals between 1 and 21 years of age (Additional Table 11). Forty-two of the included studies (80.8%) included patients admitted for medical conditions and the other ten^{53, 61,} ^{66, 73-78} included both surgical and medical patients. Of the 52 included studies 26 used a control group and had a total number of 2,479 controls of which 773 (31.2%) were vitamin D deficient.

All studies included both female and male participants. For mortality, four of the 18 studies (22.0%) carried out multivariate regression analysis with adjustment for confounders. The remaining studies presented results using a variety of methods, including Spearman's correlation analysis, chi-square or Fisher's exact tests or descriptive statistics.

20 Prevalence of vitamin D deficiency

We included 52 studies representing a total of 7,434 children hospitalised with critical or acute conditions. Of these, 3,473 (47.0%) were classified as vitamin D deficient (< 50 nmol/L).

L	Prevalence of deficiency ranged from $5.0\%^{79}$ to $95.0\%^{60}$, median (IQR) 56.3% (31.9 to 75.2%)
2	(Additional Table 12). Sample sizes ranged from 25 to 1,016, with a median of 82 individuals
3	(Additional Table 13). Using a random effects model, the pooled prevalence estimate of vitamin
1	D deficiency was 54.6% (95% CI 48.5-60.6) with a high proportion of variation attributed to
5	heterogeneity ($I^2 = 95.3\%$, 95% CI 94.5-96.0, p < 0.0001) (<i>Figure 2</i>) and evidence of funnel plot
5	asymmetry (p = 0.01, Egger's test) (Table 1 and Additional Figure 1). Trim and fill analysis
7	estimated 11 unpublished studies in the lower left-hand side of the funnel plot (Additional Figure
3	1). The re-calculated adjusted pooled estimate was lower 43.6% (95% CI 37.5-50.0) with
9	significant heterogeneity ($p < 0.0001$).

Patient category	Number of studies (Total number of individuals; number of deficient individuals)	Pooled proportion (%, 95% CI) Random effects	95% PI	pry tract infections Pooled proportion (%, 95% CI) Fixed effects	Heterogeneity (l ²) % (95% CI)	Q value, d.f. p-value for heterogeneity	Eggers p-value
All children (includes those with sepsis and respiratory tract infections)	52 (7,434; 3,473)	54.6 (48.5-60.6)	17.5-87.2	45.7 (44.4-46.9)	95.3 (94.5-96.0)	1086.6, 51, < 0.0001	0.01
Critically ill children with sepsis only	18 (889; 565)	64.0 (52.0-74.4)	17.1-93.9	63.0 (59.3-66.6)	89.3 (84.6-92.5)	158.52 17 < 0.0001	0.81
Critically ill children with respiratory tract infections only	25 (2,699; 1,076)	48.7 (38.2-59.3)	9.96-89.1	37.0 (35.0-39.1)	94.3 (92.7-95.6)	423.07 24 < 0.0001	0.05
25(OH)D <		mL). I ² statistic u	sed to estimat	freedom. Vitamin I e heterogeneity bet			
25(OH)D < considered 1 10 11	50 nmol/L (20 ng/ high heterogeneity;	(mL). I ² statistic u ; PI = Prediction I	sed to estimat	e heterogeneity bet	ween pooled stu	dies: I ² ≥ 75% v	vas
25(OH)D < considered 1 10 11 12 Figure 2	50 nmol/L (20 ng/ high heterogeneity;	(mL). I ² statistic u ; PI = Prediction I	sed to estimat Interval	e heterogeneity bet	ween pooled stu	dies: I ² ≥ 75% v	vas
25(OH)D < considered 1 10 11 12 Figure 2 13 14	50 nmol/L (20 ng/ high heterogeneity;	mL). I ² statistic u ; PI = Prediction I	sed to estimat Interval	e heterogeneity bet	ween pooled stu	dies: I ² ≥ 75% v	vas

Page 13 of 83

BMJ Open

We did not detect material differences in prevalence after exclusion of the 12 studies which did
not directly report prevalence < 50 nmol/L (53.0%, 95% CI 46.4-59.5; I² = 95.5%, 95% CI 94.596.2, p < 0.0001) (*Additional Table 14*).

When examining results by median sample size (defining "large" as ≥ 82 and "small" as < 82), we found that the 26^{8, 53, 55-58, 66-68, 72-74, 77, 78, 80-91} studies with larger sample size included 6,094 total individuals and gave a prevalence estimate of 51.5% (95% CI 43.6-59.4; I² = 96.8%, 95% CI 96.0-97.4, p < 0.0001). The remaining 26 studies with "smaller" sample sizes included 1,340 total children and estimated pooled prevalence as 58.2% (95% CI 47.5-68.2; I² = 90.9%, 95% CI 87.9-93.2, p < 0.0001) (*Additional Table 14*).

We also conducted analysis by study design. Cohort studies (n = 30) yielded a prevalence estimate
of 49.6% (95% CI 42.7-56.4; I² = 94.9%, 95% CI 93.6-95.9, p < 0.0001). In case-control studies
(n = 18) the estimate was 68.1% (95% CI 56.5-77.8; I² = 93.0%, 95% CI 90.4-94.9, p < 0.0001)
and in cross-sectional (n = 4) 34.8% (95% CI 12.8-66.0; I² = 96.7%, 95% CI 94.0-98.2, p < 0.0001)
(*Additional Table 14, Figure 2*).

We assessed whether studies' country of origin influenced results. Studies in India gave an estimate of 68.9% (95% CI 54.9-80.1; $I^2 = 96.7\%$ (95% CI 94.0-98.2, p < 0.0001). Similarly, we found higher pooled prevalence estimates for studies from Turkey (76.3%, 95% CI 60.9-87.0; $I^2 =$ 91.1%, 95% CI 84.2-95.0, p < 0.0001). We also grouped studies by geography and economic development. Group 1: USA, Chile, Australia, Canada, Ireland, Japan, Spain; group 2: South Africa, China, Egypt, Iran, Turkey, Saudi Arabia; and group 3: Bangladesh, Thailand, and India. Prevalence was 37.2% (95% CI 29.7-45.5) for group 1 (n = 20), 61.8% (95% CI 53.2-69.7) for

3
4
5
6
4 5 6 7 8 9 10
8
9
10
11
12
13
14
15
13 14 15 16 17 18 19
17
18
19
20
20 21 22 23 24 25 26 27 28 29 30
∠∠ วว
23
24
25
20
28
20
30
31
32
33
34
35
36
36 37
38
39
40
41
42
43
44
45
46
47
48
49 50
50
51 52
52 53
53 54
54 55
55 56
50 57
58
59
60

16

1 2

1

2

3

group 2 (n = 19) and 70.8% (95% CI 58.3-80.7) for group 3 (n = 13) (Additional Figure 2). Variation attributable to heterogeneity was still high in the three subgroups ($I^2 > 90.0\%$). Given the broad age range in included studies, we combined studies with only neonates^{54, 65, 67, 69-}

 72 and observed a prevalence estimate of 83.0% (95% CI 73.1-89.8) with less variation attributable 4 to heterogeneity ($I^2 = 76.6\%$, 95% CI 51.0-88.9, p = 0.0003). In all other studies (n = 45) that 5 6 included children of other age ranges, estimated prevalence was lower at 49.7% (95% CI 43.5-55.8; $I^2 = 95.2\%$, 95% CI 94.3-96.0, p < 0.0001) (Additional Table 14, Additional Figure 3). 7

Post-hoc investigation to determine sources of heterogeneity 8

9 To investigate the substantial heterogeneity observed in prevalence estimates, we incorporated study-specific characteristics (year of publication, total study sample size, quality score, study 10 design, country group and clinical setting) as covariates in a random effects meta-regression 11 12 model. We identified clinical setting and country groups as significant predictors, p < 0.01 (Figure 3). We found that the model fitted with all available covariates can explain 32.9% of I² with F =13 4.57, p = 0.001 (Additional Table 15). We also conducted univariate meta-regressions for each of 14 the six predictors (Additional Figure 4).

15

17 Figure 3 Bubble plots of univariate meta-regressions. 18 Prevalence of vitamin D deficiency in children with sepsis and in those with respiratory tract 19 infections 20 A total of 889 (median 42, range 9 -160) patients had a diagnosis of sepsis, of which 565 (63.5%) 21

22 were vitamin D deficient. Sixteen of the eighteen studies including septic patients were cohort

BMJ Open

(88.9%) and two (11.1%) case-control (Additional Table 16). Most studies originated from India (n = 7) Turkey (n = 3) or Ireland (n = 2) and 16 were published between 2014 and 2017. Thirteen studies took place in a PICU and the remaining^{65, 67, 70, 72} in NICUs. We found that all studies were of medium to high quality (median NOS score 7, range 6 - 8). Pooled prevalence of vitamin D deficiency was 64.0% (95% CI 52.0-74.4) (Figure 4) and median (IQR), 68.5% (50.4 to 71.6%). Variation attributable to heterogeneity was high ($I^2 = 89.3\%$, 95% CI 84.6-92.5, p < 0.0001). Funnel plot was symmetric (p > 0.05) suggesting no small-study effects (p = 0.81, Egger's test) (Additional Figure 5).

Figure 4 Pooled prevalence estimate for vitamin D deficiency in children with sepsis.

We also separately analysed studies of patients admitted for respiratory tract infections (n = 25)such as acute lower respiratory tract infection (ALRTI), pneumonia and bronchiolitis. Of these 2,699 total individuals (median 50), 1,076 (39.9%) were vitamin D deficient. These studies were of high to medium quality (median NOS score 7, range 6 - 8). Most originated from India (n = 6)and Spain (n = 4). We found a prevalence estimate of 48.7% (95% CI 38.2-59.3; $I^2 = 94.3\%$, 95% CI 92.7-95.6, p < 0.0001) and median (IQR) at 36.7% (24.3 to 83.6%) with marginally non-significant evidence of bias (p = 0.05, Egger's test) (*Table 1*). We therefore applied the trim and fill method and obtained an adjusted pooled estimate of 37.4% (95% CI 27.6-48.4) after four studies were added.

20 Sensitivity analysis for prevalence in children with sepsis

Exclusion of the studies^{64, 67, 72, 92} utilising thresholds other than < 50 nmol/L for deficiency yielded a similar estimate of prevalence at 62.0% (95% CI 47.3-74.7; I² = 89.7%, 95% CI 84.5-93.2, p <0.0001) (Additional Table 17).

We examined pooled prevalence estimates according to median sample size (< 42 versus \ge 42). Studies with a smaller sample size (n = 9; 204 total individuals) showed a pooled prevalence estimate of 64.7% (95% CI 52.5-75.3) with moderate variation attributable to heterogeneity (I² = 57.9%, 95% CI 11.8-79.9, p = 0.015). For the remaining nine studies (sample sizes \ge 42, 685 total individuals) the estimate was 63.2% (95% CI 44.6-78.5) with high variation attributable to heterogeneity (I² = 94.3%, 95% CI 91.1-96.3, p < 0.0001).

There was no material change in prevalence estimates when analysed according to study design. The sixteen cohort studies (749 total individuals) gave an estimate of 61.4% (95% CI 48.6-72.8) with high variation attributable to heterogeneity ($I^2 = 88.8\%$, 95% CI 83.5-92.4, p < 0.0001). Casecontrol studies (n = 2; 140 total individuals) showed a pooled prevalence of 80.0% (95% CI 58.8-91.8; $I^2 = 81.3\%$, 95% CI 20.5-95.6, p < 0.0001) (Additional Table 17, Additional Figure 6).

Studies from India (n = 7) gave a prevalence estimate of 66.0% (95% CI 51.4-78.1); I² = 81.1%,
95% CI 61.8-90.6, p < 0.0001). The three studies from Turkey assessing septic patients gave a
pooled estimate of 59.2% (95% CI 13.6-93.1; I² = 97.8%, 95% CI 95.8-98.8, p < 0.0001)
(Additional Table 17).

The pooled prevalence estimate in the four studies^{65, 67, 70, 72} including neonates with sepsis was 73.7% (95% CI 60.3-83.8, $I^2 = 76.0\%$ 34.1-91.3, p = 0.006). The fourteen studies with children of different ages, excluding neonates, gave a pooled estimate of 60.7% (95% CI 45.5-74.0); $I^2 =$ 90.1%, 95% CI 85.2-93.4, p < 0.0001) (*Additional Table 17*). Four of the studies^{56, 61, 87, 89} included children admitted with either sepsis or respiratory tract infections.

21 Mortality in acute and critically ill children

Page 17 of 83

BMJ Open

1
2
3
4
2 3 4 5 6 7 8 9 10 11 23 4 5 6 7 8 9 10 11 23 24 25 26 7 8 9 30 31 23 34 35 37 38
6
/
8
9
10
11
12
13
14
15
16
10
17
18
19
20
21
22
23
24
25
26
27
27
20
29
30
31
32
33
34
35
36
37
38
39
40
40
41
43
44
45
46
47
48
49
50
51
52
52
55 54
55
56
57
58
59

60

1	We identified 18 cohort studies ^{8, 53, 56-59, 61, 64, 66, 72, 74-78, 82, 89, 92} assessing vitamin D status and
2	mortality. These studies included a total of 2,463 individuals, from which 220 deaths (17.2%) were
3	observed in 1,278 (51.9%) individuals with vitamin D deficiency and 99 deaths (8.4%) were
4	observed in 1,185 individuals without deficiency (48.1%).
5	All 18 studies took place in a PICU apart from one ⁷² , which considered only NICU patients.
6	Sixteen of these studies (89.0%) were published between 2014 and 2017. Almost half ($n = 7$) of
7	the studies originated from India. Quality scores ranged from 5 to 8 with a median of 6.5.
8	Using a random effects model, we found that vitamin D deficiency in critically ill children
9	significantly increased the risk of death (OR 1.81, 95% CI 1.24-2.64, $p = 0.002$) with low, non-
10	significant heterogeneity ($I^2 = 25.7\%$, 95% CI 0.0-58.0, p = 0.153) (<i>Figure 5</i>). However, small-
11	study effects cannot be easily excluded ($p = 0.084$, Egger's test) (<i>Additional Figure 7</i>) and the 95%
12	prediction interval (0.71-4.62) included the null value.
13	
14 15	Figure 5 Pooled odds ratio (OR) of risk of mortality in vitamin D deficient versus vitamin D non-deficient acute and critically ill children.
16	
17	Sensitivity analysis for mortality in acute and critically ill children
18	We obtained similar results through the fixed effects model (OR 1.72, 95% CI 1.27-2.33, $p =$
19	0.0005) (Additional Figure 8). When excluding studies with thresholds other than < 50 nmol/L
20	indicating deficiency, we found the association between vitamin D deficiency and increased risk
21	of mortality still significant but lower, both with the random (OR 1.59, 95% CI 1.05-2.41, $p =$
22	0.028; I ² = 24.3%, 95% CI 0.00-59.9, p = 0.191) and fixed effect models (OR 1.52, 95% CI 1.08-

2.13, p = 0.016) without clear indication of small-study effects (p = 0.120, Egger's test) (Additional *Table 18).*

The association was positive but not-significant when pooling the seven studies from India with the random effects model (OR 1.08, 95% CI 0.70-1.69, p = 0.710; $I^2 = 0.0\% 0.0-62.4$, p = 0.589) and similar with fixed effects (OR 1.08, 95% CI 0.70-1.69, p = 0.710) (Additional Table 18).

Mortality in patients with sepsis and respiratory tract infections

We were unable to identify a sufficient number of studies assessing vitamin D and mortality for meta-analysis in individuals with sepsis. Three studies^{8, 64, 67} measured vitamin D levels in paediatric patients with sepsis. One study⁸ assessed mortality and did not find a significant association in children from 1 to 12 years with sepsis (n=124). None of the studies with children admitted for respiratory tract infections looked at the association between vitamin D deficiency iezo, and childhood mortality.

DISCUSSION

Vitamin D deficiency is highly prevalent worldwide, even in countries with abundant sunshine. Studies have shown high prevalence of vitamin D deficiency in otherwise healthy children from high-income countries (9 to 24%) but also from middle and low-income countries in the Indian subcontinent (36 to 90%).⁸

We identified 52 studies representing a total of 7,434 children treated in ICU or emergency units for acute conditions who had blood 25(OH)D levels measured close to or upon admission. Our analysis shows that prevalence of vitamin D deficiency is generally high but very variable (range

BMJ Open

5%⁷⁹ to 95%⁶⁰) across ICU and emergency units in the paediatric population, particularly in individuals with sepsis. Importantly, our analysis showed a significantly increased risk of mortality in critically ill children with vitamin D deficiency. We carried out several analyses for sensitivity including fixed effects models, by study design, country group, age and sample size and found generally consistent results. A recently published meta-analysis⁹³ also investigated prevalence of vitamin D deficiency in critically ill children and its association with risk of mortality and showed similar results to ours. The study did not clearly report heterogeneity and small-study effects however, which we found to be critical limitations that must be addressed. Subgroup analyses in patients with sepsis or respiratory tract infections demonstrated a high prevalence of vitamin D deficiency, consistent with the increased risk of bacterial or nosocomial infection in vitamin D deficient individuals identified elsewhere.93 Although sepsis is a leading cause of paediatric mortality and morbidity worldwide,⁹⁴ we found few studies assessing the relationship between vitamin D status and mortality in this population. We were unable to identify sufficient studies including patients with sepsis to perform a meta-analysis of vitamin D status and mortality. Sepsis remains an area of unmet need with high social and financial costs.²⁴ Diagnostic criteria,⁹⁵ a lack of adequate biomarkers⁹⁶ and targeted treatment remain important challenges in research on sepsis. We did not find studies that assessed the risk of mortality in relation to vitamin D deficiency in children admitted for respiratory tract infections either. Strengths of our review include the large number of studies and large total sample size, allowing a high-powered investigation to identify meaningful associations. For our systematic review and meta-analysis, we followed pre-specified eligibility criteria and used the PRISMA²⁷ and MOOSE

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

guidelines²⁸ for reporting. We carried out multiple sensitivity analyses with few material differences in results. However, we note that the relationship between vitamin D deficiency and mortality was sensitive to study design and studies from India, probably due to the smaller number of individuals in those analyses. As expected for prevalence estimates, heterogeneity across studies was high overall. Only the prevalence analysis with neonates indicated somewhat lower variation attributable to heterogeneity ($I^2 = 76.6\%$) along with a higher prevalence estimate (83.0%) compared to other analyses. We utilised meta-regression to investigate this substantial heterogeneity. From the six variables in our multi-variable model, only clinical setting and country groups were found to be significant predictors of pooled prevalence estimates of vitamin D deficiency and the full model could explain 32.9% of heterogeneity (1²). Studies in NICU yielded higher prevalence estimates compared to studies in PICU. Studies from group 3 countries were also associated with higher prevalence estimates compared to studies from countries of group 1 and 2. Other variables, mainly individual patient characteristics such as age and ethnicity, were not directly available to us and may account for significant heterogeneity.

Our systematic review did not identify longitudinal studies with multiple time-point, pre-disease or pre-admission vitamin D measurements. The majority of studies were single centre with heterogeneous patient groups and relatively small sample sizes. Few studies accounted for important confounders that influence vitamin D levels such as age, gender, BMI, season of measurements, vitamin D supplementation and comorbidities. The relationship observed between vitamin D deficiency and mortality could be due to reverse causation and future studies will need to control for covariates and other confounders. Low vitamin D levels could also represent a chronically deficient state due to reduced sunlight exposure, because of chronic illness, lifestyle factors or different country latitudes. In addition, we cannot rule out measurement bias such as

Page 21 of 83

BMJ Open

dilution from intravenous fluids. Our results should be interpreted with caution since our review
is based on evidence from observational studies. More research is warranted to strengthen the
evidence and investigate whether vitamin D could be causally linked to acute or critical illness and
what its contribution might be through various mechanisms such as anti-inflammatory or antimicrobial peptide responses.

Although included studies were generally of good quality, sample sizes varied considerably and were typically small. Half of the studies included less than 100 cases and only 10 (19.2 %) had a total sample size of more than 200 individuals. In addition, studies used a variety of definitions and age ranges to designate individuals as children. Our analysis only included mortality as a clinical outcome. A further general limitation is the difference in thresholds for vitamin D deficiency, particularly in the levels which are considered normal for infants and young children. Our assessment used the currently recommended threshold for deficiency $(25(OH)D \le 50)$ nmol/L)¹⁶ and a conservative estimate for studies which used different criteria. Although our review included a large number of studies and individuals, all studies were observational, and results could be subject to small-study effects.

Vitamin D remains an attractive biomarker and potential therapeutic agent in acute and critical care patients. Our review suggests that high quality focussed studies in each relevant paediatric population are needed first, which could then be followed by trials to establish safety and appropriate treatment regimens in children with acute or critical illness.

21 Availability of data and materials

3	
4	
5	
6	
7	
, 8	
9	
10	
11	
12	
13	
14	
15	
16	
17	
18	
19	
20	
21	
22	
23	
24	
25	
26	
27	
28	
29	
30	
31	
32	
33	
34	
35	
36	
37	
38	
39	
40	
41	
42	
43	
44	
45	
46	
47	
48	
49	
50	
51	
52	
53	
54	
55	
56	
57	
58	
59	

1 2

Data and computational code used for processing and analysis are available at 1 2 https://github.com/margarc/VitaminD children 3 **Author contributions** 4 AJBT conceived the study. AJBT and IT designed the study. MC collected data and performed the analysis with input from MAC, IT, ABJT and EE. MC and AJBT wrote the manuscript with 5 contributions from all authors. 6 **Declaration of interests** 7 The authors declare no conflicts of interest. 8 Funding Medical Research Council UK 9 Acknowledgements 10 AJBT was supported by the Medical Research Council (UK MED-BIO Programme Fellowship, 11 MR/L01632X/1). 12 Ethics committee approval: Not applicable. 13 14 15 16 **Main Figures** 17 Figure 1 Flow chart of study selection process 18 Figure 2 Pooled prevalence estimate for vitamin D deficiency in acute and critically ill children by study design. 19 Forest plot shows results from the random effects model. Each diamond represents the pooled proportion of 25(OH)D 20 deficiency for each of the subgroups (case-control, cohort, cross-sectional study designs). The diamond at the bottom 21 represents the overall pooled proportion of all the 52 studies together. Each square shows the prevalence estimate of 22 each study and the horizontal line across each square represents the 95% confidence interval (CI) of the prevalence 23 estimate.

1 2

60

BMJ Open

3	1	Figure 3 Bubble plots of univariate meta-regressions. Each study is represented by a circle. Predictor variables;
4 5	2	A clinical setting and B country groups are shown on the x-axis and the effect measure logit transformed proportion
6	3	shown on the vertical (y-axis). NICU = Neonatal Intensive Care Unit; PICU = Pediatric Intensive Care Unit; grp =
7	4	country group; country group 1 = USA, Chile, Australia, Canada, Ireland, Japan, Spain; country group 2 = South
8	5	Africa, China, Egypt, Iran, Turkey, Saudi Arabia; and country group 3 = Bangladesh, Thailand, and India
9	6	Figure 4 Pooled prevalence estimate for vitamin D deficiency in children with sepsis. Forest plot shows result
10	7	from the random effects model. The diamond represents the overall pooled proportion of 25(OH)D deficiency from
11	8	the meta-analysis of the 18 studies. Each square shows the prevalence estimate of each study and the horizontal line
12	9	across each square represents the 95% confidence interval (CI) of the prevalence estimate.
13	9	across each square represents the 95% confidence interval (C1) of the prevalence estimate.
14	10	Figure 5 Pooled odds ratio (OR) of risk of mortality in vitamin D deficient versus vitamin D non-deficient acute
15	11	and critically ill children. Forest plot shows result from the random effects model. Diamond represents the
16	12	overall OR (with corresponding 95% Confidence Interval). Each square shows the odds ratio of each study and the
17	13	horizontal line across each square represents the 95% confidence interval (CI) of the estimate.
18	13	nonzontar fine across each square represents the 95% confidence interval (Cr) of the estimate.
19	14	
20		
21	15	
22 23		
25 24	16	
24 25	10	
25 26	17	Supplementary Material
20	17	
28	18	Additional Tables
20	10	
30	19	Additional Table 1 PRISMA Checklist 2009
31	20	
32	20	Additional Table 2A Search terms used in OVID
33		
34	21	Additional Table 2B Search terms used in PubMed
35		
36	22	Additional Table 3A Newcastle Ottawa study quality scoring system (cohort studies)
37	• •	
38	23	Additional Table 3B Newcastle Ottawa study quality scoring system (case-control studies)
39	24	
40	24	Additional Table 3C Newcastle Ottawa study quality scoring system (cross sectional studies)
41	25	Additional Table 4A Circulating 25(OH)D threshold levels used in the selected studies
42	23	Additional Table 4A Circulating 25(OH)D threshold levels used in the selected studies
43	26	Additional Table 4B Circulating 25(OH)D threshold levels used in the selected studies for prevalence in sepsis
44	20	Additional Fuble 4D Chedidaning 25(011)D difestiona levels used in the selected studies for prevalence in sepsis
45	27	Additional Table 5 Studies with thresholds other than <50 nmol/L
46		
47	28	Additional Table 6 Excluded studies
48		
49	29	Additional Table 7 Characteristics of the 52 included studies
50		
51	30	Additional Table 8 Objectives and outcomes of included studies
52		
53	31	Additional Table 9 Assay used in each study to measure Vitamin D levels
54		
55 56	32	Additional Table 10 Funding and ethical approval of included studies
56 57		
57 58		
58 59		23
55		

2	
3	
4	
5	
6 7	
7	
8	
9	
9	
10	
11	
12	
13	
14	
14	
15	
16	
11 12 13 14 15 16 17 18	
18	
19	
20	
20	
21	
22	
21 22 23	
24	
24	
25	
26	
27	
28	
29	
30	
31	
32	
33	
34	
25	
35	
36	
37	
38	
39	
40	
41	
42	
43	
44	
44	
46	
47	
48	
49	
50	
51	
52	
53	
54	
55	
56	
57	

12

13

14

1

1 Additional Table 11 Age groups of children in each study

- 2 Additional Table 12 Prevalence of vitamin D deficiency in each study of acute and critically ill children (sorted from
- 3 highest to lowest)
- 4 Additional Table 13 Characteristics of studies used in the meta-analysis for prevalence
- 5 Additional Table 14 Sensitivity analyses for prevalence of vitamin D deficiency in acute and critically ill children
- 6 Additional Table 15 Multivariate meta-regression model for prevalence
- 7 Additional Table 16 Characteristics of studies included in the meta-analysis for prevalence in individuals with sepsis
- 8 Additional Table 17 Sensitivity analyses for prevalence of vitamin D deficiency in acute and critically ill children
 9 with sepsis
- 10 Additional Table 18 Sensitivity analyses for mortality

Additional Figures

- 15 Additional Figure 1 Funnel plot of studies of prevalence of vitamin D deficiency in acute and critically ill children
- Additional Figure 2 Pooled prevalence estimate for vitamin D deficiency in acute and critically ill children
 (subgroup analysis by country group)
- Additional Figure 3 Pooled prevalence estimate for vitamin D deficiency in acute and critically ill children (subgroup analysis of neonates versus all other age groups)
- 5 20 Additional Figure 4 Bubble plots of univariate meta-regressions.
- Additional Figure 5 Funnel plot for prevalence of vitamin D deficiency in acute and critically ill children with sepsis
- Additional Figure 6 Pooled prevalence estimate for vitamin D deficiency in acute and critically ill children with sepsis (subgroup analysis by study design)
- Additional Figure 7 Funnel plot of risk of mortality in vitamin D deficient versus vitamin D non-deficient acute and critically ill children
- Additional Figure 8 Pooled odds ratio and 95% CI for risk of mortality in vitamin D deficient versus vitamin D non deficient acute and critically ill children (fixed effects model)
 - 28

58

59

References

1. Shuler FD, Wingate MK, Moore GH, *et al.* Sports health benefits of vitamin d. *Sports health* 2012;4(6):496-501.

2. Verceles AC, Weiler B, Koldobskiy D, *et al.* Association Between Vitamin D Status and Weaning From Prolonged Mechanical Ventilation in Survivors of Critical Illness. *Respir Care* 2015;60(7):1033-9.

3. Braegger C, Campoy C, Colomb V, *et al.* Vitamin D in the healthy European paediatric population. *J Pediatr Gastroenterol Nutr* 2013;56(6):692-701.

4. Holick MF, Binkley NC, Bischoff-Ferrari HA, *et al.* Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. *J Clin Endocrinol Metab* 2011;96(7):1911-30.

5. Holick MF. Vitamin D deficiency. *N Engl J Med* 2007;357(3):266-81.

6. Aranow C. Vitamin D and the immune system. *J Investig Med* 2011;59(6):881-6.

7. Zhang YP, Wan YD, Sun TW, *et al.* Association between vitamin D deficiency and mortality in critically ill adult patients: a meta-analysis of cohort studies. *Crit Care* 2014;18(6):684.

8. Ponnarmeni S, Kumar Angurana S, Singhi S, *et al.* Vitamin D deficiency in critically ill children with sepsis. *Paediatr Int Child Health* 2016;36(1):15-21.

9. Kulie T, Groff A, Redmer J, *et al*. Vitamin D: an evidence-based review. *J Am Board Fam Med* 2009;22(6):698-706.

10. Hewison M. Antibacterial effects of vitamin D. *Nat Rev Endocrinol* 2011;7(6):337-45.

11. Kempker JA, West KG, Kempker RR, *et al.* Vitamin D status and the risk for hospital-acquired infections in critically ill adults: a prospective cohort study. *PLoS One* 2015;10(4):e0122136.

12. Martineau AR, Jolliffe DA, Hooper RL, *et al.* Vitamin D supplementation to prevent acute respiratory tract infections: systematic review and meta-analysis of individual participant data. *BMJ* 2017;356:i6583.

13. Absoud M, Cummins C, Lim MJ, *et al.* Prevalence and predictors of vitamin D insufficiency in children: a Great Britain population based study. *PLoS One* 2011;6(7):e22179.

14. Greer FR. Defining vitamin D deficiency in children: beyond 25-OH vitamin D serum concentrations. *Pediatrics* 2009;124(5):1471-3.

15. Abou-Zahr R, Kandil SB. A pediatric critical care perspective on vitamin D. *Pediatr Res* 2015;77(1-2):164-7.

16. Ross AC, Manson JE, Abrams SA, *et al*. The 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine: what clinicians need to know. *J Clin Endocrinol Metab* 2011;96(1):53-8.

17. Ala-Kokko TI, Mutt SJ, Nisula S, *et al.* Vitamin D deficiency at admission is not associated with 90day mortality in patients with severe sepsis or septic shock: Observational FINNAKI cohort study. *Ann Med* 2016;48(1-2):67-75.

18. Putzu A, Belletti A, Cassina T, *et al.* Vitamin D and outcomes in adult critically ill patients. A systematic review and meta-analysis of randomized trials. *J Crit Care* 2017;38:109-14.

19. Han JE, Jones JL, Tangpricha V, *et al.* High Dose Vitamin D Administration in Ventilated Intensive Care Unit Patients: A Pilot Double Blind Randomized Controlled Trial. *J Clin Transl Endocrinol* 2016;4:59-65.

20. Quraishi SA, De Pascale G, Needleman JS, *et al.* Effect of Cholecalciferol Supplementation on Vitamin D Status and Cathelicidin Levels in Sepsis: A Randomized, Placebo-Controlled Trial. *Crit Care Med* 2015;43(9):1928-37.

21. Singer M, Deutschman CS, Seymour CW, *et al.* The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). *JAMA* 2016;315(8):801-10.

1 2 3

4

5

6

7

8

9 10

11

12

13

14

15

16

17

18

19 20

21

22

23

24

25

26

27

28 29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

59

60

NHS-England. Improving outcomes for patients with sepsis: a cross-system action plan 2015 22. [Available from: https://www.england.nhs.uk/ourwork/part-rel/sepsis/. 23. Plunkett A, Tong J. Sepsis in children. BMJ 2015;350:h3017. 24. Weiss SL, Fitzgerald JC, Pappachan J, et al. Global epidemiology of pediatric severe sepsis: the sepsis prevalence, outcomes, and therapies study. Am J Respir Crit Care Med 2015;191(10):1147-57. 25. Mayr FB, Yende S, Angus DC. Epidemiology of severe sepsis. Virulence 2014;5(1):4-11. De Pascale G, Ranzani OT, Nseir S, et al. Intensive care unit patients with lower respiratory tract 26. nosocomial infections: the ENIRRIs project. ERJ Open Res 2017;3(4). Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-27. analyses: the PRISMA statement. PloS Med 2009;6. 28. Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 2000;283(15):2008-12. 29. Wells GA SB OCD, Peterson J, Welch V, Losos M, Tugwell P. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses [Available from: http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp. 30. Newcombe RG. Two-sided confidence intervals for the single proportion: comparison of seven methods. Stat Med 1998;17(8):857-72. 31. DerSimonian R, Laird N. Meta-analysis in clinical trials revisited. Contemp Clin Trials 2015;45(Pt A):139-45. Higgins JP, Thompson SG, Spiegelhalter DJ. A re-evaluation of random-effects meta-analysis. J R 32. Stat Soc Ser A Stat Soc 2009;172(1):137-59. 33. Borenstein M, Hedges LV, Higgins JP, et al. A basic introduction to fixed-effect and randomeffects models for meta-analysis. Res Synth Methods 2010;1(2):97-111. 34. Haidich A-BJ. Meta-analysis in medical research. *Hippokratia* 2010;14(Suppl 1):29. 35. Lau J, Ioannidis JP, Schmid CH. Quantitative synthesis in systematic reviews. Ann Intern Med 1997;127(9):820-6. Ioannidis JP, Patsopoulos NA, Evangelou E. Uncertainty in heterogeneity estimates in meta-36. analyses. BMJ 2007;335(7626):914-6. 37. Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. BMJ 2003;327(7414):557-60. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 38. 2002;21(11):1539-58. Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple, 39. graphical test. BMJ 1997;315(7109):629-34. 40. Sterne JA, Sutton AJ, Ioannidis JP, et al. Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. BMJ 2011;343:d4002. 41. Duval S, Tweedie R. Trim and fill: A simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. *Biometrics* 2000;56(2):455-63. Panityakul T, Bumrungsup C, Knapp G. On estimating residual heterogeneity in random-effects 42. meta-regression: a comparative study. J Stat Theory Appl 2013;12(3):253. 43. Knapp G, Hartung J. Improved tests for a random effects meta-regression with a single

44. Schwarzer G. meta: An R package for meta-analysis. *R news* 2007;7(3):40-5.

covariate. Stat Med 2003;22(17):2693-710.

45. Viechtbauer W. Conducting meta-analyses in R with the metafor package. *J Stat Softw* 2010;36(3).

BMJ Open

3	46. Garg D, Sharma VK, Karnawat B. Association of serum vitamin D with acute lower respiratory
4	infection in Indian children under 5 years: a case control study. Int J Contemp Pediatrics 2016;3(4):1164-
5	9.
6	47. Aydemir G, Cekmez F, Kalkan G, et al. High serum 25-hydroxyvitamin D levels are associated
7	with pediatric sepsis. Tohoku J Exp Med 2014;234(4):295-8.
8 9	48. Gamal TS, Madiha AS, Hanan MK, <i>et al.</i> Neonatal and Maternal 25-OH Vitamin D Serum Levels in
10	Neonates with Early-Onset Sepsis. <i>Children (Basel)</i> 2017;4(5).
11	49. Seliem MS, Abdel Haie OM, Mansour AI, <i>et al.</i> The relation between vitamin D level and
12	increased risk for early-onset neonatal sepsis in full-term infants. Medical Research Journal
13	2016;15(1):16-21.
14	50. McNally JD, Leis K, Matheson LA, <i>et al.</i> Vitamin D deficiency in young children with severe acute
15	lower respiratory infection. Pediatr Pulmonol 2009;44(10):981-8.
16	51. McNally JD, Doherty DR, Lawson ML, <i>et al.</i> The relationship between vitamin D status and
17	adrenal insufficiency in critically ill children. J Clin Endocrinol Metab 2013;98(5):E877-81.
18	
19	52. McNally JD, Iliriani K, Pojsupap S, <i>et al.</i> Rapid normalization of vitamin D levels: a meta-analysis.
20	Pediatrics 2015;135(1):e152-66.
21	53. McNally JD, Menon K, Chakraborty P, <i>et al.</i> The association of vitamin D status with pediatric
22	critical illness. Pediatrics 2012;130(3):429-36.
23	54. Karatekin G, Kaya A, Salihoglu O, et al. Association of subclinical vitamin D deficiency in
24	newborns with acute lower respiratory infection and their mothers. Eur J Clin Nutr 2009;63(4):473-7.
25	55. Vo P, Koppel C, Espinola JA, et al. Vitamin D Status at the Time of Hospitalization for
26	Bronchiolitis and Its Association with Disease Severity. J Pediatr 2018;203:416-22.e1.
27	
28	56. Shah SK, Kabra SK, Gupta N, <i>et al.</i> Vitamin D Deficiency and Parathyroid Response in Critically-ill
29	Children: Association with Illness Severity and Clinical Outcomes. Indian Pediatr 2016;53(6):479-84.
30	57. Sankar J, Lotha W, Ismail J, <i>et al.</i> Vitamin D deficiency and length of pediatric intensive care unit
31	stay: a prospective observational study. Ann Intensive Care 2016;6(1):3.
32	58. Dayal D, Kumar S, Sachdeva N, <i>et al.</i> Fall in Vitamin D Levels during Hospitalization in Children.
33	Int J Pediatr 2014;2014:291856.
34	59. Prasad S, Raj D, Warsi S, et al. Vitamin D Deficiency and Critical Illness. Indian J Pediatr
35	2015;82(11):991-5.
36	
37	60. Wayse V, Yousafzai A, Mogale K, <i>et al.</i> Association of subclinical vitamin D deficiency with severe
38	acute lower respiratory infection in Indian children under 5 y. <i>Eur J Clin Nutr</i> 2004;58(4):563-7.
39	61. Ebenezer K, Job V, Antonisamy B, et al. Serum Vitamin D Status and Outcome among Critically III
40	Children Admitted to the Pediatric Intensive Care Unit in South India. <i>Indian J Pediatr</i> 2016;83(2):120-5.
41	62. Narang GS, Arora S, Kukreja S. Association of Vitamin D Deficiency with Acute Lower Respiratory
42	Infection in Toddlers. Journal of Nepal Paediatric Society 2016;36(1):14-6.
43	63. Jat KR, Kaur J, Guglani V. Vitamin D and Pneumonia in Children: A Case Control Study. J Pulm
44	Med Respir Res 2016;2(004).
45	64. Sankar J, Ismail J, Das R, <i>et al.</i> Effect of Severe Vitamin D Deficiency at Admission on Shock
46	· · · · · · · · ·
47	Reversal in Children With Septic Shock. J Intensive Care Med 2017.
48	65. Dhandai R, Jajoo M, Singh A, et al. Association of vitamin D deficiency with an increased risk of
49	late-onset neonatal sepsis. Paediatr Int Child Health 2018;38(3):193-7.
50	66. Asilioglu N, Cigdem H, Paksu MS. Serum Vitamin D Status and Outcome in Critically III Children.
51	Indian J Crit Care Med 2017;21(10):660-4.
52	67. Say B, Uras N, Sahin S, et al. Effects of cord blood vitamin D levels on the risk of neonatal sepsis
53	in premature infants. <i>Korean J Pediatr</i> 2017;60(8):248-53.
54	68. Cayir A, Turan MI, Ozkan O, <i>et al.</i> Vitamin D levels in children diagnosed with acute otitis media.
55	• • • • • • •
56	J Pak Med Assoc 2014;64(11):1274-7.
57	
58	27
59	For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml
60	i of peer review only integr/onlyopen.only.com/site/about/guidelines.xittin

69. Cetinkaya M, Cekmez F, Buyukkale G, *et al.* Lower vitamin D levels are associated with increased risk of early-onset neonatal sepsis in term infants. *J Perinatol* 2015;35(1):39.

70. Cizmeci MN, Kanburoglu MK, Akelma AZ, *et al.* Cord-blood 25-hydroxyvitamin D levels and risk of early-onset neonatal sepsis: a case-control study from a tertiary care center in Turkey. *Eur J Pediatr* 2015;174(6):809-15.

71. Dinlen N, Zenciroglu A, Beken S, *et al.* Association of vitamin D deficiency with acute lower respiratory tract infections in newborns. *J Matern Fetal Neonatal Med* 2016;29(6):928-32.

72. Onwuneme C, Martin F, McCarthy R, *et al.* The Association of Vitamin D Status with Acute Respiratory Morbidity in Preterm Infants. *J Pediatr* 2015;166(5):1175-80.e1.

73. Madden K, Feldman HA, Smith EM, *et al.* Vitamin D deficiency in critically ill children. *Pediatrics* 2012;130(3):421-8.

74. Rippel C, South M, Butt WW, *et al.* Vitamin D status in critically ill children. *Intensive Care Med* 2012;38(12):2055-62.

75. Korwutthikulrangsri M, Mahachoklertwattana P, Lertbunrian R, *et al.* Vitamin D deficiency and adrenal function in critically ill children. *J Med Assoc Thai* 2015;98(4):365-72.

76. Elmoneim A, Rhill R, Rahalli M, *et al.* Vitamin D level in pediatric intensive care unit (PICU) patients: its relation to severity of illness. *Pediat Therapeut* 2016;6(293):2161-0665.

77. García-Soler P, Morales-Martínez A, Rosa-Camacho V, *et al.* Vitamin D deficiency and morbimortality in critically ill paediatric patients. *Anales de Pediatría (English Edition)* 2017;87(2):95-103.

78. Badawi NES, Algebaly HAF, El Sayed R, *et al*. Vitamin D deficiency in critically ill children. *Kasr Al Ainy Medical Journal* 2017;23(1):6.

79. Roth DE, Jones AB, Prosser C, *et al.* Vitamin D status is not associated with the risk of hospitalization for acute bronchiolitis in early childhood. *Eur J Clin Nutr* 2009;63(2):297-9.

Cebey-Lopez M, Pardo-Seco J, Gomez-Carballa A, *et al.* Role of Vitamin D in Hospitalized
 Children With Lower Tract Acute Respiratory Infections. *J Pediatr Gastroenterol Nutr* 2016;62(3):479-85.
 Alonso MA, Pallavicini ZF, Rodriguez J, *et al.* Can vitamin D status be assessed by serum 250HD

in children? Pediatr Nephrol 2015;30(2):327-32.

82. Ayulo M, Jr., Katyal C, Agarwal C, *et al*. The prevalence of vitamin D deficiency and its relationship with disease severity in an urban pediatric critical care unit. *Endocr Regul* 2014;48(2):69-76.

83. Rey C, Sanchez-Arango D, Lopez-Herce J, *et al.* Vitamin D deficiency at pediatric intensive care admission. *J Pediatr (Rio J)* 2014;90(2):135-42.

84. Onwuneme C, Carroll A, Doherty D, *et al.* Inadequate vitamin D levels are associated with culture positive sepsis and poor outcomes in paediatric intensive care. *Acta Paediatr* 2015;104(10):e433-8.

85. Jia K-P, Zhao L-F, Feng N, *et al.* Lower level of vitamin D3 is associated with susceptibility to acute lower respiratory tract infection (ALRTI) and severity: a hospital based study in Chinese infants. *Int J Clin Exp Med* 2017;10(5):7997-8003.

86. Halwany AS, Deghady AAE, Moustafa AAA, *et al.* Study of Serum Vitamin D Level among Critically III Patients Admitted to Alexandria University Pediatric Intensive Care Unit. *JMSCR* 2017;5(4):20776-81.

87. Li W, Cheng X, Guo L, *et al.* Association between serum 25-hydroxyvitamin D concentration and pulmonary infection in children. *Medicine* 2018;97(1):e9060.

88. El Sakka AS, Imam SS, Amer HA, *et al.* Vitamin D deficiency and low hemoglobin level as risk factors for severity of acute lower respiratory tract infections in Egyptian children: A case-control study. *Egyptian Pediatric Association Gazette* 2014;62(1):1-7.

89. Bustos R, Rodriguez-Nunez I, Peña RZ, *et al.* Vitamin D deficiency in children admitted to the paediatric intensive care unit. *Revista chilena de pediatria* 2016;87(6):480-6.

90. Hurwitz JL, Jones BG, Penkert RR, *et al.* Low Retinol-Binding Protein and Vitamin D Levels Are Associated with Severe Outcomes in Children Hospitalized with Lower Respiratory Tract Infection and Respiratory Syncytial Virus or Human Metapneumovirus Detection. *J Pediatr* 2017;187:323-7.

91. Yaghmaie B, Sayarifard F, Modarresi M, et al. Investigation of serum 25 hydroxy vitamin D level in critically ill children and its relation with demographic and clinical risk factors. *Biomed Res* 2017;28(5).
92. El-Gamasy M, Eldeeb M, Abdelmageed M. Prognostic Value of Vitamin D Status in Pediatric Patients with Acute Kidney Injury in Tanta University Emergency Hospital, Egypt. *J Emerg Intern Med* 2017;1(1):5.

93. McNally JD, Nama N, O'Hearn K, *et al.* Vitamin D deficiency in critically ill children: a systematic review and meta-analysis. *Crit Care* 2017;21(1):287.

94. Randolph AG, McCulloh RJ. Pediatric sepsis: important considerations for diagnosing and managing severe infections in infants, children, and adolescents. *Virulence* 2014;5(1):179-89.

95. Vincent JL. The Clinical Challenge of Sepsis Identification and Monitoring. *PLoS Med* 2016;13(5):e1002022.

96. Mathias B, Mira JC, Larson SD. Pediatric sepsis. *Curr Opin Pediatr* 2016;28(3):380-7.






Figure 1 Flow chart of study selection process



design. Forest plot shows results from the random effects model. Each diamond represents the pooled proportion of 25(OH)D deficiency for each of the subgroups (case-control, cohort, cross-sectional study designs). The diamond at the bottom represents the overall pooled proportion of all the 52 studies together. Each square shows the prevalence estimate of each study and the horizontal line across each square represents the 95% confidence interval (CI) of the prevalence estimate.

203x254mm (300 x 300 DPI)






Figure 4 Pooled prevalence estimate for vitamin D deficiency in children with sepsis. Forest plot shows result from the random effects model. The diamond represents the overall pooled proportion of 25(OH)D deficiency from the meta-analysis of the 18 studies. Each square shows the prevalence estimate of each study and the horizontal line across each square represents the 95% confidence interval (CI) of the prevalence estimate.

254x152mm (300 x 300 DPI)

1
2 3
4
5 6
7 8
8 9
10 11
12
13 14
15
16 17
18
19 20
21
22 23
24
25 26
27
28 29
30
31 32
33 34
35
36 37
37 38
39 40
41
42 43
44
45 46
47
48 49
50
51 52
53
54 55
56 57
58
59




Figure 5 Pooled odds ratio (OR) of risk of mortality in vitamin D deficient versus vitamin D non-deficient acute and critically ill children. Forest plot shows result from the random effects model. Diamond represents the overall OR (with corresponding 95% Confidence Interval). Each square shows the odds ratio of each study and the horizontal line across each square represents the 95% confidence interval (CI) of the estimate.

203x127mm (300 x 300 DPI)

Supplementary Material

Table of Contents

Additional Table 1 PRISMA Checklist 2009	3
Additional Table 2A Search terms used in OVID	5
Additional Table 2B Search terms used in PubMed	6
Additional Table 3A Newcastle Ottawa study quality scoring system (cohort studies)	7
Additional Table 3B Newcastle Ottawa study quality scoring system (case-control studies)	8
Additional Table 3C Newcastle Ottawa study quality scoring system (cross-sectional studies)	9
Additional Table 4A Circulating 25(OH)D threshold levels used in the selected studies	10
Additional Table 4B Circulating 25(OH)D threshold levels used in the selected studies for prevalence in sepsis	
Additional Table 5 Studies with thresholds other than < 50 nmol/L	
Additional Table 6 Excluded studies	15
Additional Table 7 Characteristics of the 52 included studies	16
Additional Table 8 Objectives and outcomes of included studies	22
Additional Table 9 Assay used in each study to measure Vitamin D levels	26
Additional Table 10 Funding and ethical approval of included studies	27
Additional Table 11 Age groups of children in each study	30
Additional Table 12 Prevalence of vitamin D deficiency in each study of acute and critically ill childr (sorted from highest to lowest)	
Additional Table 13 Characteristics of studies used in the meta-analysis of prevalence	33
Additional Table 14 Sensitivity analyses for prevalence of vitamin D deficiency in acute and critically ill children	•
Additional Table 15 Multivariate meta-regression model for prevalence	36
Additional Table 16 Characteristics of studies included in the meta-analysis for prevalence in individuals with sepsis	37
Additional Table 17 Sensitivity analyses for prevalence of vitamin D deficiency in acute and critically ill children with sepsis	-
Additional Table 18 Sensitivity analyses for mortality. Pooled odds ratios for risk of mortality in deficient versus not deficient children	39
Additional Figures	40

Additional Figure 1 Funnel plot of studies of prevalence of vitamin D deficiency in acute and critically ill children
Additional Figure 2. Pooled prevalence estimate for vitamin D deficiency in acute and critically ill children (by country group)
Additional Figure 3. Pooled prevalence estimates for vitamin D deficiency in acute and critically ill children (neonates versus all other age groups)
Additional Figure 4 Bubble plots of univariate meta-regressions
Additional Figure 5 Funnel plot for prevalence of vitamin D deficiency in acute and critically ill children with sepsis
Additional Figure 6 Pooled prevalence estimate for vitamin D deficiency in acute and critically ill children with sepsis (subgroup analysis by study design)
Additional Figure 7 Funnel plot of risk of mortality in vitamin D deficient versus vitamin D non- deficient acute and critically ill children
Additional Figure 8 Pooled odds ratio (OR) and 95% CI for risk of mortality in vitamin D deficient versus vitamin D non-deficient acute and critically ill children (fixed effects model)

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

1 2	
3 4 5	
6 7	
8 9 10	
11 12	
13 14 15	
16 17	
18 19 20	
21 22	
23 24 25	
26 27	
28 29 30	
31 32	
33 34 35	
36 37	
38 39 40	
41 42	
43 44 45	
46 47	
48 49 50	
51 52 53	
53 54 55	
56 57 58	
58 59 60	

Section/topic	#	Checklist item	Reported o page #
TITLE			
Title	1	Identify the report as a systematic review, meta-analysis, or both.	1
ABSTRACT			
Structured summary	2	Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.	2-3
INTRODUCTION			
Rationale	3	Describe the rationale for the review in the context of what is already known.	4-5
Objectives	4	Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).	6-8
METHODS			
Protocol and registration	5	Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.	9
Eligibility criteria	6	Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.	5-7
Information sources	7	Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.	6-7
Search	8	Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.	6 and supplementary material
Study selection	9	State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).	6-7
Data collection process	10	Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.	7
Data items	11	List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.	7-8
Risk of bias in individual studies	12	Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.	8
Summary measures	13	State the principal summary measures (e.g., risk ratio, difference in means).	8
Synthesis of results	14	Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I^2) for each meta-analysis.	8-10

Additional Table 1 PRISMA Checklist 2009

2 3	
3 4	
4 5	
6	
/	
8	
9	
10	
11	
12	
13	
14	
15	
16	
17	
18	
19	
19 20	
21	
22	
22	
24	
24 25	
25	
26	
27 28	
28	
29	
30	
31	
32	
33	
34	
35	
36	
37 38	
38	
39	
40	
41	
42	
43	
44	
45	
46	
47	
48	
49	
50	
50	
52	
52 53	
53 54	
54 55	
56	
57	
58	
59	
60	

Section/topic	#	Checklist item	Reported on page #
Risk of bias across studies	15	Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).	8
Additional analyses	16	Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta- regression), if done, indicating which were pre-specified.	9-10 and 15
RESULTS			
Study selection	17	Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.	10
Study characteristics	18	For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.	14-19 (supplementary material)
Risk of bias within studies	19	Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).	5-7 (supplementary material)
Results of individual studies	20	For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.	13,15,18 and supplementary material
Synthesis of results	21	Present results of each meta-analysis done, including confidence intervals and measures of consistency.	13 and supplementary material pages 32-36
Risk of bias across studies	22	Present results of any assessment of risk of bias across studies (see Item 15).	5-7 (supplementary material)
Additional analysis	23	Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).	supplementary material pages 32-36
DISCUSSION			
Summary of evidence	24	Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).	19-21
Limitations	25	Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).	20-22
Conclusions	26	Provide a general interpretation of the results in the context of other evidence, and implications for future research.	22
FUNDING			
Funding	27	Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.	22

1.	Vitamin D
2.	Sepsis or septic shock
3.	Vitamin D or cholecalciferol* or ergocalciferol or 25-hydroxyvitamin D or calcidiol or calcitriol
4.	Intensive care unit* or critical care
5.	Multiple organ dysfunction syndrome or multiple organ failure
6.	(1 and 2) or 5
7.	((1 or 3) and 2 or 4
8.	(1 or 3) and 2
9.	(1 or 3) and 4
10.	(1 or 3) and 5
11.	Sepsis
12.	multi* organ dysfunction syndrome or multiple organ failure
13.	multi* organ dysfunction syndrome or multi* organ failure
14.	(2 or 8) and 3
15.	critical* ill or acute condition* or intensive care unit
16.	child* or pediatric*
17.	vitamin D or cholecalciferol or ergocalciferol or 25-hydroxyvitamin D or calcidiol or calcitriol
18.	15 and 16 and 17
19.	Vitamin D blood levels or 25-hydroxyvitamin
20.	5 and 3 and 15 and 16
21.	2 and 15 and 16 and 17
22.	16 and 2
23.	16 and 2 and 3
	Pediatric*
25.	Pediatric* and 5 and 2
26.	24 and 3 and 15

1 2	
2 3 4	
5 6	
7 8	
9 10	
11 12	
13 14	
15 16	
17 18	
19 20	
21 22	
23 24 25	
25 26 27	
28 29	
30 31	
32 33	
34 35	
36 37	
38 39	
40 41 42	
42 43 44	
44 45 46	
47 48	
49 50	
50	

Vitamin D.mp. (sepsis or septic shock).mp. (vitamin D or cholecaliferol* or ergocalciferol or 25-hydroxyvitamin D or calcidiol or calcitriol) (intensive care unit* or critical care).mp. (multi* organ dysfunction syndrome or multiple organ failure).mp. (critical* ill or acute condition* or intensive care unit).mp. (toddler or infant or child* or neonate* or baby or teenager or pediatric* or paediatric*).mp. 3 and 6 and 2 and 7	Ferm se	arched
 (sepsis or septic shock).mp. (vitamin D or cholecalciferol* or ergocalciferol or 25-hydroxyvitamin D or calcidiol or calcitriol) (intensive care unit* or critical care).mp. (mult* organ dysfunction syndrome or multiple organ failure).mp. (critical* ill or acute condition* or intensive care unit).mp. (toddler or infant or child* or neonate* or baby or teenager or pediatric* or paediatric*).mp. 3 and 6 and 2 and 7 		
 (vitamin D or cholecalciferol* or ergocalciferol or 25-hydroxyvitamin D or calcidiol or calcitriol) (intensive care unit* or critical care).mp. (multi* organ dysfunction syndrome or multiple organ failure).mp. (critical* ill or acute condition* or intensive care unit).mp. (toddler or infant or child* or neonate* or baby or teenager or pediatric* or paediatric*).mp. 3 and 6 and 2 and 7 		
 4. (intensive care unit* or critical care).mp. 5. (multi* organ dysfunction syndrome or multiple organ failure).mp. 6. (critical* ill or acute condition* or intensive care unit).mp. 7. (toddler or infant or child* or neonate* or baby or teenager or pediatric* or paediatric*).mp. 8. 3 and 6 and 2 and 7 		(vitamin D or cholecalciferol* or ergocalciferol or 25-hydroxyvitamin D or calcidiol or calcitriol).m
 5. (multi* organ dysfunction syndrome or multiple organ failure).mp. 6. (critical* ill or acute condition* or intensive care unit).mp. 7. (toddler or infant or child* or neonate* or baby or teenager or pediatric* or paediatric*).mp. 8. 3 and 6 and 2 and 7 		
 6. (critical* ill or acute condition* or intensive care unit).mp. 7. (toddler or infant or child* or neonate* or baby or teenager or pediatric* or paediatric*).mp. 8. 3 and 6 and 2 and 7 		(intensive care unit* or critical care).mp.
7. (toddler or infant or child* or neonate* or baby or teenager or pediatric* or paediatric*).mp. 8. 3 and 6 and 2 and 7	5.	(multi* organ dysfunction syndrome or multiple organ failure).mp.
7. (toddler or infant or child* or neonate* or baby or teenager or pediatric* or paediatric*).mp. 8. 3 and 6 and 2 and 7	6	/ '-' 14-'11 / 1'-' 4- '-' '-' '-'
8. 3 and 6 and 2 and 7		(critical* ill or acute condition* or intensive care unit).mp.
	0.	

Study			Selection		Comparability		Outcome		
	Represent ativeness of the exposed cohort	Selection of the non-exposed cohort	Ascertainment of exposure	Demonstration that outcome of interest was not present at the start of the study	Comparability of cohorts on the basis of the design or analysis (maximum 2 stars)	Assessment of outcome	Was follow-up long enough for outcome to occur (\geq 28 days after admission to the ICU)	Adequacy of follow up of cohorts	Numbe of stars (out of total)
Ebenezer 2016	1	1	1	1	0	1	0	1	6
Sankar 2016	1	1	1	1	2	1	0	1	8
Rippel 2012	1	1	1	1	1	1	1	1	8
Madden 2012	1	1	1	1	2	1	0	1	8
McNally 2012	1	1	1	0	1	1	1	1	7
Dayal 2014	1	1	1	1	0	1	0	1	6
Ayulo 2014	1	1		1	2	1	0	0	7
Bustos 2016	1	1	1	0	2	1	0	1	7
Prasad 2015	1	1	1	0	2	1	0	1	7
Onwuneme 2015 (2)	1	1	1	1	2	1	0	1	8
Inamo 2011	1	1	1	-0	1	1	0	1	6
Shah 2016	1	1	1		0	1	0	1	6
Lopez 2016	1	1	1	1	2	1	0	1	8
Garcia-Soler 2017	1	1	1	1	2	1	0	0	7
Sankar 2017	1	1	1	1	2	1	0	1	8
Asilioglu 2017	1	1	1	1	1	1	0	1	7
Halwany 2017	1	1	1	1	• 1	1	0	0	6
Hurwitz 2017	1	1	1	0	1	1	0	1	6
Banajeh 2009	1	1	1	0	1	1	1	1	7
Badawi 2017	1	1	1	1	1	1	1	1	8
Rey 2014	1	1	1	1	2	0	0	1	7
Ponnarmeni 2016	1	0	1	1	1	1	0	1	6
Onwuneme 2015 (1)	1	1	1	1	1	1	0	1	8
El-Gamasy 2017	1	0	1	1	2	1	0	1	7
Dhandai 2018	1	1	1	1	1	1	0	1	7
Hebbar 2014	1	0	1	1	1	1	0	1	6
Korwutthikulrangsri 2015	1	1	1	1	2	1	0	0	7
Elmoneim 2016	1	1	1	1	0	1	0	1	7
Vo 2018	1	1	1	1	2	1	0	1	8
Mathias 2017	1	1	1	1	0	1	0	1	6

Study		SELE	CTION		COMPARABILITY		EXPOSURE		Number of stars
	Is the case definition adequate?	Representati veness of the cases	Selection of controls	Definition of controls	Comparability of cases and controls on the basis of the design or analysis (maximum 2 stars)	Ascertainment of exposure	Same method of ascertainment for cases and controls (yes or no or 0 star if no mention)	Non- response rate	_ (out of 9 total)
Wayse 2004	1	1	0	0	1	1	1	1	6
Karatekin 2009	1	1	0	0	1	1	1	1	6
Roth 2009	1	1	0	1	1	1	1	0	7
Roth 2010 Cetinkaya 2015		1		0	2	1	1	0	8 6
Cizmeci 2015	1	1	0	0	2	1	1	1	6
Narang 2016	1	1	0	0	1	1	1	1	6
Narang 2016 Dinlen 2016	1	1	0	0	1	1	1	1	6
Ahmed 2015	1	1	0	Î	2	1	1	1	8
Cayir 2014	1	1	0	0	2	1	1	1	7
Say 2017	1	1	0	0	2	1	1	0	6
Basha 2014	1	1	0	1	2	1	1	0	7
Jia 2017	1	1	0	1	1	1	1	1	7
Jat 2016	1	1	0	1	2	1	1	1	8
	1	1	0	1	1	1	0	1	6
Sakka 2014	1	1	0	1	2	1	1	1	8
Khakshour 2015 Li 2018	1	1	0	0	1 2	1	1	0	5
									8

1	
2	

1		SELECTION (Maximum 5 stars)			COMPARABILITY (Maximum 2 stars)	OUTCOME (Maximum 3 stars)		
	Representativene ss of the sample	Sample size	Non- respondents	Ascertainment of the exposure (risk factor)	Subjects in different outcome groups are comparable, based on the study design or analysis. Confounding factors are controlled.	Assessment of the outcome (max=2 stars)	Statistical test (max=1 star)	Number of stars (out of 10 total)
maie 2017	1	0	0	0	1	1	1	4
ez 2016	1	0	0	1	1	2	1	6
so 2015 s 2014	1	0	0	1	1	1	1	5
2014	1	0	0	1	<u>1</u> udies in meta-analyses. Available at:	2	1	6

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

Study	Number of cases	25(OH)D categories (as given)	Number of cases in eac category
Asilioglu 2017	250	Deficiency: <20 ng/mL	120
-		Sufficiency: >=20 ng/mL	85
Halwany 2017	102	Deficiency: <20 ng/ml	38
		Insufficiency: 20-29.9 ng/ml	39
		"Normal" levels: 30 ng/ml	25
Hurwitz 2017	90	Deficiency: <20 ng/mL	11
Garcia-Soler 2017	340	Deficiency: <20 ng/mL	149
		Insufficiency: 20-30 ng/mL	128
		25(OH)D levels: 30-40 ng/mL	41
		Optimal levels >40 ng/mL	22
Badawi 2017	88	Deficiency: < 50nmol/l	39
		Severe deficiency: <30 nmol/l	30
Jia 2017	110	Severe deficiency: <10 ng/ml	36
		Deficiency: 10-20 ng/ml	56
		Insufficiency: 21-30 ng/ml	17
		Sufficiency: >30 ng/ml	1
Yaghmaie 2017	82	Deficiency: <30 ng/ml	53
		Sufficiency: >=30 ng/ml	29
Say 2017	100	Severe deficiency (group 1) <5 ng/mL.	63
		Insufficiency (group2): 5 to 15 ng/mL	24
		Sufficiency (group 3) ≥15 ng/mL	13
El-Gamasy 2017	80	Serious deficiency: < 30 nmol/L	26
		Insufficiency: 30-75 nmol/L	27
		Adequate levels >75 nmol/L	27
Sankar 2017	43	Severe deficiency: serum 25 (OH) D <10 ng/mL	31
Shah 2016	154	25(OH)D < 20 ng/mL	128
		25(OH)D ≥20 ng/mL	26
Ponnarmeni 2016	124	Deficiency: < 50nmol/L	63
		Insufficiency: 50-75 nmol/L	31
		<75, insufficient and deficient	94
	Γ	Sufficiency: >75 nmol/L	30
Sankar 2016	101	Deficiency: ≤ 20 ng/mL	75
	Γ	Severe deficiency: <15 ng/mL	62
	Γ	'No deficiency': > 20 ng/mL	26
Bustos 2016	90	Deficiency: <20 ng/ml	39
		Normal levels: >20 ng/ml	51
Ebenezer 2016	52	Deficiency: < 20ng/mL	21
		Insufficiency: 20–30 ng/ml	12
		'Normal levels: $\geq 20 \text{ ng/L}$	31
Elmoneim 2016	21	Deficiency: < 20 ng/mL	17
	Γ	Insufficiency: 20-30 ng/mL	4
	Γ	Normal levels: > 30 ng/mL	9
Jat 2016	50	Deficiency: <20 ng/ml	42
	Γ	Insufficiency: 20-30 ng/ml	2
	Γ	Sufficiency: >=30 ng/ml	1
Narang 2016	50	"Severe deficiency": <20ng/ml	28
Dinlen 2016	30	Deficiency: <=15 ng/mL	26
		Severe deficiency: <=5 ng/mL	3
Lopez 2016	347	25-OHD levels: <10 ng/mL	19
I	F	25-OHD levels: 10-20 ng/mL	65
	F	25-OHD levels: 20-30 ng/mL	134
Alvarez 2016	50	25(OH) D levels: <20 ng/mL	29
		25(OH) D levels: 20-30 ng/mL	37
Onwuneme 2015 (1)	120	25(OH) D levels: <50 nmol/L	71
Sin anome 2015 (1)		25(OH)D levels: ≥50nmol/L	49
Onwuneme 2015 (2)	94	25(OH)D levels: <20 ng/mL	86
Sitwatenie 2013 (2)		25(OH)D levels: < 30 nmol/L	60
		25(OH)D levels: < 30 http:///	34
Prasad 2015	80	Deficiency: < 20 ng/ml	67
1 Iasau 2013	00	Sufficiency: < 20 ng/mL	13
Moreno-Solis 2015	48	Deficiency: ≥ 20 ng/mL	9
woreno-sons 2015	48		
		Insufficiency: 21–29 ng/ml	16
		Sufficiency: ≥30 ng/ml	23

Page 45 of 83

BMJ Open

1 2	
2 3 4	
5 6	
7 8	
9 1(0
12	
13 14	4
1: 10 1:	5
1) 18 19	8
2(2	C
22 23	
24 25	5
20	7
28 29 30	9
3	1
33	3
3: 3(5 5
38	
39 40	0
4 42 43	2
44 44	4
40 4	5
48 49	9
5(5	1
52 53	3
54 55 50	5
5	7

58 59

60

Alonso 2015	288	Deficiency: <20 ng/ml	45
Korwutthikulrangsri 2015	32	<10 ng/ml Deficiency: < 20 ng/ml	<u>6</u> 25
Korwutulikulraligsh 2013	32	Insufficiency: 20-29.9 ng/ml	<u></u> 7
		Sufficiency: $\geq 30 \text{ ng/mL}$	0
Khakshour 2015	37	Deficiency: <20 ng/mL	9
Cizmeci 2015	40	Deficiency: <20 ng/ml	28
		Insufficiency: 21–29 ng/ml	7
		Normal levels: ≥30 ng/ml	5
Cetinkaya 2015	50	Severe deficiency: <10 ng ml ⁻¹	42
		Insufficiency: 11 to 32 ng ml ⁻¹	8
Ayulo 2014	216	Deficient: <15 ng/ml	61
		Insufficient: 15-29 ng/mL	102
Dayal 2014	92	Sufficient: ≥ 30 ng/mL Deficiency: < 50 nmol/L	53 23
Dayai 2014	92	Insufficiency: < 50 mmol/L Insufficiency: 50–75 nmol/L	41
		Sufficiency: >75 nmol/L	28
		25(OH) D levels: < 75 nmol/L	64
		'Non-deficiency': > 50 nmol/L	69
Hebbar 2014	61	Deficiency: ≤ 10 ng/mL	10
		Insufficiency: 10 to 20 ng/mL	27
		Sufficiency: $\geq 20 \text{ ng/mL}$	24
Rey 2014	156	Deficiency: < 20 ng/mL	46
NCy 2014	130	$25(OH)D$ levels: ≥ 20 ng/mL	46
		25(01)D ievels 20 lig/life	110
Ahmed 2014	50	Deficiency: <50 nmol/L	15
Basha 2014	81	Deficiency: <50 nmol/L	53
		Insufficiency: <75 nmol/L	14
		Normal level: >75 nmol/L	14
Sakka 2014	96	Severe deficiency: 0–5 ng/mL	29
		Deficiency: 5–15 ng/mL	49
		Insufficiency: 15–20 ng/mL	11
Cayir 2014	88	Sufficiency: 20–100 ng/mL Normal levels: 20 ng/mL	7 38
Cayli 2014	00	Insufficiency: 15-20ng/mL	<u></u>
		Deficiency: <15ng/mL	32
Binks 2014	74	25(OH) D levels: < 50 nmol/L	11
Madden 2012	511	25(OH) D levels: < 10 ng/mL	36
		25(OH) D levels: 10-19.9 ng/mL	169
		Deficiency: < 20 ng/ml	205
		Insufficiency: <30 ng/mL	364
Rippel 2012	316	Deficiency: < 50 nmol/L	109
		'Normal levels': ≥50 nmol/L	207
Madden 2012	511	25(OH)D levels: < 10 ng/mL	36
11111111111111		25(OH)D levels: 10-19.9 ng/mL	169
		Deficiency: < 20 ng/mL	205
		Insufficiency: <30 ng/mL	364
McNally 2012	326	Deficiency: < 50 nmol/L	225
		25(OH)D levels: 50 to 75 nmol/L	75
		'Not deficient': > 50 nmol/L	101
Inamo 2011	28	25(OH)D levels: < 10 ng/mL	4
		25(OH)D levels: < 15 ng/mL	8
		25(OH)D levels: < 25 ng/mL	12
D 1 2010		25(OH)D levels: < 40 ng/mL	28
Roth 2010	25	25(OH)D levels: < 40 nmol/L	21
Banajeh 2009 Karatekin 2009	79 25	Deficiency: <30 nmol/L Serum 25(OH)D <10 (deficiency)	29 19
Karatekin 2009	2.3	Serum 25(OH)D 11 to 20 (deficiency)	4
		Serum 25(OH)D 21 to 32 (insufficiency)	4
		Serum 25(OH)D 32 to 100 (sufficiency)	1
Roth 2009	64	<40 nmol/L	3
Wayse 2004	80	Plasma 25(OH)D3 > 22.5 nmol/L	26
2		Plasma $25(OH)D3 > 50 \text{ nmol/L}$	4
Mathias 2017	41	25(OH)D < 20 ng/ml	28

2				
3			25(OH)D < 30 ng/ml	36
4	Dhandai 2018	60	Deficiency: < 20 ng/ml	38
5	Ditalidar 2010		Insufficiency: <29 ng/ml	17
			Optimum: 30-50 ng/ml	5
6	Vo 2018	1016	25(OH)D < 20 ng/ml	298
7			20-29.9 ng/ml	352
8	L: 2010	707	>=30 ng/ml	366
9	Li 2018	797	Severe deficiency: < 10 ng/mL Deficiency: 10–20 ng/mL	159 286
10			Insufficiency: 20–30 ng/mL	223
11			Sufficiency: > 30 ng/mL	127
12	25(OH)D in nmol/L =	= 25(OH)D in ng/mL multiplied		
14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59				12
60		For peer review only - http:/	//bmjopen.bmj.com/site/about/guidelines.xhtml	

Page 47 of 83

BMJ Open

30 sepsis 100 neonatal sepsis 46	Deficiency: <20 ng/mL Sufficiency: >=20 ng/mL Severe deficiency (group 1) <5 ng/mL. Insufficiency (group 2): 5 to 15 ng/mL Sufficiency (group 3) ≥15 ng/mL	20 10 63 24
100 neonatal sepsis	Severe deficiency (group 1) <5 ng/mL. Insufficiency (group2): 5 to 15 ng/mL	63 24
neonatal sepsis	Insufficiency (group2): 5 to 15 ng/mL	24
	Sufficiency (group 3) >15 ng/mL	
16		13
40	Serious deficiency: < 30 nmol/L	20
sepsis	Insufficiency: 30-75 nmol/L	18
	Adequate levels >75 nmol/L	8
43 septic shock	Severe deficiency: serum 25 (OH) D <10 ng/mL	31
100	25(OH)D <20 ng/mL	84
sepsis		26
124	Deficiency: <50nmol/L	63
sepsis	Insufficiency: 50-75 nmol/L	31
Γ	<75, insufficient + deficient	94
Г	Sufficiency: >75 nmol/L	30
10	Deficiency: < 20 ng/ml	7
sepsis intraabdominal	Normal levels: > 20 ng/mL	3
16		8
shock		8
35		32
culture positive sepsis		3
		32
		14
11	25(OH)D <20 ng/mL	9
positive blood culture		2
17		14
shock and septicaemia		3
40		28
suspected sepsis		7
		5
9		4
-		5
		17
÷ •		13
-		
		33
		15
		28
	25(OH)D < 30 ng/ml	36
	Deficiency: < 20 ng/ml	38
		17
r	Optimum: 30-50 ng/ml	5
	septic shock 100 sepsis 124 sepsis 124 sepsis 10 sepsis intraabdominal 16 shock 35 culture positive sepsis 46 culture positive sepsis and late-onset sepsis 11 positive blood culture 17 shock and septicaemia	septic shock $25(OH)D < 20 ng/mL10025(OH)D > = 20 ng/mL124Deficiency: < 50 mmol/L$

1	
2 3	
3	
4	
5	
6	
7	
8	
9	
1	012345
1	1
1	2
1	3
1	4
1	5
1	6
1	7
1	/
1	ð
1	9
2	0
2	1
2	2
2	3 4 5 6 7 8 9 0 1 2 3 4 5 6 7 8 9 0 1 2 3
2	4
2	5
2	6
2	7
2	8
2	9
3	0
2	1
ר כ	י ר
כ ר	2 3
כ ר	כ ₄
3	4
3	3 4 5 6 7
3	6
3	
	9
	0
4	
4	_
4	3
	4
4	
4	
4	
4	

Study Roth 2009 Roth 2010 Say 2017	Threshold used by study
Roth 2010	< 40 nmol/L
	< 40 nmol/L
Say 2017	<=15 ng/mL (37.4 nmol/L)
Inamo 2011	<=15 ng/mL (37.4 nmol/L)
Ayulo 2014	<=15 ng/mL (37.4 nmol/L)
Dinlen 2016	<=15 ng/mL (37.4 nmol/L)
Onwuneme 2015 (2)	< 30 nmol/L
Yaghmaie 2017	< 30 ng/mL (74.88 nmol/L)
El-Gamasy 2017	< 30 nmol/L
Banajeh 2009	< 30 nmol/L
Sankar 2017	<= 10 ng/mL (24.9 nmol/L)
Cetinkaya 2015	<= 10 ng/mL (24.9 nmol/L)
25(OH) D values nmol/L =	= ng/mL * 2.496

Study	Design	Sample size	Characteristics of pediatric population	Country	Reasons for exclusion of paper
Seliem 2016	Hospital-based case-control	Cases, n= 30 Controls, n= 30	Cases: group 1, full-term neonates with EOS and their mothers. Controls, group 2: 30 full-term healthy neonates and their mothers with no clinical or laboratory evidence of sepsis.	Egypt	Requested data without reply or data not available
Gamal 2017	Case-control	Cases, n= 50 Control, n= 30	Cases: neonates with early onset neonatal sepsis that occurred at <72 hours Controls: Age and sex healthy neonates with no prenatal risk factor for early neonatal sepsis enrolled in the study as a control group.	Egypt	Requested data without reply or data not available
Aydemir 2014	Hospital-based case control	Cases, n=40 Controls, n= 20	Cases: children with sepsis between 1 and 16 years old Controls: children without sepsis	Turkey	Requested data without reply or data not available
Garg 2016	Hospital-based case-control	Cases, n= 40 Controls, n= 40	Cases: children from 6 months to 5 years of age admitted or attending OPD in department of Pediatrics. Controls: children receiving care at the Hospital's ambulatory, emergency or in-patient units and presenting with non-respiratory complaints also not having any clinical indication of vitamin D deficiency.	India	Requested data without reply or data not available

Of Ill-parter and having any clinical indication of vitamin is denoted by

Study	Design	Number of cases (controls, where appropriate)	Characteristics of population	Country and setting	Vitamin D thresholds as defined by the study	Quality score (NOS)
Asilioglu 2017	Historical cohort (single centre)	250	Cases: aged 1 month to ≤ 18 years	Turkey, PICU	Deficiency: <20 ng/mL	7
Halwany 2017	Cohort (single centre)		Cases: children aged >1 month to ≤ 5 years	Egypt, PICU	Deficiency: <20 ng/ml Insufficiency: 20-29.9 ng/ml "Normal" levels: 30 ng/ml	6
Hurwitz 2017	Prospective cohort (single centre)	90	Cases: aged <5 years hospitalized with LRTI and RSV and/or hMPV	USA, PICU	Deficiency: <20 ng/mL	6
Garcia-Soler 2017	Cohort (single centre)	340	Cases: aged 6 months to 17 years Critically ill with various conditions	Spain, PICU	Deficient: <20 ng/mL Insufficiency: 20-30 ng/mL 25(OH)D levels: 30-40 ng/mL Optimal levels >40 ng/mL	7
Badawi 2017	Cohort (single centre)	88	Cases: 1 month to 12 years	Egypt, PICU	Deficiency: < 50nmol/l, Severe deficiency: <30 nmol/l	8
Jia 2017	Hospital- based case- control (single centre)	110 (110)	Cases: infants (< 1 year of age) with ALRTI Controls: Healthy from similar areas attending the hospital for vaccination during study period	China, PICU	Severe deficiency: <10 ng/ml Deficiency: 10-20 ng/ml Insufficiency: 21-30 ng/ml Sufficiency: >30 ng/ml	7
Yaghmaie 2017	Cross sectional (single centre)	82	Cases: hospitalized in PICU	Iran, PICU	Deficiency: <30 ng/ml	4
Say 2017	Case- control (single centre)	100 (13)	Cases: premature infants less than 37 weeks diagnosed with early or late -onset neonatal sepsis Controls: From same population of neonates with sepsis but not vitamin D deficient	Turkey, NICU	Severe deficiency (group 1) <5 ng/mL. Insufficiency (group2): 5 to 15 ng/mL Sufficiency (group 3) ≥15 ng/mL	6

Page 51 of 83

El-Gamasy 2017	Cohort (single centre)	80 (20)	Cases: 3 months to 12 years hospitalized with acute kidney injury Controls: completely healthy subjects	Egypt, PICU	Seriously deficient: < 30 nmol/L Insufficient: 30-75 nmol/L Adequate >75 nmol/L	7
Sankar 2017	Cohort (single centre)	43	Cases: <=17 years of age	India, PICU	Severe vitamin D deficiency: serum 25 (OH) D <10 ng/mL	8
Shah 2016	Cohort (single centre)	154	Cases: aged between 1 month and 15 years	India, PICU	Deficiency: <20 μg/mL	6
Ponnarmeni 2016	Cohort (single centre)	124 (338)	Cases: aged 1–12 years admitted with a diagnosis of sepsis Controls: from previous prospective study, apparently healthy children of upper socioeconomic status who attended the out-patient department for immunization or with minor ailments	India, PICU	Deficiency: < 50 nmol/L Insufficiency: 50-75 nmol/L Sufficiency: > 75 nmol/L	6
Sankar 2016	Cohort (single centre)	101	Cases: aged 1 month to 17 years	India, PICU	Deficiency: ≤20 ng/ml Severe deficiency: <15 ng/mL	8
Bustos 2016	Cohort (single centre)	90	Cases: critically ill, greater than 37 weeks and less than 15 years of age	Chile, PICU	Deficiency: < 20 ng/ml Normal levels: > 20 ng/mL	7
Ebenezer 2016	Cohort (single centre)	52	Cases: <18 years of age; medical and surgical diagnoses	India, PICU	Deficiency: < 20 ng/ml Insufficiency: 20–30 ng/ml Normal levels: ≥ 20 ng/L	6
Elmoneim 2016	Cohort (single centre)	30	Cases: aged less than 14 years Controls: with "normal" vitamin D levels	Saudi Arabia, PICU	Deficiency: < 20ng/ml Insufficiency: 20-30 ng/mL Normal: > 30 ng/mL	7
Jat 2016	Hospital- based case- control (single centre)	50 (50)	Cases: 1 month to 12 years of age admitted with pneumonia Controls: admitted for reasons other than respiratory symptoms, required blood sampling	India, PICU	Deficiency: < 20 ng/ml Insufficiency: 20-30 ng/ml Sufficiency: >= 30 ng/ml	8
Narang 2016	Hospital- based case- control (single centre)	50 (50)	Cases: 2 months to 5 years of age admitted as in-patients or seen in the outpatient department with ALRI Controls: healthy, same age group, attending outpatients' service for immunization or admitted for minor conditions other than ALRI	India, PICU	Severe deficiency: < 20ng/ml	6

Dinlen 2016	Hospital- based case- control (single centre)	30 (30)	Cases: term neonates with ALRI Controls: healthy neonates, same age as the study group.	Turkey, NICU	Deficient: <= 15 ng/mL Severe deficiency: <= 5 ng/mL	6
Lopez 2016	Prospective cohort (multi centre)	347	Cases: 0 to >48 months admitted to hospital with ALRI prospectively recruited through the GENDRES (GENetic,vitamin D and RESpiratory infections research network)	Spain, PICU	25-OHD levels: <10 ng/mL 25-OHD levels: 10-20 ng/mL 25-OHD levels: 20-30 ng/mL	8
Alvarez 2016	Cross- sectional (single centre)	50	Cases: patients aged 0 to 18 years	USA, PICU	25(OH)D < 20 ng/mL 25(OH)D < 30 ng/mL	6
Onwuneme 2015 (1)	Cohort (single centre)	120 (30)	Cases: with suspected sepsis (<12 years old) Controls: paediatric controls admitted for elective day case surgery during the same study period and were not suspected of having sepsis	Ireland , PICU	25(OH) D levels: <50 nmol/L 25(OH) D levels: ≥50 nmol/L	8
Onwuneme 2015 (2)	Cohort (single centre)	94	Cases: preterm infants <32 weeks gestation	Ireland, NICU	Deficiency: < 30 nmol/L Sufficiency: ≥ 30 nmol/L	8
Prasad 2015	Cohort (single centre)	80	Cases: 2 months to 12 years old	India, PICU	Deficiency: < 20 ng/ml Sufficient: ≥ 20 ng/mL	7
Moreno-Solis 2015	Hospital- based case- control (single centre)	48 (30)	Cases: aged 1–11 months with acute bronchiolitis Controls: healthy, <12 months, admitted to the outpatient clinic without respiratory symptoms or history of hospitalization for bronchiolitis or wheezing	Spain, PICU	Deficiency: < 20 ng/ml Insufficiency: 21–29 ng/ml Sufficiency: ≥ 30 ng/ml	6
Alonso 2015	Cross sectional (single centre)	288	Cases: aged 1 month to 13 years	Spain, PICU	Deficient: < 20 ng/ml and < 10 ng/ml	5
Korwutthikulrangsri 2015	Cohort (single centre)	32 (36)	Cases: requiring PICU admission Controls: Healthy, enrolled during the same period of time and served as the control group (age in months)	Thailand, PICU	Deficiency: < 20 ng/mLl Insufficiency: 20-29.9 ng/ml Sufficiency: ≥ 30 ng/mL	7
Khakshour 2015	Case- control	37 (53)	Cases: below 5 years of age and suffering from respiratory infections Controls: those who were not suffering from respiratory infections	Iran, PICU	Deficiency: < 20 ng/mL	5

Page 53 of 83

Cizmeci 2015	Case- control (single centre)	40 (43)	Cases: infants with suspected early-onset neonatal sepsis. Controls: For each newborn of group 1, one healthy infant selected as a control	Turkey, NICU	Deficiency: $\leq 20 \text{ ng/ml}$ Insufficiency: $21-29$ ng/ml Normal levels: ≥ 30 ng/ml	
Cetinkaya 2015	Hospital- based case- control (single centre)	50 (50)	Cases: term infants with clinically suspected (probable) early infection (early-onset sepsis) within the first 3 postnatal days of life and were >37 weeks of gestational age Controls: healthy infants with no signs of clinical/laboratory infection	Turkey, NICU	Severe deficiency: <10 ng ml ⁻¹ Insufficiency: 11 to 32 ng ml ⁻¹ Adequacy: 32 to 100 ng ml ⁻¹	6
Ayulo 2014	Cohort (single centre)	216	Cases: between the ages of 1 and 21 years	Spain, PICU	Deficient: < 15 ng/ml Insufficient: 15-29 ng/mL Sufficient: ≥ 30 ng/mL	7
Dayal 2014	Cohort (single centre)	92	Cases: Children aged 3 months to 12 years	India, PICU	Deficiency: < 50 nmol/L Insufficiency: 50–75 nmol/L Sufficiency: > 75 nmol/L 25(OH) D levels: < 75 nmol/L	e
Hebbar 2014	Cohort (single centre)	61 (46)	Cases: children 0 to 18 years Controls: patients recruited among children in the magnetic resonance imaging suite.	USA, PICU	Deficient: $\leq 10 \text{ ng/ml}$ Insufficient: 10 to 20 ng/ml Sufficient: $\geq 20 \text{ ng/mL}$	6
Rey 2014	Cohort (single centre)	156 (289)	Cases: heterogeneous group of critically ill children aged <16 years Control group for comparison: population of healthy children	Spain, PICU	Deficient: < 20 ng/ml	Ĩ
Ahmed 2014	Hospital- based case- control (single centre)	50 (50)	Cases: aged 2–60 months hospitalized with ALRI Controls: age-matched with cases within 1 or 2 months, attending well-child clinics or general clinics without evidence of respiratory infection or admitted to the hospital for elective surgery	Africa, PICU	Deficiency: <50 nmol/L	٤
Basha 2014	Hospital- based case- control (single centre)	81 (89)	Cases: under 5 years old with severe pneumonia selected from the inpatient departments and emergency units of the hospital Controls: healthy, selected from the outpatient surgical clinics of the hospital during their visit for umbilical or inguinal hernia repair and not suffering	Egypt, PICU	Deficiency: < 50 nmol/L Insufficiency: < 75 nmol/L Sufficiency: > 75 nmol/L	

י ר	
2	
3	
4	
5	
6	
7	
8	
9	
10	
11	
12	
12	
13	
14	
15	
16	
3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 22 33 34 35 36 37 8	
18	
19	
20	
21	
22	
23	
24	
25	
26	
20	
27	
20	
29	
30	
31	
32	
33	
34	
35	
36	
37	
38	
39	
40	
40	
41	
42 43	
44	
45	
46	
47	

			from upper or lower respiratory infections			
Sakka 2014	Population based case- control (single centre)	96 (96)	Cases: <2 years old with ALRI, 48 diagnosed with pneumonia and 48 with bronchiolitis Controls: age and sex matched with no respiratory symptoms or signs from the Health office	Egypt, PICU	Severe deficiency: 0–5 ng/mL Deficiency: 5– 15 ng/mL Insufficiency: 15– 20 ng/mL Sufficiency: 20–100 ng/mL	8
Cayir 2014	Hospital- based case- control (single centre)	88 (81)	Cases: 1 to 13 years diagnosed with acute otitis media Controls: Healthy same age range	Turkey, PICU	Normal levels: 20 ng/mL Insufficiency: 15- 20ng/mL Deficiency: <15ng/mL	7
Binks 2014	Cross- sectional	74	Cases: aged <3 years admitted with acute lower respiratory infections (ALRIs) or other conditions	Australia, PICU	25(OH) D levels: < 50 nmol/L	6
Madden 2012	Cohort (single centre)	511	Cases: less than 21 years old	USA, PICU	25(OH) D levels: < 10 ng/mL 25(OH) D levels: 10- 19.9 ng/mL Deficiency: < 20 ng/ml Insufficiency: < 30 ng/mL	8
Rippel 2012	Cohort (single centre)	316	Cases: children aged 16.5 (3.1–75.2) months	Australia, PICU	Deficiency: < 50 nmol/L "Normal" levels: ≥ 50 nmol/L	8
McNally 2012	Cohort (multi- centre)	326	Cases: Newborn to 17 years of age	Canada, PICUs	Deficiency: < 50 nmol/L 25(OH) D levels: 50 to 75 nmol/L	7
Inamo 2011	Cohort (single centre)	28	Cases: between 1 and 48 months hospitalized with ALRI, 26 diagnosed with bronchiolitis and two as having pneumonia	Japan, PICU	Deficiency: ≤ 15ng/ml Severe deficiency: ≤ 5ng/mL	6
Roth 2010	Hospital- based case- control (single centre)	25 (25)	Cases: 1–18 months hospitalized with ALRI Controls: selected by population-based sampling. aged 1–23 months, and matched to cases on age (±2 months) and sex	Bangladesh, PICU	Deficiency: < 40 nmol/L	8
Banajeh 2009	Prospective cohort (single centre)	79	Cases: 2–59 months with WHO-defined very severe community acquired (VSP) pneumonia	Iran, PICU	Deficiency: < 30 nmol/L	7
Karatekin 2009	Hospital- based case-	25 (15)	Cases: newborns with acute respiratory infections	Turkey, NICU	Deficiency: < 20 ng/ml	6

	control, (single centre)		Controls: healthy, age matched from outpatients' service where they went for immunization.			
Roth 2009	Hospital- based case- control (single centre)	64 (65)	Cases: aged 1-25 months admitted with ALRI Controls: aged 1-25 months undergoing elective surgery, no history of hospitalization for ALRI	Canada, PICU	Deficiency: < 40 nmol/L	7
Wayse 2004	Hospital- based case- control, (single centre)	80 (70)	Cases: < 5 years with severe ALRI Controls: healthy, attending outpatients service for immunization	India, PICU	Deficiency: Plasma 25(OH)D3 < 50 nmol/L	6
Mathias 2017	Prospective cohort (single centre)	41	Cases: less than 18 years admitted with diagnosis of sepsis, severe sepsis or septic shock.	USA, PICU	25(OH)D levels < 20 ng/ml 25(OH)D levels <30 ng/ml	6
Dhandai 2018	Cohort (multi- centre)	60 (60)	Cases: neonates admitted with late-onset sepsis (LOS) Controls: neonates admitted during same period with clinically significant physiological hyperbilirubinaemia (without sepsis)	India, NICU	Deficiency: < 20 ng/ml Insufficiency: <29 ng/ml Optimum: 30-50 ng/ml	7
Vo 2018	Prospective cohort (multi- centre)	1016	Cases: Infants less than twelve months old hospitalized for bronchiolitis	USA, PICU	25(OH)D < 20 ng/ml 25(OH)D: 20-29.9 ng/ml 25(OH)D >= 30 ng/ml	8
Li 2018	Case- control (single- centre)	797 (785)	Cases: children with pneumonia or pneumonia-induced sepsis group	China, PICU	Severe deficiency: < 10 ng/mL Deficiency: 10–20 ng/mL Insufficiency: 20– 30 ng/mL Sufficiency: > 30 ng/mL	8

LRTI = lower respiratory tract infection; PICU = paediatric intensive care unit; RSV = respiratory syncytial virus; ALRI = acute lower respiratory infection; WHO = World Health Organization; VSP = very severe community acquired pneumonia; NICU = neonatal intensive care unit.

2	
3	
4	
5	
6	
7	
8	
9	
10	
11	
12	
13	
14	
15	
16	
17	
18	
19	
4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	
21	
22	
23	
24	
23 24 25 26 27 28	
26	
27	
28	
29	
30 21	
31 22	
32 33	
33 34	
34	
34 35 36 37 38	
37	
38	
39	
40	
41	
42	
43	
44	
45	
46	
47	

Study	Objectives/aims of study			
Madden 2012	Prevalence of vitamin D deficiency in critically ill children and factors influencing admission 25-hydroxyvitamin D (25(OH)D) levels			
Lopez 2016	Role of Vitamin D in Children hospitalized with Lower Tract Acute Respiratory Infections	25-hydroxyvitamin D levels of study population below normal range. Correlation of higher disease severity with lower levels of 25-hydroxyvitamin D.		
Garcia-Soler 2017	Prevalence and risks factors of vitamin D deficiency, as well as its relationship with length of PICU stay morbidity and mortality in a PICU.	Vitamin D deficiency is frequent in paediatric critical patients. It also has an association with higher severity scores, season of year and parental educationa attainment. Vitamin D levels associated with various laboratory parameters of SIRS. Vitamir D deficiency associated with increased risk of morbidity and mortality Inconclusive findings on its association with PICU length of stay were inconclusive		
McNally 2012	Prevalence of vitamin D deficiency, risk factors and potential association with clinically relevant outcomes in critically ill children in Canada.	Most of critically ill children vitamin D deficient at PICU admission. Lower 25(OH) D levels associated with increased catecholamine requirements, fluid bolus administration, hypocalcemia, and longer PICU admission.		
Rippel 2012	Prevalence of hypovitaminosis D and association with outcome in critically ill children requiring admitted in intensive care.	Hypovitaminosis D is frequent in critically ill children in PICU, especially in infants and children with heart disease. Hypovitaminosis D associated with hypocalcemia in non-cardiac population, and increased need for calcium replacement in the cardiac population. No association between vitamin D status and survival or PICU length of stay. Strong association with early postoperative inotropic needs in the cardiac population.		
Alonso 2015	Investigate relationship of serum 25-hydroxyvitamin D concentrations with serum parathyroid hormone (PTH) levels, body mass index (BMI), and environmental factors in a population of Caucasian children living at latitude 43°N.	Results doubt the assumption that a serum 25OH D threshold indicates vitamin D deficiency in children.		
Asilioglu 2017	Measure occurrence of VDD in critically ill children. Assess determinants of vitamin D status and compare vitamin D deficient and sufficient cases in respect of severity of illness.	Hypovitaminosis D occurrence high in critically ill children and associated with higher vasopressor requirement. Not associated with other markers of illness severity including mortality.		
Ayulo 2014	Prevalence of vitamin D deficiency among children in PICU	Vitamin D deficiency common. No significant correlation between disease severity and vitamin D levels levels of vitamin D. Mortality associated with vitamin D levels		
Rey 2014	Identify prevalence of 25 hydroxivitamin D or 25(OH) vitamin D deficiency on pediatric intensive care unit (PICU) admission, and if associated with increased prediction of mortality risk scores.	Hypovitaminosis D incidence high in PICU patients. Hypovitaminosis D not associated with higher prediction of risk mortality scores.		
Shah 2016	Determine prevalence of vitamin D deficiency in critically ill children its association with illness severity, parathyroid response and clinical outcomes.	High prevalence of vitamin D deficiency. Parathyroid gland response secondary vitamin D deficiency or hypocalcemia impaired in critically ill.		
Ponnarmeni 2016	Vitamin D deficiency in critically ill children with sepsis admitted to PICU and its association with: mortality, length of stay, illness severity, requirement for ventilation and catecholamines	High prevalence of vitamin D deficiency No significant association between vitamin D deficiency and other outcomes such as mortality		
Onwuneme 2015 (1)	Assess vitamin D status, and its determinants, in chidren with suspected sepsis admitted to PICU. Also investigated association between vitamin D status and clinical outcomes.	Children admitted to the PICU with suspected sepsis lower 25OH D compared to controls. Inadequate 25 OH D levels associated with confirmed sepsis and poor outcomes.		
Jia 2017	Association of vitamin D with ALRTI in Chinese infants	Lowered plasma level of 25-OH Vitamin D makes children susceptible to ALRTI.		
Halwany 2017	Frequency of vitamin D deficiency in critically ill pediatric intensive care unit [PICU] patients and relation to state of serum 25(OH) D to disease severity.	High prevalence of vitamin D deficiency in critically ill children. Negative correlation of Vitamin D level with PELOD score. Recommend screening of critically ill children for vitamin D deficiency to restore their serum levels.		

BMJ Open

1	
2 3	
4	
5	
6	
6 7	
8	
9	
10	
11	
12	
13	
14	
15	
16	
16 17	
18	
19	
20	
20	
27	
20 21 22 23	
24	
25	
26	
27	
28	
29	
30	
31	
32	
33	
34	
35	
36	
37	
38	
39	
40	
41	
42	
43	
44	
45	
46	
47	

Sankar 2016	Prevalence of vitamin D deficiency on admission and examine association with length of ICU stay	High prevalence of vitamin D deficiency. Vitamin D deficient children with longer ICU stay duration or mortality
Say 2017	Evaluate effects of low vitamin D levels in cord blood on neonatal sepsis in preterm infants.	No significant relationship between the cord blood vitamin D levels and the risk of neonatal sepsis in premature infants.
Sakka 2014	Determine the relation between vitamin D deficiency, anemia and the severity of ALRTIs in hospitalized children.	Vitamin D deficiency, low BMI, low hemoglobin level, rachitic signs were risk factors for the severity of ALRTIS.
Onwuneme2015 (2)	Investigate the association between serum 25-hydroxyvitamin D (250HD) levels and outcomes in preterm infants (<32 weeks gestation).	High prevalence of low 25OHD. Association between vitamin D status and acute respiratory morbidity in preterm infants after birth. In none of the following outcomes was the difference statistically significant: surfactant use, inotrope requirement, RDS, pneumothorax, pulmonary hemorrhage, chronic lung disease, sepsis, retinopathy of prematurity, intraventricular hemorrhage, periventricular leucomalacia, patent ductus arteriosus, and mortality
Dayal 2014	Prevalence of vitamin D deficiency Association of serum vitamin D levels with duration of stay in hospital, mortality and requirement of ventilation	Reduced serum vitamin D levels in children
Bustos 2016	Determine prevalence of vitamin D deficiency and its association with other clinically relevant outcomes in children admitted to Paediatric Intensive Care Unit	Vitamin D deficiency was prevalent in critically ill children and associated with adverse clinical outcomes.
Hurwitz 2017	Measure retinol binding protein and vitamin D in children aged <5 years hospitalized with lower respiratory tract infection and respiratory syncytial virus and/or human meta pneumovirus detections	Low vitamin levels in 50% of the children and associated with significantly elevated risk of the need for intensive care unit admission and invasive mechanical ventilation.
Cayir 2014	Investigate the relationship between Vitamin D deficiency and acute otitis media infection	Serum 25-hydroxy vitamin D levels significantly lower in children with acute otitis media compared to the controls. Vitamin D deficiency plays a role in otitis media infection.
Badawi 2017	Investigated if VDD is related to higher severity scores and organ dysfunction. Primary objective of study was to estimate the prevalence of VDD in a group of critically ill children, and secondary objectives was to correlate vitamin D status with pediatric logistic organ dysfunction (PELOD) and pediatric risk ofmortality III (PRISM III) scores.	VDD prevalence was reported in about half of the critically ill patients, and it was observed to be related to multiple organ dysfunctions and rapid clinical deterioration.
Yaghmaie 2017	Investigate relation of vitamin D deficiency with potential demographic and clinical factors.	Vitamin D deficiency among paediatric intensive care unit patients similar to western countries, also with similar age and BMI distribution. Significant relation observed between age and serum level of vitamin D.
Basha 2014	Aimed to evaluate vitamin D status as a risk factor for severe pneumonia in Egyptian hospitalized children under 5 years	Significant association between vitamin D deficiency and severe pneumonia in Egyptian children below 5 years
Prasad 2015	Prevalence of vitamin D deficiency in critically ill children and association with illness severity& other outcomes	High prevalence of vitamin D deficiency in critically ill children and association with PRISM III scores in a developing country. Groups did not differ in terms of PICU stay, duration of hospital stay, culture positivity, biochemical parameters (serum calcium, serum phosphate), need of ventilation or steroids, presence of coagulopathy and mortality.
Wayse 2004	If vitamin D deficiency in Indian children under 5 years old of age is risk factor for severe acute lower respiratory infection (ALRI).	Subclinical vitamin D deficiency & nonexclusive breastfeeding in four first months of life found to be significant risk factors for severe ALRI in Indian children.
El-Gamasy 2017	Assess serum 25 (OH)D level in critically ill paediatric patients with AKI at PED of Tanta University Emergency Hospital (TUEH) within the first 24 hours of admission and evaluate its correlation with duration of hospital stay and mortality outcome.	Vitamin D deficiency associated with higher incidence of sepsis and mortality.

Banajeh 2009	Determine if rickets and VDD predict the outcomes in very severe pneumonia (VSP).	In WHO-defined VSP, nutritional rickets was strongly associated with a reduce successful treatment outcome, and VDD was a significant and independen predictor of reduced circulating PMNs and persistent hypoxemia.
Binks 2014	Aimed to determine prevalence of vitamin D insufficiency among children hospitalised with ALRI in the Northern Territory.	Vitamin D insufficiency was observed in about one-third of these hospitalise children. Children hospitalised with an ALRI less likely to have vitamin insufficiency compared with children hospitalised for other condition (predominantly gastroenteritis).
Roth 2009	Test the hypothesis that vitamin D status is associated with the risk of ALRI in Canadian children (1 month to 2 years old)	Among children aged 1 month to 2 years, vitamin D status not associated with ALR requiring hospitalization
Hebbar 2014	Prevalence of vitamin D insufficiency and relationship between vitamin D levels infection and innate immunity	High prevalence of vitamin D deficiency Serum vitamin D levels - no correlation with illness severity score
Ebenezer 2016	Determine vitamin D status and association with outcomes	Vitamin D deficiency common among pediatric patients No association between vitamin D status and admission and mortality such higher mortality and/or longer PICU stay Deficiency associated with mechanical ventilation severity of illness, vasopress need
Narang 2016	Identify an effective nutritional agent that reduces the need for antibiotics, duration of pneumonia and length of hospitalization would be highly cost-beneficial.	Severe vitamin D deficiency (<20 ng/ml), nonexclusive breastfeeding in the fin six months of life, inadequate sun exposure found to be significant risk factors f ALRTI in Indian children.
Alvarez 2016	Study aimed to investigate relationship between vitamin D status and plasma markers of lutathione (GSH) and cysteine (Cys) redox and immunity in critically ill children	Vitamin D sufficiency was associated with more reduced plasma hCySS, indicati- of lower oxidative stress, in critically ill children. Plasma GSH, GSSG, an glutamine, however, were lower in the vitamin D sufficient group. Vitamin D ro in maintaining redox status during pediatric critical illness requires further study.
Cetinkaya 2015	Evaluate the effect of vitamin D levels on early-onset sepsis (EOS) in term infants	Lower maternal and neonatal 25-OHD levels associated with EOS. Suggest the adequate vitamin D supplementation during pregnancy may be helpful to preve EOS in term neonates.
Ahmed 2014	Examine relationship between vitamin D status and hospitalization for ALRTI in Nigerian children.	ALRTI not associated with vitamin D status, but associated with less exposure sunlight. Exposure to sunlight & vitamin D supplementation contributed to vitam D status in this population.
Jat 2016	Evaluate Vitamin D levels and its correlation with severity and outcome of pneumonia in children.	Majority (86.4%) of children were vitamin D deficient. Vitamin D levels we found different in cases and controls and were not related to severity and outcom of pneumonia.
Sankar 2017	Evaluate association of severe vitamin D deficiency with clinically important outcomes in children with septic shock.	Prevalence of severe vitamin D deficiency is high in children with septic sho admitted to pediatric intensive care unit. Severe vitamin D deficiency at admissi seems to be associated with lower rates of shock reversal at 24 hours of ICU stay
Cizmeci 2015	Investigate if neonates with early-onset neonatal sepsis (EONS) had lower levels of vitamin D	Cord-blood 25(OH) D levels of neonates with EONS significantly lower than th of the healthy controls, and a low level of cord-blood vitamin D was found to associated with an increased risk of EONS. Further studies are warranted to confir this association.
Khakshour 2015	Clarify the association between vitamin D deficiency and acute respiratory infection in children below age 5 years.	The group of children with respiratory disorders, 9 (42.9%) exhibited vitamin deficiency. No meaningful statistical relation vitamin D deficiency with act respiratory infections (p>0.05)
Korwutthikulrangsri 2015	Determine vitamin D status in critically ill children and its relationship with adrenal function	Higher prevalence of vitamin D deficiency in critically ill children in comparise to controls. Patients vitamin D deficiency had higher median (IQR) PRISM III sco and higher proportion of mortality than those with serum 25-OHD of equal or more than 12 ng/mL.
Elmoneim 2016	Association of the level of vitamin D on admission & length of stay in the PICU, or duration of mechanical ventilation.	High prevalence of vitamin D deficiency among PICU patients & significa association with increased LOS and need for mechanical ventilation. N significant association with mortality rate.

Page 59 of 83

 BMJ Open

Dinlen 2016	Determine the apposition between comm 25 by	Lower blood 25(OH) D levels might be associated with increased risk of ALRTI in
	Determine the association between serum 25-hydroxy vitamin D [25(OH)D] levels and acute respiratory tract infections (ALRTI) in newborns	term newborn babies. Appropriate vitamin D supplementation during pregnancy and early childhood may enhance newborns' respiratory health.
Moreno-Solis 2015	Examine prevalence of hypovitaminosis D in infants with acute bronchiolitis compared with control subjects and to evaluate the relationship between serum 25-hydroxyvitamin D (25(OH) D) and the severity of bronchiolitis.	Prevalence of hypovitaminosis D is high in Spanish infants with bronchiolitis. The severity of acute bronchiolitis increases with a decline in serum 25 (OH) D level.
Inamo 2011	Relationship between serum vitamin D concentrations and severity of ALRI in hospitalized children in Japan.	Significantly more children with ALRI that required supplementary oxygen and ventilator management were vitamin D deficient. Findings suggest: immunomodulatory properties of vitamin D may influence the severity of ALRI.
Karatekin 2009	Association of serum 25-hydroxy vitamin D concentrations in newborns with acute lower respiratory infection (ALRI) and without clinical signs of rickets, and their mothers	Newborns with subclinical vitamin D deficiency may have an increased risk of suffering from ALRI. Strong positive correlation between newborns' and mothers' 25(OH) D concentrations indicates that adequate vitamin D supplementation of mothers should be emphasized during pregnancy especially in winter months.
Roth 2010	Investigate association between vitamin D status and ALRI	Vitamin D status associated with ALRI in early childhood. Randomized trials needed to establish if interventions to improve vitamin D status could reduce burden of ALRI in early childhood.
Mathias 2017	Determination of association of 25(OH)D with cathelicidin and DBP (D binding protein) in children with sepsis	No association between vitamin D and cathelicidin or DBP (D binding protein) levels
Dhandai 2018	Assess vitamin D deficiency as possible risk factor for late-onset sepsis in term and late preterm neonates	Vitamin D deficient neonates are at greater risk for late onset sepsis compared to those with sufficient vitamin D levels
Vo 2018	Investigate the association between circulating 25-hydroxyvitamin D status upon admission and disease severity in infants hospitalized for bronchiolitis. Also, to determine if the association differs by the form of 25(OH)D (total, bioavailable or free 25 (OH) D.	Infants with total 25 (OH) D < 20 ng/ml had higher risk of intensive care and longer hospital length-of-stay
Li 2018	Assess vitamin D nutritional status of children of 3 days to 14 years and investigated the relationship between community-acquired pneumonia and serum 25(OH)D level	Children with low serum 25 (OH) D levels may be at higher risk of receiving mechanical ventilation and presenting with multiple organ dysfunction. Vitamin D supplementation could be beneficial for the treatment and prevention of CAP

Assay	Paper	Total Number of studie
Radioimmunoassay	Madden 2012; Inamo 2011; Karatekin 2009; Roth 2009; Roth 2010; Sakka 2014; Moreno-Solis 2015; Khashour 2015	8
Competitive binding enzyme linked immunoassay	Basha 2014	1
Binding protein assay	Onwuneme 2015 (2)	1
Liquid chromatography-mass spectrometry	McNally 2012; Korwutthikulrangsri 2015; Binks 2014; Cetinkaya 2015; Cizmeci 2015; Asilioglu 2017; Onwuneme (1)	7
Chemiluminescence immunoassay or chemiluminescent tracer	Alonso 2015; Rey 2014; Sankar 2016; Shah 2016; Prasad 2015; Ahmed 2015; Lopez 2016; Alvarez 2016; Say 2017; Sankar 2017; Jat 2017; Mathias 2017; Li 2018	13
ELISA	Ponnarmeni 2016; Hebbar 2014; Elmoneim 2016; Narang 2016; Jia 2017; El-Gamasy 2017; Halwany 2017; Banajeh 2009; Badawi 2017	9
ELFA (enzyme linked fluorescent assay)	Bustos 2014	1
Electrochemiluminescence Immunoassay (ECLIA)	Dayal 2014, Ebenezer 2016, Garcia Soler 2017; Cayir 2014;	4
Clinical Laboratory Improvement Amendments–approved Vitamin D assay (Elecsys; Roche Diagnostics, Indianapolis, Indiana)	Hurwitz 2017	1
Commercial immunoassay lit (I RIA Diasorin UK)	Wayse 2004, Ayulo 2014,	2
Immunoassay analyzer	Rippel 2012	1
APPLIED 3200 Biosystem	Dinlen 2016	1
Not reported	Yaghmaie 2017; Dhandai 2018	2
Abbott Architect assay (Abbott, Waukegan, Illinois)	Vo 2018	1

Study	Funding	Approval of study and ethics			
Madden 2012	Reported	Children's Hospital Boston institutional review board. Informed consent obtained from family.			
Lopez 2016	Reported	Approved by the Ethical Committee of Clinical Investigation of Galicia (CEIC ref 010/015) and all of the regional ethic committees of the participant centres informed consent forms were obtained from either a parent or legal guardian for each subject before study inclusion.			
Garcia-Soler 2017	Not reported	Study protocol approved by regional research ethics committee. Obtained informed consent from family of patients. Data recorded anonymously (encrypted electronic database). Project adhered to the principles of Declaration of Helsinki and standards for good clinical practice.			
McNally 2012	Reported	Research ethics board approval for vitamin D sub study obtained from 6 centers, representing 337 of the original 389 st participants.			
Rippel 2012	Not Reported	Approved by Ethics Committee of The Royal Children's Hospital Melbourne			
Alonso 2015	Reported	Regional Ethics Committee of the Principality of Asturias			
Asilioglu 2017	Not reported	Approval of study by the Local Ethics Committee of Ondokuz Mayıs University (Samsun, Turkey).			
Ayulo 2014	Not reported	Institutional Review Board: Montefiore Medical Centre			
Rey 2014	Reported	Hospital Ethics Committee			
Shah 2016	Reported	Ethical approval obtained from Institutional ethics committee. Parents of children satisfying criteria gave written inform consent for participation of their child in the study.			
Ponnarmeni 2016	Not reported	The institution's ethics committee. Informed consent obtained			
Onwuneme 2015 (1)	Reported	Approval by ethics committees of: Children's University Hospital, Temple Street and Our Lady's Children's Hospital, Dublin, Ireland. Participants were informed and provided written consent before recruitme			
Jia 2017	Not reported	Approved by Human Ethical Committee of Affiliated Hospital of Yan'an University, Yan'an. Informed consent was taken from mothers and/or parent of infants.			
Halwany 2017	Not reported	Approval by the Medical Ethics Committee of the Faculty of Medicine, Alexandria University			
Sankar 2016	Not reported	Institutional Ethics committee. Informed consent obtained			
Say 2017	Not reported	Approval by the local Ethics Committee and informed parental consent was obtained for all infants.			
Sakka 2014	Not reported	Not reported			
Onwuneme2015 (2)	Reported	Ethics Committee of National Maternity Hospital. Informed written consent obtained from parents before recruitment			
Dayal 2014	Not reported	Ethics Committee of the Institute. Informed consent obtained.			
Bustos 2016	Reported	Comité Ético Científico del Servicio de Salud de Concepción			
Hurwitz 2017	Reported	Informed consent obtained and study protocol approved by the Institutional Review Boards at the University of Tennessee, St Jude Research Hospital, and the Centers for Disease Control and Prevention.			
Cayir 2014	Not reported	Approval from the institutional ethics committee and consent from the parents of all children in the study.			
Badawi 2017	Not reported	Children's Cairo University institutional review board approved study. Informed consent obtained from parents			
Yaghmaie 2017	Not reported	Study carried out in accordance with the Declaration of Helsinki, and the ethics committee of the Tehran University of Medical Sciences approved the protocols of the study. Records of patients' were kept confidential. Patients' consent provide			

1 2 3 4 5 6 7	
6 7	
8 9	
10 11	
12	
14 15	
12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29	
18 19	
20 21	
22 23 24	
25 26	
27 28	
29 30	
31 32	
33 34	
35	
36 37 38	
39 40	
41 42	
43 44	
45 46	
47	

		for blood sampling and vitamin D serum level was assessed from patients' files, so no invasive method or extra blood sampling was done.
Basha 2014	Not reported	Oral consent from the mothers.
Prasad 2015	Not reported	Institutional review board approved the protocol. Written informed consent obtained from parents or guardians.
Wayse 2004	Reported	Information not provided
El-Gamasy 2017	Not reported	Study approved from the Ethical Committee of the Faculty of Medicine, Tanta University. Informed verbal or written parental consents from all subjects involved in the study.
Banajeh 2009	Reported	Protocol approved and described in previous paper
Binks 2014	Reported	Testing performed after approval by the Human Research Ethics Committee of the Northern Territory Department of Health and Menzies School of Health Research
Roth 2009	Reported	Caregiver of each participant provided written informed consent and completed a questionnaire Study approved by the Human Research Ethics Board of the University of Alberta Health Sciences Faculties
Hebbar 2014	Reported	Institutional Review Boards of Emory University and Children's Healthcare Atlanta Informed consent obtained
Ebenezer 2016	Reported	Institutional Review Board (IRB), Informed consent from parents
Narang 2016	Not reported	Not reported
Alvarez 2016	Reported	Study approved by both the Emory University and Children's Healthcare of Atlanta Institutional Review Boards, and informed consent was obtained from patients' guardians prior to any study procedures
Cetinkaya 2015	Not reported	Study protocol approved by the local Ethics Committee. Informed parental consent was obtained for all infants
Ahmed 2014	Not reported	Informed written or oral consent obtained from the parents, and the study was approved by the National Hospital Abuja Ethics Committee
Jat 2016	Not reported	Ethics committee approval was taken before commencing the study. Parent's informed consent was taken before enrolling children into study.
Sankar 2017	No funding	Study approved by the institutional ethics committee.
Cizmeci 2015	Reported	Acquisition of cord-blood was approved by the local ethics committee of Fatih University Medical School.
Khakshour 2015	Not reported	Obtained informed consent from parents, data collection done using demographic questionnaire and serum level of 25-dehydroxycalcciferol was measured. Samples taken by a trained nurse at admission based on physician's orders.
Korwutthikulrangsri 2015	Not reported	Ramathibodi Hospital Ethics Committee. Written informed consent from legal guardians of all participants
Elmoneim 2016	Reported	MCH hospital Ethics Committee approved study protocol
Dinlen 2016	Not reported	Study approved by the Local Ethics Committee. All parents fully informed about this investigation as well as its aim. Written consent was obtained from all parents.
Moreno-Solis 2015	Reported	Written informed consent obtained from parents or legal guardian of all enrolled children. Protocol of study approved by the Ethics Committee before the beginning of this study.
Inamo 2011	Not reported	Ethics Committee of Nihon University Nerima-Hikarigaoka Hospital. Informed consent obtained from the parents of all patients before inclusion in the study.
Karatekin 2009	Not reported	Study approved by the Institution's Ethics Committee, and informed consent was obtained from the study participants.
Roth 2010	Reported	Approved by The Johns Hopkins Bloomberg School of Public Health Institutional Review Board and the ethics committee of the Bangladesh Institute for Child Health at the Dhaka Shishu Hospital, Bangladesh. Signed permission prior to enrolment from parents/guardians.

 BMJ Open

26.11. 2015	D 1	
Mathias 2017	Reported	The institution's Human Investigation Committee approved the study after a full board review and informed consent obtained
Dhandai 2018	Not reported	The institute's ethics committee approved the study and informed written consent had been given by their parents or guardians
Vo 2018	Reported	The institutional review boards at all participating sites approved the protocol and informed consent obtained from the infants'
		parents/legal guardians
Li 2018	Not reported	Protocols for the study and written consent approved by the ethics committee of the Capital Institute of Pediatrics at Beijing,
		China

For beer review only

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

First author, date	Age group
Wayse 2004	<5 years
Karatekin 2009	Neonates
Roth 2009	<2 years
Roth 2010	1–18 months
Inamo 2011	<4 years
Madden 2012	<21 years
Rippel 2012	16.5 (3.1 to 75.2) months
McNally 2012	Newborn to 17 years
Ayulo 2014	1 to 21 years
Dayal 2014	3 months to 12 years
Hebbar 2014	0 to 18 years
Rey 2014	<16 years
Cetinkaya 2015	>37 weeks
Onwuneme (1) 2015	<12 years
Onwuneme (2) 2015	<32 weeks gestation
Prasad 2015	2 months to 12 years
Alonso 2015	1 month to 13 years
Korwutthikulrangsri 2015	79 (61) cases; 92 (40) controls months
Cizmeci 2015	Neonates
Shah 2016	1 month to 15 years
Ponnarmeni 2016	1 to 12 years
Sankar 2016	1 month to 17 years
Bustos 2016	>37 weeks and <15 years
Ebenezer 2016	<18 years
Elmoneim 2016	<14 years
Narang 2016	2 months to 5 years
Dinlen 2016	Neonates
Lopez 2016	0 to >48 months
Alvarez 2016	0 to 18 years
Garcia-Soler 2017	6 months to 17 years
Sankar 2017	
Ahmed 2015	2 to 60 months
Cayir 2014	1 to 13 years
Say 2017	<pre></pre> <pre></pre> <pre></pre>
Asilioglu 2017	<=18 years
Basha 2014	<=18 years
	<1 year
lia 2017	
at 2017	1 month to 12 years
Yaghmaie 2017	Age range not stated
El-Gamasy 2017	3 months to 12 years
Binks 2014	<3 years
Halwany 2017	>1 month to $<= 5$ years
Badawi 2017	1 month to 12 years
Moreno-Solis 2015	1 to 11 months
Sakka 2014	<2 years
Hurwitz 2017	<5 years
Banajeh 2009	2 to 59 months
Khakshour 2015	< 5 years
Mathias 2017	<= 18 years
Dhandai 2018	Neonates
Vo 2018	< 12 months
Li 2018	3 days to 14 years

critically ill children (sorted Study	Prevalence of vitamin D deficiency (%)	Number of vitamin D deficient children	Total number of children	
Wayse 2004	95.00	76	80	
Sakka 2014	92.70	89	96	
Karatekin 2009	92.00	23	25	
Onwuneme2015 (2)	91.48	86	94	
Say 2017	87.00	87	100	
Dinlen 2016	86.70	26	30	
Cetinkaya 2015	84.00	42	50	
Jat 2016	84.00	42	50	
Roth 2010	84.00	21	25	
Prasad 2015	83.75	67	80	
Jia 2017	83.64	92	110	
Shah 2016	83.11	128	154	
Korwutthikulrangsri 2015	78.12	25	32	
Sankar 2016	74.26	75	101	
Sankar 2017	72.09	31	43	
Cizmeci 2015	70.00	28	40	
Mathias 2017	70.00	28	41	
McNally 2012	69.02	225	326	
Basha 2014	65.43	53	81	
Yaghmaie 2017	64.63	53	82	
Dhandai 2018	63.30	38	60	
Hebbar 2014	60.66	37	61	
Onwuneme 2015 (1)	59.16	71	120	
Alvarez 2016	58.00	29	50	
Cayir 2014	56.82	50	88	
Elmoneim 2016	56.67	17	30	
Narang 2016	56.00	28	50	
Li 2018	55.83	445	797	
Ponnarmeni 2016	50.81	63	124	
Asilioglu 2017	48.00	120	250	
Badawi 2017	44.30	39	88	
Garcia-Soler 2017	43.82	149	340	

BMJ Open

Page	66	of	83
------	----	----	----

Bustos 2016	43.30	39	90
Ebenezer 2016	40.38	21	52
Madden 2012	40.12	205	511
Halwany 2017	37.25	38	102
Banajeh 2009	36.71	29	79
Rippel 2012	34.49	109	316
El-Gamasy 2017	32.50	26	80
Ahmed 2014	30.00	15	50
Rey 2014	29.49	46	156
Vo 2018	29.33	298	1,016
Inamo 2011	28.50	8	28
Dayal 2014	25.00	23	92
Khakshour 2015	24.32	9	37
Lopez 2016	24.20	84	347
Alonso 2015	15.63	45	288
Ayulo 2014	15.63	61	216
Binks 2014	14.86	11	74
Moreno-Solis 2015	13.33	9	48
Hurwitz 2017	12.22	11	90
Roth 2009	4.69	3	64
		20,	

Study	Total number of patients	Total number of vitamin D deficient patients	Country, setting	Age range	Design	Quality score (NOS)
Vo 2018	1,016	298	USA, PICU	< 12 months	cohort	8
Li 2018	797	445	China, PICU	3 days to 14 years	case-control	8
Madden 2012	511	205	Boston US, PICU	< 21 years	cohort	8
Lopez 2016	347	84	Spain, hospitalised	0 to >48 months	cohort	8
Garcia-Soler 2017	340	149	Spain, PICU	6 months to 17 years	cohort	7
McNally 2012	326	225	Canada, PICU	newborn to 17 years of age	cohort	7
Rippel 2012	316	109	Australia, PICU	16.5 (3.1–75.2) months	cohort	8
Alonso 2015	288	45	Spain, PICU	1 month to 13 years	cross sectional	5
Asilioglu 2017	250	120	Turkey, PICUs	<= 18 years	cohort	6
Ayulo 2014	216	61	Spain, PICU	1 month to 13 years	cross sectional	5
Rey 2014	156	46	Spain, PICU	<16 years	cohort	7
Shah 2016	154	128	India,PICU	1 month-15 years	cohort	6
Ponnarmeni 2016	124	63	India, PICU	aged 1-12 years	cohort	6
Onwuneme 2015 (1)	120	71	Ireland, PICU	<12 years old	cohort	8
Jia 2017	110	92	China, PICU	infants <1 years old	case-control	7
Halwany 2017	102	38	Alexandria, PICU	>1 month to \leq 5 years	cohort	6
Sankar 2016	101	75	India, PICU	1 month to 17 years	cohort	8
Say 2017	100	87	Turkey, NICU	gestational age <37 weeks	case-control	6
Sakka 2014	96	89	Egypt, hospitalized	infants (<2 years old)	case-control	8
Onwuneme 2015 (2)	94	86	Ireland, NICU	preterm infants at <32 weeks gestation	cohort	8
Dayal 2014	92	23	India, PICU	3 months to 12 years	cohort	6
Bustos 2016	90	39	Chile, PICU	>37 weeks and <15 years	cohort	7
Hurwitz 2017	90	11	USA, hospitalised	<5 years old	cohort	6
Cayir 2014	88	50	Turkey, PICU	1 to 13 years	case-control	7
Badawi 2017	88	39	Cairo, Egypt PICU	1 month to 12 years	cohort	7
Yaghmaie 2017	82	53	Iran, PICU	children undefined	cross sectional	4
Basha 2014	81	53	Cairo Egypt, PICU	<5 years old	case-control	7
Prasad 2015	80	67	India, PICU	2 months-12 years	cohort	7
Wayse 2004	80	76	Indapur India, PICU	<5 years	case-control	6
El-Gamasy 2017	80	26	Egypt, PICU	3 months to 12 years	cohort	7
Banajeh 2009	79	29	Iran, hospitalised	aged 2-59 months	cohort	7
Binks 2014	74	11	Australia, PICU	<3 years old	cross sectional	6
Roth 2009	64	3	Canada, PICU	aged 1-25 months	case-control	7
Hebbar 2014	61	37	Atlanta, PICU	0 to 18 years	cohort	6
Dhandai 2018	60	38	India, NICU	neonates	cohort	7

Ebenezer 2016	52	21	India, PICU	<18 years	cohort	
Narang 2016	50	28	Punjab, India, PICU	2 months to 5 years	case-control	
Alvarez 2016	50	29	Atlanta, PICU	0 to 18 years	cross sectional	
Cetinkaya 2015	50	42	Instabul/Turkey, NICU	neonates	case-control	
Ahmed 2014	50	15	Nigeria, PICU	2–60 months	case-control	
Jat 2016	50	42	India, PICU	1 month to 12 years	case-control	
Sankar 2017	43	31	India, PICU	<=17 years	cohort	
Mathias 2017	41	28	USA, PICU	<= 18 years	cohort	
Cizmeci 2015	40	28	Instabul/Turkey, NICU	neonates	case-control	
Khakshour 2015	37	9	Iran, hospitalized	<5 years	case-control	
Korwutthikulrangsri 2015	32	25	Bangkok, PICU	months not more specific range	cohort	
Elmoneim 2016	30	17	Saudi Arabia, PICU	<14 years	cohort	
Dinlen 2016	30	26	Ankara Turkey, NICU	neonates	case-control	
Moreno-Solis 2015	48	9	Spain, PICU	infants 1-11 months	case-control	
Inamo 2011	28	8	Tokyo Japan, PICU	1-48 months	cohort	
Karatekin 2009	25	23	Istanbul Turkey, NICU	neonates	case-control	
Roth 2010	25	21	Bangladesh	1-18 months	case-control	

Studies arranged from largest to smallest total sample size. NOS = Newcastle Ottawa Score

Patient category	Number of studies (Total number of individuals; number of vitamin D deficient individuals)	Pooled proportion % (95% CI) Random effects model	95% PI	Pooled proportion % (95% CI) Fixed effects model	Heterogeneity (I ²) % (95% CI)	Q value, d.f. p-value for heterogeneity	Median % (IQR) of vitamin D deficiency
Acute and critically ill children, excluding studies that used other thresholds	40 (6,543; 3,000)	53.0 (46.4-59.5)	17.7-85.5	45.1 (43.8-46.5)	95.5 (94.5-96.2)	859.8, 39, < 0.0001	55.9 (33.4-55.9)
Sample size >= 82 (large)	26 (6,094; 2,731)	51.5 (43.6-59.4)	16.5-85.2	44.0 (42.6-45.3)	96.8 (96.0-97.4)	773.1, 25, < 0.0001	46.2 (30.7-67.9)
Sample size < 82 (small)	26 (1,340; 742)	58.2 (47.5-68.2)	13.2-92.8	54.8 (51.7-58.0)	90.9 (87.9-93.2)	275.4, 25, < 0.0001	62.0 (33.6-82.3)
Cohort studies	30 (5,119; 2,197)	49.6 (42.7-56.4)	17.6-81.9	42.1 (40.7-43.6)	94.9 (93.6-95.9)	567.0, 29, < 0.0001	44.1 (33.0-67.1)
Case-control	18 (1,821; 1,138)	68.1 (56.5-77.8)	19.3-95.0	60.8 (58.2-63.3)	93.0 (90.4-94.9)	243.9, 17, 0.0001	76.8 (55.9-86.0)
Cross sectional	4 (494; 138)	34.8 (12.8-66.0)	0.10-99.6	30.3 (25.9-35.2)	96.7 (94.0-98.2)	90.4, 3, < 0.0001	36.8 (15.4-59.7)
Studies from India	11 (886; 592)	68.9 (54.9-80.1)	18.3-95.6	64.0 (60.4-67.5)	96.7 (94.0 98.2)	140.2, 10, < 0.0001	72.1 (53.4-83.4)
Studies from Turkey	7 (583; 376)	76.3 (60.9-87.0)	20.9-97.5	61.0 (56.6-65.2)	91.1 (84.2-95.0)	67.5, 6, < 0.0001	84 (63.4-86.8)
Studies that only recruited neonates	7 (399; 330)	83.0 (73.1-90.0)	42.4-97.0	80.7 (76.1-84.5)	76.6 (51.0-88.9)	25.7, 6, 0.0003	86.7 (77.0-89.2)
Studies with children of all other ages except neonates	45 (7,035; 3,143)	49.7 (43.5-55.8)	16.1-83.5	44.2 (43.0-45.5)	95.2 (94.3-96.0)	919.9, 44, < 0.0001	48.0 (29.5-68.3)

 $CI = confidence intervals; I^2 = heterogeneity; df = degrees of freedom. Vitamin D deficiency defined in our study as <50 nmol/L (20 ng/mL) I^2 statistic used to estimate heterogeneity between pooled studies: I^2 >= 75% was considered as high heterogeneity, PI= Prediction interval; IQR = interquartile range: Lower (Q1) to Upper (Q3) quartile$

Predictors	k	b- coefficient	se	t-value	p-value	ci.lb	ci.ub	F-value	I^2 (%)	R^2 (%)	QE
Full model: year + clinical setting + quality score + design + country group + total sample size	52							4.57	95.7	32.9	702.6, p < 0.0001
year		-0.015	0.058	-0.256	0.799	-0.132	0.103				
total study sample size		-0.001	0.001	-0.731	0.469	-0.002	0.001				
country group (group 1 or 2 versus group 3)		1.009	0.356	2.831	0.007	0.291	1.726				
clinical setting (NICU versus PICU)		-1.573	0.465	-3.384	0.002	-2.510	-0.637				
design group (cohort vs other i.e. case-control or cross sectional)		0.482	0.324	1.488	0.144	-0.170	1.135				
quality score		0.296	0.170	1.744	0.088	-0.046	0.637				

 k = number of outcomes included in the model fitting; se = standard errors of the coefficients; ci.lb = lower bound of the confidence intervals for the coefficients; QE = test statistic for the test of (residual) heterogeneity; I^{^2} = residual heterogeneity / unaccounted variability; R^{^2} (amount of heterogeneity accounted for; PICU = pediatric intensive care units, NICU = neonatal intensive care units

Study	Total number of patients with sepsis	Total number of vitamin D deficient patients with sepsis	Country, setting	Age	Design	Qualit score (NOS
Shah 2016	160	135	India, PICU	1 month to 16 years	cohort	6
Asilioglu 2017	120	20	Turkey, PICU	1 month to ≤18 years	cohort	7
Say 2017	100	87	Turkey, NICU	preterm infants at <37 weeks gestation	case-control	6
Dhandai 2018	60	38	India, NICU	neonates	cohort	7
Ponnarmeni 2016	62	32	India, PICU	1 to 12 years	cohort	6
McNally 2012	48	33	Canada, PICU	newborn to 17 years	cohort	7
Onwuneme 2015 (2)	46	32	Ireland, NICU	preterm infants at <32 weeks gestation	cohort	8
El-Gamasy 2017	46	20	Egypt, pediatric emergency department	3 months to 12 years	cohort	7
Sankar 2017	43	31	India, PICU	<=17 years	cohort	8
Mathias 2017	41	28	USA, PICU	<=18 years	cohort	6
Cizmeci 2015	40	28	Turkey, NICU	neonates	case-control	7
Onwuneme 2015 (1)	35	32	Ireland, PICU	<12 years old	cohort	8
Hebbar 2014	30	17	Atlanta, PICU	0 to 18 years	cohort	6
Ebenezer 2016	16	8	India, PICU	<18 years	cohort	6
Korwutthikulrangsri 2015	12	4	Bangkok, PICU	moths (<8/9)	cohort	7
Prasad 2015	11	9	India, PICU	2 months to 12 years	cohort	7
Bustos 2016	10	7	Chile, PICU	>37 weeks and < than 15 years	cohort	7
Dayal 2014	9	4	India, tertiary care hospital	3 months to 12 years	cohort	6

Additional Table 17	Sensitivity analyses for	prevalence of v	1	ienciency in act	the and critically	in children with	
Patient category	Number of studies (Total number of individuals; number of vitamin D deficient individuals)	Pooled proportion (%, 95% CI) Random effects	95% PI	Pooled proportion (%, 95% CI) Fixed effects	Heterogeneity (I ²) %, 95% CI	Q value, d.f. p-value for heterogeneity	Median % (IQR) of vitamin D deficiency
Excluding studies that used other thresholds	14 (654; 395)	62.0 (47.3-74.7)	13.3-94.5	60.4 (56.0-64.7)	89.7 (84.5-93.2)	126.5, 13, < 0.0001	65.8 (50.4-70.0)
Sample size >= 42 (large)	9 (685; 428)	63.2 (44.6-78.5)	9.4-96.6	62.5 (58.2-66.6)	94.3 (91.1-96.3)	139.2, 8 < 0.0001	68.8 (51.6-72.1)
Sample size < 42 (small)	9 (204; 137)	64.7 (52.5-75.3)	29.5-89.0	64.7 (57.4-71.4)	57.9 (11.8-79.9)	19.0, 8, 0.0148	68.3 (50.0-70.0)
Cohort studies	16 (749; 450)	61.4 (48.6-72.8)	15.5-93,2	60.0 (55.9-63.9)	88.8 (83.5-92.4)	134.2, 15, < 0.0001	65.8 (48.6-70.5)
Case-control	2 (140; 115)	80.0 (58.8-91.8)	NA	81.0 (73.3-86.9)	81.3 (20.5-95.6)	5.35, 1, 0.0207	78.5 (74.2-82.8)
Studies from India	7 (361; 257)	66.0 (51.4-78.1)	21.3-93.3	69.2 (63.9-74.1)	81.1 (61.8-90.6)	31.7, 6 < 0.0001	63.3 (50.8-77.0)
Studies from Turkey	3 (260; 135)	59.2 (13.6-93.1)	0.00-100	51.2 (43.2-59.3)	97.8 (95.8-98.8)	90.0, 2, < 0.0001	70.0 (43.3-78.5)
Studies that only included neonates	4 (246; 185)	73.7 (60.3-83.8)	15.9-97.7	73.5 (67.3-78.9)	76.0 (34.1-91.3)	12.5, 3, 0.0058	69.8 (68.0-74.3)
Studies that included children of all other ages except neonates	14 (643; 380)	60.7 (45.5-74.0)	11.8-94.7	58.7 (54.2-63.0)	90.1 (85.2-93.4)	131.8, 13 < 0.0001	62.5 (45.8-71.6)

 $CI = confidence intervals; I^2 = heterogeneity; df = degrees of freedom. Vitamin D deficiency defined in our study as <50 nmol/L (20 ng/mL). I² statistic used to estimate heterogeneity between pooled studies: I² >= 75% was considered as high heterogeneity; PI= Prediction interval; IQR = interquartile range: Lower (Q1) to Upper (Q3) quartile; NA= Not available$

-only


Patient category	Number of studies (Total number	Pooled OR (Vitamin D deficient/ Vita p-valu	amin D non-deficient	Heterogeneity (I ²) % (95% CI)	Q value, d.f. p-value for	Eggers p-value
	of individuals)	Random effects	Fixed effects		heterogeneity	
Excluding studies that used other thresholds	14 (2,030)	1.59 (1.05-2.41) p-value = 0.028	1.52 (1.08-2.13) p-value = 0.016	24.3 (0.0-59.9)	17.18, 13, 0.1910	p-value = 0.120
Studies from India	7 (646)	1.08 (0.70-1.69) p-value = 0.710	1.08 (0.70-1.69) p-value = 0.710	0.0 (0.0-62.4)	4.56, 6, 0.589	Number of studies to small to test for smal study effects (k.min=1

CI = Confidence Intervals; I² = I squared statistic used to estimate heterogeneity (inconsistency); df = degrees of freedom, results reported in 1 decimal place; OR= odds ratio. Vitamin D deficiency defined as < 50 nmol/L or 20 ng/ml. We used the I² statistic to estimate heterogeneity between pooled studies: I² >= 75% was considered as high heterogeneity.

Additional Figures

Additional Figure 1 Funnel plot of studies of prevalence of vitamin D deficiency in acute and critically ill children. Horizontal axis shows logit transformed proportion and the standard error of the logit transformed proportion is plotted on the vertical axis. Each dot represents an individual study and the vertical line represents the pooled proportion from a random-effects meta-analysis. The diagonal lines represent pseudo 95% confidence limits (p=0.01, Egger's test).

Plot A shows the funnel plot before trim and fill method was applied and B after. Solid circles in plot B represent original data and open circles represent imputed filled studies (11 studies added) on the left-hand side of the funnel plot.



BMJ Open

Additional Figure 2. Pooled prevalence estimate for vitamin D deficiency in acute and critically ill children (by country group). Forest plot shows results from the random effects model. Diamonds represent pooled proportion of vitamin D deficiency for the countries in each subgroup (group 1, group2, group 3). The diamond at the bottom shows the overall pooled estimate of all the 52 studies. Each square shows the prevalence estimate of each study and the horizontal line across each square represents the 95% confidence interval (CI) of the prevalence estimate.

Study	VD deficient (n)	Total (N)		Prevalence	95% CI	Weight
Study group1 Vo 2018 Madden 2012 Lopez 2016 Garcia-Soler 2017 McNally 2012 Rippel 2012 Alonso 2015 Ayulo 2014 Rey 2014 Onwuneme 2015 (1) Onwuneme2015 (2) Bustos 2016 Hurwitz 2017 Binks 2014 Roth 2009 Hebbar 2014 Alvarez 2016 Mathias 2017 Moreno-Solis 2015 Inamo 2011 Random effects model	298 205 84 149 225 109 45 61 46 71 86 39 11 11 11 3 37 729 28 9 8	Total (N) 1016 511 347 340 326 316 288 216 156 120 94 90 94 90 74 64 61 50 41 48 28 4276		Prevalence 0.29 0.40 0.24 0.44 0.69 0.34 0.28 0.29 0.59 0.59 0.59 0.91 0.43 0.12 0.15 0.05 0.61 0.58 0.68 0.68 0.19 0.29 0.37	95% Cl [0.27; 0.32] [0.36; 0.45] [0.20; 0.29] [0.64; 0.74] [0.29; 0.40] [0.12; 0.20] [0.22; 0.35] [0.22; 0.35] [0.22; 0.35] [0.22; 0.35] [0.50; 0.68] [0.30; 0.68] [0.06; 0.21] [0.08; 0.25] [0.01; 0.13] [0.47; 0.73] [0.43; 0.72] [0.52; 0.82] [0.09; 0.33] [0.13; 0.49] [0.30; 0.45]	Weight 2.1% 2.1% 2.1% 2.1% 2.1% 2.1% 2.1% 2.1%
Removin Criteria model group2 Li 2018 Asilioglu 2017 Jia 2017 Halwany 2017 Say 2017 Sakka 2014 Cayir 2014 Badawi 2017 Yaghmaie 2017 Badawi 2017 Yaghmaie 2017 Banajeh 2009 Cetinkaya 2015 Ahmed 2014 Cizmeci 2015 Khakshour 2015 Khakshour 2015 Khakshour 2015 Khakshour 2016 Dinlen 2016 Karatekin 2009 Random effects model Heterogenetty: $l^2 = 91.5\%, t^2$	= 0.5336, p < 0.01 445 120 92 38 87 89 50 39 53 53 53 53 26 29 42 29 42 215 28 9 17 26 23	797 250 110 102 100 96 88 88 82 81 80 79 50 50 40 37 30 30 30 25 2215		0.56 0.44 0.37 0.93 0.57 0.44 0.65 0.65 0.32 0.37 0.84 0.30 0.70 0.24 0.37		2.1% 2.1% 2.0% 2.0% 2.0% 2.0% 2.0% 2.0% 2.0% 2.0
group3 Shah 2016 Ponnarmeni 2016 Sankar 2016 Dayal 2014 Prasad 2015 Wayse 2004 Dhandai 2018 Ebenezer 2016 Narang 2016 Jat 2016 Sankar 2017 Korwutthikulrangsri 2015 Roth 2010 Random effects model Heterogeneity: l^2 = 91.8%, τ^2	21	154 124 101 92 80 80 60 52 50 50 50 50 30 32 25 943		0.83 0.51 0.74 0.84 0.95 0.63 0.40 0.56 0.84 0.72 0.78 0.84 0.71	$ \begin{bmatrix} 0.76; \ 0.89 \\ 0.42; \ 0.60 \\ 0.65; \ 0.82 \\ 0.17; \ 0.35 \\ 0.74; \ 0.91 \\ 0.88; \ 0.99 \\ 0.50; \ 0.75 \\ 0.27; \ 0.55 \\ 0.27; \ 0.55 \\ 0.41; \ 0.70 \\ 0.71; \ 0.93 \\ 0.60; \ 0.81 \\ 0.64; \ 0.95 \\ 0.58; \ 0.81 \\ \end{bmatrix} $	2.0% 2.1% 2.0% 1.9% 1.6% 2.0% 1.9% 1.9% 1.9% 1.9% 1.7% 24.4%
Random effects model Prediction interval Heterogeneity: $l^2 = 95.3\%$, τ^2		7434	0.2 0.4 0.6 0.8	0.55	[0.48; 0.61] [0.18; 0.87]	100.0%


For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

BMJ Open

Additional Figure 3. Pooled prevalence estimates for vitamin D deficiency in acute and critically ill children (neonates versus all other age groups). Forest plot shows results from the random effects model. Diamonds represent pooled proportion of vitamin D deficiency for the studies in neonates and all other age groups. The diamond at the bottom shows the overall pooled estimate of all the 52 studies. Each square shows the prevalence estimate of each study and the horizontal line across each square represents the 95% confidence interval (CI) of the prevalence estimate.

Study	VD deficient (n)	Total (N)		Prevalence	95% CI
neonates					
Karatekin 2009	23	25	_	0.92	[0.74; 0.99]
Cizmeci 2015	28	40		0.70	[0.53; 0.83]
Dinlen 2016	26	30		0.87	[0.69; 0.96]
		50			
Cetinkaya 2015	42			0.84	[0.71; 0.93]
Onwuneme2015 (2)	86	94		0.91	[0.84; 0.96]
Say 2017	87	100		0.87	[0.79; 0.93]
Dhandai 2018	38	60		0.63	[0.50; 0.75]
Random effects model Heterogeneity: l^2 = 76.6%, τ^2	² = 0.4533, <i>p</i> < 0.01	399		0.83	[0.73; 0.90]
other					
Mathias 2017	28	41		0.68	[0.52; 0.82]
Vo 2018	298	1016	-	0.29	[0.27; 0.32]
Li 2018	445	797	in the second se	0.56	[0.52; 0.59]
Rippel 2012	109	316		0.34	[0.29; 0.40]
Jia 2017	92	110		0.84	[0.75; 0.90]
Halwany 2017	38	102		0.37	[0.28; 0.47]
Sakka 2014	89	96		0.93	[0.86; 0.97]
Hurwitz 2017	11	90		0.12	[0.06; 0.21]
Basha 2014	53	81		0.65	[0.54; 0.76]
Wayse 2004	76	80		0.95	[0.88; 0.99]
Banajeh 2009	29	79		0.37	[0.26; 0.48]
Binks 2014	11	74		0.15	[0.08; 0.25]
Narang 2016	28	50		0.56	[0.41; 0.70]
Ahmed 2014	15	50		0.30	[0.18; 0.45]
Khakshour 2015	9	37		0.24	[0.12; 0.41]
Moreno-Solis 2015	9	48		0.19	[0.09; 0.33]
Inamo 2011	8	28		0.29	[0.13; 0.49]
Roth 2010	21	25		0.84	[0.64; 0.95]
Roth 2009	3	64		0.05	[0.01; 0.13]
	205	511		0.40	
Madden 2012					[0.36; 0.45]
Lopez 2016	84	347		0.24	[0.20; 0.29]
Garcia-Soler 2017	149	340		0.44	[0.38; 0.49]
McNally 2012	225	326		0.69	[0.64: 0.74]
Alonso 2015	45	288		0.16	[0.12; 0.20]
Asilioglu 2017	120	250		0.48	[0.42; 0.54]
Ayulo 2014	61	216		0.28	[0.22; 0.35]
Rey 2014	46	156		0.29	[0.22; 0.37]
Shah 2016	128	154		0.83	[0.76; 0.89]
Ponnarmeni 2016	63	124		0.51	[0.42; 0.60]
Onwuneme 2015 (1)	71	120		0.59	[0.50; 0.68]
	75	101		0.74	
Sankar 2016					[0.65; 0.82]
Dayal 2014	23	92		0.25	[0.17; 0.35]
Bustos 2016	39	90		0.43	[0.33; 0.54]
Cayir 2014	50	88		0.57	[0.46; 0.67]
Badawi 2017	39	88		0.44	[0.34; 0.55]
Yaghmaie 2017	53	82		0.65	[0.53; 0.75]
Prasad 2015	67	80		0.84	[0.74; 0.91]
El-Gamasy 2017	26	80		0.32	[0.22; 0.44]
Hebbar 2014	37	61		0.61	[0.47; 0.73]
Ebenezer 2016	21	52		0.40	[0.27; 0.55]
Alvarez 2016	29	50		0.58	[0.43; 0.72]
Jat 2016	42	50		0.84	
					[0.71; 0.93]
Sankar 2017	31	43		0.72	[0.56; 0.85]
Korwutthikulrangsri 2015	25	32	· · · · · ·	0.78	[0.60; 0.91]
Elmoneim 2016	17	30	— <u>—</u>	0.57	[0.37; 0.75]
Random effects model		7035		0.50	[0.44; 0.56]
Heterogeneity: I^2 = 95.2%, τ^2	$^{2} = 0.6427, p < 0.01$	1000		0.00	[0.11, 0.00]
Random effects model Prediction interval		7434		0.55	[0.48; 0.61]
	- 0 7000 0 01				[0.18; 0.87]
Heterogeneity: $I^2 = 95.3\%$, τ^2	r = 0.7300, p < 0.01				
			0.2 0.4 0.6 0.8		


Additional Figure 4 Bubble plots of univariate meta-regressions. Each study is represented by a circle. Predictor variables: A study design, B year of publication, C quality score and D total children are plotted on the x-axis with the effect measure logit transformed proportion shown on the vertical (y-axis).



BMJ Open

Additional Figure 5 Funnel plot for prevalence of vitamin D deficiency in acute and critically ill children with sepsis. Horizontal axis shows logit transformed proportion and the standard error of the logit transformed proportion is plotted on the vertical axis. Each dot represents an individual study and the vertical line represents the pooled proportion from a random-effects meta-analysis. The diagonal lines represent pseudo 95% confidence limits (p=0.81, Egger's test).

Funnel Plot with pseudo 95% Confidence Intervals



Logit Transformed Proportion

BMJ Open

Additional Figure 6 Pooled prevalence estimate for vitamin D deficiency in acute and critically ill children with sepsis (subgroup analysis by study design). Forest plot shows results from the random effects model. Diamonds represent the pooled proportion of vitamin D deficiency for the studies in each subgroup (case-control and cohort). The diamond at the bottom shows the overall pooled estimate of all the 18 studies. Each square shows the prevalence estimate of each study and the horizontal line across each square represents the 95% confidence interval (CI) of the prevalence estimate.


87 28 = 0.4514, p = 0.02 135 20 32 38 33 32 20 31 28 32 17 8 4 9 7 4	100 40 140 160 120 62 60 48 46 46 46 43 30 16 12 11 10 9					*	0.87 0.70 0.80 0.84 0.17 0.52 0.63 0.69 0.70 0.43 0.72 0.68 0.91 0.57 0.50 0.33 0.82	[0.79; 0.93] [0.53; 0.83] [0.59; 0.92] [0.10; 0.25] [0.39; 0.65] [0.50; 0.75] [0.54; 0.81] [0.54; 0.82] [0.29; 0.59] [0.56; 0.82] [0.77; 0.98] [0.37; 0.75] [0.25; 0.75] [0.10; 0.65] [0.48; 0.98]	6.0° 5.9° 11.9° 6.3° 6.2° 6.2° 6.0° 6.0° 5.9° 5.9° 5.8° 5.8° 5.8° 5.8° 5.8° 5.8° 5.8° 5.8
28 = 0.4514, p = 0.02 135 20 32 38 33 32 20 31 28 32 20 31 28 32 17 8 4 9 7	40 140 120 62 60 48 46 46 43 41 35 30 16 12 11 10	* 				*- 	0.70 0.80 0.84 0.17 0.52 0.63 0.69 0.70 0.43 0.72 0.68 0.91 0.57 0.50 0.33 0.82	[0.53; 0.83] [0.59; 0.92] [0.10; 0.25] [0.39; 0.65] [0.50; 0.75] [0.54; 0.81] [0.54; 0.82] [0.52; 0.82] [0.77; 0.98] [0.37; 0.75] [0.25; 0.75] [0.25; 0.75] [0.10; 0.65] [0.48; 0.98]	5.9 11.9 6.3 6.2 6.2 6.1 6.0 6.0 5.9 5.9 4.8 5.8 5.2 4.7 4.0
28 = 0.4514, p = 0.02 135 20 32 38 33 32 20 31 28 32 20 31 28 32 17 8 4 9 7	40 140 120 62 60 48 46 46 43 41 35 30 16 12 11	- * -					0.70 0.80 0.84 0.17 0.52 0.63 0.69 0.70 0.43 0.72 0.68 0.91 0.57 0.50 0.33 0.82	[0.53; 0.83] [0.59; 0.92] [0.10; 0.25] [0.39; 0.65] [0.50; 0.75] [0.54; 0.81] [0.54; 0.82] [0.52; 0.82] [0.77; 0.98] [0.37; 0.75] [0.25; 0.75] [0.25; 0.75] [0.10; 0.65] [0.48; 0.98]	5.9 11.9 6.3 6.2 6.2 6.0 6.0 6.0 5.9 5.9 4.8 5.2 4.8 5.2 4.7 4.0
= 0.4514, <i>p</i> = 0.02 135 20 32 38 33 32 20 31 28 32 17 8 4 9 7	140 120 62 60 48 46 46 43 41 35 30 16 12 11 10	-*-					0.84 0.17 0.52 0.63 0.69 0.70 0.43 0.72 0.68 0.91 0.57 0.50 0.33 0.82	[0.59; 0.92] [0.78; 0.90] [0.10; 0.25] [0.50; 0.75] [0.54; 0.82] [0.54; 0.82] [0.52; 0.82] [0.77; 0.98] [0.37; 0.75] [0.25; 0.75] [0.25; 0.75] [0.10; 0.65] [0.48; 0.98]	11.9 6.3 6.2 6.2 6.1 6.0 6.0 5.9 5.9 4.8 5.8 5.2 4.0
135 20 32 38 33 32 20 31 28 32 17 8 4 9 9 7	160 120 60 48 46 46 43 41 35 30 16 12 11	+ 					0.84 0.17 0.52 0.63 0.69 0.70 0.43 0.72 0.68 0.91 0.57 0.50 0.33 0.82	[0.78; 0.90] [0.10; 0.25] [0.39; 0.65] [0.50; 0.75] [0.54; 0.82] [0.29; 0.59] [0.56; 0.85] [0.52; 0.82] [0.77; 0.98] [0.37; 0.75] [0.25; 0.75] [0.25; 0.75] [0.10; 0.65] [0.48; 0.98]	6.3 6.2 6.1 6.0 6.0 5.9 4.8 5.2 5.2 4.0
135 20 32 38 33 32 20 31 28 32 17 8 4 9 9 7	120 62 60 48 46 46 43 35 30 16 12 11 10					₽- - <u>-</u>	0.17 0.52 0.63 0.69 0.70 0.43 0.72 0.68 0.91 0.57 0.50 0.33 0.82	[0.10; 0.25] [0.39; 0.65] [0.50; 0.75] [0.54; 0.81] [0.54; 0.82] [0.29; 0.59] [0.56; 0.85] [0.52; 0.82] [0.77; 0.98] [0.37; 0.75] [0.25; 0.75] [0.10; 0.65] [0.48; 0.98]	6.2 6.2 6.1 6.0 6.0 5.9 5.9 4.8 5.8 5.2 4.7 4.0
20 32 38 33 32 20 31 28 32 17 8 4 9 7	120 62 60 48 46 46 43 35 30 16 12 11 10						0.17 0.52 0.63 0.69 0.70 0.43 0.72 0.68 0.91 0.57 0.50 0.33 0.82	[0.10; 0.25] [0.39; 0.65] [0.50; 0.75] [0.54; 0.81] [0.54; 0.82] [0.29; 0.59] [0.56; 0.85] [0.52; 0.82] [0.77; 0.98] [0.37; 0.75] [0.25; 0.75] [0.10; 0.65] [0.48; 0.98]	6.2' 6.2' 6.0' 6.0' 5.9' 5.9' 4.8' 5.2' 4.7' 4.0'
20 32 38 33 32 20 31 28 32 17 8 4 9 7	120 62 60 48 46 46 43 35 30 16 12 11 10			*			0.17 0.52 0.63 0.69 0.70 0.43 0.72 0.68 0.91 0.57 0.50 0.33 0.82	[0.10; 0.25] [0.39; 0.65] [0.50; 0.75] [0.54; 0.81] [0.54; 0.82] [0.29; 0.59] [0.56; 0.85] [0.52; 0.82] [0.77; 0.98] [0.37; 0.75] [0.25; 0.75] [0.10; 0.65] [0.48; 0.98]	6.2 6.2 6.1 6.0 6.0 5.9 5.9 4.8 5.8 5.2 4.7 4.0
20 32 38 33 32 20 31 28 32 17 8 4 9 7	120 62 60 48 46 46 43 35 30 16 12 11 10		-	* 	*	-	0.17 0.52 0.63 0.69 0.70 0.43 0.72 0.68 0.91 0.57 0.50 0.33 0.82	[0.10; 0.25] [0.39; 0.65] [0.50; 0.75] [0.54; 0.81] [0.54; 0.82] [0.29; 0.59] [0.56; 0.85] [0.52; 0.82] [0.77; 0.98] [0.37; 0.75] [0.25; 0.75] [0.10; 0.65] [0.48; 0.98]	6.2 6.2 6.1 6.0 6.0 5.9 5.9 4.8 5.8 5.2 4.7 4.0
32 38 32 20 31 28 32 17 8 4 9 9 7	62 60 48 46 43 41 35 30 16 12 11 10		-		-		0.52 0.63 0.69 0.70 0.43 0.72 0.68 0.91 0.57 0.50 0.33 0.82	[0.39; 0.65] [0.50; 0.75] [0.54; 0.81] [0.54; 0.82] [0.56; 0.85] [0.52; 0.82] [0.77; 0.98] [0.37; 0.75] [0.25; 0.75] [0.10; 0.65] [0.48; 0.98]	6.2 6.1 6.0 6.0 5.9 5.9 4.8 5.8 5.2 4.7 4.0
38 33 20 31 28 32 17 8 4 9 9 7	60 48 46 43 41 35 30 16 12 11 10		-		-		0.63 0.69 0.70 0.43 0.72 0.68 0.91 0.57 0.50 0.33 0.82	[0.50; 0.75] [0.54; 0.81] [0.54; 0.82] [0.29; 0.59] [0.56; 0.85] [0.52; 0.82] [0.77; 0.98] [0.37; 0.75] [0.25; 0.75] [0.10; 0.65] [0.48; 0.98]	6.1 6.0 6.0 5.9 4.8 5.8 5.2 4.7 4.0
33 32 20 31 28 32 17 8 4 9 9 7	48 46 43 41 35 30 16 12 11 10						0.69 0.70 0.43 0.72 0.68 0.91 0.57 0.50 0.33 0.82	[0.54; 0.81] [0.54; 0.82] [0.29; 0.59] [0.56; 0.85] [0.52; 0.82] [0.37; 0.75] [0.37; 0.75] [0.25; 0.75] [0.10; 0.65] [0.48; 0.98]	6.0 6.0 5.9 5.9 4.8 5.8 5.2 4.7 4.7
32 20 31 28 32 17 8 4 9 9 7	46 46 43 41 35 30 16 12 11				-		0.70 0.43 0.72 0.68 0.91 0.57 0.50 0.33 0.82	[0.54; 0.82] [0.29; 0.59] [0.56; 0.85] [0.52; 0.82] [0.77; 0.98] [0.37; 0.75] [0.25; 0.75] [0.10; 0.65] [0.48; 0.98]	6.0 6.0 5.9 5.9 4.8 5.8 5.2 4.7 4.0
20 31 28 32 17 8 4 9 9 7	46 43 41 35 30 16 12 11		-	-	-		0.43 0.72 0.68 0.91 0.57 0.50 0.33 0.82	[0.29; 0.59] [0.56; 0.85] [0.52; 0.82] [0.77; 0.98] [0.37; 0.75] [0.25; 0.75] [0.10; 0.65] [0.48; 0.98]	6.0 5.9 5.9 4.8 5.8 5.2 4.7 4.0
20 31 28 32 17 8 4 9 9 7	46 43 41 35 30 16 12 11		-	-	-		0.43 0.72 0.68 0.91 0.57 0.50 0.33 0.82	[0.29; 0.59] [0.56; 0.85] [0.52; 0.82] [0.77; 0.98] [0.37; 0.75] [0.25; 0.75] [0.10; 0.65] [0.48; 0.98]	6.0 5.9 5.9 4.8 5.8 5.2 4.7 4.0
31 28 32 17 8 4 9 7	43 41 35 30 16 12 11		_	-	-		0.72 0.68 0.91 0.57 0.50 0.33 0.82	[0.56; 0.85] [0.52; 0.82] [0.77; 0.98] [0.37; 0.75] [0.25; 0.75] [0.10; 0.65] [0.48; 0.98]	5.9 5.9 4.8 5.8 5.2 4.7 4.0
28 32 17 8 4 9 7	41 35 30 16 12 11		*	*	-	-#-	0.68 0.91 0.57 0.50 0.33 0.82	[0.52; 0.82] [0.77; 0.98] [0.37; 0.75] [0.25; 0.75] [0.10; 0.65] [0.48; 0.98]	5.9 4.8 5.8 5.2 4.7 4.0
32 17 8 4 9 7	35 30 16 12 11 10		*	*			0.91 0.57 0.50 0.33 0.82	[0.77; 0.98] [0.37; 0.75] [0.25; 0.75] [0.10; 0.65] [0.48; 0.98]	4.8 5.8 5.2 4.7 4.0
17 8 4 9 7	30 16 12 11 10		-	-			0.57 0.50 0.33 0.82	[0.37; 0.75] [0.25; 0.75] [0.10; 0.65] [0.48; 0.98]	5.8 5.2 4.7 4.0
8 4 9 7	16 12 11 10		-	-			0.50 0.33 0.82	[0.25; 0.75] [0.10; 0.65] [0.48; 0.98]	5.2 4.7 4.0
8 4 9 7	16 12 11 10		×	-			0.50 0.33 0.82	[0.25; 0.75] [0.10; 0.65] [0.48; 0.98]	5.2 4.7 4.0
4 9 7	12 11 10		*				0.33 0.82	[0.10; 0.65] [0.48; 0.98]	4.7
9 7	11 10						0.82	[0.48; 0.98]	4.0
	10				-				
		-	_						
4	9						0.70	[0.35; 0.93]	4.4
	9						0.44	[0.14: 0.79]	4.5
	749				1		0.61	[0.49; 0.73]	88.1
= 0.9437, <i>p</i> < 0.01								[
	889						0.64	[0.52: 0.74]	100.0
						_	0.01		10010
- 0.0672 - < 0.01			1					[0.11, 0.04]	
- 0.9073, p < 0.01									
		0.2	0.4	0.6	0.8				
	0.9673, <i>p</i> < 0.01	889 0.9673, <i>p</i> < 0.01		0.9673, p < 0.01	0.9673, <i>p</i> < 0.01	0.9673, <i>p</i> < 0.01	0.9673, <i>p</i> < 0.01	0.9673, <i>p</i> < 0.01	0.9673, p < 0.01

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

BMJ Open


Additional Figure 7 Funnel plot of risk of mortality in vitamin D deficient versus vitamin D non-deficient acute and critically ill children. Horizontal axis shows logit transformed odds ratio and the standard error of the log odds ratio is plotted on the vertical axis. Each dot represents an individual study and the vertical line represents the overall pooled odds ratio from random-effects meta-analysis. The diagonal lines represent pseudo 95% confidence limits (p=0.084, Egger's test).

Funnel Plot with pseudo 95% Confidence Intervals



For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

Additional Figure 8 Pooled odds ratio (OR) and 95% CI for risk of mortality in vitamin D deficient versus vitamin D non-deficient acute and critically ill children (fixed effects model). Diamond represents the overall odds ratio (with corresponding 95% Confidence Interval). Each square shows the odds ratio of each study and the horizontal line across each square represents the 95% confidence interval (CI) of the estimate.



MOOSE (Meta-analyses Of Observational Studies in Epidemiology) Checklist

A reporting checklist for Authors, Editors, and Reviewers of Meta-analyses of Observational Studies. You must report the page number in your manuscript where you consider each of the items listed in this checklist. If you have not included this information, either revise your manuscript accordingly before submitting or note N/A.

Reporting Criteria	Reported (Yes/No)	Reported on Page No
Reporting of Background		
Problem definition		
Hypothesis statement		
Description of Study Outcome(s)		
Type of exposure or intervention used		
Type of study design used		
Study population		
Reporting of Search Strategy		
Qualifications of searchers (eg, librarians		
and investigators)		
Search strategy, including time period		
included in the synthesis and keywords		
Effort to include all available studies,		
including contact with authors		
Databases and registries searched		
Search software used, name and		
version, including special features used		
(eg, explosion)		
Use of hand searching (eg, reference		
lists of obtained articles)		
List of citations located and those		
excluded, including justification		
Method for addressing articles		
published in languages other than		
English		
Method of handling abstracts and		
unpublished studies		
Description of any contact with authors		
Reporting of Methods		
Description of relevance or		
appropriateness of studies assembled for		
assessing the hypothesis to be tested		
Rationale for the selection and coding of		
data (eg, sound clinical principles or		
convenience)		
Documentation of how data were		
classified and coded (eg, multiple raters,		
blinding, and interrater reliability)		
Assessment of confounding (eg,		
comparability of cases and controls in		
studies where appropriate		

Reporting Criteria	Reported (Yes/No)	Reported on Page No.
Assessment of study quality, including		
blinding of quality assessors;		
stratification or regression on possible		
predictors of study results		
Assessment of heterogeneity		
Description of statistical methods (eg,		
complete description of fixed or random		
effects models, justification of whether		
the chosen models account for predictors		
of study results, dose-response models,		
or cumulative meta-analysis) in sufficient		
detail to be replicated		
A		
Provision of appropriate tables and		
graphics		
Reporting of Results		
Table giving descriptive information for		
each study included		
Results of sensitivity testing (eg,		
subgroup analysis)		
Indication of statistical uncertainty of		
findings		
Reporting of Discussion		
Quantitative assessment of bias (eg,		
publication bias)		
Justification for exclusion (eg, exclusion		
of non–English-language citations)		
Assessment of quality of included studies		
Reporting of Conclusions		
Consideration of alternative explanations		
for observed results		
Generalization of the conclusions (ie,		
appropriate for the data presented and		5
within the domain of the literature review)		
Guidelines for future research		
Disclosure of funding source		

Once you have completed this checklist, please save a copy and upload it as part of your submission. DO NOT include this checklist as part of the main manuscript document. It must be uploaded as a separate file.

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml